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Abstract 
Malaria remains one of the world’s most widespread and deadly parasitic diseases, killing 
hundreds of thousands of people per year, most of whom are children under the age of 5 years old. 
There have been great efforts to deliver novel effective antimalarial chemotherapies over the recent 
decades, however, the development of such therapies remains a significant challenge. The ability of 
the malaria parasite to rapidly acquire resistance to chemotherapies makes the disease an ever-
present threat to populations living in endemic areas. The emergence of resistance to all current 
frontline therapies is a fundamental issue. Thus far, all of the successful therapies target the same 
small number of clinically validated pathways, however, as the same pathway is targeted resistance 
to the new therapy develops within a matter of years or even months.  
More recently, focus has turned to the development of therapies targeting novel pathways 
and enzymes to circumvent the resistance problem. This research focuses on the inhibition of the 
methyl erythritol phosphate (MEP) pathway for the chemical interruption of isoprenoid biosynthesis 
in the malaria parasite. Isoprenoids have a large number of crucial biological roles within all living 
organisms, however, their synthesis in mammals is enzymatically distinct from the MEP pathway. This 
potentially allows for the species specific targeting of isoprenoid biosynthesis, thereby making the 
MEP pathway a highly attractive target for antimalarial drug development. Fosmidomycin has been 
found to effectively target the second enzyme in the MEP pathway IspC, validating the pathway as 
amenable to small molecule inhibition. Here, our goal is to target the next pathway enzyme IspD, with 
the aim of developing a lead candidate to be taken forward as an effective antimalarial therapeutic.  
Extensive structure activity relationships (SAR) were carried out on 3 chemotypes: 
MMV008138 a tetrahydro-β-carboline was recently elucidated to possess potent PfIspD activity; and 
we were successful in our SAR studies to deliver 2 new compounds that possessed an improved 
cellular potency (Pf3D7 EC50 248 nM (n = 1) and 275 ± 10.5 nM n = 4) one of which possessed an 
improved pharmacokinetic profile. A targeted HTS identified a 1,2-benzo[d]isothiazol-3(2H)-one as a 
potent inhibitor of PfIspD, which is believed to operate through covalent modification of the IspD 
active site. SAR yielded 4 compounds with improved PfIspD activity (PfIsPD IC50 <300 nM) over the hits 
in the HTS screen, however, cellular potency requires further investigation. Finally, a second HTS 
screen identified a benzothiazine chemotype as another potent inhibitor of PfIspD. A compound set 
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1.1 Introduction 
1.1.1 Global Impact 
Despite the concerted efforts over several decades to generate effective antimalarial 
therapies, malaria remains one of the world’s most widespread and deadly parasitic diseases, killing 
approximately 438,000 people per annum, most of whom are children under the age of five.1  
The World Health Organisation in 2015 estimated that 212 million people were diagnosed 
with malaria worldwide, with 90 % of incidence occurring in Africa.1 Clearly the African continent holds 
an overwhelming share of the malaria burden, and this causes great economic strain on the countries 
within this region that suffer from deep poverty.1 The prevention and treatment of the disease within 
African countries is responsible for approximately 40 % of all public health spending, increasing further 
the poverty and economic burden on this region, eventually resulting in the poorest areas being 
unable to afford prevention and / or treatment methods for the disease.1,2  
Other malaria endemic areas include central and south East Asia, and the Americas (Figure 
1.1). Current estimates predict that half of the world’s population, 3.3 billion people, are at risk of 
contracting the disease. This combined with the issues mentioned above, highlights the need for 
continued preventative and control strategies in order to reduce both the incidence and mortality 
rates.1  
 
Figure 1.1. Global Distribution of Malaria. Figure reproduced from World Malaria Report 2016. Geneva: World Health 
Organization; 2016. Permission of use allowed by Creative Commons Licence: CC BY-NC-SA 3.0 IGO.1 
The malaria parasite is a vector-borne disease caused by the eukaryotic single celled 
protozoan organism belonging to the genus Plasmodium (Phylum Apicomplexia).1 It is transmitted 
through the bite of a female Anopheles mosquito when she takes a blood meal. The malaria parasite 
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is found in regions where these mosquitos flourish, such as in warm tropical climates including sub-
Saharan Africa, south East Asia, and the regions of Americas.1 
There are five main species of malaria that infect humans; these are Plasmodium falciparum, 
P. vivax, P. malariae, P. ovale, P. knowlesi.1,3 Of these five strains, P. falciparum, and P. vivax are the 
most challenging to control, causing the vast majority of malarial infection.1,4 P. falciparum is 
recognised as the most deadly of these protozoa due to its prevalence throughout Africa, and its 
widely documented mortality rates.1 P. vivax on the other hand, has higher rates of incidence outside 
of Africa; it is responsible for approximately 16 million cases per annum and as a result, is a significant 
cause of mortality outside of the African continent.1,5    
1.2 General Life Cycle of Plasmodium 
 The Plasmodium life cycle is one of complexity allowing for the parasite to evade host immune 
defence systems.6,7 As malaria is vector borne, it requires two hosts for its survival and within these 
hosts there are a total of three key cycles, one of which is a sexual stage which takes place within the 
mosquito, whist the other two cycles are asexual and take place within the human host. The whole 
life cycle is displayed in Figure 1.2 and discussed below. 
 
Figure 1.2. The Malaria Life cycle image reproduced from the Center of Disease Control and Prevention (CDC). Image is in 
the public domain and free of copyright restrictions. CDC - DPDx/ Alexander J. da Silva Melanie Moser.8 
Liver stage: When an infected mosquito takes a blood meal she injects infective sporozoites 
from the salivary glands into the human host blood stream; the parasite then rapidly travels through 
the blood to the liver within 30 minutes of infection, initiating the liver stage. Sporozoites infect liver 
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cells, where they evade human immune defence systems, mature into schizonts and then replicate 
asexually into thousands of merozoites. The liver cells become overloaded with parasites, rupture, 
and release infective merozoites into the blood stream. A process that takes between 6 – 16 days.9–15  
 Blood stage: Merozoites proceed to invade red blood cells beginning the blood stage cycle. 
Asexual division occurs in the red blood cell causing the parasites to propagate. During this stage the 
parasite matures, first into trophozoites, also known as the ring form, then into schizonts. This stage 
digests the host’s haemoglobin as a source of amino acids for replication. The schizonts produce 
approximately 20 merozoites, which then burst through the red blood cell upon schizont rupture 
ready to infect new red blood cells; this stage takes approximately two days. It is this cycle that causes 
the clinical manifestations of malaria to take place. Most drugs target the parasite at this stage of its 
life cycle. After numerous cycles, some of the parasites diverge into male and female gametocytes, 
which are up taken by another mosquito when she takes a blood meal. The gametocytogenesis stage 
takes 10 – 12 days, and begins the sexual stage if the parasite life cycle.6,7,11,15,16  
 Mosquito stage: Once the mosquito takes a blood meal the gametocytes are ingested into 
the mosquito gut and form gametes. The gametes undergo sexual fertilisation and form a zygote 
followed by an ookinete. This penetrates a cell wall in the gut and develops into an oocyst. The oocyst 
produces many sporozoites and eventually ruptures allowing the sporozoites to migrate to the salivary 
glands. The cycle up to this stage takes about 10 – 18 days and the mosquito can be infective for up 
to two months. The mosquito can then infect a new human host when she takes a blood meal.15,17,18  
Malaria affects numerous systems within the body. After initial infection, the clinical 
manifestations of malaria begin to become apparent generally after 10 – 20 days, which are due to 
the blood stage of the parasite.1 The early symptoms of malaria infection include fever-like symptoms, 
such as headache, cough, nausea, aches, and often paroxysm of fever, these symptoms are referred 
to as uncomplicated malaria which can be caused by all strains of Plasmodium.19,20 In the case of P. 
falciparum, the disease can quickly proceed to complicated malaria if left untreated.1 Symptoms 
include vomiting, diarrhoea, anaemia, renal failure, hypoglycaemia and severe respiratory distress all 
of which can lead to death. Further to this, complicated P. falciparum infection can progress to form 
cerebral malaria, symptoms include headaches, coma, and ultimately death.20 Though P. falciparum is 
well known to be the most lethal of strains, there is increasing evidence that P. vivax mortality is 
underestimated.21–28 P. vivax has a slightly different life cycle and possesses a dormant liver stage; if 
these dormant liver stage parasites (hypnozoites) are not eliminated completely, malaria symptoms 
can relapse weeks, or even months after treatment. Both strains should be treated as serious, and 
both strains are becoming difficult to treat due to the emergence of drug resistance.5,29–33    
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1.3 Malaria Prevention and Treatment 
1.3.1 Vector Control 
Vector control is an integral part in reducing incident rates in the fight against malaria. 
Between 2000 – 2015 case incidence has dropped globally by 41 %, and 21 % between 2010 – 2015, 
this can in part be attributed to effective vector control.1 There are three strategies for the protection 
of individuals in high risk areas; indoor residual spray (IRS), insecticide treated nets (ITN), and 
vaccines.1 The insecticide dichlorodiphenyltrichloroethane (DDT)  (1) (Figure 1.3), was the first 
efficacious IRS in successfully reducing malaria transmission worldwide.34 Unfortunately, however, the 
fallout from using 1 led to extensive environmental damage particularly to birds.34–36 The compound 
is highly lipophilic and resistant to metabolism, meaning it has a long half-life, and has a risk of 
bioaccumulation.34,37 1 was classified as being probably carcinogenic to humans, these factors, 
coupled with emerging mosquito resistance to the compound, eventually led to the substance use 
being banned.34,37,38 
 
Figure 1.3. DDT (1). 
Other IRSs with a better safety profile have been introduced such as pyrethroid insecticides 
which, though more expensive than 1, are the only insecticide recommended by the WHO for use as 
both IRSs and on ITNs.1,39 Once again, however, resistance is emerging for pyrethroids and eventually 
new insecticides will need to be developed to continue to aid a fall in incidence rates.1,40 The 
effectiveness of IRSs and ITNs has been substantial, in sub-Saharan Africa the proportion of the 
population sleeping under an ITN or protected by an IRS has risen to 51 % in 2015, compared with 37 
% in 2010, this has led to both a reduction in incidence rates, along with a reduction in mortality rates, 
highlighting the importance of this strategy as a preventive method.1 
The development of a working vaccine against malaria would be a significant feat in aiding the 
prevention of the disease. A number of vaccine development projects are currently on-going, 
however, only one vaccine, RTS,S/AS01, has completed phase III clinical trials. After administration of 
the required four doses, RTS,S/AS01 demonstrated a reduction of incidence of uncomplicated malaria 
by 39 %, and severe malaria by 31 % in children ages 5 – 17 months. In 2018, a pilot scale vaccination 
is due to begin, which if successful, could begin wide scale use of this vaccine as another weapon in 
the arsenal of malarial preventative measures.1   
 Chapter 1: Introduction to Malaria and the Methyl Erythritol Phosphate (MEP) Pathway 
 6 
1.3.2 Antimalarial Chemotherapy 
 Indeed, whilst vector control is providing aid in high risk areas where malaria is a burden, it is 
only a prevention strategy, and until a viable vaccine is fully developed, drug chemotherapy will 
remain crucial in the fight against malaria both as a preventative measure and as a treatment option. 
This following section will discuss past and current antimalarial therapeutics categorised by class and 
mode of action. 
1.3.2.1 Quinolines 
 It is true that most of the most efficacious antimalarial therapeutics are, or have been, derived 
or inspired from natural products. Often in drug discovery programmes it is ill-advised to use natural 
products as starting points for drug optimisation, due to the poor drug like properties of these 
compounds, difficulty in isolation, and often highly complex synthetic routes, where isolation is a not 
an option. Ultimately these issues mean that natural product use can be very cost ineffective. Despite 
this, malaria treatment has been largely successful utilising natural products as a basis for further 
candidate development.41 
 The first mainstream antimalarial compound quinine (2) (Figure 1.4), is a compound belonging 
to the quinoline class. Indeed quinine is a natural product, and is isolated from the bark of the Andean 
Cinchona tree. It was the only known antimalarial drug for over 300 years and was discovered almost 
400 years ago, even with this long history of use, it remains an efficacious treatment in many regions 
where malaria is prevalent.42  
Quinine is a type of alkaloid and was first isolated by Pelletier and Caventou in 1820.42 It is a 
chiral 4-aminoalcohol-quinoline, can be considered as a small molecule (Mr <500 gmol-1), and shows 
some favourable physiochemical properties. The limitation of quinine from natural sources is 
associated with the difficulty in isolation of large enough quantities to fulfil the demand for the drug. 
Attempts towards the total synthesis of quinine was first described by Woodward and von Doering in 
1945, however, the synthesis was too complicated for commercial use and also non-
stereoselective.43,44 It was not until the beginning of the 21st century that the first stereoselective 
synthesis of quinine was successfully achieved by Stork, since then, in 2004, Kobayashi and Jacobsen 
have independently also synthesised the enantiopure molecule.45–47 
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Figure 1.4. Quinine (2). 
Due to the difficulty in both synthesis and isolation of quinine, efforts shifted to the synthesis 
of simpler alternatives to cope with the demand for antimalarial therapeutics. The discovery of 
methylene blue (3) (Figure 1.5) in 1891 by Ehrlich, which was advantageous due to its simple synthesis, 
cost effectiveness, and accessibility to large scale synthesis.42,48 This prompted the development of 
the second synthetic antimalarial, pamaquine also known as plasmoquine (4) (Figure 1.5) by German 
scientists in the 1920s.49 Pamaquine belongs to the 8-aminoquinoline template and was efficacious 
treatment at preventing P. vivax relapse, the first compound of its kind to accomplish such a feat.50–52 
Pamaquine (4) shows activity against the liver stage of the parasite and hypnozoites. It was also 
moderately active against the blood stage of  P. vivax and P. malariae, however, inactive against blood 
stage P. falciparum infection.50–52 Despite this, it was very effective against the sexual stage of the P. 
falciparum, more specifically, it showed potent gametocytocidal activity.52 However, though these are 
promising results, toxicity issues were found with this class of chemotype. It was later identified that 
toxicity was particularly observed with glucose-6-phosphate dehydrogenase deficient (G6PD) 
patients, who suffer from haemolytic anaemia if they take this drug.50–52  
 
Figure 1.5. Methylene blue (3), Pamaquine (4). 
It was believed that the basic side chain of pamaquine was important for compound efficacy, 
this led to the synthesis and discovery of Mepacrine (5) (Figure 1.6) by Bayer.41,48 Although not a 
quinoline this aminoacridine does share a similar structure and was found to be efficacious against 
the parasite, but showed no advantages over quinine in terms of safety and physiochemical profile.41,48 
Bayer therefore decided to remove the acridine portion of the core, re-utilising the quinoline core of 
quinine, leading to the development of potentially the most efficacious compound for the eradication 
of the parasite, chloroquine (6) (Figure 1.6).   
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Figure 1.6. Mepacrine (5), Chloroquine (6). 
6 was used extensively as the main treatment for malaria for the decades following World 
War II due to its high efficacy, low production cost, high scalability and low rates of major side effects. 
This made chloroquine the gold standard for antimalarial chemotherapy.41,42,48  
The mechanism of action of the 4-aminoquinoline / 4-aminoalcohol-quinoline template is 
believed to be the inhibition in the formation of hemozoin (10) (Figure 1.7). When the parasite is in 
the blood stage, it digests the protein portion of haemoglobin to obtain the essential amino acids it 
needs to survive and replicate. As a by-product, haem (7) is generated and can be autooxidised to a 
hematin monomer (8) both are toxic to the parasite. To circumvent the toxicity, the parasite dimerises 
7 or 8 to a hematin dimer (9) which is crystallised to a non-toxic form known as hemozoin (10) within 
the parasitic food vacuole.53–55 The 4-aminoquinoline drug class, is believed to complex with free 
haem, inhibiting the formation of haematin, and increasing the levels of toxic haem within the 
parasite, resulting in parasite death.54,56–64  
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Figure 1.7. Inhibition of hemozoin (10) formation by chloroquine (6).  
Unfortunately due to the over use of chloroquine (6), resistance to the drug developed in the 
late 1950s and early 1960s.65 This resulted in the loss of efficacy of the drug, and 6 is now no longer 
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recommended for treatment of P. falciparum.66 The generally accepted mechanism of resistance to 6 
involves a point mutation in the Plasmodium falciparum chloroquine resistance transporter (PfCRT) 
gene in which lysine76 is converted into threonine (K76T) in the protein chain.67–70 6 can exist in 
protonated and unprotonated forms at physiological pH, however, only the unprotonated form is 
membrane permeant. Upon administration, unprotonated 6 diffuses into the red blood cell, and then 
the parasite, before making its way to the parasite digestive vacuole.54 This vacuole is acidic and 
protonates one or both of the basic nitrogen atoms in 6, this removes the drugs ability to diffuse back 
out of the digestive vacuole, allowing for accumulation of the drug, here is where the drug binds to 
free haem, causing parasite death.62,63 The PfCRT is a transmembrane transporter protein found in the 
membrane of the digestive vacuole.54,67 In chloroquine-sensitive strains of P. falciparum, the K76 
amino acid residue is positively charged, which will repel the also positively charged chloroquine away 
from the transporter. In resistant strains, however, the mutation to T76 results in charge loss, allowing 
6 to associate with the transporter, which facilitates the removal of the drug out of the digestive 
vacuole.71–73 There have been efforts to develop chloroquine resistance reverser drugs, which has 
been successfully carried out in vitro. Common features of these compounds are two aromatic side 
chains believed to interact with the substrate binding site of PfCRT, and a basic amino-alkyl chain 
which after protonation, is thought to restore the positive charge that repels chloroquine away from 
the transporter.64  The mechanism of resistance is depicted in Figure 1.8.  
 
Figure 1.8. Chloroquine resistance transporter A) unmutated (chloroquine sensitive) B) mutated (chloroquine resistance) 
C) Chloroquine resistance reversed. 2HCQ2+ equals doubley protonated chloroquine 
To overcome this resistance problem, new 4-aminoquinoline candidates were developed. 
Modifying the alkyl chain to an aromatic linker led to the development of amodiaquine (11) in the late 
1940s, and it was discovered to be efficacious against chloroquine resistant strains in the early 
1950s.74–76 The main drawback of 11 is that its metabolites can show unacceptable levels of 
hepatoxicity in certain individuals (a proposed mechanism to hepatoxicty is depicted in Figure 1.9), 
this restricts its use as a prophylactic and treatment, however, it is still in use as part of an artemisinin 
combination therapy (ACT) with artesunate (46) (see Section 1.3.2.5).66,75–77  
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Figure 1.9. Amodiaquine (11) and its proposed route to heptoxicity via P450 oxidation to compound 12, followed by 
reaction with glutathione forming compound 13. 
In the 1960s a bis-4-aminoquinoline was developed which contains two quinoline cores, 
named piperaquine (14) (Figure 1.10).78 Despite being very effective against both chloroquine 
sensitive and resistant strains, resistance to this drug developed quickly, and new alternatives needed 
to be found.64,78 Though there is evidence of resistance, piperaquine is marketed as part of a 
combination therapy with dihydroartemisinin. 
 
Figure 1.10. Piperaquine (14). 
Mefloquine (15) (Figure 1.11) a 4-aminoalcohol-quinoline was discovered in the 1970s and 
due to urgent demand for new antimalarial chemotherapies; it was brought to market and 
administered without phase III trials. The drug, though carrying some health concerns, is currently still 
used as a treamtent option, as part of an ACT in combination with artesunate due to the drugs 
extensively long half-life.64,79–81 More recently in the 1990s ferroquine (16) (Figure 1.11) has been 
developed which contains a ferrocene moiety within the basic side chain of the 4-aminoquinoline 
structure. It is highly active against chloroquine resistant strains and is currently undergoing phase II 
clinical trials.64,82–85  In 2003, O’Neill et al. developed Isoquine (17) (Figure 1.11), a regioisomer of 11, 
in order to circumvent potential metabolism to a toxic quinone-imine.76 One of the N-ethyl groups 
was replaced with N-tBu, forming N-tBu-isoquine (18) (Figure 1.11), which displayed very good activity 
against chloroquine resistant strains, and entered phase I clinical trials.76,86 Unfortunately, the 
compound did not progress further as it showed no advantage over 11 in terms of safety during these 
trials.87 
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Figure 1.11. Mefloquine (15), ferroquine (16), isoquine (17), tBu-isoquine (18). 
After the success of pamaquine (4) against both liver and blood stages of the parasite, 
attention turned back to 8-aminoquinolines as a template for antimalarial candidate development. 
Simple removal of the ethyl groups of the terminal amine, resulted in the compound primaquine (19) 
(Figure 1.12).52 19 was discovered to be less toxic than 4, and possessed improved efficacy against the 
liver stage of the parasite, particularly for P. vivax.52,88 It is also effective against the blood stage of P. 
vivax, though interestingly, it is not effective for blood stage P. falciparum.52,89–91 However, it is 
outstanding in clearing gametocytes of P. vivax and P. falciparum in a single dose (between 0.25 mg / 
kg and 7.5 mg / kg in combination with an artemisinin based drug), therefore it is recommended as a 
prophylactic, especially in regions suffering from high P. vivax incidence.52,66,92 The downside to 19 is 
that it still toxic for G6PD deficient patients, causing hemolysis, and this population cannot take this 
drug.50,52,93,94 To date 19 is the only marketed antimalarial that is able to clear the dormant liver stage 
parasites for P. vivax.52 Another 8-aminoquinoline is currently undergoing phase III clinical trials, 
named tafenoquine (20) (Figure 1.12). 20, like 19 and 4 is efficacious in the treatment of the liver stage 
of P. vivax, it has the advantage of a better safety profile, longer half-life and thus the potential for 
single dose cure. Once again, however, G6PD patients cannot take this drug due to the potential to 
cause hemolysis.52,95–97  
 
Figure 1.12. Primaquine (19) (left), tafenoquine (20) (right). 
The exact mechanism of action of the 8-aminoquinoline template, is yet to be elucidated, at 
present 19 and likely 4, are believed to act as prodrugs.52 During metabolism, 19 can be oxidised at 
the 5-position of the quinoline ring, forming 5-hydroxy-primaquine (21), which is rapidly oxidised to 
the quinone-imine (22), before demethylation of the 6-OMe group forming 23 (Figure 1.13). This 
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compound could be responsible for its antimalarial activity, and likely the side effects associated with 
G6PD deficiency, but exactly how is still unknown, it should also be noted that other potentially active 
primaquine metabolites have been identified.52,98 In the case of tafenoquine (20), one could envisage 
that this active metabolite can still be formed, as 20 harbours an O-aryl linker at this 5-position.  
 
Figure 1.13. Routes to potential primaquine reactive metabolite(s). 
1.3.2.2 Antifolate inhibitors 
 Dihydrofolate (24) (Figure 1.14) and folate-derived compounds are important cofactors 
involved in the supply of one carbon subunits for the essential biosynthesis of methionine, serine, 
glycine, and also nucleic acids, where the latter, is also needed for the generation of DNA.99–102 Parasite 
growth and survival, is highly dependent on compound 24. Humans lack the biosynthesis pathways 
necessary for production of 24, and rely on folate intake from the diet.99,101,102 Malaria, however, does 
have the ability to synthesise 24, and it does so via the reaction of a phosphorylated pteridine 
compound (derived from a purine precursor) with para-aminobenzoate (PABA) to form 
dihydropteroate. L-glutamate is then coupled with dihydropteroate which completes the biosynthesis. 
Dihydropteroate synthase (DHPS) is the enzyme responsible for the coupling of PABA to the pteridine 
portion of the compound, and is an enzyme that humans lack, this makes it an attractive target for 
antimalarial therapeutics.99,101–103  
 24 itself is not biochemically active until it is reduced to tetrahydropteroate.101 5,10 
Methyltetrahydropteroate, is used in the biosynthesis of nucleotides, more specifically, it transfers a 
methyl group to deoxyuridine monophosphate (dUMP) forming deoxythymidine monophosphate 
(dTMP).99,101–103 This results in the formation of 24 which needs to be reduced back to 
tetrahydropteroate, this is done by the enzyme dihydrofolate reductase (DHFR).99,101–103 This enzyme 
is present in humans and malaria, however, the structural differences between the two enzymes 
means the malarial form can be targeted safely.104,105 It is also very sensitive to inhibition and so has 
been targeted for antimalarial drug development.101 Inhibition of this enzyme results in dTMP 
biosynthesis cessation, resulting in the failure of parasitic DNA synthesis.99–103 
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Figure 1.14. Dihydrofolate (24) structure.  
 Inhibitors targeting DHFR and DHPS enzymes are placed into different classes, for DHFR, 
inhibitors are termed class I, for DHPS, inhibitors are termed class II. The first inhibitor of DHFR (class 
I set) was proguanil (25) (Figure 1.15), discovered in the 1940s and demonstrated improved activity 
over quinine against avian malaria with an improved therapeutic index, which led to its use in 
humans.105,106 The mechanism of action of 25 was elucidated after it was found to be a prodrug.105,107 
The compound is metabolised to cycloguanil (26) (Figure 1.15), which contains a triazine moiety, which 
was confirmed to target DHFR.108 When used alone, this drug is recommended as a prophylactic, it 
can also be used as part of a combination based therapy, with chloroquine (6), or atovaquone (39).109–
112 The combination of atovaquone (39) with proguanil (25), is the only other method effective to clear 
parasites from the liver stage without the use of primaquine (19), however, this combination does not 
kill hypnozoites in the case of P. vivax and cannot be used to prevent relapsing malaria.109,113   
 
Figure 1.15. Proguanil (25) is metabolised to the active cycloguanil (26). 
 To optimise further the efficacy of 25, structural activity relationship studies were undertaken, 
which led to the identification of chlorproguanil (27) (Figure 1.16). Also a prodrug, it was simply 
developed by incorporation of an extra chlorine atom within the phenyl portion of the drug. 27 is more 
potent than 25, and has been used as part of a combination therapy with dapsone (29).105 
 
Figure 1.16. Chlorproguanil (27). 
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 Pyrimethamine (28) (Figure 1.17), a compound sharing structural similarity to 26, is a 2,4-
diaminopyrimidine. First discovered in the late 1940s, it was believed due to this structural similarity, 
that this class of compounds could also show efficacy against the parasite, and the folate 
pathway.105,114 This hypothesis indeed proved to be true, and 28 is one of the most widely used DHFR 
inhibitors. It is used in combination with sulfadoxine, providing potent antimalarial activity.105   
 
Figure 1.17. Pyrimethamine (28). 
 The class II set of inhibitors targeting DHPS, are mainly sulfa-drugs. These drugs compounds 
block the de novo synthesis of folate, which gained interest due to the parasite specificity of the DHPS 
enzyme. Unfortunately most of the drugs belonging to this class showed poor efficacy and high levels 
of toxicity, which ruled them out as a monotherapy.105 Fortuitously, however, it was observed that the 
compounds show a synergistic effect when taken as part of a combination with class I inhibitors, 
leading to the development of antifolate combination therapies.105  
 The first compound showing activity against DHPS was dapsone (29) (Figure 1.18) and it is the 
most potent compound to date.105 29 was first discovered in 1908 as a result for a search of molecules 
to produce azo dyes. However, it was not until the 1930s that its antimicrobial effects were observed, 
when Buttle et al. and Fourneau et al. explored its chemotherapeutic effect against numerous 
pathogens. They observed that 29 was able to suppress the growth of pathogens including 
mycobacteria and crucially the malaria parasite.105,115 It does possess high toxicity and development 
of the drug was halted.116,117 It can be taken as part of a combination therapy with pyrimethamine 
(28), marketed as Maloprim. It has also been used, as stated above as part of a combination with 
chloroproguanil (27).105  
 Pyrimethamine (28) has also been combined with sulfadoxine (30) (Figure 1.18), which 
demonstrates a long half-life >80 hours, marketed as Fansidar.118 Compared with Maloprim, Fansidar, 
shows a much better therapeutic window, as the half-life of dapsone (29) is approximately 24 hours, 
after this time, the drug synergy with pyrimethamine (28) begins to fall.119,120 Therefore, Fansidar has 
been much more widely used. 
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Figure 1.18. Dapsone (29), sulfadoxine (30). 
 Like the quinoline series of compounds, resistance has become a major issue concerning the 
efficacy of these drugs. A single point mutation in the DHFR enzyme at codon 108 serine (S) to 
asparagine (N) or threonine (T) (S108N/T) is sufficient in reducing efficacy of pyrimethamine (28) by 
100 fold.121–125  In order to circumvent the problem, novel antifolate inhibitors must be developed to 
address this issue.  
 A potential solution was found when the Walter Reed Army Institute of Research discovered 
WR99210 (31) (Figure 1.19), which showed good in vitro efficacy against pyrimethamine resistant 
strains with mutated DHFR. However, it suffered the drawback of having poor oral bioavailability, 
which gave hindered in vivo potency.126,127  Yuthavong et al. reasoned this could be due to the basicity 
of the triazine moiety in the drug, to test the hypothesis they synthesised P65 (32) (Figure 1.19), a less 
basic 2,4-diaminopyrimidine mimic of 31, which demonstrated improved oral bioavailability in rats, 
83 % vs  <1 %, and thus improved in vivo efficacy. Using structure based studies and X-ray 
crystallography; the group were able to develop a potent inhibitor of wild type, and 4-point mutated 
PfDHFR, with greater affinity for this enzyme, than the human isoform, named P218 (33) (Figure 1.19). 
This resulted in the molecule potentially possessing a good safety profile; at present this drug is in 
phase I clinical trials.127 
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1.3.2.3 Pyrimidine Biosynthesis Inhibitors 
 A closely related biosynthetic pathway to the folate pathway is the de novo biosynthesis of 
pyrimidines. The two pathways are linked via the enzyme thymidylate synthetase (TS), indeed TS is 
part of the bi-functional DHFR protein, also named DHFR-TS, a validated drug target.103,128 The 
biosynthesis pathway contains six linear, enzyme-catalysed steps, starting from biacarbonate, 
glutamine, and adenosine triphosphate, finishing with uridine monophosphate (UMP).103,129 The 
pathway though present in mammals can be targeted, as mammals have efficient pyrimidine salvage 
mechanisms to support DNA synthesis, whereas parasites have poor salvage ability.130,131  
 Whilst the first few enzymes of the pathway are poorly characterised, the fourth enzyme in 
the pathway dihydroorotate dehydrogenase (DHODH), responsible for the oxidation of 
dihydroorotate to orotate, has been of particular interest for small molecule inhibition.130,132–136 It has 
been demonstrated that human DHODH and malaria DHODH have different binding sites for the same 
inhibitor leflunomide, meaning that the enzyme can be potentially targeted specifically.137 Further to 
this, DHODH is linked to the electron transport chain in the malaria parasite by the ubiquinone co-
enzyme.136 The electron transport system is a validated target within the malaria parasite.103,134,137,138 
Thus it could be possible that inhibition of DHODH could show synergistic effects with both folate 
inhibitors, and electron transport inhibitors.     
 Numerous high-throughput screens (HTS) have been carried out and indeed inhibitors 
specifically targeting PfDHODH have been successfully identified. These include, Genz 667348 (34), 
MMV020439 (35), MM007571 (36), DSM1 (37) and DSM265 (38) (Figure 1.20).139–142 The most 
promising candidate came from the HTS that identified DSM1 (37), led by Phillips et al.140 37 had very 
good in vitro potency (PfDHODH IC50 47 ± 22 nM, Pf3D7 EC50 79 ± 45 nM) but its main drawback was 
its poor pharmacokinetic profile, and thus, poor in vivo potency.140 The group used structure-guided 
studies to optimise the molecule, which led to the development of DSM265.143 This shows excellent 
in vivo potency and DMPK properties, it is currently in phase IIa clinical trials and if successful the 
molecule will be the first chemotype targeting DHODH.144   
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Figure 1.20. Inhibitors of PfDHODH. 
1.3.2.4 Cytochrome bc1 Inhibitors 
 The cytochrome bc1 complex is used as part of the mitochondrial electron transport chain, a 
crucial part of the respiratory cycle (Figure 1.21). The complex is used to transport protons across the 
mitochondrial membrane, into the intermembrane space. It does this via the oxidation of two 
ubiquinol molecules to two ubiquinone molecules followed by reduction of one bound ubiquinone 
molecule to ubiquinol. The net result is 4 protons are transported into the intermembrane space, 
while 2 protons are gained from the mitochondrial matrix. As mentioned in the previous section, the 
electron transport chain and pyrimidine biosynthesis are linked together, cytochrome bc1 provides 
the required ubiquinone molecule for DHODH for orotate production.136  
Atovaquone (39) (Figure 1.22) a 2-hydroxynapthoquinone was the first commercially used bc1 
inhibitor. Discovered first in the 1980s it demonstrated efficacy against the parasite, and was one of 
the few quinones found stable to human microsomes.145 39 acts as a competitive inhibitor of ubiquinol 
at the bc1 complex.146 This results in two situations; first the electron transport chain is halted, as 
protons can no longer be passed into the mitochondrial intermembrane space, meaning that a proton 
gradient is no longer generated resulting in the loss of function of the ATP-synthase enzyme further 
down the chain.147 Second, a pool of ubiquinone is no longer generated for the enzyme DHODH, 
resulting in the loss of pyrimidine biosynthesis.148 The loss of mitochondrial function ultimately leads 
to parasite death.148–153 
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Figure 1.21. Simplified electron transport chain in malaria.  
Resistance to 39 as a monotherapy developed quickly, and can be attributed to the single 
point mutations of leucine 271 to valine (L271V), lysine 272 to arginine (K272R), isoleucine 258 to 
methionine (I258M), phenylalanine 267 to isoleucine (F267I), or tyrosine to serine / cysteine / 
asparagine (Y268S/C/N).64,149,154,155 This means that 39 is not recommended for use as a monotherapy 
or as a prophylaxis on its own, however, the same point mutation Y268/N has also emerged for 
malarone (atovaquone (39) / proguanil (25)).149,156 The result is a 1000 fold loss of activity for any single 
point mutation.154,157 
 
Figure 1.22. Atovaquone (39). 
The emergence of resistance to 39 has led to the development of novel drug molecules against 
the electron transport chain. ELQ-300 (40) (Figure 1.23), a quinolone-3-diarylether, has been 
developed by Nilsen et al. in 2013.147 It demonstrates good potency (PfDd2 IC50 2.2 nM) and is active 
against liver, blood, and sexual stages of P. falciparum and P. vivax. It selectively targets the bc1 
complex, and possesses good drug metabolism and pharmacokinetic (DMPK) properties, and despite 
poor aqueous solubility, it has good oral bioavailability in mice at efficacious doses (~100 % at 0.3 mg 
/ kg).147 Promisingly 40 shows synergy with 39, which could help slow the resistance problem.158 Whilst 
other enzymes of the electron transport chain have been targeted, nothing as of yet has reached 
clinical trials. At present ELQ-300 is the most promising lead, it was in preclinical development as of 
2015.159 
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Figure 1.23. ELQ-300 (40). 
The O’Neill group were successful in the synthesis of another inhibitor of the electron 
transport chain, however, this time the specific target was not bc1, instead it was NADH : ubiquinone 
reductase (PfNDH2), involved in ubiquinol production. After high-throughput screening and medicinal 
chemistry optimisation two potent inhibitors of the enzyme were discovered, CK-2-68 (41) and SL-2-
25 (42) (Figure 1.24). Both also showed potent antimalarial activity in vitro and in vivo, low toxicity and 
high metabolic stability. The drawback of the series was poor solubility of the compounds (<5 M at 
pH 7.4) and as such did not pass preclinical development stage.160,161 
 
Figure 1.24. CK-2-68 (41) and SL-2-25 (42). 
1.3.2.5 Artemisinins and Endoperoxides 
 Artemisinin (43) and its derivatives (44 – 46) (Figure 1.25), often combined with another agent, 
are currently the frontline therapies against the malaria parasite. Like quinine (2) before it, artemisinin 
(43) is also a natural product. The molecule has an unusual structure; it is a sesquiterpene lactone and 
possesses an endoperoxide bridge as part of a 1,2,4-triozane ring. It is this trioxane moiety that acts 
as the warhead for antiparasitic activity.41,162 43 is isolated from the leaves of the Chinese plant, 
Artemisia annua also known as sweet wormwood.4 For many years it was known that Artemisia annua 
leaves alleviated the symptoms of malaria, however, it was not until 1979 that the active compound 
was isolated and fully characterised.163 43 has demonstrated fast killing ability, via the destruction of 
the early-ring stages, which aids in the clearance of symptoms rapidly upon administration.164–167 43 
in its natural form, however, suffers with the issue of poor oral bioavailability, and fast metabolism to 
inactive forms of the drug, which called for efforts to generate semi-synthetic derivatives.168  
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 This led to the development of dihydroartemisinin (44) (DHA), which surprisingly, can be 
formed by reduction of the lactone to a lactol, without cleavage of the endoperoxide bridge when 
sodium borohydride is used as the reducing agent.169 Though 44 showed improved potency, it still 
showed poor DMPK properties in vivo.170 The hydroxy of the lactol was converted into its methoxy 
derivative, giving artemether (45), which demonstrated greater potency and stability, making it the 
most prescribed treatment from this class.41,169 Another derivative artesunate (46), was also 
developed which has enhanced water solubility. 46 is used for intravenous administration when oral 
administration is not possible, as can be the case with severe and cerebral malaria.41 Both 45, and 46 
are rapidly metabolised in the body to the active form of the drug DHA (44).169 
 
Figure 1.25. Artemisinin derivatives. Warhead highlighed in red. Artemisinin (43), dihydroartemisinin (44), artemeter 
(45), artesunate (46). 
 Despite the improvements to the DMPK properties with semi-synthetic derivatives, the 
artemisinin class still has a very short half-life in the body (15  –  60 minutes) and thus these 
compounds are normally administered as part of an artemisinin combination therapy (ACT).41,171 This 
in itself holds two advantages, first, the dual mode of action allows for complete parasite clearance, 
the artemisinin compound, quickly kills most of the parasites, whilst the remaining, are killed by the 
other therapy, which is usually a compound possessing a long half-life and separate mode of action. 
Second, the dual, or sometimes triple use of therapy, is more likely to delay or halt the spread of 
resistance, as it is unlikely that the parasite will develop resistance mechanisms to both compounds 
at the same time, if resistance develops to one therapy, the resistant parasites will likely be killed by 
the other. It is due to this intelligent approach to a problem, which has led to ACTs becoming the 
frontline treatment of malaria.172,173 ACTs are generally used for uncomplicated malaria, and are taken 
as part a of 3-day treatment regime vs 7 days as an artemisinin monotherapy. Even after 7 days, 
artemisinin monotherapy is known to cause recrudescence. The shorter ACT treatment regime not 
only aids in patient compliance to the treatment, but is also more likely to ensure complete parasite 
clearance.172 The most frequently used combinations are artemether-lumefantrine, artesunate-
amodiaquine, artesunate-mefloquine, and artesunate-sulfadoxine-pyrimethamine.174–177 
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 The success of the artemisinin class of antimalarials is substantial, however, like quinine (2), it 
suffers the drawback of isolation from the natural source, resulting in poor cost ineffectiveness.41 In 
addition to this, modifications to the structure are required to produce the efficacious semi-synthetic 
derivatives, further increasing costs. Attempts towards the total synthesis of 43 have been successfully 
carried out, but again, they are too complicated for commercial use.178–187 Like with quinine (2) this 
has driven the development of fully synthetic analogues of artemisinin (43).  
 The exact mode of action of the artemisinin class is still widely debated.162,188 It is generally 
accepted that it acts in a similar manner as chloroquine (6), blocking the formation of hemozoin 
(10).189 Free Fe2+ generated from haemoglobin degradation, reduces the endoperoxide bridge thereby 
activating artemisinin, forming an oxygen-centred radical before rearranging to carbon centred radical 
(47).190 These radicals have been shown to react with haem (7) directly forming (48) (Figure 1.26), 
which could block hemozoin (10) formation.189,191 Recently, using biological probes and click 
chemistry, it has been demonstrated that 43 has a number of potential targets, via the alkylation of 
molecular targets in the glycolytic, haemoglobin degradation, antioxidant defence and protein 
synthesis pathways.192,193 This therefore, could show that 43 has more than one mode of action. 
Although 43 and ACT resistance has emerged, this could be why it has not yet resulted in a failure of 
the drug, parasite desensitisation for now, can be overcome provided the partner drug remains 
effective, there is no evidence of full artemisinin resistance yet according to the WHO.194 
 
Figure 1.26. Haem adducts identified by mass spectrometry.191 
 The emergence of resistance and the need for cheaper derivatives of 43, led to Vennerstrom 
et al. to utilise the trioxolane warhead for SAR studies. They developed a symmetrical trioxolane (49), 
fused at both sides by cyclohexane rings. The compound was inactive in vivo and suffered a lack of 
stability. Replacement of the cyclohexyl rings to adamantane rings (50) increased the stability of the 
molecule, but was also inactive in vivo, whilst replacement of only one of the cyclohexyl ring to 
adamantane led to both a potent, stable compound 51 (Figure 1.27).195,196 
 Chapter 1: Introduction to Malaria and the Methyl Erythritol Phosphate (MEP) Pathway 
 23 
 
Figure 1.27. Vennestrom initial trioxolane SAR.195,196 
 To make the trioxolane series more drug-like, OZ277 (52) (Figure 1.28) was developed by 
Vennerstrom, which displayed improved DMPK properties.196,197 52 was the first synthetic peroxide to 
be used in the market, currently only on the Indian market as part of a three dose cure with 
piperaquine.198 OZ439 (53) (Figure 1.28) was developed with a much-improved half-life over 52, which 
gave the molecule hope for a single dose cure; it is currently in phase IIb clinical trials with the partner 
drug still to be determined.198 It is also being explored by the MMV in combination with ferroquine 
and is also in phase IIb clinical trials.199 53 crucially, has demonstrated efficacy against artemisinin 
resistant strains.200  
 
Figure 1.28. OZ277 (52) (left) and OZ439 (53) (right).198 
 O’Neill et al. have generated 1,2,4,5-tetraoxanes for potential use as antimalarial 
chemotherapy.201–203 The tetraoxane moiety can stabilise the O-O bond by the anomeric effect,204 and 
baring two peroxide bridges, the structure gives an opportunity for improved potency. The two most 
promising compounds to date are RKA182 (54) and E209 (55) (Figure 1.29), both of which show good 
potency against the parasite.201–203 54 had an extended half-life, good stability and maintained 
potency, but unfortunately was not able to deliver a single dose cure.201–203 55 is the next in 
development, which outperforms artesunate (46) with a 66 % cure rate at single oral doses of 30 mg 
/ kg. It demonstrates low nanomolar activity against chloroquine sensitive strains of P. falciparum.201 
 
Figure 1.29. RKA182 (54) (left) E209 (55) (right).201 
 
 
 Chapter 1: Introduction to Malaria and the Methyl Erythritol Phosphate (MEP) Pathway 
 24 
1.3.2.6 Selected Novel Targets in the Pipeline 
 The emergence of resistance to all current frontline therapies is a fundamental problem which 
could potentially derail all of the successful milestones antimalarial chemotherapy has accomplished 
to date. With the exception of DSM and DHODH inhibitors, all of the treatments acknowledged thus 
far, target the same clinically validated pathways through chemotype modification. This modification 
is usually a minor structural change that regains potency against drug resistant strains, the 4-
aminoquinoline compounds exemplifies this. As such, resistance commonly develops to the new 
treatments within a matter of years, or even months. 
 Medicinal chemists have looked for novel pathways within the parasite to circumvent this 
problem, targeting an as of yet untargeted enzyme / protein, is more likely to develop resistance 
slowly. These new compounds offer renewed hope for the future of antimalarial chemotherapy, which 
was under severe threat with the emergence of artemisinin resistant strains located along the Thai-
Cambodian border.205 
 Most of the current novel targets have been identified by whole cell high-throughput 
screening. A Novartis based screen identified imidazolopiperazines as an active chemotype against 
the parasite; the lead compound generated from information from this screen was KAF156 (56) (Figure 
1.30).206–208 It is a very effective compound, potentially delivering a radical cure, it is active across all 
stages of the Plasmodium life cycle and gives IC50 values of 6 nM against drug resistant blood stage 
parasites, furthermore it demonstrates a mouse in vivo ED50 of 0.6 mg / kg.207 As of yet the target of 
the drug is not fully known, but is believed to be a protein with unknown function and is known as 
Plasmodium falciparum cyclic amine resistance locus (PfCARL). This is thought to be the target as 
parasite resistance correlates with the accumulation of mutations in this protein. The compound has 
progressed to phase IIb clinical trials in combination with lumefantrine (MMV portfolio).200  
 
Figure 1.30. KAF156 (56).207 
 Like KAF156 (56), MMV390048 (57) (Figure 1.31) (also known as MMV048) has demonstrated 
efficacy across all stages of the Plasmodium life cycle. It was discovered from a HTS that elucidated 
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the template belonging to 3,5-diaryl-2-aminoquinoline possessed antimalarial activity.209 After SAR 
optimisation around the initial hit, the lead was discovered, with improved potency and a better DMPK 
profile, showing single oral dose cures of P.berghei at 30 mg / kg in the mouse model.209 At the time 
of discovery the target was unknown, however, recently it has been identified to target PI 4 kinase.210 
57 is currently entering phase IIa clinical trials (MMV portfolio). 
 
Figure 1.31. MMV048 (57).209 
 Another example of a novel chemotype in the pipeline is DDD107498 (58) (Figure 1.32) now 
renamed to DDD498. The hit molecule was also identified from a whole cell screen and belongs to 2,6 
disubstituted quinoline-4-carboxamide scaffold.211 It showed promising potency of 120 nM against the 
parasite. Optimisation of the template generated not only a 100-fold increase in potency for the lead, 
but also enhanced DMPK properties, this coupled with an estimated low cost of goods shows good 
promise for the future of this compound.211 The compound entered human trials in 2017 (MMV 
portfolio). The molecular target of 58 was found to be eEF2, responsible for mediating GTP-dependent 
translocation of the ribosome across mRNA, causing the ribosome to stall, which shuts down peptide 
synthesis.211 
 
Figure 1.32. DDD498 (58).211 
 Of the novel drug targets currently being addressed, perhaps the most exploited is the 
ATPase4 enzyme in the malaria parasite. Selected inhibitors include, but are not limited to, PA92 (59) 
(Figure 1.33), SJ733 (60) (Figure 1.33), and Cipargamin (63) previously KAE609 (Figure 1.34). ATPase4 
acts as a sodium transporter in the parasite, and inhibition of this, leads to lethal levels of Na+ building 
within the parasite causing parasite death.212 PA92 (59) belongs to the imidazole family possessing a 
aryl substituted pyrazole, bound to the imidazole by an amide linker, it is fast killing and demonstrates 
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good physiochemical properties,212,213 but suffers from a potential ames positive potential metabolite 
(MMV portolio). Currently it is in pre-clinical development. SJ733 (60) also is being pursued to be part 
of a single dose radical cure, and it too possesses good physiochemical properties, it is a novel 
chemotype that contains a dihydroisoquinalone core, the drawbacks are high cost of goods as it is a 
chiral molecule. Currently it is in phase I clinical trials.212,214  
 
Figure 1.33. PA92 (59) (left), SJ733 (60) (right).212–214  
The most successful compound to date inhibiting ATPase4 is Cipargamin (63) (Figure 1.34).215–
217 Developed by Novartis, it is a compound of noteworthy similarity to our hit chemotype discussed 
as part of this thesis. The molecule is a tetrahydro-β-carboline structure with a fused spiroindalone 
ring. The original hit (61) was identified from a HTS against the malaria parasite that showed efficacy 
against chloroquine resistant strains of the parasite.215–218 The 7 membered C ring of the hit from the 
screen was changed to a 6 membered ring (62), which improved activity. The compound, however, 
suffered from poor metabolic stability, to circumvent this, halogens were incorporated into the A ring 
of the tetrahydro-β-carboline, which not only solved the metabolism problem, it also led to improved 
potency.215–218 Since the lead compound (63) was discovered it has demonstrated an acceptable safety 
profile in humans and as a result has currently completed phase IIa clinical trials.215–218 
 
Figure 1.34. Route to the discovery of KAE609.216–218 
1.4 Isoprenoid Biosynthesis and the Methyl Erythritol Phosphate (MEP) Pathway 
The emergence of strains of Plasmodium falciparum that are resistant to frontline therapies 
is a threat to the efforts to eradicate the disease. Further to this, if widespread resistance occurs, the 
malaria burden will only be exacerbated and will likely lead to increased mortality rates worldwide.  
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To regain control, medicinal chemists are targeting novel pathways that are less likely to show 
resistance, with the ultimate aim of developing a candidate drug to be taken to market. The 
requirements for the novel drug candidate are; ideally single dose cure; low human toxicity, activity 
across all stages of the Plasmodium life cycle, and the ability to be taken as part of a combination 
therapy to hamper any potential resistance developing.219  
During the extensive research efforts to find druggable novel pathways within the parasite, 
the methyl erythritol phosphate (MEP) pathway has emerged as another potential target due to its 
parasite specificity over mammalian systems. The MEP pathway is responsible for the biosynthesis of 
crucial isoprenoid precursors; therefore the inhibition of precursor development provides a unique 
opportunity to chemically interrupt numerous biological pathways within the parasite which require 
isoprenoids to function. The MEP pathway presents another potential tool for the eradication of the 
parasite as interruption of isoprenoid biosynthesis can result in a loss of parasite viability.   
1.4.1 Isoprenoids 
 Isoprenoids are a diverse class of compounds that are essential natural products for all living 
organisms. The isoprenoid family consists of over 55,000 members; all of which are generated from 
the repeated head to tail (regular) or head to head / tail to tail (irregular) condensations of one or 
both of two precursors, isopentyl-pyrophosphate (IPP) (90) and dimethylallyl-pyrophosphate 
(DMAPP) (91).220–223 These condensations coupled with the incorporation of functional groups leads 
to the generation of many cyclic, acyclic, chiral, or achiral molecules all belonging to the isoprenoid 
family.221,224 Indeed isoprenoids show a large degree of structural diversity and are required for 
numerous biological processes including but not limited to, protein prenylation, protein degradation, 
apoptosis, transcription regulation, post translational modifications, cell wall biosynthesis, 
photosynthesis and regulation of the electron transport chain.221,225,226 Some examples of isoprenoid 
derived compounds include terpenes, sterols, ubiquinone, pigments (e.g. chlorophyll), cholesterol, 
hormones, and natural fragrances.225 The antimalarial drugs quinine (2) and artemisinin (43) are also 
biosynthesised from isoprenoid derived compounds.227–229    
 The IPP (90) and DMAPP (91) precursors are both generated biosynthetically within all living 
organisms; these 5 carbon isoprene units are responsible for the regulation and maintenance of many 
differing species specific biological processes and as such have gained interest from pharmaceutical 
industries.225 Until relatively recently, it was believed that the mevalonate (MVA) pathway was used 
exclusively by all organisms for the generation of 90 and 91. It was not until the 1990s when research 
by Rohmer and Arigoni independently discovered a completely distinct biosynthetic pathway named 
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the non-mevalonate pathway, alternatively known as the MEP pathway.230–232 A comparison between 
both pathways is depicted below (Figure 1.35).221  
 
Figure 1.35. Comparative pathways for the production of DMAPP and IPP. Left (red) MEP pathway, right (blue) MVA 
pathway. Enzymes are highlighted in purple, cofactors are highlighted in pink, leaving groups are highlighted in green, 
metals are highlighted in black.  
Once the MEP pathway was elucidated, efforts began to discover the distribution of the two 
independent pathways within living organisms.232 These studies demonstrated that humans, 
mammals, archaebacteria, fungi and some plants species synthesise 90 and 91 via the MVA pathway, 
whereas the MEP pathway is responsible for precursor synthesis in green algae, plant species, 
numerous pathogenic bacteria, eubacteria, and crucially apicomplexan protozoa including 
Plasmodium falciparum.232,233 Interestingly it has been demonstrated that in higher plants, both 
pathways are in operation together, with clear compartmentalisation; terpene and sterol production 
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occurs in the cytoplasm via the MVA pathway, whereas carotenoids and phytol are biosynthesised 
within plastid organelles via the MEP pathway.233,234   
1.5 The Methyl Erythritol Phosphate (MEP) Pathway 
1.5.1 Discovery 
Though the MEP pathway was discovered within the last two decades, evidence for its 
existence dates back to the 1960s when it was observed that maize seedling-feeding experiments with 
14C radiolabelled CO2 and MVA led to distinct labelling in specific terpenes. When labelled 14C CO2 is 
used alone, β-carotene and phytol where heavily labelled with 14C whereas sterols and β-amyrin and 
the prenyl side chain of mitochondrial ubiquinone are only slightly labelled. Inversely when 14C 
radiolabelled MVA (68) is used, sterols, β-amyrin and ubiquinone are heavily radiolabelled, whilst β-
carotene and phytol are not. Whilst this was not direct evidence of an alternate pathway it did indicate 
that plastidic isoprenoids are synthesised within the chloroplast whereas sterols are synthesised 
outside of the chloroplast.235,236 To explain this result it was proposed that, first; 68 may not be able 
to penetrate the chloroplast effectively, explaining why radiolabelled 68 preferentially led to 
cytoplasmic sterols and second; that IPP (90) and DMAPP (91) biosynthesis was segregated into 
plastid, mitochondrial, and cytoplasmic compartments.235–237 
Further inconsistencies from the MVA pathway arose when it was demonstrated that the 
fungal metabolite mevinolin, a highly potent and specific inhibitor of the MVA pathway enzyme (S)-3-
hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGR), was used against radish species.238 As 
expected, the cytoplasmic sterol biosynthesis was inhibited, but curiously chloroplast derived 
terpenes were not. Again a possible explanation is that mevinolin could not penetrate the chloroplast 
effectively, thus no mevinolin could reach the potential HMGR enzyme in the chloroplast.237,238 
Another explanation was that chloroplasts do not use 68 for isoprenoid biosynthesis, but at the time 
no evidence existed to support this. With regards to mitochondrial ubiquinone, it was demonstrated 
that mevinolin also led to a reduction of total ubiquinone, and showed that its biosynthesis seemed 
to be reliant on the biosynthesis of IPP (90) from the cytoplasm, which is in contrast to chloroplast 
derived terpenes. Another curiosity is that no HMGR enzyme had ever been isolated from purified 
chloroplasts.237,239 Following a similar experiment, further inconsistencies with the MVA pathway were 
found when addition of mevinolin also did not inhibit the growth of E. coli, which is devoid of 
chloroplasts, but mevinolin completely inhibited H. halobium growth.240  
 The identification of the alternative pathway began to be uncovered when work on the 
biosynthesis of bacterial hopanoids using C1 and C2 13C labelled acetate by Flesch and Rohmer again 
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found inconsistencies from the classical pathway.241  Using C1 labelled acetate led to unexpected 
labelling of numerous positions within the hopanoid skeleton with 13C. With C1 labelled acetate it is 
expected that two of the carbons in the isoprenic units contain 13C if the MVA pathway is followed 
directly (Path A Figure 1.36, compounds 72 and 73). Based on the retrosynthetic analysis of what was 
observed, only one carbon was labelled per isoprenic unit (Path B Figure 1.36, compounds 74 and 
75).241  
 
Figure 1.36. Labelling of hapanoid skeleton and retrosynthesis to IPP. A. Expected 13C labelling patterns. B. Observed 13C 
labelling patterns. 13C labels are depicted as red spheres.241   
It appeared at first glance that MVA (68) had been biosynthesised by an unlabelled pool of 
acetoacetate, and by one molecule of 2C 13C acetate, which had been interconverted with respect to 
the starting 1C 13C acetate, this interconversion can be achieved via the glyoxylate / tricarboxylic acid 
cycles (G / TCA cycles), gluconeogenesis and glucose metabolism via the Entner-Doudoroff (ED) 
pathway (these pathways will not be discussed in the scope of this thesis).241 However, further studies 
using labelled glucose (64), pyruvate (77) and erythrose later uncovered that the isoprenic units of 
hopanoids and the prenyl side chains of ubiquinones still did not appear to follow the expected 
labelling patterns from an MVA pathway.237,242  
It was identified that labelling patterns of a novel biosynthesis matched for numerous 
bacterium species including, Alicyclobacillus acidocaldarius, Escherichia coli, Methylobacterium 
fujisawaense, Methylobacterium organophilium, Rhodopseudomonas acidophila, Rhodopseudomonas 
palustris and Zymomonas mobilis. The incorporation of labelled glucose (64), acetate, pyruvate (77) 
and erythrose precursors into isoprenoids led to the identification of two new starting molecules; one 
possessing a two-carbon unit, and another possessing a three-carbon unit. The two-carbon unit was 
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identified to be derived from pyruvate (77) and the three-carbon unit was identified to be 
glyceraldehyde-3-phosphate (GAP) (80).231,232,234,242  
The initial clues into the identity of the novel substrates came using labelled 13C glucose (64) 
as a sole feeding source for the bacterium Z. mobilis. Glucose (64) is metabolised to pyruvate (77) and 
GAP (80) by the ED pathway, but in Z. mobilis pyruvate (77) is not converted into GAP (80).232,243 This 
meant that labelling glucose (64) at each of its positions allowed determination of the GAP fragment, 
which must arise from the C4, C5, and C6 positions of glucose (64). It was clear from the labelling 
studies that the C1, C2 and C4 atoms of the isoprenic units came from GAP (80) corresponding to 
labelling positions C4 – 6 in glucose (64). In Z. mobilis pyruvate (77) is obtained equally by the 
metabolism of glucose (64) from either C1 – 3 positions, or C4 – 6 positions after further GAP (80) 
metabolism. Labelling the C2 / C5 position or C3 / C6 position of glucose (64) resulted in the respective 
labelling of positions C3 and C5 of the isoprenic units corresponding to the metabolism of GAP (80) to 
pyruvate (77). Finally labelling positions C1 and C4 of glucose (64) only leads labelling of position 4 of 
the isoprenic unit, which indicated that a decarboxylation of pyruvate (77) occurs, followed by 
condensation to the 3 carbon triose unit of GAP (80), this can be rationalised as C1 labelling will always 
be lost as CO2 (Figure 1.37).231,232,234,242    
 
Figure 1.37. Labelling studies with Z. mobilis. A. Z. mobilis glucose metabolism, atom numbers are shown for clarity. B. 
Observed hopanoid labelling with glucose labelled at each respective position, singular isoprene building blocks rather 
than the hopanoid skeleton are shown for clarity. Labels arising from direct incorporation of pyruvate fragment (C2 and 
3 from glucose) are shown in red, labels arising from GAP fragment directly (C4-6 in glucose) are shown in blue, labels 
arising from pyruvate after further GAP metabolism are shown in purple (C5 and 6 in glucose). C. Expected labelling of 
IPP if MVA pathway is followed directly, labelled 1C acetate is shown in green, labelled 2C acetate is shown in yellow.       
It was proposed that decarboxylation of pyruvate followed by condensation with GAP (80) led 
to the formation of 1-deoxyxyluslose 5-phosphate (DXP) (81) and was thiamine diphosphate (ThDP) 
(78) dependent (Figure 1.38). This then yielded another curiosity, the same labelling studies identified 
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that the C1, C2, and C4 positions of IPP where derived from GAP (80), whilst positions C3 and C5 where 
derived from pyruvate (77), this led to the conclusion that a rearrangement must occur after DXP (81) 
formation (Figure 1.38).231,242 From this it was discovered that the complete MEP pathway occurs via 
a 7 step enzyme sequence which at no point forms MVA (68) as an intermediate. All 7 enzymes 
involved in the pathway have been isolated and their functions are known, although the exact 
mechanism by which some enzymes carry out their substrate transformations remains a topic of 
debate. 
 
Figure 1.38. Proposed formation and rearrangement of DXP (81). 
1.5.2 1-Deoxy-D-xylose 5-phosphate synthase (DXS) 
DXS was the first enzyme of the MEP pathway discovered after the thiamine diphosphate 
(ThDP) (78) dependent reaction of pyruvate (77) with GAP (80) was uncovered.233,242 The E. coli 
genome was examined for enzymes by searching for reactions involving the decarboxylation of 
pyruvate (77) with ThDP (78) dependence; eventually an enzyme was found that could accept 77, 78 
and 80 as substrates, which also converted the substrates to DXP (81).244 
 
Figure 1.39. ThDP dependent formation of DXP (81). 
The mechanism by which the enzyme acts is via an acyloin condensation. ThDP (78) is first 
activated via deprotonation of the C2 carbon atom forming a reactive ylide. Deprotonation is believed 
to occur either by, the N4 nitrogen of the aminopyrimidine ring, or by glutamate and arginine side 
chains (for E. coli) within the enzyme active site. The ylide can then attack the ketone group of 
pyruvate after substrate binding. The resulting iminium moiety then acts as an electron acceptor for 
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the decarboxylation step. This results in an enamine (79) that can then attack the aldehyde of GAP 
(80). A final deprotonation releases the ThDP ylide and results in the formation of deoxyxyulose 5-
phosphate (DXP) (81) (Figure 1.39).244–246 
1.5.3 1-Deoxy-D-xylose 5-phosphate reductisomerase (IspC) 
 After the formation of DXP (81) it was postulated that a rearrangement must occur due to the 
apparent migration of one of the carbons coming from the GAP unit en-route to the isoprenic building 
blocks.231,242 It was believed that this rearrangement started from 81 as 2-C-methyl-D-erythritol-2,4-
cyclodiphosphate (cMEPP) (88) had been identified in bacterial species and could be derived from 2-
C-methyl-D-erythritol-4-phosphate (MEP) (85).232,247,248 Therefore the formation of 85 was 
hypothesised to occur by the rearrangement and reduction of 81. The enzyme responsible for the 
transformation was elucidated after observed incorporation of 2H-labelled 2-C-methyl-D-erythritol 
(ME) into E. coli ubiquinone.249 Research led by Seto et al. created E. coli K-12 mutants auxotrophic for 
MEP.250 Transformation of these mutants with a genome fragment library of the same E. coli strain 
identified that the expression of the gene yaeM was able to rescue the E. coli mutants that were 
auxotrophic. The protein adduct created by this gene was isolated and demonstrated that it could 
catalyse the intramolecular rearrangement of 81 to 2-C-methyl-D-erythrose-4-phosphate (84) before 
reduction to MEP (85) which is dependent on NADPH as a cofactor. The enzyme was later named 1-
deoxy-D-xylose 5-phosphate reductisomerase or IspC.250  
 The enzyme has a sequential reaction mechanism, first the NADPH co-factor, along with a 
divalent metal co-factor  bind in the active site causing a conformational change on the protein that 
allows binding of DXP (81).251 The isomerisation of 81 is then undertaken, however, the exact 
mechanism by which this is carried out is not fully understood; at present two mechanisms have been 
hypothesised.  
The first hypothesised mechanism for the isomerisation of 81 is an α-ketol rearrangement 
which occurs by migration of the C3 – C4 bond onto the ketone of 81, forming 2-C-methyl-D-erythrose-
4-phosphate (84) (Figure 1.40). This rearrangement is thought to be mediated by protonation or 
coordination of the ketone group to the divalent metal cofactor allowing build-up of positive charge 
on the C2 atom of 81.251 The second hypothesised mechanism is a retro-aldol / aldol condensation. 
Deprotonation of the C4 hydroxyl group of 81 and retro-aldol cleavage of C3 – C4 bond yields 
hydroxyacetone enolate (82) and phosphoglycolaldehyde (83). An aldol condensation can then occur 
forming 84.251 Though it has not yet been proven which mechanism is in operation, it is generally 
believed that the α-ketol rearrangement is the likely mode of action of the enzyme, due to the difficult 
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requirements of substrate containment if the retro-aldol mechanism is followed.252 It should be noted, 
however, that kinetic isotope effects support the retro-aldo proposal, but curiously the enzyme cannot 
accept 82 or 83 as exogenous substrates and cannot convert them to 84.251–254 84 is finally reduced by 
the NADPH cofactor, releasing MEP (85) as the product, and NADP+ as a by-product (Figure 1.40).  
 
Figure 1.40. Proposed mechanisms for the formation of MEP (85). 
1.5.4 2-C-methyl-D-erythritol-4-phosphate cytidyltransferase (IspD) 
 Plasmodium falciparum 2-C-methyl-d-erythritol-4-phosphate cytidyltransferase (IspD) is the 
main focus of the work described within this thesis, it has been less extensively examined than IspC, 
but has had over 20 reported crystal structures solved.255 A structure for Plasmodium falciparum, 
however, has not yet been elucidated. The first IspD enzyme was discovered from E. coli quickly after 
the identification of IspC. C2 14C radiolabelled MEP (85) was added to E. coli cell extracts and a new 
radioactive product was observed, after NMR spectroscopy the product was identified to be 4-
diphosphocytidyl-2-C-methyl-D-erythritol (CDPME) (86).256 The addition of a cytidine-5-
monophosphate (CMP) moiety to MEP (85) pointed towards the existence of a cytidyltransferase 
enzyme using cytidine-5-triphosphate (CTP) as substrate. CTP is not commonly found as a substrate 
and cofactor in comparison to adenosine triphosphate (ATP) and guanosine triphosphate (GTP), this 
coupled with the unusual MEP (85) substrate makes this enzyme particularly attractive to target for 
small molecule inhibition. The gene ygbP was discovered to be responsible for the production of the 
resulting IspD enzyme after a database search for enzymes responsible for the transfer of CTP onto 
another molecule with loss of pyrophosphate as a by-product.256 Seto et al. also identified the ygbP 
gene by blocking the conversion of 85 in E. coli. After identification and expression of the gene 
followed by purification of the resultant enzyme, they showed that the enzyme converted MEP (85) 
into CDPME (86) in the presence of CTP (Figure 1.41).257  
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 Catalytic activity was found to depend on the presence of a divalent metal ion, predominantly 
Mg2+.257 Like IspC the enzymatic mechanism occurs sequentially. First a divalent metal ion coordinates, 
this is followed by CTP and then MEP coordinates last.258 Both CTP and MEP are bound by hydrogen 
bonding and ionic interactions, CTP is bound via a glycine-rich loop, the α and γ-phosphate groups of 
CTP are hydrogen bonded with the enzyme. The divalent metal ion is coordinated by all of the 
phosphate groups from both substrates. The exact mechanism of phosphate attack for IspD has not 
been determined, and there are numerous mechanisms by which the phosphate of MEP could attack 
the α-phosphate of CTP.259–261 It has been proposed in the literature that attack of the phosphate of 
85 onto the α-phosphate of CTP follows an associative in-line mechanism, this is proposed to form a 
negatively charged pentacoordinate transition state which is stabilised by positively charged lysine 
and arginine residues, along with the metal ion within the enzyme active site.221,255,258,262 
 
Figure 1.41. Formation of CDPME (86). 
 The IspD structure is similar to other cytidyltranferases, it exists as a homodimer with the 
monomer units existing as a single domain which adopts an α / β fold conformation.258,262 This domain 
is connected to a subdomain known as the β arm of the protein, the two monomer β arms associate 
to form the dimer interface and is the location of active site, the interface is solvent exposed.258,263 
The E. coli IspD crystal structure with bound CDPME and Mg2+ is depicted below (Figure 1.42).262  
 
Figure 1.42. E. coli IspD crystal structure (PDB code: 1INI).262 Protein rendered as white cartoon CDPME is coloured by 
element, yellow for carbon, red for oxygen, blue for nitrogen, and orange for phosphorous. Mg2+ is depicted as a green 
sphere. Image created in Pymol.264 
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1.5.5 4-Diphosphocytidyl-2-C-methyl-D-erythritol kinase (IspE) 
 The IspE enzyme is an ATP dependent member of the galacto-homoserine-mevalonate-
phosphomevalonte kinase (GHMP) family.255  It was discovered after the observation that the E. coli 
ychB gene followed the same pattern of occurrence as other genes that were possessed by organisms 
possessing other MEP pathway genes.221 Expression of this gene followed by testing the enzyme in the 
presence of ATP and 2C 14C radiolabelled CDPME (86) led to the formation of 4-diphosphocytidyl-2-C-
methyl-D-erythritol-2-phosphate CDPMEP (87) (Figure 1.43).265 Using a genetic engineering approach 
the same gene was identified by generating E. coli mutants deficient in biosynthetic steps from MEP 
(85) to IPP (90).266  
 The mechanism of the reaction has not been fully elucidated, but is proposed to be similar to 
that of IspD and other enzyme catalysed phospho-group transfers.267–270 The C-2 hydroxyl group is 
deprotonated before nucleophilic attack on the ATP γ-phosphate group to yield the product 87 and 
ADP as a by-product.221,270–272 Again the catalytic mechanism is believed to be sequential where the 
substrate binds first, followed by the cofactor.221,273 The C-2 hydroxyl group is believed to be 
deprotonated by highly conserved aspartate and lysine residues after forming hydrogen bonds with 
them. It is postulated that the lysine residue is responsible for the stabilisation of negative charge 
build up in the transition state.221,270–272 Although a divalent metal cation has been shown to be crucial 
for activity of this enzyme, no crystal structure to date has been isolated with this metal bound.221  
 
Figure 1.43. Formation of CDPMEP (87).  
1.5.6 2-C-methyl-D-erythritol-2,4-cyclodiphosphate synthase (IspF) 
 IspF was discovered alongside the IspD enzyme as the ygbP gene belonging to IspD was 
coupled with the ygbB.256 The ygbB gene was identified as a likely MEP pathway enzyme as it was 
distributed along all other MEP gene containing organisms. After the gene was expressed in E. coli, 
and the enzyme isolated and purified, IspF was found to convert CDPMEP (87) into the corresponding 
cMEPP (88) (Figure 1.44).274 The structure of cMEPP had already been elucidated in numerous 
bacterial species confirming cMEPP as an intermediate within the MEP pathway. 
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 The catalytic mechanism is dependent on two divalent metal cations in order to proceed, a 
Zn2+ metal ion coordinates to the β-phosphate, polarising it, promoting attack by the C-2 phosphate. 
Another metal cation either Mg2+ or Mn2+ help align the substrate and stabilise the build-up of negative 
charge before ring closure to the product (88) and loss of CMP.275–277 
 
Figure 1.44. Formation of cMEPP (88).  
1.5.7 4-Hydroxy-3-methyl-2-(E)-butenyl-4-diphosphate synthase (IspG) 
 The penultimate step of the MEP involves the conversation of cMEPP (88) into 4-hydroxy-3-
methyl-2-(E)-butenyl-4-diphosphate (HMBPP) (89) (Figure 1.45). Again this distribution of the gene 
gcpE encoding for the enzyme was found in organisms possessing other MEP pathway genes, and led 
to the belief this was another gene involved in the MEP pathway.278–280 13C labelled experiments with 
DXP (81) and overexpression of all current MEP genes and gcpE led to the identification of HMBPP 
(89) by NMR.281 The enzyme corresponding to the gene was isolated and named IspG. The IspG enzyme 
in isolated form unexpectedly demonstrated poor activity, it was later elucidated that the enzyme 
likely possessed an [4Fe-4S]2+ cluster, which is sensitive to air.282 Protein purification in oxygen free 
conditions followed by activity studies led to the improved activity of the enzyme, whose role is the 
reductive dehydroxylation of cMEPP (88) into HMGPP (89).283,284 Similar to IspC, the reaction 
mechanism of the IspG enzyme remains a matter of debate. Differing mechanisms have proposed the 
involvement of radical, carbocation, and carbanion intermediates.285 The current accepted mechanism 
is complicated and is discussed elsewhere.286–289  
 
Figure 1.45. Formation of HMGPP (89). 
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1.5.8 4-Hydroxy-3-methyl-2-(E)-butenyl-4-diphosphate reductase (IspH) 
 The final step of the MEP pathway requires another reductive dehydroxylation reaction 
resulting in the formation of IPP (90) or DMAPP (91). The gene encoding for the final enzyme was lytB, 
and again this gene was believed to be involved in the MEP pathway after it was identified in organisms 
possessing other MEP pathway genes.290 Adding insertions into the gene led to death in 
cyanobacterium, and also led to changes in the observed ratio of 90 and 91.291 In E. coli disruption of 
the gene also led to cell death.292 Confirmation of the enzyme function was elucidated using 13C 
labelled deoxyxyulose, the enzyme was found to convert 89 to both 90 and 91 in a ratio of 5 : 1 and 
the enzyme named IspH.293 Similar to IspG, activity studies on IspH in air led to poor activity suggesting 
another [4Fe-4S]2+ cluster, this was confirmed upon repeating the isolation and studies in oxygen free 
conditions, and using EPR.294–297  
 Again similar to IspG the enzymes mechanism for the conversion of HMBPP (89) to the 
products 90 and 91 (Figure 1.46) was complex and is a matter of debate. Proposed intermediates 
within the mechanism included radical, carbocation, carbanion, and ferraoxetane structures, but none 
could be identified definitively.285,294–296 Isotopic labelling studies have aided a proposed mechanism 
which is described elsewhere.298–300  
 
Figure 1.46. Formation of IPP (90) and DMAPP (91). 
1.6 Targeting the MEP Pathway 
 The P. falciparum parasite belongs to a group of organisms of the phylum Apicomplexa, which 
can be identified by the existence of an additional plastid organelle known as the apicoplast.301 The 
apicoplast is a relict plastid organelle; its heritage is similar to that of chloroplasts and mitochondria, 
as it contains its own unique DNA sequence. This plastid is derived from a secondary endosymbiotic 
origin; it was derived first from the invasion of a eukaryotic cell by a cyanobacterium, this was was 
subsequently engulfed by a second eukaryotic cell which preserved the first cell as a plastid.302 A 
unique feature of the apicoplast is that it contains four cell membranes, and though derived from 
photosynthetic origin, has lost the ability to photosynthesise.302  
 The exact functions of the apicoplast within the malaria parasite are not fully known, however, 
it has been identified that the MEP pathway is localised within this organelle along with all of the 
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pathways constituent enzymes.303,304 Interestingly the enzymes are not encoded by the apicoplast 
DNA, rather encoded by the parasite nucleus and then transported to the apicoplast where they carry 
out their function.273 The biosynthesis of isoprenoids by the apicoplast is in operation during 
intraerythrocytic stage of the parasite and is essential for parasite survival.305 Other known functions 
of the apicoplast include type II fatty acid biosynthesis and de novo haem biosynthesis, however, in 
contrast to the MEP pathway, these functions are essential to parasite survival at the mosquito and 
liver stages.303,306 These plastid specific functions make the apicoplast an interesting organelle for drug 
development, indeed the antibiotic tetracycline which can be used for antimalarial chemotherapy is 
known to target the apicoplast, validating it as a drug target.307 Further to this the MEP pathway has 
also been validated as a potential target for antimalarial chemotherapy since the discovery that 
fosmidomycin (92) (Figure 1.47) inhibits the second enzyme in the pathway IspC. 
 The MEP pathway is gaining interest for chemical interruption due to its parasite specificity 
over human hosts.305 The pathway has been genetically validated in numerous organisms and is 
already being explored for the development of treatments of numerous antimicrobial diseases 
including malaria and tuberculosis.255,308,309 Further to this the phylogenic exclusivity of the pathway 
to these organisms raises the potential to avoid unwanted drug side effects via inhibition of human 
isoprenoid biosynthesis, through the selective inhibition of the enzymes belonging to the pathway.  
 The seven steps belonging to the MEP pathway are all linear and each enzyme is highly 
substrate specific generating a specific product for the next enzyme. Chemical interruption of any of 
the enzymes should prove fatal to the parasite, as each specific step is fundamental for the 
continuation of the pathway and thus the de novo biosynthesis of isoprenoids.273,310 To date there is 
no known alternate pathway for the generation of the intermediates of the MEP pathway in the 
malaria parasite. Though should they exist, an argument can be made to target the earlier stages of 
the pathway to avoid these problems, furthermore due to the linearity of the pathway, targeting 
earlier stages could lead to higher levels of parasite death. 
 The exact requirement for isoprenoids in malaria has not yet been fully elucidated due to the 
complexity of the parasite and its scavenging capabilities.310 For example the parasite cannot 
synthesise certain isoprenoids, such as sterols and cholesterol, instead it requires uptake of these 
compounds from the host cells.311 Thus inhibiting the MEP pathway will have no effect of sterol 
regulation. However, other isoprenoids have been identified that are synthesised de novo by the 
parasite due to the lack of scavenger pathways and have functions that are essential for parasite 
survival. These include, first; ubiquinone, which is synthesised de novo within the parasitic 
mitochondria and is reliant on the synthesis of IPP (90) and DMAPP (91). Ubiquinone is required for 
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the function of the DHODH enzyme discussed in Section 1.3.2.3 and interruption of this causes 
cessation of pyrimidine biosynthesis.310 Second; protein prenylation, a post-translational modification 
of proteins which is responsible for protein-protein interactions and is required for numerous 
processes such as DNA replication.312 Third; carotenoids, which are thought to function as antioxidants 
in the parasite,313 and fourth; the biosynthesis of dolicol, which is required for N-linked glycoslation 
and is essential for intraerythrocytic parasitic development.313 The disruption in the available pool of 
90 and 91 could potentially show fallout for all of the above mentioned pathways and therefore result 
in unrecoverable parasite death. 
To summarise, the MEP pathway has emerged as a novel chemotherapeutic target for the 
development of new antimalarial drug therapies. The pathway is parasite specific with the constituent 
enzymes possessing a differing evolutionary background; this gives a unique opportunity to interrupt 
the biosynthesis of IPP (90) and DMAPP (91) without the issue of interrupting host biosynthesis due 
to the existence of an entirely distinct pathway, potentially circumventing toxicity issues. The pathway 
has been validated as a viable target since the identification of fosmidomycin (92) (Figure 1.47) as an 
efficacious inhibitor of the IspC enzyme (Section 1.6.1). It is a completely linear pathway with all seven 
of the enzymes having the potential to be targeted for small molecule inhibition, and due to its 
exclusivity, novel combination therapeutics could target numerous enzymes in the pathway in order 
to ensure complete parasitic clearance. The remainder of the chapter will give an overview of known 
inhibitors of IspC, known inhibitors of IspD and introduce our line of work on the IspD enzyme. 
1.6.1 Inhibitors of IspC 
 IspC is the most extensively studied enzyme of the MEP pathway, this can in part be attributed 
to the discovery that fosmidiomycin (92) is a potent inhibitor of P. falciparum and E. coli IspC (Figure 
1.47).314 Despite the discovery of 92 and the numerous available crystal structures of IspC, the rational 
development of novel inhibitors is difficult, owing to the conformational change of the enzyme upon 
substrate or inhibitor binding.315 Due to the flexibility of the active site, some inhibitors based on the 
fosmidomycin scaffold are hypothesised to possess a reversed binding mode in comparison to 92 
itself, further complicating the target based design of inhibitors.316  
 
Figure 1.47. Fosmidomycin (92).304,314,317 
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 92 is a natural product isolated from Streptomyces lavendulae and was first identified in the 
1980s, after which it was initially used as an antibiotic agent. It was later discovered to act as a 
substrate mimic of DXS in vitro against IspC where it acts as a competitive inhibitor.318 92 showed good 
promise during the early activity studies of the compound, demonstrating the ability to cure rodent 
malaria P. vinckei in mice and also demonstrated activity against multidrug resistant P. falciparum 
strains.304 Both fosmidomycin (92) and its closely related acetyl analogue FR-900098 (93) (isolated 
from S. rubellomurinus) (Figure 1.48) have demonstrated high potency in the inhibition of the Dd2 
strain of P. falciparum growth in vitro, with IC50 values of 290 ± 130 nM and 90 ± 20 nM, respectively.304 
Fosmidomycin (92) demonstrates an excellent safety profile with a half maximal lethal dose (LD50) 
concentration of 11,000 mgkg-1 in mice.319 This impressive result confirms the MEP pathway can be 
selectively and safely targeted over the MVA pathway in mammals. Despite these promising activities 
the two drug molecules cannot be taken as part of a single dose regimen, they are highly polar, water 
soluble molecules. This results in a sub-optimal pharmacokinetic profile, showing in a poor in vivo half-
life, poor oral bioavailability, rapid clearance from the parasite and high recrudescence rates.320 
Although fosmidomycin (92) is also a potent inhibitor of M. tuberculosis IspC in vitro it demonstrates 
little activity in the cellular assay, likely due to the inability of the drug to pass through the bacterial 
cell wall.315 92 progressed to clinical trials with clindamycin (94) (Figure 1.48) as a combination therapy 
in 2004, but was halted due to the lack of efficacy in children under the age of three coupled with high 
recrudescence rates.321 It is currently in phase II clinical trials with piperaquine (14) as part of another 
combination therapy.322      
 
Figure 1.48. FR900098 (93) and clindamycin (94).304,317 
 Most of the inhibitors of IspC to date are based around the fosmidomycin scaffold, with 
attempts focused on boosting the lipophilicity to obtain better in vivo and pharmacokinetic profiles. 
Attempts have been made to replace the hydroxamate moiety of fosmidomycin (92) despite knowing 
that this functional group is required for strong cation binding in the active site.317 However, the 
hydoxamate group can be rapidly metabolised in vivo either by hydrolysis, glucuronidation or 
sulfonation.315 To date, replacement of either the hydroxamate, replacement of the phosphonate 
 Chapter 1: Introduction to Malaria and the Methyl Erythritol Phosphate (MEP) Pathway 
 42 
group or modifications to the carbon backbone have mainly resulted in diminished metabolic stability 
or a loss of affinity.323–325 
 Promisingly a series of α-aryl substituents led to the development of 95 (Figure 1.49) with 
antimalarial potency greater than that of 92 against PfDd2.326 Reverse fosmidomycin derivatives have 
also been synthesised which contain a hydroxamic acid moiety as the core.327 Of these derivatives 
those possessing an aryl substituent α to the phosphate drove the development of 96 (Figure 1.49) 
which is a highly potent antimalarial compound that also possesses good activity against E. coli.327 
Research by Deng et al.  identified a non-fosmidomycin like scaffold which displayed moderate activity 
against E. coli IspC. The novel chemotype is an aryl-substituted hydroxy-pyridinone scaffold 97 (Figure 
1.49), the same group also identified a similar scaffold compound 98, which displayed improved sub-
micromolar activity against E. coli IspC (Figure 1.49).316,328 These findings suggest that a thorough 
exploration of chemical space may be crucial to further discover new inhibitors of the IspC enzyme.  
 
Figure 1.49. -aryl inhibitors, reverse fosmidomycin, inhibitors, and novel scaffolds targeting IspC.316,326–328 
1.6.2 Inhibitors of IspD 
 IspD has been much less studied than its IspC counterpart despite the number of available 
crystal structures. Fosmidomycin (92) is the only MEP pathway inhibitor to find its way into clinical 
trials and thus there is a vast array of unexplored opportunities to further develop novel 
chemotherapies to target the other constituent enzymes of the MEP pathway. The IspD enzyme is a 
cytidyltransferase, which is uncommon as CTP is not often found as a substrate for enzymatic 
transformations in comparison to ATP and GTP. The enzyme therefore possesses two unusual 
substrates, with the other substrate being MEP. These attributes potentially mean the enzyme can be 
targeted safely. This led us to our goal, which is to identify and design novel inhibitors of this enzyme 
in P. falciparum, with the ultimate aim of developing a lead candidate to be taken forward as an 
effective antimalarial therapeutic targeting the MEP pathway.  
 In a similar manner to fosmidomycin (92) the first known inhibitor of IspD was a demethylated 
structural mimic of the substrate MEP (85), known as erythritoyl 4-phosphate (99) with unspecified 
 Chapter 1: Introduction to Malaria and the Methyl Erythritol Phosphate (MEP) Pathway 
 43 
configuration (Figure 1.50). Unlike fosmidomycin (92), the molecule showed very weak activity against 
both E. coli, with an IC50 value of 1.38 mM329 Masini et al. demonstrated that the IspD active site is the 
most polar active site of all of the MEP pathway enzymes; furthermore the CTP binding site is exposed 
to solvent, which therefore means there is a significant challenge in the generation of substrate 
competitive inhibitors of this enzyme.330  
 
Figure 1.50. Erythritol 4-phosphate (99).329 
 A diversity-based HTS was carried out by BASF for the purpose of identifying new herbicidal 
based molecules targeting Arabidopsis thaliana IspD, after it was discovered that IspD functionality 
was essential for plant survival.331 From the screen the most active hit 100 (Figure 1.51) possessed a 
triazolopyrimidine scaffold with an unprecedented sub-micromolar IC50 activity of 140 ± 10 nM. The 
group led by Witschel, identified that based on the crystal structure of A. thaliana IspD there was no 
reasonable docking mode of the hit within the enzyme active site. The group decided to co-crystallise 
the hit with the enzyme, they successfully elucidated that the hit binds within an allosteric pocket 
proximal to the active site, causing a conformational change, decreasing the size of the active site and 
resulting in the failure of substrate binding.331 Further optimisation of the template led to the 
development of the nitrile derivative of 101 with an IC50 value of 35 ± 7 nM (Figure 1.51).331 
 After the success of the triazolopyrimidines Kunfermann et al. carried out another HTS screen, 
which identified the highly halogenated marine alkaloids belonging to the pseudilin class, as inhibitors 
of the IspD enzyme.332 The compounds were tested against AtIspD and PvIspD, interestingly in the 
case of AtIspD the activity was shown to be dependent on the addition of divalent cations, in 
particular, Cd2+ which gave a 7-fold increase in activity for the hit molecule 102 with an IC50 of 1400 ± 
200 nM (Figure 1.51).332 The inhibitors were less potent against PvIspD showing double-digit µM IC50 
values with little dependence on cations. The crystal structure of AtIspD was solved with the inhibitor 
and the Cd2+ metal ion bound within the same allosteric pocket as the triazolopyrimidines.331,332 
Unfortunately, this specific class of inhibitors was found to be cytotoxic to mammalian cells suggesting 
multiple molecular targets. Furthermore, the poorer activity associated with PvIspD suggests that this 
allosteric pocket is structurally different or not present with other IspD homologues and thus is species 
specific.332 
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 Another class of inhibitors was identified by BASF in their HTS of AtIspD with a scaffold 
belonging to acetylated aminobenzothiazoles 103 (Figure 1.51). However, the activities where only in 
the low µM range and were not optimised, further to this the mechanism of action was not 
investigated.333   
 Recently a HTS screen of PfIspD carried out by our research group(s) in collaboration with 
Biofocus, discovered a novel class of inhibitors belonging to the benzoisothiazolinone (BITZ) scaffold 
104 (Figure 1.51). Unfortunately, due to the absence of PfIspD enzyme crystal structures, exact binding 
modes could not be determined. In spite of this, the proposed mechanism of action is thought to 
proceed via the formation of a covalent adduct within the enzyme active site preventing substrate 
binding, this class of inhibitors is further investigated in Chapter 3 of this thesis.334 Wu et al. also 
determined a tetrahydro-β-carboline chemotype as another inhibitor of PfIspD named MMV008138 
(105) (Figure 1.51).335 105 was initially found to possess potent antiplasmodial activity from a 
phenotypic screen of the of the GlaxoSmithKline (GSK) compound library.336 The structure of 105 and 
other newly discovered antimalarial compounds were made available free of charge by the Medicines 
for Malaria Venture (MMV) as part of the malaria box programme.337 The target of 105 was identified 
to be IspD after mutations in the ygbP gene led to resistance against the compound. Research from 
our group and Yao et al. from chemical rescue screens and activity studies have demonstrated that 
this compound is a potent PfIspD inhibitor displaying low nM activity against the enzyme, and 
moderate nM activity against Pf whole cell assays.338,339 Therefore this scaffold presents a highly 
promising opportunity for further development in order to develop a candidate drug targeting PfIspD, 
and is discussed in Chapter 2 of this thesis. 
 
Figure 1.51. Inhibitors of IspD.331–335 
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1.7 Aim 
The MEP pathway is responsible for the biosynthesis of crucial isoprenoid precursors IPP (90) 
and DMAPP (91) from which all isoprenoids are derived. Its absence from mammalian cells makes this 
particular pathway an attractive drug target as compounds can be designed to be enzyme selective, 
there-by reducing potential unwanted side effects. The chemical interruption of precursor 
development has the potential to shut down numerous parasitic biological functions which rely on the 
de novo synthesis of isoprenoids, were the loss of these crucial compounds could result in parasite 
death. This research focuses on the inhibition of specifically the P. falciparum homologue of the third 
enzyme in the MEP pathway IspD. The enzyme has been genetically validated and has been 
demonstrated to be druggable. The pathway itself has been validated as a drug target owing to the 
success of fosmidomycin, inhibiting the second enzyme of the MEP pathway IspC and the only MEP 
pathway inhibitor to be taken to clinical trials.   
There are very few known inhibitors of IspD, and until recently there were no inhibitors with 
an IC50, of sub 1 µM. This coupled with the unusual substrates for this enzyme made this particular 
enzyme of interest to us. As the MEP pathway is linear and IspD is an early enzyme, the inhibition of 
this upstream enzyme could have a greater potential to cause parasite death. Furthermore, the 
downstream IspF enzyme has been proposed to rely upon cMEPP and MEP to carry out potential 
regulatory functions for the MEP pathway.340,341 Sustained levels of cMEPP have also been 
demonstrated to be essential for other biochemical processes as well; therefore the loss of function 
of IspD could ultimately also cause a loss of function of the MEP pathway as a whole along with other 
biochemical targets.315 As the MEP pathway and IspD are novel biochemical targets, there is high 
potential that any compounds targeting IspD will have the potential to kill multidrug resistant strains 
of P. falciparum thus offering renewed hope for the eradication of the disease, and against the battle 
of P. falciparum strains now resistant to all frontline therapies.  
The ultimate goal of this research is to identify and develop a novel lead candidate template 
through the guidance of SAR studies that has potent in vitro activity against PfIspD and P. falciparum 
parasites. The strain of P. falciparum being used for this research is the 3D7 strain, which is 
chloroquine sensitive, but sulfadoxine resistant. Compounds of interest will be taken for studies on 
their in vitro pharmacokinetic profile, with identified leads taken forward to in vivo studies. 
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2.1 Discovery of a Specific Stereoisomer of MMV008138 as an Inhibitor of PfIspD 
 MMV008138, also known as 1-(2,4-dichlorophenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole-3-carboxylic acid (1), was identified in 2010 as possessing antiplasmodial activity through 
phenotypic screening of the GlaxoSmithKline (GSK) compound library.1 The structure of 1 (Figure 2.1) 
and other newly discovered antimalarial compounds were made available free of charge by the 
Medicines for Malaria Venture (MMV) as part of the malaria box programme.2 
 
Figure 2.1. Structure of MMV008138 (1), each ring is labelled A, B, C and D. 
From this discovery, Bowman et al. were successful in utilising a chemical rescue screen that 
identified compounds from the malaria box as possessing likely apicoplast activity.3 This was achieved 
by examining the growth effect of IPP supplementation with active compounds. As mentioned in 
Chapter 1, the biosynthesis of IPP is localised within the apicoplast, therefore if parasite growth is 
rescued by IPP supplementation it is reasonable to assume the compound targets this organelle. Of 
all the compounds tested only MMV008138 (1) possessed both potent activity (<1000 nM), and led to 
parasite rescue when supplemented with IPP. 1 belongs to the tetrahydro-β-carboline (THBC) 
chemical scaffold and bares substituents at the C1 and C3 positions (Figure 2.1), this gives rise to 4 
stereoisomers (Figure 2.2). Bowman examined MMV008138 (1) as a mixture of all stereoisomers, and 
determined that its specific IC50 activity was 350 nM vs the Dd2 strain for Plasmodium falciparum.3  
 
Figure 2.2. Structure of all stereoisomers of MMV008138 (1a – d). Positions bearing stereogenic centres are numbered 
accordingly with stereochemistry displayed. 
Both Bowman and Wu et al. also gave evidence to support that the MEP pathway as the likely 
metabolic target within the apicoplast.3,4 Bowman showed that parasites exposed to MMV008138 (1) 
suffered a loss of mitochondrial membrane potential, an observation that is seen when ubiquinone 
production is also inhibited. Fosmidomycin has already been demonstrated to inhibit ubiquinone 




synthesis and targets the MEP pathway enzyme IspC, suggesting MMV008138 (1) possesses a similar 
mode of action.3,5,6 Both research groups also compared the kinetics of fomidomycin and 1 with other 
apicoplast specific drugs such as doxycylicine and clindamycin.3,4 These drugs exhibit a delayed death 
phenomenon from their mechanisms of action, interfering with the apicoplast genome development 
via the inhibition of transcription and translation.7 Unlike doxycycline and clindamycin, both 
fosmidomycin and 1 exhibit immediate death characteristics.3,4 Furthermore doxycycline, clindamycin, 
fosmidomycin and 1 all disrupt apicoplast morphology; this change in morphology is not rescued in 
parasites treated with doxycycline and clindamycin in the presence of exogenous IPP. In fosmidomycin 
and 1, however, the apicoplast is fully rescued from IPP supplementation and parasites remain viable, 
again suggesting a mode of action on a direct metabolic pathway within the organelle.3 
Wu and co-workers undertook research to confirm the molecular target of 1. They first 
isolated all four diastereoisomers and found the (1R, 3S)-enantiomer (1a) to be the most potent, 
demonstrating an EC50 of 110 nM against PfW2 strain, whilst the other diastereoisomers showed 
substantially reduced inhibition or no inhibition >50 µM (Table 2.1).4  
Table 2.1. Inhibitory activities of each MMV008138 diastereoisomer against parasite growth (Dd2), both with and 
without IPP supplementation. 
Stereoisomer PfDd2 EC50 (µM) PfDd2 EC50 (µM) + IPP rescue 
(1R, 3S)-1a 0.11 (0.10 – 0.12) >25 
(1R, 3R)-1b 3.8 (2.7 – 5.3) >25 
(1S, 3R)-1c 18.6 (12.4 – 28.0) >25 
(1S, 3S)-1d >50 >50 
 
They then generated three separate populations of parasites that were drug resistant to 1a 
and examined their genomes. Mutations were shared in the IspD coding gene suggesting that IspD 
was the target. To confirm if this was the case, non-mutated IspD was purified and its activity 
interrogated using a pyrophosphate release assay. Indeed the (1R, 3S)-enantiomer 1a demonstrated 
potent activity against the enzyme displaying a potent IC50 value at 7.0 nM. These lines of evidence 
provide very good support that IspD is the molecular target (Table 2.2).4  
Table 2.2. Inhibitory activities of each MMV008138 diastereoisomer against Plasmodium falciparum IspD. 
Stereoisomer PfIspD EC50 (µM) 
(1R, 3S)-1a 0.0071 (0.0061 – 0.0083) 
(1R, 3R)-1b 0.17 (0.14 – 2.0) 
(1S, 3R)-1c 2.5 (1.9 – 3.1) 
(1S, 3S)-1d >25 
 




Interestingly the authors state that the compound has no activity against the Plasmodium 
vivax homologue of IspD and is specific to Plasmodium falciparum, which may be due to only a 31 % 
sequence similarity between the two homologues.4 In contrast to this, however, the Odom group also 
purified PvIspD and identified 1a as an inhibitor with an IC50 value of 310 nM. Running the same screen 
with recombinant PfIspD yielded an IC50 of 47 nM, indicating that Plasmodium falciparum is more 
sensitive to inhibition.8 Although demonstrating the potential ability to kill both Pf and Pv strains of 
malaria, 1a is not active against bacterial IspD homologues such as M. tuberculosis, or E. coli displaying 
no inhibition of these enzymes at >30 µM.4,8 Furthermore the compound is also not active against the 
plant homologues as demonstrated by the observation that there is no activity against A. thaliana IspD 
at 1 mM.4 The IspD homologues of the Plasmodium species therefore possibly have a distinct binding 
pocket that is susceptible to selective small molecule inhibition.  
 In order to confirm whether inhibition of PfIspD leads to effective shutdown of the MEP 
pathway, the expected levels of in vivo MEP pathway metabolites should decrease further 
downstream after inhibition. Imlay and Odom demonstrated that administration of 1a to Plasmodium 
falciparum led to a decrease in the levels of cMEPP within the parasite to just 12 % ± 4 of the control, 
a result which is consistent with previously described fosmidomycin inhibition.8 Furthermore the 
levels of DXP, an upstream metabolite in the MEP pathway, do not change upon treatment with either 
fosmidomycin or (1R, 3S)-MMV008138 (1a). In the same experiment the inactive (1S, 3S)-MMV008138 
(1d) (Figure 2.2) did not show any change in cMEPP levels, nor did structurally unrelated antimalarial 
compounds such as chloroquine. Taken all together this data suggests that IspD is a valid drug target 
and leads to both effective shut down of the MEP pathway, along with loss of parasite viability.8      
2.1.1 Known SAR around the Tetrahydro-β-carboline Scaffold 
 With the identification of MMV008138 (1), its biological target and stereochemical 
requirement, we initially focused our research on the development of this novel tetrahydro-β-
carboline scaffold by conducting SAR studies at numerous points around the motif with the aim of 
enhancing phenotypic whole cell activity and / or PfIspD inhibition. 
 During our initial development around the chemotype Yao et al. published their research on 
the same chemical motif.9 They focused and evaluated their research on the phenotypic activity of 
compounds derived from 1 against the PfDd2 strain, and did not test for IspD activity. Despite this, 
their research indicated strict structural requirements are needed in order to maintain levels of 
potency, where even small changes in substituent size can lead to a loss of activity, potentially 
indicating that the binding side of PfIspD is quite restricted.9  




2.1.2 Modifications to MMV008138 D-ring 
 The research conducted by Yao first examined the modification of the D-ring aryl substituent 
(highlighted green) bound at the C1 position of the tetrahydro-β-carboline core for the (1R, 3S)-
enantiomer and (1S, 3S)-enantiomers. Their results are summarised in Table 2.3 below, only results 
for the (1R, 3S)-enantiomer (1a, 2a – j) are displayed.9     
 
Table 2.3. Inhibitory activities of each D-ring substituent pattern against parasite growth (Dd2). X = substituent pattern. 
X PfDd2 IC50 (nM) 
2-Cl, 4-Cl (1a) 250 ± 70 
3-OMe, 4-OMe (2a) >20,000 
2-H, 4-H (2b) >10,000 
2-Cl, 4-H (2c) 3280 ± 990 
2-H, 4-Cl (2d) 1170 ± 60 
2-Cl, 4-Me (2e) 410 ± 40 
2-Me, 4-Cl (2f) 700 ± 90 
2-Me, 4-Me (2g) 70 % inhibition at >10,000 
2-F, 4-F (2h) 780 ± 175 
2-OMe, 4-OMe (2i) >20,000 
2-CF3, 4-CF3 (2j) >10,000 
 
 It is apparent that there is a strict spatial and / or electronic requirement for the 2, 4 
substitution pattern of this aryl ring. Only one 3, 4 substitution pattern was explored (2a), however, it 
led to complete loss of activity. Similarly removal of all substitution (2b) also results in a loss of activity. 
Activity is regained upon addition of a chlorine atom at either the 2-position (2c) or 4-position (2d) of 
the aryl ring, albeit with greatly diminished potency compared to 1a. Of the substitution patterns 
explored only the 2-Cl, 4-Me (2e) or 2-Me, 4-Cl (2f) substitution came close to replicating the potent 
activity of 1a, however, they were not as potent as the parent compound. Interestingly the halogens 
seem to influence the potency greatly, whether this is through steric or electronic effects was not 
explored in the paper. Substitution of both chlorine atoms with Me groups (2g) results in greatly 
diminished potency, replacement of the chlorine atoms to fluorine atoms (2h) retains activity but 
again is less potent than the parent. Both the 2, 4-bis(methoxy) (2i) and 2, 4-bis(trifluoromethyl) (2j) 
analogues show no activity at 20,000 and 10,000 nM, respectively.9 




It is interesting that even small modifications to this D-ring can influence activity so 
substantially; Yao et al. postulated that there is a very tight binding pocket for this region resulting in 
potentially limited SAR. They also postulated that the 2-position is required to constrain the D-ring to 
lie perpendicular to the tetrahydro-β-carboline core, potentially forcing a particular binding mode.9 
2.1.3 Modifications at the C3 Position 
Yao et al. also evaluated the effect of substitution of the carboxylate moiety at C3 on the 
tetrahydro-β-carboline (THBC) core. Similar to their findings on the C1 D-ring, there also appears to 
be critical steric and electronic constraints for potential SAR. Again it was observed even minor 
changes appear to dramatically influence potency.9 Their initial rationale for the substitution of this 
position was to examine if the carboxylic acid moiety could be replaced.9 Carboxylic acids are often 
believed to be non-ideal in a drug development programme as they can exist in their deprotonated 
form at physiological pH, this can cause issues such as cell permeability as the negatively charged 
carboxylate cannot cross an also negatively charged phospholipid cell membrane.10 They can also be 
susceptible to glucuronidation via phase II metabolism which both reduces the amount of available 
drug in the body, and can cause undesirable side effects.10 Therefore, the bioisoteric replacement of 
this moiety can aid in both reducing potential unwanted side effects, and can increase the metabolic 
half-life of the drug in the body, thus improving the overall pharmacokinetic profile of the compound. 
Table 2.4 summarises their findings. 
 
Table 2.4. Inhibitory activities of each C3 substituent against parasite growth (Dd2). R = substituent. 
R PfDd2 IC50 (nM) 
H (3a) 10,000 ± 1600 
CONH2 (3b) 1200 ± 100 
CONHiPr (3c) 50 % inhibition at 10,000 
CONHnBu (3d) 80 % inhibition at 10,000 
aCONHC6H11 (3e) 2830 ± 500 
CONHNHMe (3f) 1940 ± 200 
CO2Me (4) 6800 ± 1400 
CONHMe (6) 190 ± 30 
a = Growth inhibition was not rescued by addition of exogenous IPP 




Yao et al. removed the carboxylate moiety entirely, eliminating the stereogenic centre at C3. 
They administered the resulting compound 3a as the C1 (R / S)-racemic mixture and found loss of 
activity. Consequently, they switched their attention to amide derivatives of 1a, interestingly the 
primary amide (3b), similar in size and shape to the acid, led to only moderate inhibitory activity. The 
group also examined amides with increased steric bulk including NH-iPr (3c), and NH-nBu (3d) and 
observed greatly diminished activity. Surprisingly NH-cyclohexane (3e) maintains moderate potency, 
examination of the molecule within an IPP rescue screen showed no rescue of parasites, therefore in 
the absence of an IspD assay it is reasonable to assume this compound shows off target effects. 
Replacement to the NHNHMe hydrazide (3f) showed a reduction in activity; potentially due to extra 
steric bulk.9 Yao et al. also examined the methyl ester of (1R, 3S)-MMV008138 (4) after separation 
from its inactive (1S, 3S)-isomer (5). This ester is an intermediate for the synthesis of the parent 
compound (1a) and so if active, it would reduce the number of steps en route to the target compound 
to just one step starting from cheap starting materials, a very desirable trait indeed for any possible 
novel drug candidate. Unfortunately replacement to the ester displayed weak activity, however, the 
group postulate this compound could serve as a useful prodrug if the ester functionality is hydrolysed 
to the acid in vivo. Though not reported, the authors state a number of esters were also examined and 
all were found to be inactive.9 Using CONHMe (6) as the amide, led to improved potency over the 
parent compound (1a).  This is interesting as it is a similar size to the methyl ester (4), and slightly 
bigger than acid (1a), this indicates that there is a small degree of manipulation that can be tolerated 
at the C3 position. It does appear that based on these results that the heteroatom directly bonded to 
the carbonyl must be a hydrogen bond donor. 
Figure 2.3 summaries what is known from the template thus far. 
 
Figure 2.3. Summary of the known SAR of the template.9 
 




2.1.4 Is MMV008138 a Good Template? 
 The MMV008138 compound (1a) contains a distinct chemical motif known as a tetrahydro-β-
carboline as the core of the molecule. Indeed whilst the compound has strict requirements of the 
stereochemistry at positions 1 and 3, therefore potentially complicating synthesis, there are a large 
number of potential drug therapies that utilise not only the tetrahydro-β-carboline (THBC) core, but 
also the chirality, which can be crucial in delivering chemotherapies with good efficacy.11 A review of 
the literature shows that optically active THBC scaffolds are of great pharmacological importance and 
are present in not only in drugs but also are present in natural products as well.11 Some examples are 
given in Figure 2.4. 
 
Figure 2.4. Examples of optically active THBC scaffolds that have been used for various chemotherapies. 
 Reserpine (7) and ajmalicine (8), are both natural optically active THBC alkaloids which have 
been used as antihypertensive therapies.11 Perhaps the most pharmacologically important synthetic 
THBC to date is tadalafil (9) which under the brand name Cialis earns over $2 billion in annual sales; it 
is used primarily to treat erectile dysfunction but also is used to treat pulmonary arterial 
hypertension.12 9 contains some degree of structural similarity to MMV008138 (1a) but bears a 
diketopiperazine ring. Yao et al. even tested it for its antiplasmodial activity, however, the result was 
disappointing and showed no activity against the parasite. It should be noted, however, that during 
this test 9 was used as the (1R, 3R)-stereoisomer, rather than the (1R, 3S)-stereoisomer, which is 
required for IspD activity. It also lacks the 2, 4 aryl substitution, and finally the C-ring nitrogen atom is 
locked as an amide and thus has lost its basicity.9   
 10 has been used also been used as a mitotic spindle protein inhibitor for potential use as a 
cancer chemotherapy.13 11 has also been reported to possess excellent activity against plasmodium 




falciparum displaying an minimum inhibitory concentration (MIC) of 50 nM.14 Perhaps most 
importantly for this project is the extremely positive results seen from the molecule KAE609 (12) also 
known as Cipargamin. Developed by Novartis, it is another compound with high structural similarity 
to MMV008138 (1a) the molecule is a tetrahydro-β-carboline structure with a fused spiroindalone at 
its C1 stereogenic centre, and a methyl group at the C3. Since the lead compound was discovered with 
an PfNF54 EC50 value of 9.2 nM it has demonstrated an outstanding safety profile in humans, has a 
good half-life and as a result has currently completed phase IIa clinical trials.15–18 Although possessing 
the formal labels of (1R, 3S)-configuration, which match 1a, the spatial arrangement of these 
substituents does not resemble (1R, 3S)-MMV008138 (1a) but rather the (1R, 3R)-diastereoisomer 1b, 
therefore it is not likely to dual inhibit IspD.  
In summary, it has been demonstrated in the literature that compounds harbouring an 
optically active tetrahydro-β-carboline scaffold have success within drug development programmes, 
particularly as shown with the success of tadalafil (9) and KAE609 (12). The fact that one of these 
compounds has made it to market and the other to human trials demonstrates there is potential for 
an excellent safety profile working with the MMV008138 template. The specificity of 1a to a parasite 
specific pathway would also reduce the potential of unwanted side effects. Whilst SAR has been 
carried out on the MMV008138 template by Yao, there is more than can be explored around the C 
and D-ring, and the as of yet unexplored A-ring. The aim of our work is to expand on the known SAR 
to deliver a compound with improved activity against the malaria parasite, and ideally have that same 
compound as an inhibitor as PfIspD with the ultimate aim of producing a new lead compound to be 
taken forward to in vivo studies.          
2.2 Results and Discussion 
2.2.1 General Synthesis of Compounds Exploring C and D-ring Modification 
 The generation of most compounds in the series was successfully achieved from a two-step 
synthesis, and any deviations from this route will be discussed as appropriate (Scheme 2.1). The first 
and most crucial step in the reaction pathway involved utilising the well-established Pictet-Spengler 
reaction between the aldehyde of choice (to set the D-ring functionalisation) and L-tryptophan methyl 
ester (13). Classically the Pictet-Spengler reaction is known as an acid-catalysed transformation 
between a β-aryl amine and an aldehyde or ketone.19–21 In the case of tryptamine, the reaction with 
the desired carbonyl compounds generates a tetrahydro-β-carboline scaffold with a stereogenic 
centre at C1 that exists as a mixture of enantiomers (unless formaldehyde is used as the carbonyl 
source). In the case of tryptophan derivatives, a stereogenic centre is also present at C3. Provided that 




starting tryptophan is optically pure; the result of the Pictet-Spengler reaction is a mix of two 
diastereoisomers. The C3 stereogenic centre does not racemise under standard reaction conditions 
thus allowing for ease of isolation of optically pure products.20,21 Tryptophan ester products were 
expected to be easier to isolate and handle than their carboxylic acid counter parts, and for these 
reasons we chose L-tryptophan methyl ester (13) as the starting point for our synthesis. The final step 
in the general synthetic scheme involves a simple amide coupling from the desired (1R, 3S)-isomer 
(from here on stated as trans) via direct displacement of the ester in a large excess of the desired 
amine. Compounds were then successfully recrystallised from methanol (Scheme 2.1).9 
 
Scheme 2.1. General synthesis for final targets. 
2.2.2 Pictet-Spengler Reaction Mechanisms 
 The Pictet-Spengler reaction can be regarded as a reaction similar to a Mannich type reaction. 
The detailed reaction mechanism remains a topic of debate with two possible courses the reaction 
can take (Figure 2.5). In both cases the first step of the mechanism is believed to be the same. First, 
the acid catalyst acts to protonate the carbonyl source (B) which facilitates the nucleophilic attack of 
the amine (A) to the protonated carbonyl forming intermediate C before loss of H2O. The resulting 
iminium ion (D) causes the sp2 carbon to become sufficiently electrophilic for ring closure.22 It is this 
ring closing step that is debated in the literature, the reaction can proceed either via nucleophilic 
attack of the indole 3-position resulting in the formation of a 5-membered spiroindolenine 
intermediate (E) (Figure 2.5 route a). Migration of the highlighted bond onto the 2-position of the 
indole results in the formation of a 6-membered ring (F), following proton loss aromaticity is restored 
and the tetrahydro-β-carboline core is completed (product G). Alternatively the reaction can proceed 
via direct attack of the 2-position of the indole, presumably via delocalisation into the A-ring, forming 
the 6-membered ring (F) immediately without the need to pass through the spiroindolenine 
intermediate (E) (Figure 2.5 route b, for clarity, the delocalisation is omitted), again proton loss 
restores aromaticity and completes the reaction (G) . There is currently no compelling evidence either 




way for which mechanism is in operation, literature presents evidence both for and against either 
pathway.20,23–25 
 
Figure 2.5. Proposed reaction mechanisms of the Pictet-Spengler reaction, route a is depicted with red arrows, route b is 
depicted with blue arrows. 
As tryptophan derivatives are used as part of this project, we generate two diastereoisomers 
whenever a Pictet-Spengler reaction is carried out with optically pure starting materials. Fortuitously 
in most cases the ease of isolation of both diastereoisomers along with sufficient generation of 
material for the desired trans product meant that this was not a problem. In general cis to trans 
selectivity was approximately 2 : 1 to 3 : 1. However, this is slightly problematic for a waste perspective 
as a substantial amount of reaction product can be discarded.  
The use of a trans-selective Pictet-Spengler reaction would be very beneficial indeed. Cook et 
al. report of two ways to achieve trans-product, and both involved a benzylation protocol. They 
demonstrated that carrying out the reaction with N-benzyl tryptophan derivatives yields highly 
selective trans product.24,26–28 Alternatively benzylating any isolated cis isomer and exposing it to an 
acidic environment leads to ring opening, bond rotation and ring closing forming the desired trans 
isomer.29–31 The drawback of this protocol, however, is the benzyl group cannot be easily removed 
without running the risk of affecting other parts of the MMV008138 derived compound, such as 
dehalogenation of the D-ring. Therefore no final target was made using this protocol, however, it 




should be noted that all cis isomers were isolated in case new methods to carry out this isomerisation 
were discovered or were needed.   
2.2.3 Confirming Series Activity and Introducing Drug Metabolism and Pharmacokinetic (DMPK) 
Properties. 
To order to confirm activity of the series, 1a was resynthesised by our research group 
following the procedure reported by Yao et al. The group used an amberlyst catch and release protocol 
to generate the COOH functionality from the methyl ester (synthesis was specifically carried out by a 
postdoctoral research assistant in the group Dr Chandrakala Pidathala. Note, unless otherwise stated 
all reported compounds have been made by myself).9 The assessment of biological activity for final 
compounds was generously undertaken by members of the Odom group. We also decided to 
resynthesise and reconfirm the activity of 6 also following the reported procedure by Yao et al. 
following Scheme 2.2.9 
 
Scheme 2.2. Synthetic route to compound 6. 
L-Tryptophan methyl ester (13) was purchased as the hydrochloride salt and was isolated as 
the free base by stirring in a biphasic solution of saturated NaHCO3 and EtOAc. Following extraction 
and isolation, the free-base L-tryptophan methyl ester (13) was carried forward into the Pictet-
Spengler reaction using 1.1 equivalents of trifluoroacetic acid. Isolation of the cis and trans 
diastereoisomers from column chromatography, gradient elution from 100 % DCM to 2 % EtOAc in 
DCM, results in the isolation of 4 and 5. After recrystallisation from hot methanol 5 was isolated as 
long transparent needles in 49 % yield, and the 4 was isolated as transparent crystals in 30 % yield. 
Reacting 4 in the presence of a large excess of methylamine gave the final product 6 in 99 % yield 
following recrystallisation from methanol.  




In order to determine unambiguously which compound from 4 and 5 is cis and which is trans, 
2D Nuclear Overhauser Effect Spectroscopy (NOESY) experiments were carried out on each 
diastereoisomer. As it is impossible to determine which diastereoisomer will come off the column first 
when substituents are varied, NOESY experiments provide an efficient method to differentiate cis 
from trans. The NOE is an effect that monitors through space coupling; this is particularly useful for 
ring systems as it allows the determination of which protons are near each other, but not necessarily 
coupling through traditional through-bond coupling, for example 1, 3 diaxial interactions can be 
observed via the NOE, as these protons are near each other occupying the same face.32 For this 
template we can use NOE to assess whether or not the C1 and C3 protons interact, in the case of the 
cis isomer a correlation will be observed in the spectrum as the substituents occupy the same face 
and are therefore near each other. This can then be confirmed by analysing the trans isomer, which 
will show an absence of through space coupling between the same protons (Figure 2.6 and 2.7, 
Appendix 1).  Final confirmation that the correct diastereoisomer and enantiomer was isolated, was 
carried out via X-ray crystallography.33–35 The trans product 4 was crystallised from hot methanol and 
examined for its crystal structure by Dr Craig Robertson and images visualised in OLEX2 (Figure 2.8).36 
The trans product was confirmed clearly demonstrating the C1 and C3 substituents on differing faces.  
 
Figure 2.6. Identification of 4 and 5 by NOESY. Protons on the same face show a correlation as displayed in the top 
portion of the diagram, which indicate a cis isomer and therefore compound 5. Protons on differing faces show an 
absence of a correlation as displayed in the bottom portion of the diagram which indicates a trans isomer and therefore 
compound 4.   









Figure 2.7. Representative NOESYs for compounds 4 and 5. A, shows a correlation between C1 and C3 hydrogens, 














Figure 2.8. X-ray crystal structure of 4, Flack parameter = -0.002 (9). Image is rendered as ball and stick, carbon, coloured 
in grey, chlorine in green, hydrogen in white, nitrogen in blue and oxygen in red. Compound was visualised using 
OLEX2.36 
To confirm series activity the biochemical and cellular assays undertaken as part of this project 
were carried out by our collaborators at the University of Washington Department of Molecular 
Microbiology in the Odom group.  
To determine enzyme activity, the Odom lab developed an enzyme-linked assay to detect the 
release of pyrophosphate by the PfIspD enzyme. IspD reacted in the presence of its substrates MEP 
and CTP yields the product CDPME and inorganic pyrophosphate. The assay utilises the generation of 
inorganic phosphate (iP) formed from inorganic pyrophosphate (iPP) by reaction of iPP with an 
inorganic phosphatase enzyme iPPTase. The generated iP can then be monitored by subsequent 
reaction with the synthetic substrate 2-amino-6-mercapto-7-methylpurine (MESG) (14) (Figure 2.9) in 
the presence of the enzyme PNP (purine nucleoside phosphorylase), which releases ribose-1-
phosphate (15) and 2-amino-6-mercapto-7-methylpurine (16) a product with a well-defined 
characteristic maximal absorption at 360 nm wavelength.37 The assay is linear with respect to time 
and enzyme concentration and activity is dependent on concentrations of PfIspD, MEP and CTP. Upon 
inhibition, the generation of iPP is reduced, thus the generation of the observed product from the 










Figure 2.9. Representation of pyrophosphate release assay. 
The P. falciparum cellular assay was carried out on the intraerythrocytic stage of the parasite 
using standard methods, which involved intercalation of P. falciparum DNA with the fluorophore 
PicoGreen – an ultrasensitive nucleic acid stain for measurement of double stranded DNA in solution.38 
Erythrocyte cells do not contain DNA whereas P. falciparum does, therefore fluorescence can be 
detected in infected erythrocyte cells, and effective concentration (EC50) values can be calculated 
based on the drug concentration that yields 50 % of the net fluorescence compared with untreated 
infected erythrocyte cells. The strain of P. falciparum that is used as part of the essay is a chloroquine 
resistant strain known as 3D7, and the erythrocyte cells are from human.  
Selected compounds also had their DMPK profiles analysed for certain parameters including 
LogD7.4, aqueous solubility, and metabolic stability. Each of these parameters is especially important, 
and certain requirements from these parameters need to be met for a hit drug to become a lead 
candidate and are discussed below. 
i) LogD  
LogD, (the distribution coefficient of a compound between an organic (octanol) phase and 
aqueous phase at a specific pH), is a measure of the pH dependent lipophilicity of a molecule, i.e. the 
affinity a molecule has for a non-polar hydrophobic (lipophilic) environment. Lipophilicity is a 




physiochemical property can influence numerous factors of a drug including; the distribution across a 
phospholipid bilayer of cells; the absorption and binding of a drug; and also the solubility of the drug 
in aqueous or organic environments.39  
 The rule of five set by Lipinski is a set of parameters that are used to predict oral bioavailability 
of orally administered compounds,40 in particular for predicting the adsorption of a drug. These rules 
assist in the knowledge of whether a drug is likely to succeed or fail in the clinic.40 The rule itself is 
based on the properties of hundreds of drugs were a trend was found with successful drug 
compounds. Many successful drug compounds shared the following parameters.39,40  
i) ≤ 5 hydrogen bond donors 
ii) ≤ 500 gmol-1 
iii) LogP ≤ 5 (related to LogD) 
iv) ≤ 10 hydrogen bond acceptors 
A drug is more likely to fail in the clinic if two or more of these parameters are not met.40 As 
LogP (the partition coefficient of a compound between an organic (octanol) and an aqueous phase 
were all molecules are in neutral form), is related to LogD clearly lipophilicity is an important 
parameter in the success of a drug compound.39 As a general rule for LogD7.4 a value between 1 and 3 
is considered as the optimal point for a drug to possess good oral bioavailability. LogD7.4 can be seen 
to influence other DMPK properties for values outside of this range, for example, LogD7.4 <1 has an 
advantage of low metabolic liability, but may suffer from poor permeability and rapid in vivo renal 
clearance. A LogD7.4 >5 would likely possess low aqueous solubility, poor oral bioavailability and high 
metabolic liability.39,41,42  
There is increasing evidence that clinical drug candidates are overly hydrophobic, which may 
be responsible for the high rates of attraction observed during the drug development process.43 
Though LogD7.4 can be used to estimate the likelihood of a particular drug compound to be soluble in 
an aqueous environment, work undertaken by Hill and Young show that measured and calculated 
Log7.4 values of tens of thousands of compounds show poor correlation.43 This was particularly true 
when they analysed compounds based on aqueous solubility. Poorly aqueous soluble compounds 
showed the poorest measured to calculated LogD7.4 correlation, while this correlation was improved 
with highly aqueous soluble compounds, it was still statistically poor.43  
Using solubility categorised box plots, Hill and Young demonstrated that for poorly soluble 
compounds, if calculated logD7.4 is predicted between 3 and 7, then there was no statistical difference 
between measured values of the same compounds, which gave average measured logD7.4 values 




between 2.5 and 3.5.43 The observations suggest that the factors causing poor aqueous solubility may 
be perturbing the octanol / water system preventing true equilibrium from being obtained.43 This can 
possibly be explained through the tendency of poorly soluble compounds to form aggregates 
(discussed in the next section on aqueous solubility).43,44 The data presented by Hill and Young shows 
therefore, that the measured logD7.4 value should only be used in context of the aqueous solubility of 
the molecule in question, or, that the calculated logD7.4 value may be a better indicator of 
hydrophobicity than a measured value.43 
Hill and Young, amongst others, have highlighted the negative impact of aromaticity on 
solubility.43–47 This effect can be explained by an increase in lattice energy, and melting point caused 
by -stacking of the planar aromatic rings, or by a reduction of entropy contribution in the free energy 
of solvation due to the molecules being more rigid.43,48,49 Hill and Young therefore, demonstrated in 
their review, that the proportion of poorly soluble compounds increases as either hydrophobicity 
increases, or the number of aromatic rings increases.43 From this, they formulated the solubility 
forecast index (SFI), which is the sum of ClogD7.4 + the number of aromatic rings, were bi- or tri-fused 
rings count as two and three rings, respectively.43  They demonstrated that if the SFI is <5, (instead of 
CLogD7.4 <5) then there is an enhanced chance of compounds possessing good aqueous solubility, 
rather than just taking ClogD7.4 into account alone.43 From the equation, it is implied that for each 
aromatic ring there is a penalty equal to one log unit of hydrophobicity. Each compound within this 
chapter will have its SFI calculated, compared with measured logD7.4 and measured aqueous solubility 
where appropriate. To calculate SFI Clog7.4 was first calculated using the estimation method developed 
by Csizmadia et al. and pipeline pilot.50,51 
ii) Aqueous solubility   
Solubility is defined the maximum dissolved concentration of a drug in a particular solvent at 
a particular temperature.39  Aqueous solubility is important because poorly aqueous soluble 
compounds result in limited absorption from the gastrointestinal tract further resulting in poor oral 
bioavailability. Therefore, lead candidates with poor solubility can require special formulation in order 
to remain efficacious which can be both costly and can result in delays.39 There are numerous factors 
that affect solubility, such as molecular weight, lipophilicity, pKa, temperature and many more. In 
general compounds possessing high molecular weight, high degree of lipophilicity, used in their 
neutral forms and used at lower temperatures will all suffer poor solubility. Introducing compounds 
as salts can aid in increasing aqueous solubility as can increasing the temperature, thus the 
temperature in solubility assessments should be kept constant.39 In addition, the solid form of a 
compound can also affect solubility. Using compounds in crystal form can result in increased time it 




takes for a compound to dissolve, as the compound exists as a highly ordered lattice with low surface 
area. Using amorphous solids, however, means that this ordered lattice is not present and thus a 
compound can be easier to dissolve in this form due to the presence of a higher surface area and ease 
of access of solvent to solute.39 A compound is considered to be poorly soluble for values <30 M, and 
considered to possess good solubility for values >200 M.43  
Aqueous solubility also is an increasingly important parameter for the correct interpretation 
of data resulting from enzymatic biochemical assays and high-throughput screens (HTS). Enzymatic 
HTSs are dominated by false positives, many of which are due to inhibition by colloidal aggregates.46 
It is known that there is a tendency for poorly aqueous soluble compounds to form aggregates, and 
many organic molecules form submicrometer aggregates at µM concentrations in aqueous solution.45 
These aggregates are known to cause unusual nonspecific inhibition of enzymes in biochemical 
assays.44–46,52 The interference of aggregates in biochemical assays has known characteristics, these 
include, reversal of inhibition by non-ionic detergent, steep dose response curves, and acute 
sensitivity to enzyme concentration, and these attributes aid in the identification of aggregate based 
inhibition.45,46,52 
 Coan et al. examined aggregate formation and found that for seven aggregate forming 
molecules, aggregates were not observed until the concentration of monomer passed a certain 
threshold known as the critical aggregate concentration (CAC).46 They elucidated that aggregates 
behave in a similar manor to micelles, and that above the CAC, the concentration of monomer units 
and the size of aggregate particles is constant above the CAC. In addition to this, aggregate count 
increases linearly with added organic material above the CAC, and when the particles are diluted 
below the CAC the aggregates redissolve back into solution.46 Using a flow cytometer, the group were 
able to determine aggregate concentration of two known aggregate molecules, nicardipine and 
miconazole, and found the concentration in solution to be between 5 – 30 fM.46 The group then 
measured the stoichiometry of the aggregate enzyme interaction for the two aggregators, and 
discovered a surprising stoichiometric ratio of the number of bound enzyme molecules per aggregate. 
This was determined to be 12,850 ± 875 for nicardipine, and 10,040 ± 440 for miconazole.46 Though 
surprising, this data is consistent with known aggregate behaviour, aggregate inhibition is sensitive to 
changes in enzyme concentration and increasing enzyme concentration 10 fold eliminated observed 
inhibition.46,52 As aggregates are only present at the fM range, increasing enzyme concentration 
overwhelms the ability of the aggregate to sequester enzyme. The group also elucidated that these 
aggregates are composed of 108 monomer units, that these aggregates are densely packed and that 




the surface of the aggregates is large enough to accommodate all of the calculated bound enzyme 
molecules.46   
McGovern et al. uncovered three mechanistic features of aggregate molecules.52 First, 
inhibition occurs through direct binding of the enzyme to the aggregate, as observed by the ability to 
sediment protein-aggregate complexes via centrifugation, the punctate fluorescence as seen in 
microscopy in mixtures of aggregates with green fluorescent protein, and direct observation of 
protein-aggregate complexes by electron transmission microscopy. Second, addition of non-ionic 
detergent results in reversal of aggregate based inhibition. Third, several experiments rule out full 
denaturation of the enzyme. Coan et al. used these concepts to uncover a proposed mechanism of 
aggregate particles on enzymes.52 Using 1H – 2H exchange mass spectrometry and proteolysis of 
enzyme-aggregate complexes, the group proposed that aggregate inhibition is due to partial unfolding 
of the enzyme when bound to an aggregate particle.45  
In 2007, a HTS identified 95 % of hits showed aggregate based behaviour, this represents an 
overwhelming amount of molecules that may be false positives, and thus substantially reduces the hit 
rate of non-aggregating specific inhibitors.53 Another major issue with poorly aqueous soluble 
compounds is the tendency of the compound to precipitate out of solution during biological assays 
which causes difficulties in the interpretation of activity values.54 The above mentioned research 
exemplifies the importance of aqueous solubility on the interpretation of biological data resulting 
from biochemical assays. If poor aqueous solubility tracks with increased enzyme activity, care must 
be taken to ensure this activity is not from false readout through aggregate based inhibition.     
iii) Drug metabolism 
Drug metabolism is an enzymatic chemical biotransformation of a drug compound to more 
hydrophilic water soluble metabolites to aid excretion from the body. In humans the liver is the most 
important site of drug metabolism. Drug metabolism is split into two phases.39  
i) Phase I metabolism. Involves reduction, oxidation and hydrolysis reactions of a 
particular compound. One of the major routes of metabolism of numerous 
compounds is through cytochrome P (CYP) metabolism, specifically via the CYP450 
superfamily.39 
ii) Phase II metabolism. Involves the additions of highly polar molecules to the drug. An 
example of phase II metabolism is glucuronidation. Note phase I and II metabolism do 
not have to be sequential. A drug can be metabolised by phase I followed by phase II, 
phase I exclusively, phase II exclusively, or phase II followed by phase I.39       




Drug metabolism affects numerous parameters such as oral bioavailability, clearance time, 
and half-life. This can then have significant impact of toxicity and efficacy of a drug. As a chemical 
transformation of a drug takes place its structure is inadvertently altered. This can result in a loss of 
therapeutic effect, or in some cases a gain of therapeutic effect, compounds that are metabolised to 
an active drug in this manner are known as prodrugs. Further to the alteration of a therapeutic effect, 
the drug metabolite can become toxic to the host via affecting off-target biochemical pathways, 
something which of course is highly disfavoured.39  
In terms of entering the clinic, drug metabolism and efficacy affect the dosing regimen. Drugs 
that are metabolised quickly can require multiple dosings per day or higher dosing to show a desirable 
therapeutic effect.39 Drugs that are metabolised slowly are ideal, however, too slow can also be 
problematic as a drug that bio-accumulates can itself then become toxic over a certain concentration 
threshold.39 
The gold standard for a drug is a half-life at a point where a once daily dosing regimen can be 
taken with no issues of toxicity.39 A perfect drug would ideally be administered as single dose cure. 
Dosing in this manner holds a major advantage in patient compliance and in the case of pathogens 
this can help slow the spread of resistance.    
To examine the metabolic stability of a particular drug in vitro, subcellular fractions such as 
liver microsomes are used to predict the hepatic clearance of a drug as they contain many of the phase 
I metabolising enzymes found in the liver but do not have an intact cell membrane. A down side to 
microsomes, however, is that metabolism can be underestimated especially if the primary metabolism 
route is via phase II. To this end hepatocytes have an advantage of possessing an intact cell membrane, 
and hold all enzymes from phase I and phase II metabolism, therefore they more accurately represent 
an in vivo system. As mentioned above compounds that are metabolised (or cleared) quickly are 
discouraged as upon entering an in vivo model the compounds will be cleared rapidly giving a poor 
half-life and thus poor therapeutic window.39  
Selected compounds have been tested for human microsomal (mics) stability to assess the 
stability of a compound when it enters CYP450 oxidation via phase I metabolism. The same 
compounds have also been tested in the presence of rat hepatocyte cells (heps) to assess the potential 
situation should the compound enter in vivo studies. Some selected compounds were also been tested 
for mouse microsomal (mics) stability as the majority of early in vivo models for malaria are examined 
in mouse. Table 2.5 below indicates the rate when a compound is considered to be metabolically 




cleared slowly or quickly. As mentioned above selected compounds were also examined for their 
LogD7.4 and aqueous solubility profiles.39,55  
Table 2.5. Criteria to assess the rate of metabolic clearance. High clearance is shown in red (poor), low clearance is 
shown in green (good). 
Clearance 
Catagory 
In vitro microsomal intrinsic clearance 
mL / min / mg protein 
In vitro hepatocyte intrinsic clearance 
mL / min / 106 cells 
Human Mouse Rat 
Low ≤ 8.6 ≤ 8.8 ≤ 5.1 
High ≥ 47 ≥ 48 ≥ 28 
 
In vitro testing of 1a and 6 with both PfIspD using a pyrophosphate release assay, and Pf3D7 
whole cell assay gave respective IC50 values and EC50 values of 25.3 ± 5.6 nM and 349 ± 30 nM for 1a, 
and 21.6 ± 2.7 nM and 373 ± 86 nM for 6. This is encouraging as both 1a and 6 yield similar activities 
as observed by Yao et al. as summarised in Table 2.6 below. Note there are some minor discrepancies 
between the values, and this is likely due to the slightly different Pf strains used between our group 
and Yao et al. 
Table 2.6. Inhibitory activities of 1a and 6 against PfIspD, parasite growth (3D7 our work) and (Dd2 Yao et al. work).9 
Compound  PfIspD IC50 (nM) Pf3D7 EC50 (nM) Yao PfDd2 IC50 (nM) 
1a 25.3 ± 5.6 n = 3 349 ± 30 n = 6 250 ± 70 
6 21.6 ± 2.7 n = 3 373 ± 86 n = 4 190 ± 30 
 
It was our initial goal to synthesise both acid and methylamide derivatives of the majority of 
compounds, however, for three reasons we changed this strategy to synthesise amide derivatives 
solely. Firstly, upon exploring C-ring modifications, the amberlyst catch and release protocol reported 
by Yao et al. failed, and no reactions were observed.9 Although this ester can be hydrolysed easily in 
the presence of base, the zwitterionic nature of the final compounds made removal of salt 
contamination difficult even after column chromatography; this was noticeable as CHN analysis was 
consistently and considerably out of the target range. Furthermore, there was concern that addition 
of hydroxide as the base and long reaction times could run the risk of epimerisation of the C3 
stereogenic centre, potentially further complicating purification procedures. Therefore these 
compounds were not tested and are not included as part of this work. Secondly, synthesising amide 
derivatives possessed numerous advantages; purification was trivial with most reactions progressing 
to completion with little to no side products. Thirdly, the amides are considered less susceptible to 
drug-metabolism, therefore, are likely to increase the half-life and pharmacokinetic profile of the drug. 
The amides had also already demonstrated potential improved potency over the hit molecule. Finally, 
crystallisation was simple, all compounds could be successfully recrystallised from neat methanol, in 




some cases these recrystallisations gave rise to X-ray quality crystals, and as such X-ray analyses on 
these compounds were used as structural characterisation. X-ray analysis gives us extra confidence 
that the correct stereoisomers were indeed used in our studies as absolute stereochemistry can be 
determined.33–35 
2.2.4 C-ring Modifications     
 We began our SAR of the template first investigating exploration of the C ring asking three 
questions. 
i) Can the C-ring nitrogen be substituted? 
ii) Is basicity of the C-ring nitrogen required?  
iii) Are there alternatives to the NHMe amide? 
To answer the first question intermediate 17 was prepared. This was accomplished in good 
yield of 67 % through simple addition of MeI to 4 in the dark Scheme 2.3. The same reaction in light 
led to highly diminished yields and side products that needed to be removed on column. The final 
compound 18 was then successfully synthesised from the direct amide coupling of MeNH2 following 
Scheme 2.3 in excellent an yield 99 %.    
 
Scheme 2.3. Synthesis of compound 18. 
To answer the second question molecules 20 and 21 were generated through slightly different 
procedures. A further rationale behind the synthesis of 20 was to investigate if a compound mirroring 
tadalafil (9) could target PfIspD and be antiplasmodial. Unlike the investigation using (1R, 3R)-tadalafil 
(9) by Yao et al., we conducted this study with (1R, 3S)-configuration. We also replaced the aryl ring 
with that of the MMV template with the required 2-Cl, 4-Cl substitution pattern. This compound was 
generated via the addition of bromoacetyl bromide to 4 forming 19 in 80 % yield. Cyclisation to 20 
was successfully achieved in the presence of 5 equivalents of MeNH2 in moderate yield of 57 % 
(Scheme 2.4). We reduced the number of equivalents of MeNH2 substantially to overcome the 
potential of the addition of two molecules of MeNH2, one into the ester, and the other into the alkyl 
bromide side chain. 





Scheme 2.4. Synthesis of compound 20. 
Finally, 21 was designed to see if activity benefited from being cyclic or not as 21 is essentially 
a ring-opened form of 20. 21 was initially planned to be generated following a similar route to 20, 
reacting 4 in the presence of AcCl and NEt3 before amide coupling to the final target. However, this 
first reaction despite apparent full conversion to a single spot via TLC resulted in an NMR spectrum 
that was difficult to interpret. We initially believed that the reaction conditions had epimerised the 
carboxylate group at C3 as this would explain the presence of extra peaks due to the formation of a 
diastereoisomer, but no separation on TLC could be observed. We instead resynthesised compound 
6, and performed the coupling of AcCl at this stage as the final step giving a yield of 60 % (Scheme 2.5). 
Similar to the reaction with the ester the NMR led to broadened signals and more peaks than 
expected. We postulated that this compound therefore existed as a rotamer, as we did not expect 
epimerisation of the C3 stereogenic centre with either the ester or the amide. Analytical chiral HPLC 
of 21 appears to back this postulation up as only one peak is seen using the protocol described in the 
experimental section (Section 2.5.2). 
 
Scheme 2.5. Synthesis of 21. 
To answer question three we examined the SAR from Yao et al. and noticed two molecules of 
interest that they had not tested. These include utilising a two other alkyl amides, the first cyclopropyl 
and the second ethyl. We are interested in cyclopropyl amide as it is sterically smaller than the tested 
iPr and thus offers renewed chance to regain activity if it spatially complements the fit of the IspD 
active site. The second amide, an ethyl amide would be the smallest straight chain alkyl tested after 
methyl amide. Yao et al. did not test smaller than nBu and thus it was possible that a methyl amide is 
not the best fit for the IspD active site, therefore there is a chance of improving potency by testing 
longer chain alkyls bigger than Me, but smaller than nBu.  




Generation of the two alkyl amides 22 and 23 followed a similar procedure to that described 
for the hit molecule (Scheme 2.6). In the case of 22 the reaction required heating to 50 °C likely due 
to the extra steric demand the cyclopropyl amine compared with methyl amine. This reaction required 
purification by column chromatography due to the formation of unknown side products, however, the 
reaction yield was moderate of 49 %. 23 was synthesised following a similar protocol to 6 in also in 
moderate yield of 51 % Further to these two alkyl based amides, we also tested an unsubstituted 
hydrazide moiety (synthesised by 4th year project student Lauren Wray) 24 and a hydroxamic acid 
moiety (synthesised by 4th year project student Lauren Wray and Erasmus student Giacomo Paloscia) 
25 as potential bioisosteres (Scheme 2.6).  
 
Scheme 2.6. Synthesis of compounds 22 and 23. 
2.2.4.1 Biological Activity of C-Ring Modifications against PfIspD and Pf3D7 
C-ring modifications of 1a were tested in vitro for their inhibitory activity against PfIspD and 
were also tested against Pf3D7 cells as displayed in Table 2.7 (for direct comparison 1a and 6 are also 
displayed). Table 2.7 reveals that optimal activity was achieved from 1a and 6. It is apparent that 
potency is dramatically affected by the incorporation of substituents at the C-ring nitrogen. The 
incorporation of a simple Me group as seen with 18 retains basicity of this nitrogen atom, however, 
this still results in the loss of potency of approximately 100 fold vs the IspD enzyme and approximately 
50 fold in the cellular assay. Similarly compounds 20 and 21, were the C-ring nitrogen atom has greatly 
reduced basicity, exhibit complete loss of potency against both enzyme and cell. Based on the values 
obtained it appears that there is at least one of the following requirements: i) the nitrogen must be 
unsubstituted due to a strict spatial requirement of the active site, ii) the nitrogen atom must be a 




hydrogen bond donor as activity is lost with substitution, iii) the nitrogen must also be basic as activity 
is further reduced via amide incorporation.    
 
Table 2.7. Inhibitory activities of C-ring modifications against PfIspD, and Pf3D7, values are colour coded with a traffic 
lights system according to how good or bad a specific value is. Green = good, amber = acceptable, red = poor.  
Entry R R’ PfIspD IC
50
 (nM) Pf3D7 EC
50
 (nM) ClogD7.4 Aq. Sol. (M) SFI 
1a OH H 25.3 ± 5.6 n = 3 349 ± 30 n = 6 2.9 N/A 5.9 
6 NHMe H 21.6 ± 2.7 n = 3 373 ± 86 n = 4 4.1 16 7.1 
18 NHMe Me >2000 n = 2 8070 ± 115 n = 4 4.6 9 7.6 
20 N(Me)R’ COCH2R >5000 n = 1 >10000 n = 3 3.7 N/A 6.7 
21 NHMe Ac >5000 n = 1 >10000 n = 3 3.9 N/A 6.9 
22 NH-cycPr H 594 ± 178 n = 2 6000 ± 341 n = 4 4.5 N/A 7.5 
23 NHEt H >1000 n = 2 8110 n = 1 4.4 N/A 7.4 
24 NHNH2 H 83 n = 1 4920 n = 1 3.4 N/A 6.4 
25 NHOH H Not tested 1000 ± 90 n = 3 3.9 N/A 6.9 
 
Of the whole series only two compounds (6 and 18) had aqueous solubility measured. 
Compound 6 possessed a lower ClogD7.4 value and SFI than 18, as can be predicted from this, 
compound 6 demonstrates higher aqueous solubility than 18. When comparing the enzyme activities 
of these two compounds, the activity is substantially dropped with decreased solubility. When 
considering compound 1a, the SFI is lower than 6 or 18, therefore, it would be predicted to possess 
improved aqueous solubility in comparison to 6 or 18. Comparing SFI to activity, 1a is still active when 
it has the highest predicted solubility, this could back up that the activity of this series is not due to 
aggregate formation. However, for future work a measured solubility assessment of 1a would be 
required. Despite these trends suggesting non-aggregate behaviour, the SFI of all compounds 
(including 1a) is higher than ideal, the predicted aqueous solubility of 1a will likely still be low, and the 
aqueous solubility is low for compound 6. Therefore, aggregate formation of 1a and 6 cannot be ruled 
out. For future work regarding all compounds, assays could be repeated with non-ionic detergent, if 
activity is retained in the presence of non-ionic detergent it is likely the activity is not due to aggregate 
formation.  
 Upon examination of potential replacements of NHMe as the amide from 6, again we can see 
a clear trend that 6 retains the best potency against both enzyme and cell assays. Replacement to the 




cyclopropyl amide 22 results in approximately 30 fold drop in activity against IspD and this result is 
mirrored by poor potency vs Pf3D7. Surprisingly the NHEt amide demonstrates a 45 fold drop in 
potency against IspD. We would have expected that 22 and 23 would possess similar activity, as 
sterically they are not too different and both possess a similar ClogD7.4, similar SFI value, and thus, 
similar predicted aqueous solubility. We postulate that the terminal CH3 of the ethyl is bound by a 
rotatable bond and is not constrained in a ring like is seen with the equivalent carbon atom in the 
cyclopropyl derivative. This free rotation could cause unfavourable steric clashes in a small binding 
pocket.  
Compound 24 bearing a hydrazide moiety regains activity vs IspD but surprisingly suffers poor 
cell potency, this could be due to poor membrane permeability but it is not related to lipophilicity 
(measured as ClogD7.4 defined in Section 2.2.3) or aqueous solubility. As can be seen in Table 2.7, 1a 
and 6 both possess lower and higher ClogD7.4 values, respectively when compared with 24 and 
aqueous solubility would be predicted to be in between the 1a and 6. Again, aggregate formation in 
the enzyme assay cannot be ruled out at this time. Finally, though not yet tested vs IspD, compound 
25 displays moderate potency against Pf3D7 cells. We believe that in the IspD assay the compound 
should possess good inhibitory activity, as 25 was designed to act as a potential metal chelator to bind 
to Mg2+ in the IspD active site in a similar manner to how fosmidomycin binds within IspC. Indeed the 
moderate activity seen in cell is promising and therefore may back this postulation up. However, we 
were disappointed with the cell activity of 25, it appears that there is also a potential issue with 
membrane permeability of this compound, but again, if that is the case it is not related to ClogD7.4. 
2.2.4.2 Analysis of the Drug Metabolism and Pharmacokinetic (DMPK) Properties of the Hit 6 and 
Compound 18 
 To date an in vitro DMPK assessment of 1a and 6 had not been carried out in the literature. 
Thus as part of the programme we also analysed compound 6, for its DMPK profile in order to see if 
the MMV template had any metabolic short-comings. As part of C-ring optimisation we also decided 
to take compound 18 forward for DMPK testing to examine what effect increasing ClogD7.4 or SFI has 
on the DMPK profile.  
It is clear from Table 2.8 below that the template needs major improvement of DMPK 
properties. 6 has a measured LogD7.4 just outside the desirable 1 – 3 range. SFI is larger than the upper 
threshold of 5 and thus solubility is predicted to be low. Compound 6 is also classified as possessing 
increased metabolic liability, as shown in the metabolic stability profile it has medium clearance from 
human microsomes and rapid clearance from rat hepatocytes. A major drawback for 6 is its metabolic 




stability when exposed to mouse microsomes. 6 possesses an extremely high rate of clearance; 
because of this it is unlikely that it would show efficacy in in vivo testing within the mouse malaria 
model. As expected, 18 has an increased measured LogD7.4 when compared with 6, it is more lipophilic 
and therefore, has lower aqueous solubility than 6. Furthermore, as the LogD7.4 value for 18 is higher 
than that of 6, this suggests that 18 may be highly susceptible to metabolism compared with 
compound 6. Examination of the metabolic stability profile confirms that 18 is highly susceptible to 
metabolism as this compound possesses clearance rates almost twice as fast as 6 against human 
microsomes, and rat hepatocytes. As a result, this compound was not tested for mouse clearance 
which we also expect to be further diminished in comparison to 6.     
Table 2.8. DMPK profiles of compounds 6 and 18. Green = good, amber = acceptable, red = poor. 
Entry LogD7.4 ClogD7.4 Aq. Sol. 
(M) 
SFI Human Mics CLint 
(mL / min / mg) 
Rat Heps CLint 
(mL / min / 
106) 
Mouse Mics CLint 
(mL / min / mg) 
6 3.8 4.1 16 7.1 30.17 44.26 202.4 
18 4.8 4.6 9 7.6 76.40 76.43 Not tested 
 
2.2.4.3 Conclusion of C-ring Series SAR 
 
Figure 2.10. Conclusion of C-ring SAR. 
 Compound 6 remains optimal for activity against both IspD and 3D7. It appears as though any 
extra steric demand of the carboxylate group after NHMe significantly drops inhibitory activity, 
indicating that this moiety fits within a tight binding pocket. Substitution of the C-ring N atom of any 
kind is not tolerated at all as part of the SAR; incorporation of a Me group leads to greatly diminished 
potency whilst incorporation of amide functionality results in complete loss of potency. Examination 
of the DMPK profile of 6 gave concern for the metabolic stability of the compound in rat hepatocytes, 
human microsomes, and mouse microsomes. Compound 6 exhibits extremely rapid clearance times, 




potentially hampering any future in vivo testing of the compound in the mouse model of malaria. 
Finally, all compounds possess high a SFI value, and when measured, also possess poor aqueous 
solubility leading to difficulties in the interpretation of the SAR. Due to the results of the C-ring SAR 
presented here all compounds retain the optimal C-ring core (presented in Figure 2.10). 
2.2.5 D-ring modifications 
2.2.5.1 D-ring Di-substitution  
 
Figure 2.11. Explored D-ring di-substitution patterns. 
      Regarding D-ring functionalisation we focused our SAR on numerous substitution patterns. 
Initially, we examined further the effect of di-substituted ring motifs on activity to gain further 
knowledge of the specific requirements of this ring. Based on work by Yao et al.  the 2-Cl seems to be 
a requirement when a substituent is at the 4-position of the aromatic ring. Therefore in our SAR this 
2-Cl substitution was always kept in place. We found it very unusual that the loss of potency against 
cell observed with 2, 4-bisCF3 substitution had occurred in the SAR studies carried out by Yao et al.9 
We therefore wanted to examine the effect of 2-Cl, 4-CF3-substitution on IspD and cellular potency, 
and thus generated compound 28 (Figure 2.11).   
 In addition we wanted to explore the steric demand around the 4-position; the active site 
itself appears to tolerate sterically demanding groups, as 2-Cl, 4-Cl is already relatively large from a 
steric point of view. Of commercially available aldehydes at the time, we located and obtained 2-Cl, 
4-Br benzaldehyde. The incorporation of an even bigger halogen allows us to assess what we can 
manipulate around this aryl ring. Furthermore, the bromine atom is essentially acting as a source of 
lipophilicity allowing us to probe not only steric demand, but electronics of the D-ring as-well. From 
this benzaldehyde compound 29 was generated (Figure 2.11). 
 As the last of the di-substitution patterns explored we deviated away from a 2, 4-di-
substitution pattern and instead wanted to probe the 6-position generating compound 30 (Figure 
2.11). As of yet this position on the molecule had not been explored, this allows us to probe the steric 
demand of the other half of the D-ring, and if the substituent is big enough this should force without 




ambiguity the D-ring to lie perpendicular to the tetrahydro-β-carboline core. In order to nullify the 
potential effect of atropisomerism, 2-Cl, 6-Cl was chosen as the substitution pattern. Furthermore this 
pattern is more suitable for a direct comparison with 2-Cl, 4-Cl substitution.  
2.2.5.2 D-ring Tri-substitution 
 Following from the exploration of di-substituted patterns we were also interested in looking 
at tri-substitution. As previously mentioned the D-ring appears to tolerate relatively sterically 
demanding substitution, it can therefore be proposed that additional small or even large substituents 
could optimise potency. The first logical course of action to take was the exploration of 2, 3, 4-
substitution were the 2, and 4-positions remained as Cl atoms. We chose to generate compounds 31 
and 32 baring F and Cl atoms, respectively (Figure 2.12). 31 baring small functionality (Van der Waals 
radius of F = 1.47 Å vs H = 1.20 Å) and a potential H-bond acceptor in fluorine could improve potency 
if the fluorine atom is in proximity to a hydrogen bond donor in the active site.56,57 The small size of 
fluorine should not have a big impact in terms of steric requirements and thus should still fit within 
the IspD binding pocket. 32 on the other hand allows us to probe steric demand, if activity is improved, 
32 may indicate some flexibility within the binding site to accommodate the change. The advantage 
of incorporating halogens in this way means that metabolic stability can potentially be improved, 
especially in the case of fluorine incorporation. The fluorine atom is highly electronegative and 
furthermore the C-F bond has very high bond strength (C-F strength = 513.8 KJmol-1 vs C-H = 338.4 
KJmol-1); the advantage of this is that positions occupied by fluorine become less metabolically labile 
as biological transformations become less favoured compared with the same position occupied with 
a hydrogen atom.57,58 
  In addition to halogen substitution, the 3-position carbon was also replaced with a nitrogen 
atom (Figure 2.12), i.e. turning the D-ring into a pyridyl aromatic ring (34a) (Synthesised by 4th year 
project student Lauren Wray). This holds three advantages in comparison to the addition of 
substituents to the C3 carbon. Firstly, steric demand is not a factor, in effect what we really have is a 
2, 4-di-substituted pyridyl, rather than a tri-substituted Ar-ring. In terms of comparison to compound 
6 there should be very little difference from a steric point of view. Secondly, similar to fluorine, the 
nitrogen atom has the ability to pick up an extra hydrogen bond in the active site, nitrogen is more 
prone to hydrogen bonding than fluorine, which may enhance binding energy within the enzyme; in 
turn this could lead to enhanced potency.57,59,60 Thirdly, another major advantage of using a nitrogen 
atom in this way is that because of the increased polarity of nitrogen, the LogD7.4 will drop, as a 
consequence, aqueous solubility should increase and metabolic liability should decrease. For this 
reason this compound and derivatives of it are very interesting to explore. 




 In addition to 2, 3, 4-substitution 2, 4, 5-substitution and 2, 4, 6-substitution has also been 
examined. The rationale for exploring these positions is the same as it was for 2, 3, 4-substitution. The 
advantage with 2, 4, 5 and 2, 4, 6-substitutions is that we can explore the other side of the D-ring, 
allowing us to determine if substituents can be either sterically or electronically tolerated in the active 
site. For 2, 4, 5-substitution, due to the commercial availability of the aldehydes only compounds 35 
(5-F) and 36a (5-N in place of 5-C) were examined. For 2, 4, 6-substitution, (synthesis carried out by 
former PhD student Dr Kathyrn Price) compounds 37 (6-F), 38 (6-Cl), 39 (6-OH), 40 (6-OMe), 41 (6-N 
in place of 6-C) were examined. Compound 38 is interesting to explore as like 30 a chlorine atom is at 
both 2 and 6-positions, however, if activity is also dependent on a 4-position substituent, any loss of 
activity for 2, 6-di-substitution could be regained with 2, 4, 6-tri-substitution. For compound 39, in 
contrast to halogen substitution which acts as a potential hydrogen bond acceptor, a hydroxyl 
derivative examines the effect of a hydrogen bond donor. Examining the methoxy derivative 40 then 
allows us to probe the steric demand again around the active site (Figure 2.12).   
 
Figure 2.12. Differing substation patterns explored as part of the SAR of the D-ring. 
With the exception of 34a and 36a all compounds were synthesised following Scheme 2.7. 
The free base of L-tryptophan methyl ester (13) was coupled with various di-and tri-substituted 
aldehydes utilising the Pictet-Spengler reaction yielding 26a – l as trans isomers and 27a – l as cis 
isomers. With the exception of 26c and 27c, all diastereomers could be separated at the ester stage. 
26c and 27c were taken forward to the amide coupling forming 30a (trans) plus 30b (cis) which were 
then separated at this stage.  





Scheme 2.7. Synthesis of D-ring modifications. 
Isolated reactions yields of both trans and cis isomers from the Pictet-Spengler reactions of 
each differing substitution pattern from Scheme 2.7 are displayed in Table 2.9 below, subsequent 
Table 2.10 displays yields for the final amide couplings, all yields are reported after recrystallisation. 
Note only compounds synthesised by myself are included in the data tables. Therefore please also 
note compounds not displayed are 26g – l, 27g – l, and 37 – 41, and that 37 – 41 are synthesised 
chronologically from 26g – l (Synthesis carried out by former PhD student Dr Kathryn Price).    
 
Table 2.9. Yields of the Pictet-Spengler reaction with various different aldehydes.  
Compound X % Yield 
26a 4-CF3 33 
26b 4-Br 17 
26c & 27c 6-Cl 80 
26d 3-F, 4-Cl 26 
26e 3-Cl, 4-Cl 29 
26f 4-Cl, 5F 29 
27a 4-CF3 55 
27b 4-Br 34 
27d 3-F, 4-Cl 60 
27e 3-Cl, 4-Cl 48 
27f 4-Cl, 5F 58 
 





Table 2.10. Yields of the final amide couplings. 
Starting material Product X % Yield 
26a 28 4-CF3 91 
26b 29 4-Br 87 
26c & 27c 30a (trans) 6-Cl 14 
26c & 27c 30b (cis) 6-Cl 34 
26d 31 3-F, 4-Cl 99 
26e 32 3-Cl, 4-Cl 88 
26f 35 4-Cl, 5F 87 
 
In general the combined cis and trans Pictet-Spengler reaction yields were very good ranging 
from 77 % to 88 %, with the exception of 4-Br substitution giving a yield of 51 %. Generally cis to trans 
ratio was 2 : 1. Compounds of interesting note are 26c and 27c. There are two reported cases in the 
literature which state that 26c cannot be observed and that cis selectivity is 100 %.61,62 The general 
procedure for this compound differed slightly to what was described in literature, the difference being 
that at the time of reaction for this compound lab temperature was 12 °C not standard room 
temperature. Therefore at least for this substitution pattern, cooler temperatures seemed to lead to 
higher trans selectivity. Unfortunately, as described above the compounds could not be separated at 
ester stage, the presence of the trans product needed to be confirmed by NOESY of the combined 
diastereoisomers, fortuitously, the C1 and C3 hydrogen atoms of the two diastereoisomers have 
differing chemical shifts which allowed the determination of the cis and trans product. As can be 
observed from Table 2.10, amide couplings generally proceeded well, with the exception of 30a and 
30b. Although separation could be achieved on column, it was minimal, and some fractions remained 
mixed. Reported in Table 2.10 are the isolated yields only.    
The synthesis of 34 and 36 required alternate approach. It was observed that reacting the 
trans ester of 2-Cl, 4-Cl, 5-N, with MeNH2 led to substitution of one of the chlorine atoms with MeNH2 
along with amide formation. Unfortunately we could not determine which chlorine had been 
substituted and is not included as part of the reported data. (Out of interest, however, it was tested 
anyway and proved to be inactive). As we did not know whether the 2-chlorine atom (para to the 
pyridine nitrogen atom) or 4-chlorine atom (ortho to the pyridine nitrogen atom) had been substituted 
we did not want to run the risk of having the same side reaction occur again when pyridine nitrogen 




atom was at the 3-position, in this case both chlorine atoms are ortho to the pyridine nitrogen atom 
and either one could be substituted. We instead carried out the reactions in reverse order, amide 
coupling MeNH2 into L-tryptophan methyl ester (13) first forming 33 in 99 % yield, and then carried 
out the Pictet-Spengler reaction as the last step yielding the 36a and 36b in yields of 6 % and 31 %, 
respectively (Scheme 2.8). When a nitrogen atom is at the 6-position as displayed in 41 this approach 
is not necessary as Cl atoms are meta and cannot be easily substituted (Note 34a and 34b synthesised 
by 4th year project student Lauren Wray, compounds not shown). 
 
Scheme 2.8. Alternative synthesis for the generation of compounds 36a. 
2.2.5.3 Biological Activity of D-Ring Modifications against PfIspD and Pf3D7 
 Most D-ring modifications of 6 were tested in vitro for their inhibitory activity against PfIspD 
and against Pf3D7 cells as displayed in Table 2.11 and selected compounds were also assessed for 











Table 2.11. Inhibitory activities of D-ring modifications against PfIspD, and Pf3D7 Green = good, amber = acceptable, red 
= poor. 








ClogD7.4 Aq. Sol. 
(M) 
SFI 
1a OH 4-Cl 25.3 ± 5.6 n = 3 349 ± 30 n = 6 2.9 N/A 5.9 
6 NHMe 4-Cl 21.6 ± 2.7 n = 3 373 ± 86 n = 4 4.1 16 7.1 
28 NHMe 4-CF3 80.2 ± 18.3 n = 4 3730 ± 534 n = 3  4.3 N/A 7.3 
29 NHMe 4-Br 160 ± 24.2 n = 3 248 n = 1 4.1 10 7.1 
30a NHMe 6-Cl >5000 n = 2 >250000 n = 1 4.1 19 7.1 
31 NHMe 3-F, 4-Cl 1140 ± 241 n = 3 3260 n = 1 4.3 0.5 7.3 
32 NHMe 3-Cl, 4-Cl 2530 ± 161 n = 2 598 n = 1 4.7 6 7.7 
34 NHMe 3-aza, 4-Cl Not tested 8960 ± 2380 n = 3 3.3 N/A 6.3 
35 NHMe 4-Cl, 5-F >5000 n = 1 >100000 n = 1 4.3 3 7.3 
36a NHMe 4-Cl, 5-aza >5000 n = 2 >250000 n = 1 3.1 9 6.1 
37 NHMe 4-Cl, 6-F 2220 n = 1 Not Tested 4.3 N/A 7.3 
38 NHMe 4-Cl, 6-Cl >5000 n = 1 Not Tested 4.7 N/A 7.7 
39 NHMe 4-Cl, 6-OH >5000 n = 1 Not Tested 3.6 N/A 6.6 
40 NHMe 4-Cl, 6-OMe >5000 n = 1 Not Tested 4.0 N/A 7.0 
41 NHMe 4-Cl, 6-aza >2000 n = 1 Not Tested 3.3 N/A 6.3 
 
From the results displayed around the SAR in the D-ring it is apparent that there appears to 
be restricted requirements in order to maximise potency. The first compound from the di-substituted 
series examined was 28 to see what effect CF3 substitution on the aryl ring has on potency. Our initial 
thoughts on the Yao et al. study showing a loss of cellular potency with 2, 4-bisCF3 substitution were 
that this was unusual. While we looked only at the 4-substitution it is clear that the compound inhibits 
IspD effectively as we believed it should, bearing only a 4 fold loss of potency. However, our poor 
whole cell potency seems to mirror the result observed by Yao et al.9 Similar to the C-ring optimisation, 
cell activity does not correlate with CLogD7.4 or SFI values, as 28 is almost identical to 6. We then 
examined the steric effect by adding Br to the 4-position in 29. Much to our delight, and also surprise, 
this compound is still potent against IspD, whilst it is 8 fold less potent then the hit, the cellular potency 
though only tested once, very much to our surprise, is our current most active compound in the 
phenotypic assay, which also shows potency against IspD. We can deduce that there is a range of steric 
tolerance at the 4-position; it could be therefore a place of chemical manipulation. It may possibly be 
that the 4-position of the D-ring is pointing out into solvent exposed space. For future work it would 
be ideal to examine the effect of adding a potential solubilising group at this position, to explore steric 




demand while also attempting to reduce the LogD7.4 of the template as a whole. This should aid in 
reducing the potential for aggregate formation and may improve the DMPK profile of the series. The 
final di-substitution pattern with 2-Cl, 6-Cl 30a unfortunately showed complete loss of activity 
suggesting that the 6-position cannot be substituted.  
From the di-substituted series compounds 6, 29, and 30a were assessed for their aqueous 
solubility. The SFI is >7 for all compounds in this series and this translates to the poor aqueous 
solubility of these compounds. Compounds 6 and 29 both possess potent enzyme and cell activity, the 
SFI value of these two compounds is also the same (SFI = 7.1 for 6, and 29). However, compound 6 
shows slightly improved aqueous solubility compared with 29. Due to the compounds both possessing 
the same SFI value and similar aqueous solubility values, aggregate formation cannot be ruled out for 
either of these compounds due to the poor aqueous solubility observed. Compound 30a is inactive in 
both the enzyme and phenotypic assay despite possessing the same SFI, but has improved aqueous 
solubility over compound 6. Compound 28 was not sent for aqueous solubility assessment, but of the 
di-substituted series it possess the highest SFI, and so is predicted to possess the lowest aqueous 
solubility of the series, it is active in the enzyme assay but not in the phenotypic assay. 
 It is clear is that steric demands around the D-ring cannot be the only determining factor for 
potency. In all examples of tri-substitution, only the 3-F substituent (compound 31) gives moderate 
enzyme potency, all other compounds are considered inactive. But again on transferring to the cell, 
all compounds including fluorine substitutions are inactive, with the exception of 2, 3, 4 tri-chloro 
substitution (compound 32), which is only moderately active against enzyme, but displays good 
activity in cell. Therefore, it is highly likely this compound is exhibiting off target effects and this could 
be confirmed with an IPP rescue screen in the future. It is odd that the incorporation of one fluorine 
affects activity so substantially. As previously mentioned, sterically it is not much larger than a 
hydrogen atom.56,57 Therefore, it should exhibit very little extra steric clashes in the active site, and 
any steric effect that may occur does not seem enough to explain the amount of potency loss we 
observe. In the case of 3-position substitution the fluorine is shielded by the much larger chlorine 
atoms, therefore steric demand does not account for the loss of potency. It does appear that there is 
a very strict but not fully understood electronic requirement for this D-ring that determines optimal 
potency.  
 Examination of the compounds with measured aqueous solubility data and comparing with 
activity values also yields results that are difficult to interpret. Compounds 31, 32, 35, and 36a were 
assessed for their aqueous solubility, all compounds show poor aqueous solubility vales of less than 
10 µM. 31 is practically insoluble in an aqueous environment, yet still shows some moderate enzyme 




activity and cell activity. Whether this is due to aggregate formation or not is not clear, and as 
previously mentioned, this can be assessed through the addition of non-ionic detergent to the assay 
in the future. However, if the compound is precipitating out of solution, then this could explain why 
this compound appears to show reduced activity when compared with 1a and 6, as what precipitates 
will not interact with the enzyme. Compound 32 has a higher SFI value than 31, however, it was 
determined to show enhanced aqueous solubility when compared with 31 (6 µM). 32 showed a 2 fold 
loss of potency in the enzyme assay, but as mentioned above it, is more potent than 31 in the 
phenotypic assay. Whether this result is due to enhanced solubility of this compound in comparison 
to 31, or due to off target effects is not clear at this stage. An off target effect could be examined with 
an IPP rescue screen as previously mentioned. Compound 35 was expected to possess similar activity 
to 31, however, complete loss of activity is observed in both enzyme and phenotypic assays. 
Compound 35 also possesses poor aqueous solubility (3 µM) and its loss of activity may be accounted 
for if it precipitated during the course of the biological assays. 
Perhaps most disappointingly is the loss of potency observed with all pyridyl analogues. These 
analogues should not have any significant effect on steric requirements in the active site compared 
with compound 6, and yet potency across all three differing substitutions is lost. Compound 36a, 
despite having a lower SFI value, was determined to possess poorer aqueous solubility than the hit 
compound (6) and lost potency. Clearly there are effects in the D-ring binding site that disfavour either 
polar interactions or an electron deficient aromatic ring. Using a ring with electron donating 
substituents may lead to improvement of potency. Other than methyl, all substitutions have been 
based around heteroatoms within the known SAR. To date larger chain alkyl chains have not been 
examined at the 4-position of the D-ring, it could be that branched alkyl chains may also lead to 
improved potency, however, from a DMPK point of view; this could make the molecule less drug-like 
and should be considered before further drug design.  
As a concluding remark on the SAR of the D-ring another point to consider is; is the template 
a substrate for an uncharacterised transporter into the apicoplast in cell? A specific transporter could 
explain why some compounds that are potent IspD inhibitors are inactive against 3D7 cells, especially 
when structures are only minimally varied.  At present the answer to this question is not known, 
however, if the drug requires a transporter of some kind to reach its target, then any future SAR may 
have to cater for the binding mode in another protein potentially complicating design. 
 
 




2.2.5.4 Analysis of the DMPK Properties of selected D-Ring Compounds 
 
Table 2.12. DMPK profiles of selected modified D-ring compounds. Green = good, amber = acceptable, red = poor. 
Entry LogD7.4 ClogD7.4 Aq. Sol. 
(M) 
SFI Human Mics 
CLint 
(mL / min / mg) 
Rat Heps CLint 
(mL / min / 106) 
Mouse Mics 
CLint 
(mL / min / mg) 
6 3.8 4.1 16 7.1 44.26 30.17 202.4 
29 4.1 4.1 10 7.1 35.40 42.40 Not tested 
30a 2.7 4.1 19 7.1 21.10 49.20 Not tested 
31 3.9 4.3 0.5 7.3 51.90 22.70 Not tested 
32 > 4.4 4.7 6 7.7 64 64.50 Not tested 
35 4 4.3 3 7.3 25.90 39.70 Not tested 
36a 2.9 3.1 9 6.1 Not tested 4.07 Not tested 
 
We selected several compounds for DMPK interrogation to assess if any substitution led to 
improvements in the DMPK profile (Table 2.12). In order for a compound to be sent for mouse 
microsomal screening our own criteria of potent inhibitory activity against at least cell and an 
acceptable DMPK profile needed to be met. Unfortunately no compound met these criteria and none 
of the D-ring substitution patterns were explored for mouse microsomal stability. Again, the SFI values 
of all compounds is above 5. Therefore as predicted, the solubility of this series is poor, similar to the 
C-ring series. Despite this, examination of Table 2.12 demonstrates some interesting results, the only 
compound showing improved cell potency (29) harbours a bromine atom which is more lipophilic than 
the chlorine atom that is present in the hit molecule 6. As expected, the aqueous solubility has 
dropped as a consequence. Interestingly, though displaying an increased LogD7.4, human microsomal 
clearance time has reduced vs 6, however, examination of clearance within rat hepatocytes shows an 
increased clearance rate. As this compound showed little improvement over 6 in terms of its DMPK 
profile it was not sent for mouse microsomal screening.  
30a is a compound that though inactive, shows an interesting DMPK profile. The incorporation 
of a chlorine atom at the 6-position has pushed LogD7.4 within a target range. The improvement in 
LogD7.4 is mirrored by improvements to aqueous solubility and a promising two-fold improvement for 




human microsomal clearance time vs 6. However, the rat hepatocyte assay demonstrates that this 
compound is rapidly cleared and unfortunately is cleared faster than 6.  
31 contains a 3-F substituent and therefore has slightly increased lipophilicity as 
demonstrated by the slight increase of LogD7.4 vs 6. This small structural change renders 31 a very 
insoluble compound which leads to activity values that are difficult to interpret. Metabolic clearance 
times for this compound are interesting, human microsomal clearance has moved into an undesirable 
range, however, rat hepatocyte clearance has improved over 6. Based on the results obtained thus far 
it seems that along with interesting specific SAR for IspD and cell potency, there is also a species 
specific requirement of SAR when testing DMPK properties.    
32 is the only other compound from the D-ring series possessing cell potency. However, it 
demonstrates a poor DMPK profile. Due to the presence of 3 chlorine atoms, the LogD7.4 and SFI value 
are significantly higher vs 6, and as a result aqueous solubility has dropped. In addition, 32 shows rapid 
clearance times in both human microsomes and rat hepatocytes. 35 is similar to 31 possessing fluorine 
substituent but at the 5-position of the D-ring. Unlike 31 it has far improved human mic clearance 
times vs 6, surprisingly, however, its rat hep clearance time is significantly higher compared with 31. 
Examining 35 and 30a which are substituted at the 5 and 6-positions, both compounds demonstrate 
improved human mic stability. This raises the question of; is one or both of these positions a potential 
site of metabolism in human? 
Perhaps the most interesting DMPK data came from compound 36a which belonged to the 
pyridyl series specifically where the nitrogen atom is at the 5-position. As expected, the increased 
polarity of nitrogen has dropped the LogD7.4 into a good range and thus also reduced the SFI value, 
however, SFI is still unfortunately higher than 5. Interestingly, the aqueous solubility was slightly 
decreased vs 6, however, very interestingly the rat hep clearance time improved almost 10 fold making 
this our most metabolically stable compound. Unfortunately, human microsomal clearance was not 
be determined.  These more positive results of the DMPK profile made the loss of potency observed 
against the IspD and 3D7 assays somewhat frustrating. However, the DMPK assessments gave us a 









2.2.5.5 Conclusion of D-ring series SAR 
 
Figure 2.13. Conclusion of D-ring SAR. 
              Compound 6 remains optimal for activity against IspD, however, at present compound 29 with 
a bromine substituent at the 4-position of the D-ring is optimal for 3D7 activity. Examination of the 
DMPK properties of 6 and 29, yields a similar result, 29 is more stable than 6 in human microsomes, 
but less stable than 6 in rat hepatocytes, however, 6 has slightly improved aqueous solubility and thus 
may possess a better profile. Electronics of the D-ring clearly play a significant role enzyme and cell 
potency. Incorporation of small atoms such as fluorine in any position exhibits a detrimental effect on 
potency; therefore steric demand alone cannot determine activity. Furthermore, incorporation of a 
pyridyl ring also leads to loss of potency. It could therefore be argued that the D-ring is bound within 
a lipophilic environment, where the presence of hydrogen bond donors or acceptors is disfavoured. 
Alternatively, there may be a requirement for an electron rich aromatic ring, instead of an electron 
withdrawing one. The aqueous solubility of the whole D-ring series is poor, and again this makes SAR 
interpretation unclear. As previously stated, aggregate formation cannot be ruled out, however, in the 
case of compound 31 and 35 aqueous solubility values are very low. Therefore, these compounds may 
precipitate during the course of the biological assay, which could explain the observed activities. The 
presence of halogens in the D-ring and the 5-pyridyl D-ring in some cases yielded to improved 
metabolic stability. Therefore, we used these results to explore SAR around the unexplored A-ring to 
examine if metabolic stability can be improved, without the loss of activity. Figure 2.13 summarises 
our findings of SAR of the D-ring.      
2.2.6 A-ring modifications 
 The incorporation of A-ring modifications was driven by two crucial reasons. Firstly, the 
incorporation of halogens and heteroatoms in the D-ring in some cases had a positive impact on 
metabolic stability and in some cases a negative effect on metabolic stability. This could suggest that 
the D-ring is a site of metabolism but the data is inconsistent. Therefore, while the D-ring could be a 




site of metabolism, other areas such as the A-ring could not be ruled out, especially considering that 
sterically the A-ring quite exposed. Secondly, examination of the development of KAE609 (12) (Figure 
2.4) showed similar issues with metabolic stability of this template. A-ring 6-F, 7-F and 6-F, 7-Cl 
modifications in this case not only solved the issue of metabolism but also improved the antiparasitic 
potency of the molecule.15 It was therefore our goal to examine if this success could be replicated with 
similar modifications to our template of interest. 
 Our homology modelling data (see Section 2.3) indicated that the PfIspD binding site is small, 
so we initially carried out A-ring modification in a step wise manner. First we examined the effect of 
mono-substitutions in the 6 and 7-positions of the tetrahydro-β-carboline A-ring, before examining 
the effect of di-substitutions so as to not interfere with potential steric clashes too much. One major 
drawback of examining the A-ring substitutions was that because the starting materials became more 
complex, this in turn reduced commercial availability. As such some enantiopure derivatives of 
tryptophan were synthesised from the corresponding starting indoles. In some cases we also 
purposely synthesised racemic forms of A-ring final compounds, to provide standards for chiral HPLC. 
In total three racemic targets were synthesised and are discussed in the following sections, all three 
show separation on a chiral column and two of which were later resynthesised in enantiopure form. 
This approach gave us confidence that our asymmetric synthesis led to enantiopure final compounds. 
In some cases X-ray crystallography was also carried out to confirm compound stereochemistry. 
Similar to the D-ring substitutions we explored both F and Cl substitutions within the A-ring, and as a 
potential metabolite, we synthesised one hydroxylated A-ring to examine if this metabolite might still 
possess activity.  
2.2.6.1 A-ring Modifications: Mono-substitutions at the 6, and 7-position 
 
Figure 2.14. Positions of potential metabolic liability in the A-ring. 
 Building from the development of KAE609 (12) (Figure 2.4), it was apparent to us that the 7-
position was the likely major position of metabolism within the MMV008138 template (Figure 2.14). 
During the development of 12, mono-Cl substitution at the 7-position led to improved metabolic 
stability in both human and mouse hepatocytes. Mono-substitution of the 6-position also improved 
metabolic stability, finally, blocking 6 and 7-positions both then gave the molecule its optimal 




properties.15  Following on from this, as we did not want to cause potential unnecessary steric clashes 
we wanted to examine the effect of fluorine substitution at the 7-position first before moving onto 
chlorine. Fluorine , as in the D-ring SAR, has a major advantage here as it is small and is effective at 
blocking potential sites of metabolism due to the high strength of the C-F bond.58 Therefore if activity 
is retained and metabolic stability is improved, we can then justify examining chlorine substitution, 
which also allows us to probe steric demand, and also examine the 6-position.  
 The 7-F substitution of the THBC A-ring was the first molecule examined and this was first 
synthesised in racemic form starting from 6-F DL-tryptophan (42a) (ideally we wanted to start from 
the methyl ester (43a), however, this was not commercially available). Synthesis of 43a was 
straightforward, exposing a suspension of 42a in methanol to thionyl chloride at 0 °C and leaving 
overnight at room temperature formed 43a in good yield of 88 %. Though in this case it does not 
matter, this reaction proceeds without racemising the stereogenic centre, therefore it is applicable for 
use when converting all L-amino acids to their corresponding methyl esters.63 The following Pictet-
Spengler reaction also proceeded well, yielding 22 % racemic trans 44a product and 77 % racemic cis 
45a, both of which were isolated and characterised by NOESY NMR. The trans isomer was reacted 
with methyl amine, which after recrystallisation gave the final product 46 in 61 % yield.  
Activity of 46 was confirmed with an activity parasite EC50 value of 730 ± 10 nM. However, for 
reasons unknown, IspD values were exhibiting highly variable results after multiple assays and are not 
reported. Bearing in mind that this cellular activity is from a racemic molecule, it was thought that the 
activity would be notably improved through synthesising the enantiopure form 47. We initially 
planned to generate compound 43b using α-chymotrypsin to enantioselectively cleave 43a to its L-
amino acid, however, when attempting this reaction no reaction was observed and was not 
repeated.64,65 Instead, 6-F L-tryptophan (42b) was purchased in order to synthesise 47. Compounds 48 
– 51 were generated analogous to Scheme 2.9 with yields for each step reported in Table 2.13 below. 
(Note for clarity, only chirality en route to enantiopure products is displayed).               





Scheme 2.9. Synthesis of compounds 46 – 51. 
Table 2.13. Yields of the Pictet-Spengler reaction and final amide coupling for mono-substituted A-ring compounds. 
Final 
Compound 
X (In final 
compound) 
% yield 43 a - f % yield 44 a – f 
trans 
% yield 45 a – f 
cis 
% yield 46 – 51 
46 (±) 7-F 88 22 77 61 
47 7-F 44 25 57 98 
48 7-Cl 85 21 42 32 
49 6-F 94 10 42 99 
50 6-Cl 87 26 59 82 
51* 6-OH 70 15* 56 89* 
* Contaminated with 16 % of cis isomer by NMR 
 In general yields throughout the synthetic scheme were acceptable; the only anomaly was the 
esterification reaction to form 43b which was low yielding (Table 2.13). Interestingly this was repeated 
twice and gave the same result; it is not clear why there is such a drop of yield on switching from 43a 
to 43b. The Pictet-Spengler reactions all proceeded as previously described, yielding the cis isomer as 




the major product in all cases with a cis to trans ratio generally between 2 : 1 and 4 : 1. All final amide 
couplings also proceeded well, it is of note that all reported final yields are after recrystallisation only.  
 In addition to previous NOESY experiments confirming trans products were isolated, X-ray 
crystallography was obtained on 47 and 48 to determine if compound chirality was correct. The crystal 
structures are displayed below in Figure 2.15 which confirm (1R, 3S)-configuration.  
 
Figure 2.15. X-ray crystal structure of 47 (left), Flack parameter = 0.094 (5) and 48 (right) Flack parameter = 0.034 (7). 
Image is rendered as ball and stick, carbon, coloured in grey, chlorine in green, fluorine in light green, hydrogen in white, 
nitrgoen in blue and oxygen in red. Compound was visualised using OLEX2.36 
2.2.6.2 Biological Activity of Mono-A-Ring Modifications against PfIspD and Pf3D7 
 Similar to C and D-ring modifications most A-ring analogues of 6 were tested in vitro for their 
inhibitory activity against PfIspD and Pf3D7 cells. Results are displayed in Table 2.14; again for 











Table 2.14. Inhibitory activities of mono-substituted A-ring modifications against PfIspD, and Pf3D7 Green = good, amber 
= acceptable, red = poor. 
Entry R X PfIspD IC
50
 (nM)  Pf3D7 EC
50
 (nM)  ClogD7.4 Aq. Sol. (M) SFI 
1a OH H 25.3 ± 5.6 n = 3 349 ± 30 n = 6 2.9 N/A 5.9 
6 NHMe H 21.6 ± 2.7 n = 3 373 ± 86 n = 4 4.1 16 7.1 
46 (±) NHMe 7-F Highly variable 730 ± 10 n = 4  4.3 N/A 7.3 
47 NHMe 7-F 117 ± 11.2 n = 4 275 ± 10.5 n = 4 4.3 10 7.3 
48 NHMe 7-Cl 1110 ± 389 n = 3 381 ± 57 n = 4 4.7 0.6 7.7 
49 NHMe 6-F Awaiting data 1038 ± 163 n = 3 4.3 36 7.3 
50 NHMe 6-Cl >5000 n =1 >10000 n = 3 4.7 0.4 7.7 
51 NHMe 6-OH 148 n = 1 5450 n = 1 3.8 N/A 6.8 
 
 Compound 46 was initially synthesised to confirm if substitution on the A-ring is tolerated. 
Even with a racemic mixture, an EC50 value of 730 ± 10 nM was obtained, confirming that the A-ring 
could be manipulated chemically without sacrificing activity. Unfortunately, IspD activity did not give 
a consistent value which can be attributed to either interference of the assay by the other enantiomer, 
through potential aggregate formation, or potential precipitation of the compound within the assay 
(aqueous solubility of enantiopure version of this compound (47) has low aqueous solubility value of 
10 µM).  The enantiopure molecule 47 was subsequently synthesised and the IspD assay gave us a 
consistent IC50 value against the enzyme, with a 4 fold loss of potency compared with 6. This loss of 
potency could be attributed to a lower aqueous solubility value, or suggests a minor electronic or 
steric requirement around the A-ring in the active site. 47 in comparison to 6, yielded improvement 
of potency against growth inhibition of 3D7 cells. We then interrogated the steric demand of the 7-
position by the incorporation of a chlorine atom instead of a fluorine atom. It appears that there is 
still a strict steric requirement around this area of the molecule as 48 demonstrates only moderate 
potency against the enzyme. However, compound 48 has a very poor aqueous solubility value of 0.6 
µM, this compound is practically insoluble in an aqueous environment and may precipitate during the 
course of the biological assay. Alternatively, because in the whole cell assay compound 48 is still very 
good (Table 2.14), this suggests that this molecule may have another target. A similar effect was 
observed with compound 32 from the D-ring series, it would be interesting to know if either one of 
these compounds cause parasite rescue in the presence of IPP which could be carried out as future 
work. If they do show rescue, it could be that these compounds are able to inhibit another MEP 




pathway enzyme. It is also possible that the increase in lipophilicity of these compounds could 
enhance apicoplast penetration. 
 In an analogous study, we also examined the effect of incorporating halogens at the 6-
position. We are currently waiting for IspD data for compound 49, however, it is only moderately 
active against 3D7 growth. Further to this, compound 50, which contains a chlorine atom, loses 
potency against both the enzyme and parasite. This suggests that there is an unfavourable steric clash 
in the active site from substituents with a Van der Walls radius > F. For the two mono-substituted 
studies, aqueous solubility and activity in some cases do not correlate well, as compounds 48 and 50 
share similar solubility values and the same SFI value, but 48 is active whilst 50 is inactive. Though 
enzyme data is missing for compound 49 a similar effect is seen between compounds 47 and 49 in the 
phenotypic assay. However, even though these compounds share the same SFI value, the aqueous 
solubility of 49 is just over 2 fold higher than 47, but 49 only shows moderate whole cell potency. This 
again makes SAR interpretation unclear.  
In this series, we wanted to prepare potential metabolite to see if hydroxylation is tolerated. 
Unfortunately 6-hydroxy-L-tryptophan is not commercially available to synthesise the corresponding 
7-substituted tetrahydro-β-carboline from. Instead 5-hydroxy-L-tryptophan 42f was purchased and 
from this 51 was synthesised. Interestingly this compound retains IspD activity, giving an impressive 
IspD activity of 148 nM especially given that it contains 16 % of the inactive cis isomer. Unfortunately, 
however, cell potency is lost, as with other compounds from all the SAR explored so far, there may be 
an issue with influx or penetration of certain compounds into the apicoplast. Alternatively 
examination of the SFI of this compounds gives a value of 6.8 which indicates that this compound too 













2.2.6.3 Analysis of the DMPK Properties of selected mono-substituted A-Ring Compounds 
 
Table 2.15. DMPK profiles of selected mono-substituted A-ring compounds. Green = good, amber = acceptable, red = 
poor. 
Entry LogD7.4 ClogD7.4 Aq. Sol. 
(M) 
SFI Human Mics 
CLint 
(mL / min / mg) 
Rat Heps CLint 
(mL / min / 106) 
Mouse Mics 
CLint 
(mL / min / mg) 
6 3.8 4.1 16 7.1 44.26 30.17 202.4 
47 4.2 4.3 10 7.3 23.30 23.31 147.5 
48 > 5.0 4.7 0.6 7.7 20.99 21.00 109.4 
49 3.7 4.3 36 7.3 45.50 46.10 Not tested 
50  4.4 4.7 0.4 7.7 17.60 44.80 155.4 
 
Selected mono-substituted compounds have been screened for their DMPK profile to assess 
whether any of them could be taken forward to in vivo studies (Table 2.15). Compounds 47 and 48 
were of most interest to us, as they possessed potent cell activity. Compound 51 was not tested as 
since it expressed a substantial loss of potency.  Incorporation of 7-F in 47 and 7-Cl in 48 both increase 
LogD7.4 in comparison to 6, the compounds are in an undesirable LogD7.4 range, and as expected 
aqueous solubility has been reduced when compared with 6. However, in the case of both 47 and 48 
metabolic stability in human microsomes and rat hepatocytes are both improved over 6; in both cases 
these values are acceptable though still not ideal. Most importantly, the clearance in mouse 
microsomes has also decreased in both cases, however, the clearance rate is still higher than desired.  
Examination of the 6-position with F (49) and Cl (50) yielded interesting results; the 
metabolism of 49 was similar to 6 in human microsomes, however, in rat hepatocytes, the rate of 
metabolism was observed to increase. This is curious and suggests that in both human and rat the 6-
position is not a primary site of metabolism, though in the case of rat it does effect the rate of 
metabolism possibly indicating a switch in the route of metabolism. 50 in human microsomes showed 
much improved metabolic stability, however, again this is curious, if we say the 6-position is not the 
site of metabolism does the Cl effectively block access to the site of metabolism in human 
microsomes? For future work metabolite ID should be performed to examine the sites of metabolism 
within this series. Another interesting observation of the 6-position series was the observed values for 




measured LogD7.4 in comparison to the analogous compounds from the 7-position series. The 
measured LogD7.4 of compound 49 was lower than analogous compound 47, it is also lower than the 
hit compound 6, this accounts for the improvement to aqueous solubility observed. A similar effect 
was seen with compounds 50 and 48 for the measured LogD7.4 values, however, in this case aqueous 
solubility was not improved for 50, it was in fact slightly worse. We next decided to see if we could 
maintain activity and further reduce metabolism rates by examining A-ring di-substitution.    
  2.2.6.4 A-ring Modifications: Di-substitutions 
 Based on the results from the mono-A-ring substitutions it is clear that the incorporation of 
halogens at the 7-position maintains potency against Pf3D7 parasites. When fluorine is the halogen, 
IspD activity is also retained. Further to this its metabolic stability is also improved over the hit 
molecule 6. In slight contrast, substitution at the 6-position leads to a small loss of potency in the case 
of fluorine substitution, and a large loss in the case of chlorine substitution. However, metabolic 
stability at these positions is also improved vs 6. Therefore we decided to examine A-ring di-
substitution.  
We examined fluorine substitution at the 6 and 7-positions together first, followed by 5 and 7 
together. We also examined 6-F, 7-Cl substitution to give a molecule that looks similar to KAE609 (12). 
It may appear strange to include 6, 7-di-substitution if we say that 6 substitution leads to loss of 
potency. However, if only a small loss of potency is observed when combining the two substitutions 
together; and a large improvement of the DMPK profile is also observed, then from a hit to lead 
perspective, this characteristic is favourable as a compound with a poor DMPK profile is more likely to 
fail in the clinic.  
 The di-substitutions complicated the synthesis as racemic or enantiopure tryptophan 
derivatives were not commercially available. Therefore the each A-Ring di-substitution was 
synthesised from the respective indole as the starting material. Enantiopure final targets can be 
successfully synthesised in five steps following Scheme 2.10. 





Scheme 2.10. Synthesis of 58 – 60. 
 Table 2.16 Yields of the reaction steps for di-substituted A-ring compounds 
Final 
Compound 
X (In final 
compound) 
% yield 
rac-53a - c 
% yield 
55a – d 
(2 steps) 
% yield 
56a – d 
trans 
% yield  
57a – d 
cis 
% yield 
58 - 61 
58 6-F, 7-F 91 33 20 54 60 
59 5-F, 7-F 19 32 15 64 87 
60 6-F, 7-Cl 92 44 19 61 68 
61 (±) 6-F, 7-Cl - 39 16 47 69 
 
From substituted indoles N-Acetylated tryptophan derivatives (rac-53a – c) were successfully 
synthesised via reaction with L-serine in acetic acid and acetic anhydride. It is worth noting that L-




serine is not strictly required to be optically pure as the reaction racemises under the reaction 
conditions as reported by the literature.66 Compounds rac-53a – c were then subjected to a kinetic 
enzymatic resolution adapted from literature procedures, allowing for the selective cleavage of the L-
enantiomer acetyl group only.66–68 This was achieved using Amano-L-acylase (I) a highly active amino 
acylase. This then allowed easy extraction of the D-N-acetyl derivatives (D-53a – c) into an organic 
phase in an acidic work up. However, this reaction came with its own drawbacks, the L-amino acids 
(54a – c) could not be extracted into an organic phase after work up. This meant that the water layers 
had to be evaporated to dryness, leaving behind undesired inorganic impurities. In order to remove 
as many inorganics as possible, the inorganics were crushed into a fine powder and MeOH was added 
and the reaction flask swirled vigorously. The MeOH was decanted off and analysed for UV activity by 
TLC, this process was repeated until the MeOH additions showed no UV activity by TLC, all washings 
possessing UV activity were combined and taken to the next step crude. Similar to the mono-
substitutions, the next step was simple esterification using thionyl chloride in MeOH, forming 
compounds 55a - c. Once the ester functionality was installed, the organic products could be easily 
extracted from residual inorganic impurities from the previous step during work up. Pictet-Spengler 
reactions were then carried out forming 56a – c (trans) and 57a – c (cis) before final amide coupling 
with methyl amine forming 58 – 60.  
We explored the possibility of using a D-amino acylase, however, this was not pursued for two 
reasons; firstly the D-amino acylase was much less active than the L-counterpart, as a result this will 
lead to increased reaction times. In addition the D-amino acylase was much more expensive, and the 
scales we would work on made this enzyme not commercially viable.67 Secondly though the resulting 
L-acetylated tryptophan derivative is easily isolated, cleavage of the resulting acetyl group requires 
very harsh conditions, and it was not known if this would lead to racemisation or not, we deemed it 
was not worth it to run the risk of any potential racemisation.  
In addition to the enantiopure molecules, one racemic molecule 61 was also synthesised, 
which was the racemate of 60. This was synthesised for the purpose of ensuring separation on 
analytical chiral column was visible to determine if the amino acylase had generated enantiopure L-
amino acids. HPLC traces containing only one peak for final compounds could be reasonably argued 
to be a pure enantiomer. The synthesis of the racemic form was almost identical to Scheme 2.10, 
however, instead of using L-amino acylase, rac-53c was deprotected in the presence of 6 M HCl for 
three days at 120 °C forming 54d. 54d was then esterified to form 55d, which was reacted through 
the Pictet-Spengler coupling procedure forming 56d (trans) and 57d (cis), 56d was separated and 




coupled with methyl amine forming 61. Table 2.16 displays the yields for all steps except 54a – d which 
were all used as crude intermediates. 
The yields of the addition of the side chain to the indole proceed well, with the exception of 
53b. For reasons unknown, the reaction yielded unidentified impurities and required column 
chromatography whereas the other reactions did not. It is possible that the reaction did not go to 
completion and the observed side products may have been intermediates. The products 55a – d were 
all relatively low yielding (yields reported are over two steps), however, considering that the crude 
54a – d intermediates had inorganic impurities in them these low yields were expected. Pictet-
Spengler cyclisation forming compounds 56a – d (trans) and 57a – d (cis) proceeded as expected 
generating cis and trans isomers in approximately 3 : 1 to 4 : 1 ratios. Final amide couplings to the 
desired targets 58 – 61 also proceeded well in good yields after recrystallisation from hot methanol. 
2.2.6.5 Biological Activity of Di-A-Ring-Modifications against PfIspD and Pf3D7 
 The di-substituted A-ring modifications of 6 were tested in vitro for their inhibitory activity 
against PfIspD and Pf3D7 cells. Results are displayed in Table 2.17; again for comparison 1a and 6 are 
also displayed. 
 
Table 2.17. Inhibitory activities of di-substituted A-ring modifications against PfIspD, and Pf3D7 Green = good, amber = 
acceptable, red = poor. 
Entry R X PfIspD IC
50
 (nM)  Pf3D7 EC
50
 (nM)  ClogD7.4 Aq. Sol. (M) SFI 
1a OH H 25.3 ± 5.6 n = 3 349 ± 30 n = 6 2.9 N/A 5.9 
6 NHMe H 21.6 ± 2.7 n = 3 373 ± 86 n = 4 4.1 16 7.1 
58 NHMe 6-F, 7-F 1355 n = 1 3110 n = 1  4.5 4 7.5 
59 NHMe 5-F, 7-F 1980 n = 1 Awaiting data 4.5 <1 7.5 
60 NHMe 6-F, 7-Cl Awaiting data 2339 ± 177 n = 3 4.9 1 7.9 
61 (±) NHMe 6-F, 7-Cl >2000 n = 3 >10000 n = 3 4.9 <0.4 7.9 
 
 It is clear from the data that all di-substitutions lead to loss of potency in both enzyme and 
cell assays. Comparison of 58 to the mono-substituted compound 47 shows 10 fold loss of potency vs 
the enzyme and 11 fold loss of potency vs cell. When comparing 58 to mono-substituted 49 a 3 fold 
loss of cell potency is observed. We had hoped that 58 would have had cell potency in between 47 




and 49, but it demonstrates reduced potency compared to either compound. A similar loss of potency 
against enzyme is seen with 59, we are currently awaiting cell data for this compound, but based on 
observed IspD inhibitory activity, we also expect this compound to be inactive. 60 in comparison to 
mono-substituted compound 48 shows a 6 fold loss of cell potency, incorporation of halogens into the 
6-position appears to have a substantial negative effect on potency. As expected 61 showed no 
inhibitory activity in comparison to 60 as it was administered in racemic form. One observation of this 
di-substituted series is the very poor aqueous solubility observed for all compounds. These 
compounds may be precipitating during the biochemical assays and this may account for the poor 
activities observed. Curiously, the racemic mixture compound 61 shows a lower aqueous solubility 
value compared with enantiopure version (60), these values were expected to be the same. Regardless 
of this, both are very insoluble in an aqueous environment.   
2.2.6.6 Analysis of the DMPK Properties of selected Di-substituted A-Ring Compounds 
 
Table 2.18. DMPK profiles of selected di-substituted A-ring compounds. Green = good, amber = acceptable, red = poor. 
Entry LogD7.4 ClogD7.4 Aq. 
Sol. 
(M) 
SFI Human Mics 
CLint 
(mL / min / mg) 
Rat Heps CLint 
(mL / min / 106) 
Mouse Mics 
CLint 
(mL / min / mg) 
6 3.8 4.1 16 7.1 44.26 30.17 202.4 
58 >4.4 4.5 4 7.5 27.90 21.50 Awaiting data 
59 3.9 4.5 <1 7.5 27.60 25.60 290.4 
60 >4.2 4.9 1 7.9 22.40 23.10 Not tested 
61 (±)  >4.3 4.9 <0.4 7.9 18.60 17.80 9.6 
  
Selected di-substituted compounds have been screened for their DMPK profile to assess 
whether there was any improvement of the DMPK profile in comparison to mono-substituted A-ring 
derivatives. As can be seen in Table 2.18 there is little difference in most cases between mono and di-
substituted A-rings in terms of measured logD7.4, SFI, aqueous solubility, or metabolic profile. 58 is 
cleared slightly faster than 47 in human microsomes but slightly slower in rat hepatocytes, we are 
currently awaiting data for mouse microsomes. 59 demonstrated a relatively similar profile to 58, 
however, this has been tested in mouse microsomes and curiously is cleared even faster than the hit 
6. Mouse microsome readout appears to be very sensitive to this molecular template. 60 in 




comparison to its mono-substituted counterpart 48 had a comparable profile and was not tested 
within mouse microsomes. The racemic version 61 has a profile that is very similar to 60, however, 
mouse microsomal turnover was tested and appears to show a remarkable improvement in metabolic 
stability. It should be noted though that this is not unusual, a similar situation was observed during 
the development of KAE609 (12), were differing stereoisomers had radically different clearance times. 
It is likely that the other enantiomer is causing this apparent spike in stability. This of course is 
unfortunate, as the other enantiomer shows little activity against IspD.15        
2.2.6.7 A-ring modifications: Incorporation of an aza A-ring 
 As discussed as part of the D-ring modifications we noticed that incorporation of an aza group 
into the D-ring led to improvement of rat hepatocyte clearance times. We decided to explore if it was 
possible to synthesise one or more A-ring substituents containing a nitrogen atom at any position. The 
rationale behind this was firstly; a reduction in logD7.4 from this compound is likely able to increase 
metabolic stability; secondly the reduction of logD7.4 should also improve aqueous solubility; thirdly 
the nitrogen atom should have very little impact on steric demand within the IspD active site; and 
fourthly the nitrogen atom has a chance to pick up a hydrogen bond in the active site increasing 
binding energy and thus potentially potency.  
 Examination of the literature showed that little research had been done to make an aza-mimic 
of MMV008138, aza-tetrahydro-β-carbolines possessing (1R, 3S)-substituents were also scarce. To 
further complicate matters no aza-tryptophan derivative could be purchased enantiopure, and only 
7-aza tryptophan was available as a hydrate with water content not reported. Despite this there is 
evidence of the synthesis of enantiopure aza-tryptophan derivatives in the literature.69,70  
The route we chose to follow (Scheme 2.11) was similar to what was reported in the literature 
by Talukder et al.70 We purchased the Schölkopf chiral auxillary in methyl ether form (66) due to its 
higher purity. 7-azaindole-3-carboxyladehye (62) was allowed to react with TsCl in the presence of 
DMAP and NEt3 to yield 63 in 99 % yield. The aldehyde was successfully reduced in the presence of 
sodium borohydride to 64 in 94 % yield.70 Compound 64 was converted to the bromide 65 in the 
presence of PBr3, 65 was dried immediately after TLC confirmed its formation was complete. During 
the time that 65 was drying, the auxillary (66) deprotonation was set up side by side; 65 could then be 
added by cannula immediately to the deprotonated auxiliary 67 once it was dry from work up 
solvents.70,71 Following this protocol, 68 was formed in 52 % yield over two steps after recrystallisation 
from 20 % DCM in hexane. Within the literature this compound is reported as a yellow oil, however, 
in our case all attempts to synthesis this molecule resulted in the formation of a solid.70 To confirm 




compound structure, the X-ray crystal structure of 68 was solved by Dr Craig Robertson and confirms 
the correct diastereoisomer was synthesised (Figure 2.16).  
 
Scheme 2.11. Synthesis of aza-A-ring derivative (73). 





Figure 2.16. Crystal structure of 68 Flack parameter = 0.01 (2). Image is rendered as ball and stick, carbon, coloured in 
grey, hydrogen in white, nitrogen in blue, oxygen in red and sulfur in yellow. Compound was visualised using OLEX2.36 
68 was deprotected to 69 using a mixture of Cs2CO3 MeOH and THF in 99 % yield.70,72 To 69 
was added 2 M HCl in MeOH to form the methyl ester of 7-aza-L-tryptophan. Attempts to extract this 
compound again into an organic phase failed, however, the work up procedure did appear to remove 
the valine methyl ester side product. In order to overcome the issue of extracting the methyl ester 
into the organic phase we instead cleaved the ester to the carboxylic acid before esterifying again with 
a more lipophilic ester. To increase the lipophilicity of the intermediate in order to aid extraction an 
nPr ester was chosen first. The methyl ester was hydrolysed to 7-aza-L-tryptophan by stirring in 1 M 
sodium hydroxide and MeOH overnight. After neutralisation, the crude product (including inorganics) 
were evaporated to dryness. The crude was suspended in nPrOH and 10 eq SOCl2 were added dropwise 
at 0 °C before refluxing overnight. This successfully formed 70 in 17 % yield over three steps, however, 
chiral HPLC had determined that the molecule racemised under these conditions. The molecule was 
subjected to a modified Pictet-Spengler procedure; a review of the literature suggests that in the 
presence of acid, particularly TsOH the molecule will fully aromatise once the Pictet-Spengler reaction 
completes which was undesired.73 The reaction instead needed to be carried out in refluxing benzene 
with no acid (due to the concerns of the health hazard of benzene we instead carried out the reaction 
in toluene under reflux in an Ar atmosphere for 24 hours). This formed 71 as the trans isomer in 16 % 
yield and 72 as the cis isomer in 12 % yield, however, the reaction still appeared to form more products 
than expected, these were more non polar on TLC and likely belong to oxidised or fully aromatised 
compounds. After separation 71 was coupled with methyl amine to yield 73 as a racemic molecule in 
49 % yield after recrystallisation from MeOH.  
Along with chiral HPLC, the X-ray crystal structure of 73 was solved by Dr Craig Robertson. The 
molecule crystallises in the Pbca space group, which has a centre of inversion. By the virtue of this 
space group, we can say the compound exists as a racemic mixture of the (1R, 3S) / (1S, 3R)-




enantiomers (trans). Depicted below is the X-ray image of both enantiomers, forming a hydrogen bond 
donor / acceptor pair from the A-ring nitrogen atom to the corresponding B-ring indole NH.    
 
Figure 2.17. Crystal structure of 73. Image is rendered as ball and stick, carbon, coloured in grey, chlorine in green, 
hydrogen in white, nitrogen in blue and oxygen in red. Compound was visualised using OLEX2.36 
Once we elucidated that 73 was racemic, and successfully identified the point of racemisation, 
we decided to see if this could be circumvented. We repeated the synthesis again, but instead of using 
a propyl ester, we checked to see if an ethyl ester could also be extracted into an organic phase. The 
ethyl ester is beneficial as the esterification step does not require reflux. The same reaction was 
carried out and the ethyl ester was isolated and did not racemise (see Appendix 2 for HPLC trace). 
However, when we subjected this to the exact same Pictet-Spengler reaction conditions, the reaction 
was not progressing past the imine after 24 hours. In fact the cyclisation was still not complete after 
5-days. The trans isomer was isolated anyway in very low yield of 7 %, however, HPLC of this showed 
that the reaction also racemises at the Pictet-Spengler stage and the synthesis was stopped here (see 
Appendix 2). We tried the reaction again using the methyl amide of aza-tryptophan in place of the 
ester in case this could overcome the issue of racemisation, however, no reaction past the imine was 
observed after 5 days and upon leaving the reaction even longer the imine appears to decompose by 
TLC. 
We tested 73 against Pf3D7 parasites to see if it demonstrated any potency before deciding 
whether or not we should send this for DMPK analysis. Upon examination of its Pf3D7 growth 
inhibitory activity, compound 73 gave an EC50 value of 6640 ± 903 nM (n = 3). This is unfortunately 
much less potent than the hit molecule in cell and thus was not sent for DMPK profiling. At present 
we are awaiting IspD activity values, it may still be that this compound effectively targets IspD, but like 
many of the other compounds tested for whatever reason it cannot access the apicoplast effectively.   
 




2.2.6.8 Conclusion of A-ring series SAR 
 
Figure 2.18. Conclusion of A-ring SAR. 
 It was our aim to design a molecule as part of the A-ring SAR that had improved DMPK 
properties without the expense of potency in comparison to the hit molecule 6, which demonstrates 
rapid metabolic clearance. During A-ring SAR, two compounds were developed that show comparable 
potency to 6, 47 and 48, possessing a 7-F and 7-Cl substitution patterns, respectively. 47 demonstrates 
a small loss of activity against the IspD enzyme, however, its cell potency and DMPK properties are 
improved over 6, therefore this molecule is our current lead compound. 48 on the other hand is only 
moderately active against the IspD enzyme, but has similar cell potency to 6 and 47, this compound 
could be demonstrating off target effects. In terms of clearance rates 48 possesses a similar profile to 
47 in human microsomes, and rat hepatocytes, however, it does demonstrate a reduced clearance in 
mouse microsomes compared to 47 thus this compound could be considered a second lead, even if 
the primary target is not IspD. It should be noted that 48 possess very poor aqueous solubility and the 
results of the IspD assay may arise because of this. The 6-position of the THBC A-ring does not appear 
to tolerate halogen substitution, when a chlorine atom is at this position there is no activity observed. 
Similarly with a fluorine atom at the 6-position cellular activity is dropped substantially. A hydroxyl 
group here maintains good IspD activity but unfortunately is poorly potent when it comes to the whole 
cell assay. Substitution of the A-ring with 2 halogens at all positions explored led only to loss of both 
enzyme and cell activities with little to no improvement of the DMPK profile. Though only one aza A-
ring THBC derivative of the hit was synthesised, and even then only in racemic form, the cell activity 
is also substantially reduced. Ideally from a drug development perspective for the remainder of this 
series of compounds to be synthesised effectively, a new method for the synthesis should be 
uncovered, due to the high cost of some start materials, number of steps involved en route to the 
targets, and the risk of racemisation at the Pictet-Spengler stage. Most compounds of the A-ring series 




showed very poor aqueous solubility which could explain the unclear SAR observed, as was similar to 
the previous two series form the C and D-rings. SAR is summarised is Figure 2.18.    
2.3 Molecular Modelling 
 In order to gain an insight into how the tetrahydro-β-carboline scaffolds bind within the IspD 
enzyme, and to try to rationalise observed SAR, molecular modelling studies were carried out on our 
most interesting compounds. To date, no X-ray crystal structure has been elucidated for the PfIspD 
enzyme, and thus there is no known drug binding pose in the enzyme active site. Therefore work was 
undertaken by our group to generate a homology model from which molecules could be assessed for 
the docking pose and potential ligand-enzyme interactions.74 
 Computational docking is used primarily to predict how a drug may bind within a specific 
protein or receptor and scores how well the molecule fits into a binding site, i.e. it assesses the 
complementary fit of the binding pose to the protein. Predictions of whether a molecule could show 
activity or not can be made based on the scoring function, as it can be reasoned that molecules with 
good scores and good complementary binding are more likely to experimentally also show good 
activity. Using this rationale, virtual screening can be carried out to assess unknown inhibitors of a 
particular enzyme for their binding affinity, if the complementary fit and scores are good the 
compounds can be examined experimentally for activity.75  
 Molecular docking involves the exploration of available space within a given bind site, ligands 
are docked in numerous orientations an conformations and are scored using scoring functions 
according to the most favourable pose.75 Docking algorithms are used to generate the poses of the 
ligand into the active site. They search for the available virtual chemical space to determine if the 
ligand will fit into the given binding pocket.75 Here we used a genetic algorithm to explore the docking 
pose space, exploring the many degrees of freedom of the ligand, and how each ligand conformation 
may complementarily fit into the active site. Very briefly scoring functions are used to rank different 
poses based on the number of interactions the ligand has in a particular pose.75 The scoring function 
used as part of this research is known as GOLDscore, which is a force-field based function that uses 
molecular mechanics to quantify the sum of two energies, the receptor-ligand interaction energy and 
internal energy, this type of scoring considers just one protein conformation in order to simplify 
scoring by removing the internal protein energy, the programme used for this research was GOLD.76,77  
 
 




2.3.1 Docking Protocol 
 As the crystal structure of PfIspD was unavailable, a suitable surrogate had to be chosen to 
identify a docking protocol. This was already undertaken by PhD student Dr Kathryn Price. It was 
identified that EcIspD shared the most sequence similarity at the active site to the known sequence of 
PfIspD and thus EcIspD was chosen to be the surrogate protein. A crystal structure with bound CDPME 
exists for EcIspD, and a protocol was identified that reproduced the crystallographic bind pose of 
CDPME in the active site. The protocol identified is described in Table 2.19 below. 
Table 2.19. Protocol for docking. 
Mg2+ Mg2+ present, no coordination geometry specified 
Protonation Hydrogens added 
Waters Water molecule HOH1091 extracted, all other waters 
deleted, water was set as toggle, spin 
Ligands CDPME extracted 
Binding site Defined as 6 Å of the CDPME ligand 
Number of GA Runs 10, 50, 100, 500 
Scoring Function GOLDscore 
   
          With the protocol in hand it was transferred to the homology model built by our group. In order 
to undertake docking all compounds were first built in chemdraw and transferred to Spartan, 
compounds were then energy minimised, Spartan was used to compute local energy minimum 
geometry using molecular mechanics with the MMFF94 forcefield.78,79 All images were generated in 
PyMol.80  
2.3.2 Modelling of MMV008138 Derived Compounds 
    The first molecule that we were interested in examining was the hit itself 1a, shown below 
in Figure 2.19 firstly with the full PfIspD protein rendered as cartoon, and the binding site surface 
shown as mesh highlighted in red, images shown display docking both with and without Mg2+, and 
secondly a zoomed in image of the binding site with binding interactions shown also images both with 
and without Mg2+ are displayed. The previously described docking protocol was run for this compound, 
however, only one run was carried out using 10 GA runs, curiously all observed poses demonstrated 
similar scores averaging at 51.0 with a standard deviation (SD) of 1.7, however, many of these poses 
were in vastly differing orientations, which may suggest the potential for multiple binding modes. One 
pose in particular with a score of 50.6, caught our attention and is displayed below (Figure 2.19). 






Figure 2.19. Binding pose of 1a. Top diagrams show protein in full view as white cartoon, bind site is highlighted in red 
depicted as mesh, images are rendered without and with Mg2+ for clarity. Bottom two diagrams display the binding site 
only, rendered as a white surface, Mg2+ is depicted and omitted for clarity. Mg2+ is rendered as a transparent green 
sphere, 1a is rendered as sticks, carbon coloured yellow, nitrogen coloured blue, oxygen coloured red, chlorine coloured 
green. Crucial amino acids are rendered as sticks carbon coloured grey, nitrogen coloured blue, oxygen coloured red. 
 This pose of 1a caught our attention for numerous reasons. Firstly as can be seen in the lower 
images of Figure 2.19, the carboxylic acid moiety of 1a has the potential to form at least 4 strong 
hydrogen bonds between Arg-208, Lys-215, Lys-412 and Thr-414 showing interatomic distances of < 
3.3 Å (heavy atom to heavy atom). In addition the same moiety has the potential to gain further 
electrostatic interactions with all but Lys-215, this moiety sits within a tight pocket which could 
rationalise why any large functionalisation here leads to a loss of potency. Furthermore, the C-ring 
nitrogen atom appears to be within distance of the Mg2+ ion to coordinate with it (2.5 Å) which may 
aid in the positioning of the inhibitor within the active site, and this could rationalise why simple 
substitution of this NH to NMe also leads to the loss of potency that is observed. Another interesting 
interaction is the potential for π-cation interactions from the aromatic D-ring, which sits almost 
directly behind the Mg2+ ion at a distance of approximately 3.4 Å. Disruption of this π-cation 
interaction could cause loss of potency. It is also interesting to note that the para-chlorine atom of 




the D-ring is pointing out into solvent exposed space, and that the ortho-Chlorine atom is proximal to 
a small cleft which could explain why the substitution of the 4-position appears to be tolerated by the 
enzyme. Finally, it is clear that the indole A-ring portion of the molecule sits inside a tight binding 
pocket within the enzyme, though no crucial interactions were observed with neighbouring amino 
acid residues here, the shape of the molecule does appear to possess a good complementary fit.  
 We then wanted to interrogate the next most promising hit 6 for its binding poses. Again the 
same docking protocol was carried out, however, no pose matched that of 1a. Most of the poses were 
in a similar orientation and displayed a low SD of the predicted binding strength, therefore the pose 
displayed in Figure 2.20 was the pose with the highest GOLDscore of 54.9 (mean and SD of 54.2 and 
0.5, respectively). With regards to the orientation vs 1a, 6 is rotated approximately 90 ° clockwise (as 
displayed), this forces the NHMe moiety to point into the back of the enzyme active site were the A-
ring of the indole lies, in this pocket the NHMe group can pick up potentially two strong and one weak 
hydrogen bonds with neighbouring Leu-201, Gly-295, and Ala-296 residues showing interatomic 
distances of 2.8, 3.3 and 3.7 Å, respectively. This rotation also forces the D-ring into the small cleft 
were the carboxylic acid moiety of 1a was situated, here there is a potential for the ortho-chlorine 
atom of the ring to pick up 3 electrostatic interactions with Arg-208, Lys-215, Lys-412 residues, with 
interatomic distances of 4.0, 3.6, and 3.0 Å, respectively. The C-ring nitrogen atom no longer points at 
the Mg2+ ion but instead has the potential to possess a hydrogen bond and an electrostatic interaction 
with the carboxylate of Asp-294 with interatomic distances of 3.5 and 4.1 Å. Finally though in a 
different orientation there appears to be a common π-cation interaction of the D-ring with the Mg2+ 
ion with a interatomic distance of 3.3 Å and instead of the C-ring nitrogen atom interacting with the 
Mg2+ ion, the indole nitrogen can now interact with it at an interatomic distance of 3.4 Å.              





Figure 2.20. Binding pose of 6. Binding site is rendered as a white surface, Mg2+ is depicted as a green cross, 6 is rendered 
as sticks, carbon coloured yellow, nitrogen coloured blue, oxygen coloured red, chlorine coloured green. Crucial amino 
acids are rendered as sticks carbon coloured grey, nitrogen coloured blue, oxygen coloured red. 
 In terms of the SAR discussed this pose also justifies some of the results obtained. Substitution 
of the C-ring nitrogen not only has the potential to cause a steric clash with the surface of the enzyme, 
but if the C-ring NH is activing as a hydrogen bond donor, then there is a clear disadvantage of the 
molecule to be substituted as this interaction will be lost. Replacement of the ortho-chlorine atom my 
also disrupt crucial electrostatic interactions, in addition to this, the cleft where the chlorine atom lies 
is small which may also rationalise some of the SAR observed by Yao et al. when substituting this 
position. Once again it should be noted that the para-chlorine atom is also pointing into solvent 
exposed space which again could indicate why there appears to be some scope for a degree of 
manipulation here. What is interesting is the indole portion of the ring is also pointing into solvent 
exposed space, therefore if this is the binding pose it is curious why there is a loss of potency observed 
in general when substituting the A-ring.   
 Next we wanted to examine our next most promising lead compound from the A-ring series 
compound 47. In order to expand the number of poses available we altered the number of GA runs to 
20 to examine if a pose mirroring 1a could be identified. However, examination of the poses showed 
that they were all in a similar orientation and the apparent spread of the scores was low, thus the 
pose displayed below is one with the highest affinity score of 56.3 (mean and SD of 55.0 and 0.7, 
respectively) (Figure 2.21).  





Figure 2.21. Binding pose of 47. Binding site is rendered as a white surface, Mg2+ is depicted as a green cross, 47 is 
rendered as sticks, carbon coloured yellow, nitrogen coloured blue, O coloured red, chlorine coloured green, fluorine 
coloured sky blue. Crucial amino acids are rendered as sticks carbon coloured grey, nitrogen coloured blue, oxygen 
coloured red. 
In a similar manner to 6, compound 47 showed no bind pose that matched that of 1a. 
Indeed the poses identified by 47 almost perfectly mirror that of 6. Thus the interactions are 
summarised in Table 2.20 below. 
Table 2.20. Main ligand – protein interactions of 47. 
Residue(s) Moiety Interaction Distance Å 
Leu-201, Gly-295 NHMe H-bond 2.7, 3.3 
Lys-215, Lys-412 Ortho-Cl Electrostatic 3.6, 3.6 
Asp-294 C-ring-NH Electrostatic 3.5 
Mg2+ D-ring π-cation ~3.3 
Mg2+ B-ring-NH electrostatic 3.3 
 
 In terms of the SAR this molecule does not reveal any more potential interactions that have 
been blocked or gained, however, the pose of 6 and 47 along with the potency of both 6 and 47 
appears to back up the bind pose observed.  
 As we knew that compound 48 though demonstrating cell potency, was only moderately 
active within the IspD assay, we wanted to use docking studies to explore the possibility of a different 
binding pose for this compound within the active site. Again the standard docking protocol was ran 
using only 10 GA runs. Again in general most poses were of similar orientation and the pose with the 
highest score of 57.6 was chosen to be imaged (mean and SD of 55.8 and 1.3, respectively (Figure 
2.22). 





Figure 2.22. Binding pose of 48. Binding site is rendered as a white surface, Mg2+ is depicted as a green cross, 48 is 
rendered as sticks, carbon coloured yellow, nitrogen coloured blue, oxygen coloured red, chlorine coloured green. 
Crucial amino acids are rendered as sticks carbon coloured grey, nitrogen coloured blue, oxygen coloured red. 
 At first glance it does appear as though 48 also adopts the same binding pose as 6 and 47, 
indeed this was somewhat surprising considering the differing enzyme activities the compounds 
possess, however, there are some subtle differences in interactions as summarised in Table 2.21 
below. 
Table 2.21. Main ligand – protein interactions of 48. 
Residue(s) Moiety Interaction Distance Å 
Leu-201, Gly-295, Ala 296 NHMe H-bond 2.9, 3.0, 3.3 
Arg-208 Ortho-Cl Electrostatic 3.3 
Lys-412 Para-Cl Weak electrostatic 3.7 
Asp-294 C-ring-NH H-bond 2.9, 3.4 
Mg2+ B-ring-NH electrostatic 3.5 
  
 Both the position and the hydrogen bonding interaction of the NHME moiety of 48 are still in 
place, however, the D-ring has clearly twisted in comparison to 47, this twisting motion has resulted 
in the loss of one potential electrostatic interaction between Lys-412 for the ortho-chlorine atom. In 
doing so, the ortho-chlorine atom is in closer proximity to Arg-208. In addition to the loss of the 
electrostatic interactions, the D-ring is now out of range to efficiently coordinate the Mg2+ ion, perhaps 
to compensate for this, the para-chlorine atom is now in proximity to gain an electrostatic interaction 
from the nearby Lys-412 residue. Another subtle difference is that the C-ring NH is closer to Asp-294 
allowed for potential hydrogen bonding to one or both of the carboxylate oxygen atoms. Indeed the 
loss of activity based on this pose is not expected; therefore we decided to examine the predicted 
pose of compound 50, a compound that showed poor activity against the enzyme. The predicted pose 




of 50 is displayed below (Figure 2.23), the pose displayed is the best score of 59.0 (mean and SD of 
56.7 and 1.0, respectively). 
 
Figure 2.23. Binding pose of 50. Binding site is rendered as a white surface, Mg2+ is depicted as a green cross, 50 is 
rendered as sticks, carbon coloured yellow, nitrogen coloured blue, oxygen coloured red, chlorine coloured green. 
Crucial amino acids are rendered as sticks carbon coloured grey, nitrogen coloured blue, oxygen coloured red. 
    Again the predicted pose for this compound mirrors that for all previously described NHMe 
derivatives of 1a. The bind pose in this case is almost identical to that of 48, in fact this compound 
shows an extra potential electrostatic interaction from the A-ring chlorine atom to the neighbouring 
Gly-204 residue. All interactions are displayed in Table 2.22. 
Table 2.22. Main ligand – protein interactions of 50. 
Residue(s) Moiety Interaction Distance Å 
Leu-201, Gly-295, Ala-296 NHMe H-bond 2.9, 3.2, 3.4 
Arg-208 Ortho-Cl Electrostatic 3.2 
Lys-412 Para-Cl Electrostatic 3.6 
Asp-294 C-ring-NH H-bond 2.9, 3.5 
Mg2+ B-ring-NH electrostatic 3.2 
   
 It became apparent at this point that we could not rationalise the loss of enzymatic potency 
observed with A-ring substituted derivatives of 6, as it was observed that all A-ring substitutions point 
out into solvent exposed space, therefore steric effects should not play a role for the inhibition of the 
enzyme based on the docking poses. We believe therefore that the poses here may not be accurate, 
this is based on two reasons; firstly, we are using a homology model of PfIspD, we are therefore 
modelling a model which could lead to the discrepancies we observe, as the actual structure of PfIspD 
may differ ever so slightly and thus in reality could give a different binding pose. Secondly, the docking 
procedure used does not allow for protein flexibility, this means that any major steric clash with not 
be added as a pose as it will give poor docking scores. It is clear that in 1a there is a very tight pocket 
for the carboxylic acid moiety to lie in, it may be that the substitution to NHMe amide causes a major 




clash in the docking run, therefore in the real situation it is more likely that the enzyme could slightly 
compensate this extra steric demand as the enzyme will be flexible. We hereby postulate then that 
the docking poses in reality are more likely to mirror that of 1a. The location were the A-ring is bound 
in 1a is very small, it is unlikely that this pocket could hold a group as large as chlorine and thus we 
predict that is why we see loss of activity for some A-ring substitutions. For completeness we also 
docked compounds 29, 36a, 51, and 73 all displayed below sequentially, in all cases the best scores 
were chosen to image (Figures 2.24 – 2.27 and Tables 2.23 – 2.26). 
29 Docking score = 56.0, mean = 54.8, SD = 0.7 
 
Figure 2.24. Binding pose of 29. Binding site is rendered as a white surface, Mg2+ is depicted as a green cross, 29 is 
rendered as sticks, carbon coloured yellow, nitrogen coloured blue, oxygen coloured red, chlorine coloured green, 
bromine coloured in dark red. Crucial amino acids are rendered as sticks carbon coloured grey, nitrogen coloured blue, 
oxygen coloured red. 
Table 2.23. Main ligand – protein interactions of 29. 
Residue(s) Moiety Interaction Distance Å 
Leu-201, Gly-295, Ala-296 NHMe H-bond 2.9, 3.1, 3.4 
Arg-208 Ortho-Cl Electrostatic 3.3 
Lys-412 Para-Br Weak electrostatic 3.8 
Asp-294 C-ring-NH H-bond 2.9, 3.5 
Mg2+ B-ring-NH electrostatic 3.4 




36a Docking score = 55.78, mean = 54.40, SD = 0.91 
 
Figure 2.25. Binding pose of 36a. Binding site is rendered as a white surface, Mg2+ is depicted as a green cross, 36a is 
rendered as sticks, carbon coloured yellow, nitrogen coloured blue, oxygen coloured red, chlorine coloured green. 
Crucial amino acids are rendered as sticks carbon coloured grey, nitrogen coloured blue, oxygen coloured red. 
 
Table 2.24. Main ligand – protein interactions of 36a. 
Residue(s) Moiety Interaction Distance Å 
Leu-201, Gly-295, Ala-296 NHMe H-bond 3.0, 3.2. 3.4 
Arg-208 Ortho-Cl Electrostatic 3.1 
Lys-412 Para-Cl Weak Electrostatic 3.7 
Lys-412 D-ring N H-bond 3.3 
Asp-294 C-ring-NH H-bond 2.9, 3.4 
Mg2+ B-ring-NH electrostatic 3.3 
 
51 Docking score = 58.4, mean = 57.2, SD = 1.0 
 
Figure 2.26. Binding pose of 51. Binding site is rendered as a white surface, Mg2+ is depicted as a green cross, 51 is 
rendered as sticks carbon coloured yellow, nitrogen coloured blue, oxygen coloured red, chlorine coloured green, 








Table 2.25. Main ligand – protein interactions of 51. 
Residue(s) Moiety Interaction Distance Å 
Leu-201, Gly-295, Ala-296 NHMe H-bond 2.9, 3.2. 3.4 
Arg-208 Ortho-Cl Electrostatic 3.2 
Lys-412 Para-Cl Electrostatic 3.7 
Asp-294 C-ring-NH H-bond 2.8, 3.3 
Mg2+ B-ring-NH electrostatic 3.3 
 
73 Docking score = 56.2, mean = 53.5, SD = 1.1 
 
Figure 2.27. Binding pose of 73. Binding site is rendered as a white surface, Mg2+ is depicted as a green cross, 73 is 
rendered as sticks carbon coloured yellow, nitrogen coloured blue, oxygen coloured red, chlorine coloured green. Crucial 
amino acids are rendered as sticks carbon coloured grey, nitrogen coloured blue, oxygen coloured red. 
Table 2.26. Main ligand – protein interactions of 73. 
Residue(s) Moiety Interaction Distance Å 
Leu-201, Gly-295 NHMe H-bond 2.9, 3.4 
Arg-208 Ortho-Cl Electrostatic 3.2 
Lys-412 Para-Cl Weak electrostatic 3.7 
H2O A-ring-N H-bond 2.2 
H2O B-ring-N H-bond 3.1 
Asp-294 C-ring-NH H-bond 2.9, 3.4 
Mg2+ B-ring-NH electrostatic 3.3 
Mg2+ A-ring-NH Weak electrostatic 3.7 
 
 It was observed that the docking pose for all these compounds matched that of all previously 
described NHMe derivatives. As all compounds have a similar binding pose, it is difficult to rationalise 
the loss of potency observed with compounds 36a and 73, both of these compounds possess and aza 
moiety, present in the D and A-rings, respectively. Based on their binding interactions both 
compounds appear to possess the potential to pick up extra interactions from all molecules previously 
described. Examining these compounds in a similar pose to 1a, should also yield extra interactions, 
therefore it is curious as to why a subtle change leads to a loss of inhibitory activity. Again it must be 




stressed that as this is a homology model, thus there is the potential for structural variation between 
the active site of this model, and the real case scenario in PfIspD, therefore it could be reasoned that 
it is this potential structure change that is responsible for the loss of potency we observe.   
2.4 Conclusion and Future Work 
 
Figure 2.28. Overall SAR conclusion. 
To conclude, extensive SAR has been undertaken around the MMV008138 template in order 
to deliver a compound with improved potency against PfIspD and Pf3D7 whole cell parasites (Figure 
2.28). We discovered that the C-ring nitrogen could not be substituted and that no improvement to 
potency could be made over the methyl amide moiety in 6. We evaluated 6 for DMPK profile and 
found that the molecule suffered from very fast clearance rates when exposed to human and mouse 
microsomes, along with rat hepatocytes. We therefore turned our attention to the D-ring and A-rings 
for SAR and DMPK profiling. We successfully synthesised compounds 29, 47, and 48 that have 
comparable or improved potency vs 6, where 29 is currently our most active compound. Compound 
48 displays improved metabolic stability in comparison to 6; we consider this compound to be a front 
runner. Finally, 47 shows improved potency in comparison to 6 and 48, it also shows an improved 
DMPK profile in comparison to both 29 and 6 and thus we consider this molecule our current lead. 
Disappointingly, however, the whole template suffers from high SFI values and low aqueous solubility, 
and these results make SAR interpretation unclear as the most insoluble compounds may either 
precipitate during the biological assays, or may form enzyme inhibiting aggregates.  




                  With regards to the future of the template we believe that the activity and DMPK profile of 
the template can be improved further. Whilst this SAR has been extensive, it is still only the initial 
studies. The discovery that the 4-position of the D-ring can maintain potency with substitutions such 
as bromine gives us hope that this part of the molecule can be further modified, particularly with 
solubilising groups. This gives hope for the future of the template, as an improved aqueous solubility 
profile should make SAR interpretation more clear. In fact, the bromine atom at this position opens 
many doors in terms of chemical manipulation as we can use Suzuki chemistry and carbonylation 
chemistry to install new functionalities of our choice. Indeed, with what we have learned, we can begin 
to combine the most promising optimisation points from each SAR study on each ring together to 
improve potency and potentially the DMPK profile of the template. In addition, in order to direct 
future SAR, metabolite identification could be carried out. With this in hand we could block the known 
site(s) of metabolism directly and with enough SAR knowledge, we may still be able to maintain or 
improve potency. Based on what we have observed with the DMPK studies, it is possible that the A-
ring is not necessarily the only site of metabolism, there are two benzylic positions of the C-ring which 
may also be prone to metabolism. Blocking groups could be explored here with a chance to improve 
metabolic stability. In addition, other future work to be carried out is to run biochemical assays in the 
presence of non-ionic detergent. This will need to be carried out in order to rule out aggregate based 
nonspecific enzyme inhibition of the template, which may occur due to the poor aqueous solubility 
profile of the template as a whole. With all of this information taken together, displayed below are 
compounds within this series which we could potentially synthesise in the future for further hit to lead 
optimisation (74 – 81) (Figure 2.29).  
 





Figure 2.29. Potential future targets. 
*Note, after completion of this work we identified that Carlier et al. published a patent 
containing a few of the reported compounds here. We want to disclose that our work was carried out 
independently of this patent, in some cases using different chemical methods.81  
2.5 Experimental 
2.5.1 General Methodologies 
Chemicals 
Chemicals and solvents were used as purchased from Sigma Aldrich, Fluorochem, Alfa Aesar, 
OxChem, BIONET or TCI with no purification needed unless stated. HOBT was bought in from sigma 
Aldrich containing approximately 12 % impurity of water, reagent values were calculated taking into 
consideration the water impurity. Anhydrous solvents were bought in or dried and distilled prior to 
use. Distillation was carried out under the flow of dry nitrogen; THF was distilled from sodium; 
dichloromethane (DCM) was distilled from calcium hydride. Anhydrous DCM and THF were also 
obtained from MBRAUN MBSPS5 solvent purification system. 
Glassware 
For anhydrous reactions, all needles, flasks, stirrer bars and any other required glassware were 
either flame or oven dried before use. All were cooled in a desiccator containing self-indicating silica 
gel or were immediately placed under a vacuum. 




Thin Layer Chromatography (TLC)  
Thin layer chromatography was carried out on Merck silica gel 60 F-254 aluminium backed 
plates. Compounds were visualised by treatment with potassium permanganate (1 % w/v in water), 
anisaldehyde, ninhydrin or by exposure to UV light and were developed as appropriate via a heat gun. 
Flash Column Chromatography  
Purification of products was achieved by flash column chromatography unless otherwise 
stated. Flash column chromatography was performed using the required amount of silica (particle size 
40 – 63 μm, supplied by Aldrich) made into a slurry with the appropriate volume of the desired eluent 
system. The slurry was added to the column over a thin base layer of sand. Crude material was applied 
to the column, either dissolved in a minimum volume of eluent system or pre-absorbed onto silica. 
The column was then eluted with the eluent and fractions were collected and analysed by TLC. 
Characterisation of compounds 
1H (400MHz) and 13C (100MHz) NMR spectra were recorded on a Bruker AMX400 
spectrometer (1H 400 MHz; 13C 101 MHz), Bruker DPX400 spectrometer (1H 400 MHz; 13C 101 MHz) or 
on a Bruker Avance III HD spectrometer (1H 500 MHz; 13C 126 MHz) in deuterated solvents as indicated 
with the experimental data. Chemical shifts are reported in parts per million (δ, ppm) downfield from 
the internal standard of TMS. Coupling constants (J) are reported in Hz. 2D NOESY experiments were 
ran with mixing time (d8) = 1 second. 
Low Resolution Mass spectrometry (LRMS) and High Resolution Mass Spectrometry (HRMS) 
were recorded using the analytical service within the Chemistry Department at the University of 
Liverpool. LRMS and HRMS was conducted on a VG analytical 7070E machine, Frisons TRIO mass 
spectrometers or Agilent QTOF 7200 using chemical ionisation (CI) or electrospray (ESI). Elemental 
analysis (%C, %H, %N and %S where specified) were determined by the University of Liverpool 
Microanalysis Laboratory.  
Infra-red spectra were recorded in the range of 4000-600 cm-1 using a JASCO FT/IR 4200 
spectrometer, or Bruker ALPHA FT-IR platinum ATR spectrometer. 
Melting points were carried out using a Gallenkamp melting point machine and values are 
recorded in degrees Celsius. 




 Chiral HPLC was carried out using Agilent 1200 HPLC machine equipped with a CHIRACEL OJ 
column. Flow rate 0.5 ml/min, using neat MeOH as eluent. UV detector recorded signals at wavelength 
of 254 nm.  
2.5.2 Procedures 
General Procedure 1: Pictet-Spengler cyclisation 
To L-tryptophan methyl ester (13) (0.97 g, 4.43 mmol, 1 eq) and 2,4-dichlorobenzaldehyde 
(0.85 g, 4.87 mmol, 1.1 eq) in a flame dried round bottomed flask under an N2 atmosphere was added 
anhydrous DCM (25 cm3), the resultant solution was cooled to 0 oC and stirred for 10 minutes before 
the addition of trifluoroacetic acid (0.37 cm3, 4.87 mmol, 1.1 eq). The reaction was allowed to slowly 
warm to room temperature and was left to stir for 24 hours. Upon completion, the reaction was 
quenched with 10 % ammonium hydroxide (25 cm3), and the product extracted into DCM (3 x 50 cm3), 
the combined organics were washed with water (50 cm3), brine (50 cm3) and dried over MgSO4. The 
diastereoisomers and remaining aldehyde were separated by column chromatography, gradient 
elution from 100 % DCM to 2 % EtOAc in DCM. Recrystallising both diastereoisomers from hot 
methanol; gave compound 4 as clear see through crystals (0.50 g, 30 %), and compound 5 as white 
needles (0.82 g, 49 %). 
Preparation of methyl (1R,3S)-1-(2,4-dichlorophenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-
carboxylate (4) and methyl (1S,3S)-1-(2,4-dichlorophenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole-3-carboxylate (5)   
 
L-tryptophan methyl ester 13 (0.97 g, 4.43 mmol, 1 eq), 2,4-dichlorobenzaldehyde (0.85 g, 
4.87 mmol, 1.1 eq) and TFA (0.37 cm3, 4.87 mmol, 1.1 eq) were used in anhydrous DCM (25 cm3) 
following general procedure 1. Gave 4 as clear see through crystals (0.50 g, 30 %). δH (400 MHz, CDCl3) 
7.75 (1H, s), 7.55 (1H, d, J 7.5 Hz), 7.46 (1H, d, J 1.7 Hz), 7.29 – 7.23 (1H, apparent m), 7.20 – 7.13 (3H, 
m), 6.90 (1H, d, J 8.4 Hz), 5.83 (1 H, s), 3.87 – 3.79 (1H, apparent t), 3.72 (3H, s), 3.25 (1H, dd, J 15.2, 
4.8 Hz), 3.08 (1H, dd, J 15.4, 7.8 Hz), 2.77 (1H, s). δC (101 MHz, CDCl3) 173.8, 137.9, 136.4, 134.52, 
134.48, 131.6, 131.0, 129.9, 127.3, 126.9, 122.4, 119.9, 118.5, 111.1, 109.8, 52.4, 52.3, 51.3, 24.9. ESI-
HRMS: m/z calculated for C19H1735Cl2N2O2 [M+H]+ requires 375.0662. Found 375.0664. 




Crystal data and structure refinement for 4  
 
Identification code 4 
Empirical formula C19H16Cl2N2O2 
Formula weight 375.24 
Temperature/K 100.0 
Crystal system monoclinic 












Crystal size/mm3 0.22 × 0.18 × 0.1 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.492 to 52.866 
Index ranges -12 ≤ h ≤ 12, -13 ≤ k ≤ 13, -21 ≤ l ≤ 21 
Reflections collected 38831 
Independent reflections 7193 [Rint = 0.0271, Rsigma = 0.0198] 
Data/restraints/parameters 7193/1/473 
Goodness-of-fit on F2 1.075 
Final R indexes [I>=2σ (I)] R1 = 0.0294, wR2 = 0.0705 
Final R indexes [all data] R1 = 0.0306, wR2 = 0.0714 
Largest diff. peak/hole / e Å-3 0.76/-0.96 
Flack parameter -0.002(9) 
 




The same procedure also gave 5 as white needles (0.82 g, 49 %). δH (400 MHz, CDCl3) 7.56 (1H, 
s), 7.53 (1H, d, J 7.3 Hz), 7.46 (1H, d, J 1.9 Hz), 7.37 (1H, d, J 8.5 Hz), 7.26 – 7.09 (4H, m), 5.78 (1H, s), 
3.97 (1H, dd, J 11.0, 4.1 Hz), 3.81 (3H, s), 3.23 (1H, ddd, J 15.1, 4.0, 1.6 Hz), 3.07 – 2.93 (1H, m 
(overlapped ddd)), 2.61 (1H, s). δC (101 MHz, CDCl3) 173.1, 137.4, 136.3, 134.8, 134.2, 133.3, 131.6, 
129.5, 128.2, 127.0, 122.3, 119.9, 118.4, 111.1, 109.5, 56.7, 52.5, 25.5. ESI-HRMS: m/z calculated for 
C19H1735Cl2N2O2 [M+H]+ requires 375.0662. Found 375.0665. 
General Procedure 2: Amide couplings from tetrahydro-β-carboline methyl ester  
To compound 4 (0.12 g, 0.31 mmol, 1 eq) was added methyl amine 33 % in EtOH (6.45 cm3, 
51.77 mmol, 167 eq) and the mixture stirred at RT overnight in a sealed tube. Solvents were removed 





Compound 4 (0.12 g, 0.31 mmol, 1 eq) and methyl amine 33 % in EtOH (6.45 cm3, 51.77 mmol, 
167 eq) were used following general procedure 2. Gave the desired product 6 as transparent crystals 
(0.11 g, 99 %). δH (500 MHz, DMSO) 10.72 (1H, s), 7.72 (1H, apparent q), 7.68 (1H, d, J 1.9 Hz), 7.47 
(1H, d, J 7.7 Hz), 7.30 (1H, dd, J 8.3, 1.7 Hz), 7.25 (1H, d, J 8.0 Hz), 7.06 (1H, apparent t), 6.99 (1H, 
apparent t), 6.68 (1H, d, J 8.4 Hz), 5.56 (1H, d, J 4.7 Hz), 3.39 – 3.33 (1H, m), 3.09 (1H, dd, J 9.6, 5.1 Hz), 
3.00 (1H, dd, J 15.2, 4.4 Hz), 2.69 (1H, dd, J 15.1, 10.0 Hz), 2.59 (3H, d, J 4.9 Hz). δC (126 MHz, DMSO) 
172.8, 138.9, 136.1, 134.5, 132.6, 132.6, 131.2, 129.1, 126.8, 126.5, 121.1, 118.5, 117.7, 111.1, 109.2, 
51.4, 50.8, 25.4, 25.2. ESI-HRMS: m/z calculated for C19H1835Cl2N3O [M+H]+ requires 374.0821. Found 
374.0821 Elemental Analysis Calculated for C19H17Cl2N3O requires C, 60.98 %, H, 4.58 %, N, 11.23 %. 
Found C, 60.81 %, H, 4.55 %, N, 11.23 %. IR (neat): νmax/cm-1: 3375 (m), 3288 (s), 3065 (m, br), 2937 – 
2901 (m, br), 1660 (s), 1588 (m), 1516 (s), 1467 (s), 1449 (vs), 1316 (s), 1258 (s), 825 (s). Melting Point 
oC: 248 – 250 (MeOH) HPLC (purity analysis %) found: Purity 100 %; Retention time: 10.20 min / 30 
min (0.5 ml/min MeOH, Signal = 254 nm, CHIRACEL OJ column). 




Preparation of methyl (1R,3S)-1-(2,4-dichlorophenyl)-2-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole-3-carboxylate (17) 
 
To compound 4 (0.26 g, 0.68 mmol, 1eq) was added acetone (5 cm3), and potassium carbonate 
(0.10 g, 0.75 mmol, 1.1 eq) in a sealed tube, the tube was purged gently with N2 before addition of 
MeI (0.047 cm3, 0.75 mmol, 1.1 eq). The tube was sealed and covered with aluminium foil to block out 
light. The reaction was heated to reflux in the dark overnight. The resulting mixture was diluted with 
brine and product extracted into EtOAc (3 x 50 cm3), combined organics were dried over MgSO4. The 
product was purified by column chromatography (10 % EtOAc in hexane) to yield the desired product 
17 as yellow crystals (0.16 g, 67 %). δH (400 MHz, CDCl3) 7.57 (1H, s), 7.49 (1H, d, J 7.4 Hz), 7.45 (1H, 
s), 7.37 (1H, d, J 8.4 Hz), 7.23 – 7.03 (4H, m), 5.88 (1H, s), 4.01 (1H, d, J 5.4 Hz), 3.64 (3H, s), 3.35 (1H, 
dd, J 15.4, 6.0 Hz), 3.26 (1H, d, J 15.4 Hz), 2.49 (3H, s). δC (101 MHz, CDCl3) 173.4, 138.6, 136.6, 134.6, 
134.1, 134.0, 131.5, 129.3, 128.1, 126.8, 122.1, 119.6, 118.3, 111.1, 106.1, 61.7, 57.2, 51.6, 40.4, 25.1. 




Compound 17 (0.07 g, 0.18 mmol, 1 eq) and methyl amine 33 % in EtOH (3.74 cm3, 30.06 
mmol, 167 eq) were used following general procedure 2. Gave the desired product 18 as a white solid 
(0.069 g, 99 %). δH (500 MHz, CDCl3) 7.85 (1H, s), 7.65 (1H, d, J 7.7 Hz), 7.50 (1H, d, J 2.1 Hz), 7.32 (1H, 
d, J 7.9 Hz), 7.24 – 7.21 (1H, m), 7.20 – 7.16 (1H, m), 7.07 (1H, dd, J 8.3, 2.1 Hz), 6.70 (1H, d, J 4.8 Hz), 
6.65 (1H, d, J 8.3 Hz), 5.14 (1H, s), 3.50 (1H, dd, J 11.5, 4.7 Hz), 3.16 (1H, dd, J 16.5, 4.7 Hz), 3.01 (1H, 
dd, J 16.5, 11.6 Hz), 2.79 (3H, d, J 5.0 Hz), 2.47 (3H, s). δC (126 MHz, CDCl3) 172.4, 137.0, 136.8, 135.9, 
134.7, 131.3, 130.2, 129.5, 127.1, 126.9, 122.6, 120.0, 119.0, 111.5, 111.2, 60.9, 56.3, 36.9, 26.1, 17.3. 




ESI-HRMS: m/z calculated for C20H2035Cl2N3O [M+H]+ requires 388.0978. Found 388.0973. Elemental 
Analysis Calculated C20H19Cl2N3O requires C, 61.86 %, H, 4.93 %, N, 10.82 %. Found C, 62.02 %, H, 4.96 
%, N, 10.81 %. IR (neat): νmax/cm-1: 3390 (m), 3261 (s), 2963 – 2798 (m, br), 1671 (s), 1523 (m), 1467 
(s), 1467 (s), 740 (s), 690 (s). Melting Point oC: 234 – 235 (MeOH). HPLC (purity analysis %) found: 
Purity 100 %; Retention time: 11.33 min / 30 min (0.5 ml/min MeOH, Signal = 254 nm, CHIRACEL OJ 
column). 
Preparation of methyl (1R,3S)-2-(2-bromoacetyl)-1-(2,4-dichlorophenyl)-2,3,4,9-tetrahydro-1H-
pyrido[3,4-b]indole-3-carboxylate (19) 
 
To compound 4 (0.20 g, 0.53 mmol, 1 eq) in a flame dried round bottomed flask was added 
anhydrous DCM (5 cm3) under a N2 atmosphere and NEt3 (0.11 cm3, 0.80 mmol, 1.5 eq). The reaction 
mixture was cooled to 0 °C before addition of bromoacetyl bromide (0.07 cm3, 0.8 mmol, 1.5 eq). The 
reaction mixture was allowed to slowly warm to room temperature and was left overnight. The 
resulting reaction was quenched by slow addition of saturated NaHCO3 solution (50 cm3) and was left 
to stir until CO2 production ceased. The product was extracted into DCM (3 x 50 cm3); combined 
organics were washed with water (50 cm3) and brine (50 cm3) before drying over MgSO4. After 
filtration the product was purified by column chromatography (100 % DCM) to yield the product 19 as 
a white solid (0.27 g, 80 %). δH (500 MHz, CDCl3) 8.11 (1H, s), 7.54 (1H, d, J 7.8 Hz), 7.43 (1H, s), 7.30 
(1H, s), 7. 21 – 7.17 (2H, m), 7.16 – 7.11 (1H, m), 6.59 (1H, s), 5.30 (1H, d, J 3.7 Hz), 3.97 (1H, d, J 11.4 
Hz), 3.85 (1H, d, J 11.4 Hz), 3.76 (1H, d, J 15.5 Hz), 3.67 (3H, s), 3.49 (1H, dd, J 15.5, 4.6 Hz). δC (101 
MHz, CDCl3) 171.4, 168.4, 139.3, 136.6, 133.5, 132.7, 132.1, 129.6, 128.3, 126.6, 126.0, 122.9, 120.2, 
118.5, 111.4, 105.0, 57.8, 53.4, 53.0, 27.2, 23.8. ESI-HRMS: m/z calculated for C21H1779Br35Cl2N2NaO3 











Compound 19 (0.078 g, 0.16 mmol) was used following a modified procedure to general 
procedure 4, using methyl amine 33 % in EtOH (0.10 cm3, 0.80 mmol, 5 eq) and diluting the reaction 
with EtOH (8 cm3). Gave the product 20 as a white solid (0.037 g, 57 %). δH (500 MHz, CDCl3) 8.09 (1H, 
s), 7.52 (1H, d, J 7.8 Hz), 7.46 (1H, d, J 2.1 Hz), 7.32 (1H, d, J 8.1 Hz), 7.25 – 7.21 (2H, m), 7.19 – 7.14 
(1H, m), 7.10 (1H, dd, J 8.4, 2.1 Hz), 6.77 (1H, d, J 8.4 Hz), 4.25 (1H, dd, J 12.0, 4.5 Hz), 4.11 (1H, d, J 
18.1 Hz), 4.04 (1H, d, J 18.1 Hz), 3.48 (1H, dd, J 15.6, 4.5 Hz), 3.01 (3H, s), 2.99 – 2.94 (1H, ddd, 15.6, 
3.6, 1.36 Hz). δC (126 MHz, CDCl3) 166.0, 163.1, 136.5, 135.8, 135.2, 133.9, 131.9, 130.4, 129.2, 127.3, 
126.3, 123.2, 120.5, 118.6, 111.5, 109.4, 53.1, 51.6, 49.5, 33.5, 27.3. ESI-HRMS: m/z calculated for 
C21H1835Cl2N3O2 [M+H]+ requires 414.0771. Found 414.0775. Elemental Analysis Calculated for 
C21H17Cl2N3O2 requires C, 60.88 %, H, 4.14 %, N, 10.14 %. Found C, 60.86 %, H, 4.21 %, N, 10.02 %. IR 
(neat): νmax/cm-1: 3258 (m, br), 3073 (w) 2918 (br) 2855 (m, br), 1666(s), 1648 (s), 1444 (s) 1321 (s), 




In a flame dried round bottom flask was added compound 6 (0.10 g, 0.27 mmol, 1 eq) 
anhydrous DCM (5 cm3) and NEt3 (0.04 cm3, 0.29 mmol, 1.1 eq) under N2. The reaction mixture was 
cooled to 0 °C before addition of AcCl (0.021 cm3, 0.29 mmol, 1.1 eq). The reaction mixture was 
allowed to slowly warm to room temperature and left to stir overnight. The resulting reaction was 
quenched by slow addition of saturated NaHCO3 solution (50 cm3) and was left to stir until CO2 




production ceased. The product was extracted into DCM (3 x 50 cm3); combined organics were washed 
with water (50 cm3) and brine (50 cm3) before drying over MgSO4. After filtration the product was 
purified by column chromatography (30 % EtOAc in DCM) to yield the product 21 as a white solid 
(0.066 g, 60 %). Note: 1H and 13C NMR appears to exist as two rotamers with little difference in ratio 
between major and minor rotamers. In 1H NMR chemical shifts are reported as the average between 
any two rotameric peaks. Most signals in 1H NMR appear as broadened singlets and as such coupling 
constants are mostly missing. In 13C NMR signals also appear broadened; all observed peaks in 13C are 
reported. δH (500 MHz, CDCl3) 8.12 (1H, s, br), 7.50 (1H, d, J 7.8 Hz), 7.44 (1H, s, br), 7.27 (1H, d, J 8.2 
Hz), 7.21 – 7.07 (3H, m, br), 6.63 (1H, s, br), 5.72 (1H, s, br), 5.16 (1H, s, br), 3.75 – 3.26 (2H, m, br), 
2.69 (3H, s), 2.12 (3H, s, br). δC (126 MHz, CDCl3) 171.6, 171.3, 139.7, 139.1, 136.5, 134.7, 133.6, 132.3, 
132.2, 132.1, 130.0, 129.7, 129.2, 128.8, 128.3, 126.8, 126.1, 122.9, 120.2, 118.7, 111.4, 107.2, 105.5, 
59.0, 55.1, 52.5, 27.0, 26.7, 26.6, 24.3, 23.3, 23.2, 23.0. ESI-HRMS: m/z calculated for 
C21H1935Cl2N3NaO2 [M+Na]+ requires 438.0747. Found 438.0740. Elemental Analysis Calculated for 
C21H19Cl2N3O2 requires C, 60.59 %, H, 4.60 %, N, 10.09 %. Found C, 59.21 %, H, 4.73 %, N, 9.60 %. IR 
(neat): νmax/cm-1: 3384 (w, br), 3291 (w, br), 3060 (m, br), 2928 (m), 2855 (w), 1644(s), 1384 (s), 741 
(s). Melting Point oC: 180 – 184. HPLC (purity analysis %) found: Purity 100 %; Retention time: 7.28 




Compound 4 (0.12 g, 0.32 mmol, 1eq) was used following a modified procedure to general 
procedure 2. Cyclopropyl amine (0.67 cm3, 9.60 mmol, 30 eq) was dissolved in EtOH (2 cm3) and added 
to compound 4 in a sealed tube. The reaction was heated to 50 °C overnight. Solvents were removed 
in vacuo and product purified by column chromatography (2 % EtOAc in DCM). Recrystallisation from 
hot methanol gave the desired product 22 as white needles (0.063 g, 49 %). δH (500 MHz, CDCl3) 7.77 
(1H, s), 7.58 (1H, d, J 7.8 Hz), 7.48 (1H, d, J 2.1 Hz), 7.31 – 7.27 (1H, m), 7.21  (1H, apparent td), 7.15 
(1H, apparent td), 7.08 (1H, dd, J 8.3, 2.1 Hz), 6.93 (1H, d, J 3.0 Hz), 6.74 (1H, d, J 8.3 Hz), 5.60 (1H, s), 
3.51 (1H, dd, J 9.7, 4.9 Hz), 3.30 (1H, dd, J 15.9, 4.9 Hz), 2.89 (1 H, ddd, J 15.9, 9.8, 1.5 Hz), 2.73 – 2.68 




(1H, m), 2.06 (1H, br s), 0.83 – 0.69 (2H, m), 0.55 – 0.43 (2H, m). δC (126 MHz, CDCl3) 174.1, 136.9, 
136.5, 135.2, 134.8, 131.4, 131.2, 130.2, 127.1, 127.0, 122.7, 120.0, 118.8, 111.5, 111.1, 52.6, 51.9, 
24.8, 22.5, 6.8, 6.5. ESI-HRMS: m/z calculated for C21H2035Cl2N3O [M+H]+ requires 400.0978. Found 
400.0981. Elemental Analysis Calculated C20H19Cl2N3O requires C, 63.01 %, H, 4.78 %, N, 10.50 %. 
Found C, 62.70 %, H, 4.77 %, N, 10.34 %. IR (neat): νmax/cm-1: 3364 (m), 3272 (s, br), 3059 (w, br), 2943 
(w, br), 2842 (w), 1658 (s), 1507, (s), 1452 (s), 825 (s). Melting Point oC: 194 – 196 (MeOH). HPLC 
(purity analysis %) found: Purity 100 %; Retention time: 7.96 min / 30 min (0.5 ml/min MeOH, Signal 




Compound 4 (0.10 g, 0.28 mmol, 1 eq) was used following a modified procedure to general 
procedure 2. EtNH2 2M in MeOH (11.76 cm3, 23.52 mmol, 84 eq) was used at the nucleophile instead 
of MeNH2. Yielded the product 23 as a white solid after recrystallisation in hot MeOH (0.055 g, 51 %). 
δH (500 MHz, DMSO) 10.70 (1H, s), 7.77 (1H, br t, J 5.5 Hz), 7.69 (1H, d, J 2.2 Hz), 7.48 (1H, d, J 7.8 Hz), 
7.30 (1H, dd, J 8.3, 2.2 Hz), 7.24 (1H, d, J 8.0 Hz), 7.09 – 7.03 (1H, m), 7.02 – 6.96 (1H, m), 6.69 (1H, d, 
J 8.4 Hz), 5.56 (1H, d, J 4.6 Hz), 3.36 (1H, apparent td), 3.13 – 3.04 (3H, m), 2.99 (1H, dd, J 15.1, 4.5 Hz), 
2.70 (1H, ddd, J 15.1, 9.8, 1.1 Hz), 1.01 (3H, t, J 7.2 Hz). δC (126 MHz, DMSO) 172.1, 138.9, 136.1, 134.5, 
132.6, 132.6, 131.2, 129.1, 126.8, 126.5, 121.1, 118.5, 117.7, 111.1, 109.1, 51.4, 50.6, 33.3, 25.2, 14.7. 
ESI-HRMS: m/z calculated for C20H2035Cl2N3O [M+H]+ requires 388.0978. Found 388.0972. Elemental 
Analysis Calculated for C20H19Cl2N3O requires C, 61.87 %, H, 4.93 %, N, 10.82 %. Found C, 61.21 %, H, 
4.92 %, N, 10.63 %. IR (neat): νmax/cm-1: 3358 (m), 3312 (m), 3222 (m, br), 3063 (w, br), 2932 (w), 2874 









Generic structure of compounds 26a – f and 27a – f following general procedure 1 
 
Preparation of methyl (1R,3S)-1-(2-chloro-4-(trifluoromethyl)phenyl)-2,3,4,9-tetrahydro-1H-
pyrido[3,4-b]indole-3-carboxylate (26a) and methyl (1S,3S)-1-(2-chloro-4-(trifluoromethyl)phenyl)-
2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate (27a) 
L-tryptophan methyl ester 13 (0.86 g, 3.93 mmol, 1 eq), 2-chloro-4-
(trifluoromethyl)benzaldehyde (0.90 g, 4.32 mmol, 1.1 eq), and TFA (0.33 cm3, 4.32 mmol, 1.1 eq), 
were used in anhydrous DCM (20 cm3) following general procedure 1. Gave 26a as white crystals (0.52 
g, 33 %). δH (400 MHz, CDCl3) 7.73 (1H, d, J 1.0 Hz), 7.69 (1H, s), 7.57 (1H, d, J 7.5 Hz), 7.38 (1H, d, J 8.2 
Hz), 7.29 – 7.25 (1H, m), 7.22 – 7.11 (3H, m), 5.93 (1H, s), 3.85 (1H, dd, J 7.6, 5.1 Hz), 3.73 (3H, s), 3.32 
– 3.24 (1H, ddd, J 15.4, 5.1, 0.8 Hz), 3.11 (1H, ddd, J 15.4, 7.6, 1.4 Hz), 2.82 (1H, s). δC (101 MHz, CDCl3) 
173.8, 143.3, 136.4, 134.4, 131.7 (q, J 33.1 Hz), 131.2, 130.7, 127.1 (q, J 3.8 Hz), 126.9, 123.9 (q, J 3.5 
Hz), 123.3 (q, J 272.7 Hz), 122.6, 120.0, 118.5, 111.2, 109.9, 52.4, 51.5, 24.9. δF (376 MHz, CDCl3) -62.8 
(3F, s). ESI-HRMS: m/z calculated for C20H1635ClF3N2O2 [M+H]+ requires 409.0925. Found 409.0933. 
The same procedure also gave 27a as white needles (0.88 g, 55 %). δH (400 MHz, CDCl3) 7.73 
(1H, s), 7.61 (1H, d, J 8.1 Hz), 7.57 (1H, s), 7.54 (1H, d, J 7.2 Hz), 7.47 (1H, d, J 8.1 Hz), 7.26 – 7.22 (1H, 
m), 7.19 – 7.10 (2H, m), 5.88 (1H, s), 4.00 (1 H, dd, J 11.0, 4.1 Hz), 3.82 (3H, s), 3.25 (1H, ddd, J 15.1, 
4.1, 1.7 Hz), 3.02 (1H, ddd, J 15.1, 11.0, 2.4 Hz). δC (101 MHz, CDCl3) 173.0, 142.9, 136.4, 134.1, 132.8, 
131.9 (q, J 33.4 Hz), 131.3, 126.9, 126.8 (q, J 3.4), 124.6 (q, J 3.5 Hz), 123.3 (q, J 272.6 Hz), 122.5, 120.0, 
118.5, 111.1, 109.7, 56.6, 52.5, 25.5. δF (376 MHz, CDCl3) -62.8 (3F, s). ESI-HRMS: m/z calculated for 
C20H1635ClF3N2O2 [M+H]+ requires 409.0925. Found 409.0934. 




Preparation of methyl (1R,3S)-1-(4-bromo-2-chlorophenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole-3-carboxylate (26b) and methyl (1S,3S)-1-(4-bromo-2-chlorophenyl)-2,3,4,9-tetrahydro-
1H-pyrido[3,4-b]indole-3-carboxylate (27b) 
L-tryptophan methyl ester 13 (0.45 g, 2.08 mmol, 1 eq), 2-chloro-4-bromobenzaldehyde (0.50 
g, 2.29 mmol, 1.1 eq) and TFA (0.18 cm3, 2.29 mmol, 1.1 eq), were used in anhydrous DCM (10 cm3) 
following general procedure 1. Gave 26b as a white solid (0.15 g, 17 %).  δH (500 MHz, CDCl3) 7.68 (1H, 
s), 7.61 (1H, d, J 2.0 Hz), 7.56 (1H, d, J 7.7 Hz), 7.27 – 7.23 (2H, m), 7.20 – 7.16 (1H, m), 7.16 – 7.12 (1H, 
m), 6.85 (1H, d, J 8.3 Hz), 5.83 (1H, s), 3.83 (1H, dd, J 7.7, 5.0 Hz), 3.73 (3H, s), 3.25 (1H, ddd, J 15.3, 
5.0, 1.0 Hz), 3.09 (1H, ddd, J 15.3, 7.8, 1.5 Hz), 2.77 (1H, br s). δC (126 MHz, CDCl3) 173.8, 138.4, 136.4, 
134.7, 132.7, 131.6, 131.4, 130.2, 126.9, 122.5, 122.3, 119.9, 118.5, 111.1, 109.8, 52.37, 52.35, 51.4, 
24.9. ESI-HRMS: m/z calculated for C19H1779Br35ClN2O2 [M+H]+ requires 419.0156. Found 419.0151. 
The same procedure also gave 27b as a white solid (0.29 g, 34 %). δH (500 MHz, CDCl3) 7.63 
(1H, d, J 1.8 Hz), 7.56 – 7.52 (2H, m), 7.37 – 7.31 (2H, m), 7.26 – 7.22 (1H, m), 7.18 – 7.11 (2H, m), 5.79 
(1H, s), 3.99 (1H, dd, J 11.0, 4.1 Hz), 3.83 (3H, s), 3.24 (1H, ddd, J 15.0, 4.1, 1.8 Hz), 3.01 (1H, ddd, J 
15.0, 11.0, 2.5 Hz), 2.63 (1H, s). δC (126 MHz, CDCl3) 173.1, 137.0, 136.3, 134.5, 133.2, 132.3, 131.9, 
131.1, 127.0, 122.5, 122.4, 119.9, 118.4, 111.1, 109.5, 56.7, 52.5, 25.5. ESI-HRMS: m/z calculated for 
C19H1779Br35ClN2O2 [M+H]+ requires 419.0156. Found 419.0151. 
Preparation of methyl (1R,3S)-1-(2,6-dichlorophenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-
carboxylate (26c) and methyl (1S,3S)-1-(2,6-dichlorophenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole-3-carboxylate (27c)  
Note reported here are the distinguishable trans signals first 26c with the full cis isomer 
reported 27c separately below. The cis isomer in this case is a highly predominant product and could 
not be separated from trans by column. The trans isomer was separated at the next step (see 
compound 30a and 30b). All Ar-H corresponding to the trans product are lost under cis signals as are 
some Ar-C signals. The aliphatic region is the only part of the spectrum were trans signals can be 
observed unambiguously. 
L-tryptophan methyl ester 13 (0.51 g, 2.31 mmol, 1 eq), 2,6-dichlorobenzaldehyde (0.45 g, 
2.54 mmol, 1.1 eq) and TFA (0.20 cm3, 2.54 mmol, 1.1 eq), were used in anhydrous DCM (15 cm3) 
following general procedure 1. It should be noted in the case of this compound lab temperature was 
12 °C throughout the course of the reaction. After column chromatography the mixture of 26c and 
27c were obtained as a pale yellow solid (0.67 g, 80 %). 26c NMR δH (500 MHz, CDCl3) 6.48 (1H, s), 4.25 
(1H, dd, J 6.0, 2.7 Hz), 3.72 (3H, s), 3.38 (1H, ddd, J 15.4, 2.7, 1.8 Hz), 3.29 – 3.25 (1H, m). δC (126 MHz, 




CDCl3) 174.4, 136.1, 135.7, 132.0, 129.9, 127.2, 121.8, 119.6, 118.3, 111.0, 107.9, 55.0, 51.0, 50.8, 
23.7.  
27c NMR δH (500 MHz, CDCl3) 7.52 – 7.50 (1H, m), 7.48 (1H, s), 7.43 (1H, dd, J 7.7, 1.7 Hz), 7.28 
– 7.19 (3H, m), 7.16 – 7.10 (2H, m), 6.19 (1H, s), 4.03 (1H, dd, J 11.2, 4.2 Hz), 3.82 (3H, s), 3.25 (1H, 
ddd, J 15.2, 4.3, 1.9 Hz), 2.95 (1H, ddd, J 15.1, 11.2, 2.7 Hz), 2.71 (1H, s). δC (126 MHz, CDCl3) 173.4, 
137.1, 136.3, 136.0, 134.5, 133.0, 130.6, 130.2, 128.9, 127.2, 122.0, 119.9, 118.1, 111.1, 108.9, 57.5, 
54.5, 52.4, 26.0. ESI-HRMS: m/z calculated for C19H1735Cl2N2O2 [M+H]+ requires 375.0662. Found 
375.0654. 
Preparation of methyl (1R,3S)-1-(2,4-dichloro-3-fluorophenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole-3-carboxylate (26d) and methyl (1S,3S)-1-(2,4-dichloro-3-fluorophenyl)-2,3,4,9-tetrahydro-
1H-pyrido[3,4-b]indole-3-carboxylate (27d) 
L-tryptophan methyl ester 13 (0.50 g, 2.29 mmol, 1 eq), 2,4-dichloro-3-fluoro-benzaldehyde 
(0.49 g, 2.52 mmol, 1.1 eq) and TFA (0.19 cm3, 2.52 mmol, 1.1 eq), were used in anhydrous DCM (15 
cm3) following general procedure 1. Gave 26d as white crystals (0.24 g, 26 %). δH (500 MHz, MeOD) 
7.48 (1H, d, J 7.8 Hz), 7.28 (1H, dd, J 8.4, 7.1 Hz), 7.24 (1H, d, J 8.0 Hz), 7.11 – 7.06 (1H, m), 7.05 – 7.00 
(1H, m), 6.63 (1H, dd, J 8.5, 1.7 Hz), 5.84 (1H, s), 3.79 (1H, dd, J 8.7, 4.8 Hz), 3.72 (3H, s), 3.21 (1H, dd, 
J 15.3, 4.8 Hz), 2.99 (1H, ddd, J 15.3, 8.7, 1.3 Hz). δC (126 MHz, MeOD) 174.9, 155.6 (d, J 248.8 Hz), 
141.6 (d, J 1.3 Hz), 138.3, 132.1, 129.3, 127.9, 126.8 (d, J 4.2 Hz), 123.4 (d, J 17.4 Hz), 122.9, 122.4 (d, 
J 18.1 Hz), 120.1, 118.9, 112.1, 109.9, 53.1, 52.7, 52.5 (d, J 2.2), 25.8. δF (376 MHz, MeOD) -116.2 (1F, 
s). ESI-HRMS: m/z calculated for C19H1635Cl2FN2O2 [M+H]+ requires 393.0567. Found 393.0575. 
The same procedure also gave 27d as white crystals (0.54 g, 60 %). δH (500 MHz, MeOD) 7.45 
(1H, d, J 7.7 Hz), 7.37 (1H, dd, J 8.5, 7.2 Hz), 7.21 (1H, d, J 8.0 Hz), 7.09 – 7.03 (2H, m), 7.02 – 6.98 (1H, 
m), 5.77 (1H, s), 3.96 (1H, dd, J 10.9, 4.3 Hz), 3.78 (3H, s), 3.17 (1H, ddd, J 15.1, 4.3, 1.7 Hz), 2.95 (1H, 
ddd, J 15.1, 10.9, 2.4 Hz). δC (126 MHz, MeOD) 174.5, 155.3 (d, J 247.9 Hz), 141.1, 138.3, 133.7, 129.9, 
128.0, 127.2 – 126.9 (m), 123.9 (d, J 17.7 Hz), 122.6, 122.5 (d, J 18.0 Hz), 120.0, 118.7, 112.1, 109.6, 
57.8, 55.5 – 55.2 (m), 52.7, 26.2. δF (376 MHz, MeOD) -115.9 (1F, s). ESI-HRMS: m/z calculated for 
C19H1635Cl2FN2O2 [M+H]+ requires 393.0567. Found 393.0561. 
Preparation of methyl (1R,3S)-1-(2,3,4-trichlorophenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-
3-carboxylate (26e) and methyl (1S,3S)-1-(2,3,4-trichlorophenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole-3-carboxylate (27e) 
L-tryptophan methyl ester 13 (0.51 g, 2.33 mmol, 1 eq), 2,3,4-trichlorobenzaldehyde (0.54 g, 
2.56 mmol, 1.1 eq), and TFA (0.20 cm3, 2.56 mmol, 1.1 eq), were used in anhydrous DCM (15 cm3) 




following general procedure 1. Gave 26e as a white solid (0.28 g, 29 %). δH (500 MHz, DMSO) 10.64 
(1H, s), 7.52 (1H, d, J 8.5 Hz), 7.48 (1H, d, J 7.8 Hz), 7.26 – 7.23 (1H, m), 7.09 – 7.04 (1H, m), 7.02 – 6.97 
(1H, m), 6.81 (1H, d, J 8.5 Hz), 5.76 (1H, d, J 4.2 Hz), 3.76 – 3.71 (1H, m), 3.63 (3H, s), 3.34 (1H, dd, J 
6.7, 4.5 Hz), 3.13 – 3.07 (1H, m), 2.88 (1H, ddd, J 15.1, 7.9, 1.2 Hz). δC (126 MHz, DMSO) 173.6, 141.2, 
136.2, 133.2, 132.4, 131.7, 130.5, 129.2, 128.3, 126.3, 121.3, 118.6, 117.8, 111.2, 107.9, 51.72, 51.70, 
51.6, 24.7. ESI-HRMS: m/z calculated for C19H1635Cl3N2O2 [M+H]+ requires 409.0272. Found 409.0268. 
The same procedure also gave 27e as a white solid (0.45 g, 48 %). δH (500 MHz, DMSO) 10.43 
(1H, s), 7.59 (1H, d, J 8.5 Hz), 7.46 (1H, d, J 7.7 Hz), 7.26 (1H, d, J 8.5 Hz), 7.21 (1H, d, J 8.0 Hz), 7.05 – 
7.00 (1H, m), 6.99 – 6.95 (1H, m), 5.71 (1H, d, J 5.6 Hz), 3.96 (1H, dt, 10.8, 4.2 Hz), 3.70 (3H, s), 3.12 – 
3.08 (1H, m), 3.08 – 3.03 (1H, m), 2.87 (1H, ddd, J 14.7, 10.9, 2.2 Hz). δC (126 MHz, DMSO) 172.7, 140.7, 
136.3, 133.7, 133.3, 131.9, 130.1, 129.8, 128.8, 126.4, 121.1, 118.6, 117.8, 111.2, 107.5, 56.0, 54.9, 
51.8, 25.1. ESI-HRMS: m/z calculated for C19H1635Cl3N2O2 [M+H]+ requires 409.0272. Found 409.0268. 
Preparation of methyl (1R,3S)-1-(2,4-dichloro-5-fluorophenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole-3-carboxylate (26f) and methyl (1S,3S)-1-(2,4-dichloro-5-fluorophenyl)-2,3,4,9-tetrahydro-
1H-pyrido[3,4-b]indole-3-carboxylate (27f) 
L-tryptophan methyl ester 13 (0.51 g, 2.32 mmol, 1 eq), 2,4-dichloro-5-fluoro-benzaldehyde 
(0.49 g, 2.55 mmol, 1.1 eq) and TFA (0.20 cm3, 2.55 mmol, 1.1 eq) were used in anhydrous DCM (15 
cm3) following general procedure 1. Gave 26f as awhite solid (0.26 g, 29 %). δH (500 MHz, CDCl3) 7.70 
(1H, s), 7.56 (1H, d, J 7.6 Hz), 7.51 (1H, d, J 6.5 Hz), 7.27 (1H, d, J 8.0 Hz), 7.22 – 7.18 (1H, m), 7.17 – 
7.13 (1H, m), 6.89 (1H, d, J 9.5 Hz), 5.85 (1H, s), 3.88 (1H, dd, J 7.1, 5.2 Hz), 3.73 (3H, s), 3.27 (1H, ddd, 
J 15.3, 5.1, 0.9 Hz), 3.12 (1H, ddd, J 15.4, 7.2, 1.4 Hz), 2.79 (1H, s). δC (126 MHz, CDCl3) 173.9, 157.1 (d, 
J 250.6 Hz), 140.4 (d, J 5.3 Hz), 136.4, 131.4, 131.1, 128.6 (d, J 3.7 Hz), 126.8, 122.7, 121.5 (d, J 19.3 
Hz), 120.0, 118.6, 117.9 (d, J 23.4 Hz), 111.2, 109.7, 52.5, 52.4, 51.3, 24.8. δF (376 MHz, CDCl3) -116.0 
(1F, s). ESI-HRMS: m/z calculated for C19H1635Cl2FN2O2 [M+H]+ requires 393.0567. Found 393.0562. 
The same procedure also gave 27f as a white solid (0.53 g, 58 %). δH (500 MHz, CDCl3) 7.57 
(1H, s), 7.55 – 7.51 (2H, m), 7.34 (1H, d, J 9.6 Hz), 7.24 (1H, apparent d overlapped with CDCl3), 7.19 – 
7.15 (1H, apparent td), 7.15 – 7.09 (1H, apparent td), 5.77 (1H, s), 3.98 (1H, dd, J 11.0, 4.0 Hz), 3.83 
(3H, s), 3.23 (1H, ddd, J 15.0, 4.0, 1.8 Hz), 3.01 (1H, ddd, J 15.0, 11.0, 2.4 Hz), 2.69 (1H, s). δC (126 MHz, 
CDCl3) 172.9, 157.6 (d, J 250.7 Hz), 139.9 (br d, J 5.7 Hz), 136.4, 132.7, 131.1, 128.3 (d, J 3.5), 126.9, 
122.5, 121.9 (d, J 19.4 Hz), 120.1, 118.5, 118.3 (d, J 23.7 Hz), 111.1, 109.6, 56.6, 54.1 (br s), 52.5, 25.4. 
δF (376 MHz, CDCl3) -115.2 (1F, s). ESI-HRMS: m/z calculated for C19H1635Cl2FN2O2 [M+H]+ requires 
393.0567. Found 393.0566. 








Compound 26a (0.098 g, 0.24 mmol, 1 eq) and methyl amine 33 % in EtOH (4.99 cm3, 40.08 
mmol, 167 eq), were used following general procedure 2. Gave 28 a white solid (0.090 g, 91 %). δH 
(500 MHz, DMSO) 10.72 (1H, s), 7.94 (1H, s), 7.74 (1H, apparent q), 7.61 (1H, d, J 8.1 Hz), 7.49 (1H, d, 
J 7.8 Hz), 7.25 (1H, d, J 8.1 Hz), 7.07 (1H, apparent t), 7.00 (1H, apparent t), 6.90 (1H, d, J 8.3 Hz), 5.65 
(1H, d, J 4.7 Hz), 3.39 – 3.31 (1H, m), 3.19 (1H, dd, J 9.5, 5.0 Hz), 3.01 (1H, dd, J 15.2, 4.4 Hz), 2.70 (1H, 
dd, J 15.2, 10.2 Hz), 2.59 (3H, d, J 4.6 Hz). δC (126 MHz, DMSO) 172.8, 144.4, 136.2, 134.4, 132.3, 130.8, 
129.4 (q, J 32.7 Hz), 126.5, 126.4 (q, J 3.6), 123.7 (q, J 3.6 Hz), 123.4 (q, J 272.5 Hz), 121.2, 118.5, 117.8, 
111.2, 109.3, 51.5, 51.0, 25.4, 25.3. δF (376 MHz, DMSO) -61.1 (3F, s). ESI-HRMS: m/z calculated for 
C20H1835ClF3N3O [M+H]+ requires 408.1085. Found 408.1082. Elemental Analysis Calculated for 
C20H17ClF3N3O requires C, 58.90 %, H, 4.20 %, N, 10.30 %. Found C, 58.83 %, H, 4.21 %, N, 10.49 %. IR 
(neat): νmax/cm-1: 3409 (m), 3319 (m), 3251 (br), 3058 (m, br), 2935 – 2841 (m, br), 1672 (m), 1650 (s), 
1530 (s), 1315 (vs), 1168 (s), 1127 (s), 740 (s). Melting Point oC: 243 – 246 (MeOH). HPLC (purity 
analysis %) found: Purity 100 %; Retention time: 7.98 min / 30 min (0.5 ml/min MeOH, Signal = 254 
nm, CHIRACEL OJ column).  
Preparation of (1R,3S)-1-(4-bromo-2-chlorophenyl)-N-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole-3-carboxamide (29) 
Compound 26b (0.14 g, 0.33 mmol, 1 eq) and methyl amine 33 % in EtOH (6.86 cm3, 55.11 
mmol, 167 eq), were used following general procedure 2. Gave 29 as a white solid (0.12 g, 87 %). δH 
(500 MHz, DMSO) 10.71 (1H, s), 7.80 (1H, d, J 2.0 Hz), 7.72 (1H, q, J 4.7 Hz), 7.47 (1H, d, J 7.8 Hz), 7.43 




(1H, dd, J 8.3, 2.0 Hz), 7.25 (1H, d, J 8.0 Hz), 7.08 – 7.03 (1H, m), 7.02 – 6.97 (1H, m), 6.62 (1H, d, J 8.3 
Hz), 5.55 (1H, d, J 4.8 Hz), 3.37 – 3.33 (1H, m), 3.09 (1H, dd, J 9.6, 5.1 Hz), 3.00 (1H, dd, J 15.2, 4.5 Hz), 
2.68 (1H, ddd, J 15.2, 10.1, 1.2 Hz), 2.59 (3H, d, J 4.7 Hz). δC (126 MHz, DMSO) 172.8, 139.3, 136.2, 
134.7, 132.6, 131.7, 131.6, 129.7, 126.5, 121.1, 120.8, 118.5, 117.7, 111.1, 109.2, 51.4, 50.8, 25.4, 
25.2. ESI-HRMS: m/z calculated for C19H1879Br35ClN3O [M+H]+ requires 418.0316. Found 418.0325. 
Elemental Analysis Calculated for C19H17BrClN3O requires C, 54.50 %, H, 4.09 %, N, 10.04 %. Found C, 
54.39 %, H, 4.09 %, N, 10.03 %. IR (neat): νmax/cm-1: 3385 (m), 3257 (m, br), 3226 (m, br), 3087 (w), 
3055 (w), 2933 (w), 2879 (w), 2840 (w), 1650 (s), 1521 (m), 1462 (m), 1450 (m), 745 (s). Melting Point 
oC: 227 – 229 (MeOH). HPLC (purity analysis %) found: Purity 100 %; Retention time: 10.85 min / 30 
min (0.5 ml/min MeOH, Signal = 254 nm, CHIRACEL OJ column). 
Preparation of (1R,3S)-1-(2,6-dichlorophenyl)-N-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-
3-carboxamide (30a) and (1S,3S)-1-(2,6-dichlorophenyl)-N-methyl-2,3,4,9-tetrahydro-1H-
pyrido[3,4-b]indole-3-carboxamide (30b) 
Compound 26c and 27c (0.10 g, 0.27 mmol, 1 eq) and methyl amine 33 % in EtOH (5.62 cm3, 
45.09 mmol, 167 eq), were used following general procedure 2. Cis and trans isomers were separated 
by column chromatography (30 % EtOAc in DCM). Yielded 30a as a white solid (0.014 g, 14 % isolated 
yield). δH (500 MHz, DMSO) 10.51 (1H, s), 7.85 (1H, q, J 4.7 Hz), 7.58 (1H, dd, J 7.0, 1.9 Hz), 7.40 (1H, 
d, J 7.7 Hz), 7.38 – 7.34 (2H, m), 7.20 – 7.17 (1H, m), 6.98 (1H, apparent td), 6.94 (1H, apparent td), 
6.06 (1H, s), 3.91 (1H, br s), 3.11 (2H, ddd, J 15.1, 4.3, 1.7 Hz + br peak), 2.92 (1H, ddd, J 15.1, 5.7, 1.7 
Hz), 2.63 (3H, d, J 4.7 Hz). δC (126 MHz, DMSO) 172.9, 136.4, 136.3, 135.9, 135.2, 132.8, 130.4, 130.0, 
128.7, 126.8, 120.4, 118.1, 117.5, 111.0, 106.9, 54.1, 50.3, 25.6, 23.1. ESI-HRMS: m/z calculated for 
C19H1835Cl2N3O [M+H]+ requires 374.0821. Found 374.0818. Elemental Analysis Calculated for 
C19H17Cl2N3O requires C, 60.98 %, H, 4.58 %, N, 11.23 %. Found C, 60.68 %, H, 4.67 %, N, 10.93 %. IR 
(neat): νmax/cm-1: 3386 (m), 3339 (s), 3226 (m, br), 3069 (m, br), 2926 (m), 2849 (m), 1652 (s), 1527 
(m), 1432 (s), 738 (s). Melting Point oC: 238 – 240 (MeOH)  
30b as a white solid (0.034 g, 34 % isolated yield). δH (500 MHz, DMSO) 10.54 (1H, s), 7.93 (1H, 
q, J 4.7 Hz), 7.64 – 7.59 (1H, m), 7.43 – 7.39 (3H, m), 7.20 (1H, d, J 7.9 Hz), 7.00 (1H, apparent td), 6.97 
– 6.93 (1H, m), 6.02 (1H, d, J 9.2 Hz), 3.69 (1H, apparent td), 3.03 (1H, ddd, J 15.1, 4.1, 1.7 Hz), 2.72 – 
2.66 (1H, m), 2.65 (3H, d, J 4.7 Hz). δC (126 MHz, DMSO) 172.5, 136.2, 136.0, 135.1, 134.9, 133.4, 130.5, 
130.4, 128.9, 126.7, 120.5, 118.4, 117.5, 111.1, 107.6, 57.5, 54.2, 25.6, 25.4. ESI-HRMS: m/z calculated 
for C19H1835Cl2N3O [M+H]+ requires 374.0821. Found 374.0821. 






Compound 26d (0.10 g, 0.25 mmol, 1 eq) and methyl amine 33 % in EtOH (5.20 cm3, 41.75 
mmol, 167 eq), were used following general procedure 2. Gave 31 as white crystals (0.099 g, 99 %).  
δH (500 MHz, DMSO) 10.70 (1H, s), 7.72 (1H, dd, J 9.0, 4.4 Hz), 7.52 – 7.42 (2H, m), 7.26 (1H, d, J 8.0 
Hz), 7.09 – 7.04 (1H, m), 7.02 – 6.97 (1H, m), 6.56 (1H, dd, J 8.6, 1.5 Hz), 5.59 (1H, d, J 5.0 Hz), 3.36 (1H, 
td, J 10.0, 4.4 Hz), 3.21 – 3.15 (1H, m), 2.99 (1H, dd, J 15.2, 4.4 Hz), 2.70 (1H, ddd, J 15.2, 10.1, 1.1 Hz), 
2.59 (3H, d, J 4.7 Hz). δC (126 MHz, DMSO) 172.77, 153.4 (d, J 246.9 Hz), 141.4 (d, J 1.4 Hz), 136.1, 
132.2, 127.9, 126.5, 125.7 (d, J 3.7 Hz), 121.7 (d, J 17.3 Hz), 121.2, 119.6 (d, J 17.9 Hz), 118.5, 117.8, 
111.2, 109.3, 51.5, 50.8, 25.4, 25.1. δF (376 MHz, DMSO) -115.7 (1F, s). ESI-HRMS: m/z calculated for 
C19H1735Cl2FN3O [M+H]+ requires 392.0727. Found 392.0733. Elemental Analysis Calculated for 
C19H1635Cl2FN3O requires C, 58.18 %, H, 4.11 %, N, 10.71 %. Found C, 58.16 %, H, 4.08 %, N, 10.71 %. IR 
(neat): νmax/cm-1: 3376 (w), 3289 (m, br) 2951 (w), 2903 (w), 2857 (w) 1655 (s), 1519 (br), 1451 (s), 
1425 (s), 1261 (m), 1217 (m), 811 (s), 745 (s), 589 (s). 
Preparation of (1R,3S)-N-methyl-1-(2,3,4-trichlorophenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole-3-carboxamide (32) 
Compound 26e (0.1 g, 0.24 mmol, 1 eq) and methyl amine 33 % in EtOH (4.99 cm3, 40.08 
mmol, 167 eq), were used following general procedure 2. Gave 32 as a white solid (0.088 g, 88 %). δH 
(500 MHz, DMSO) 10.69 (1H, s), 7.72 (1H, q, J 4.7 Hz), 7.52 (1H, d, J 8.5 Hz), 7.48 (1H, d, J 7.8 Hz), 7.25 
(1H, d, J 8.0 Hz), 7.07 (1H, apparent td), 7.00 (1H, apparent t), 6.66 (1H, d, J 8.5 Hz), 5.61 (1H, d, J 5.0 
Hz), 3.38 – 3.33 (1H, m), 3.18 (1H, dd, J 9.9, 5.3 Hz), 2.99 (1H, dd, J 15.3, 4.5), 2.69 (1H, dd, J 15.3, 10.1 
Hz), 2.59 (3H, d, J 4.7 Hz). δC (126 MHz, DMSO) 172.8, 141.2, 136.1, 133.4, 132.4, 131.6, 130.7, 128.9, 
128.0, 126.5, 121.2, 118.5, 117.8, 111.1, 109.3, 51.8, 51.5, 25.4, 25.2. ESI-HRMS: m/z calculated for 
C19H1735Cl3N3O [M+H]+ requires 408.0432. Found 408.0429. Elemental Analysis Calculated for 
C19H16Cl3N3O requires C, 55.84 %, H, 3.95 %, N, 10.28 %. Found C, 55.68 %, H, 3.97 %, N, 10.23 %. IR 
(neat): νmax/cm-1: 3392 (w), 3290 (m, br), 2922 (w), 2882 (w), 2842 (w), 1666 (s), 1510, (m), 1432 (s), 
1172 (s), 746 (s). Melting Point oC: 249 – 251 (MeOH)  
Preparation of (1R,3S)-1-(2,4-dichloro-5-fluorophenyl)-N-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole-3-carboxamide (35) 
Compound 26f (0.10 g, 0.25 mmol, 1 eq) and methyl amine 33 % in EtOH (5.20 cm3, 41.75 
mmol, 167 eq), were used following general procedure 2. Gave 35 as white crystals (0.087 g, 87 %). 
δH (500 MHz, DMSO) 10.71 (1H, s), 7.90 (1H, d, J 6.8 Hz), 7.72 (1H, q J 4.7 Hz), 7.49 (1H, d, J 7.9 Hz), 




7.27 (1H, apparent dt), 7.10 – 7.05 (1H, m), 7.03 – 6.98 (1H, m), 6.58 (1H, d, J 9.8 Hz), 5.55 (1H, d, J 
5.2), 3.42 (1H, td, J 9.8, 4.5), 3.15 (1H, dd, J 9.8, 5.4 Hz), 3.00 (1H, dd, J 15.2, 4.5 Hz), 2.70 (1H, ddd, J 
15.2, 9.8, 1.2), 2.60 (3H, d, J 4.7 Hz). δC (126 MHz, DMSO) 172.8, 155.6 (d, J 247.1 Hz), 141.4 (d, J 5.3 
Hz), 136.2, 132.1, 131.0, 129.3 (d, J 3.4 Hz), 126.4, 121.3, 119.2 (d, J 18.9 Hz), 118.6, 117.9, 117.5 (d, J 
22.9 Hz), 111.2, 109.4, 51.5, 50.9, 25.4, 25.1. δF (376 MHz, DMSO) -118.2 (1F, s). ESI-HRMS: m/z 
calculated for C19H1735Cl2FN3O [M+H]+ requires 392.0727. Found 392.0728. Elemental Analysis 
Calculated for C19H16Cl2FN3O requires C, 58.18 %, H, 4.11 %, N, 10.71 %. Found C, 58.40 %, H, 4.16 %, 
N, 10.71 %. IR (neat): νmax/cm-1: 3379 (w), 3293 (m), 3290 (m, br) 3065 (w), 2944 (w), 2902 (w), 2854 
(w), 1656 (s), 1520 (m, br), 1464 (s), 1448 (s), 1374 (m), 1357 (m), 1217 (m), 1120 (s), 868 (m), 739 (s), 
664 (s), 607 (s). Melting Point oC: 256 – 257 (MeOH). 
Preparation of (S)-2-amino-3-(1H-indol-3-yl)-N-methylpropanamide (33) 
 
L-tryptophan methyl ester 13 (0.5 g, 2.29 mmol, 1 eq) and methyl amine 33 % in EtOH (19.96 
cm3, 160.30 mmol, 70 eq), were used following general procedure 2. Gave the desired product 33 as 
a yellow solid (0.498 g, 99 %). δH (500 MHz, CDCl3) 8.45 (1H, br s), 7.66 (1H, d, J 7.9 Hz), 7.37 (1H, d, J 
8.1 Hz), 7.28 (1H, s), 7.22 – 7.18 (1H, m), 7.13 – 7.10 (1H, m), 7.06 (1H, d, J 2.1 Hz), 3.71 (1H, dd, J 9.0, 
4.2 Hz), 3.39 (1H, ddd, J 14.5, 4.2, 0.8 Hz), 2.92 (1H, dd, J 14.5, 9.0 Hz), 2.81 (3H, d, J 5.0 Hz). δC (126 
MHz, CDCl3) 175.7, 136.6, 127.6, 123.2, 122.3, 119.7, 119.1, 111.9, 111.4, 55.8, 31.0, 26.0. CI-HRMS: 












b]indole-3-carboxamide (36a) and  (1S,3S)-1-(4,6-dichloropyridin-3-yl)-N-methyl-2,3,4,9-
tetrahydro-1H-pyrido[3,4-b]indole-3-carboxamide (36b) 
 
Compound 33 (0.50 g, 2.30 mmol, 1 eq), 4,6-Dichloropyridine-3-carbaldehyde (0.45 g, 2.53 
mmol, 1.1 eq), and TFA (0.19 cm3, 2.53 mmol, 1.1 eq), were used in anhydrous DCM (15 cm3) following 
general procedure 1. Cis and trans isomers were separated by column chromatography (50 % EtOAc 
in DCM). Gave 36a as a pale yellow solid (0.054 g, 6 % isolated yield). δH (500 MHz, DMSO) 10.71 (1H, 
s), 7.89 (1H, s), 7.74 (1H, br d, J 4.7 Hz), 7.61 (1H, s), 7.49 (1H, d, J 7.8 Hz), 7.27 (1H, d, J 8.0 Hz), 7.08 
(1H, apparent t), 7.00 (1H, apparent t), 5.59 (1H, d, J 5.2 Hz), 3.40 (1H, td, J 10.0, 4.4 Hz), 3.21 (1H, dd, 
J 10.3, 5.5 Hz), 2.98 (1H, dd, J 15.2, 4.4 Hz), 2.71 (1H, dd, J 15.2, 9.8 Hz), 2.59 (3H, d, J 4.7 Hz). δC (126 
MHz, DMSO) 172.7, 149.8, 149.7, 145.7, 136.1, 135.2, 131.4, 126.5, 124.8, 121.3, 118.6, 117.9, 111.2, 
109.6, 51.6, 49.0, 25.4, 25.1. ESI-HRMS: m/z calculated for C18H1735Cl2N4O [M+H]+ requires 375.0774. 
Found 375.0775. Elemental Analysis Calculated for C18H16Cl2N4O requires C, 57.61 %, H, 4.30 %, N, 
14.93 %. Found C, 57.64 %, H, 4.26 %, N, 15.13 %. IR (neat): νmax/cm-1: 3391 (m), 3318 (m), 3220 (m, 
br), 3089 (m), 2932 (w), 2895 (w), 2838 (w), 1651 (s), 1567 (s), 1525 (s), 1445 (s), 1329 (m), 834 (s), 
751 (s). Melting Point oC: 250 – 251 (MeOH). HPLC (purity analysis %) found: Purity 100 %; Retention 
time: 10.18 min / 30 min (0.5 ml/min MeOH, Signal = 254 nm, CHIRACEL OJ column). 
36b was isolated as a yellow solid (0.26 g, 31 % isolated yield). δH (500 MHz, DMSO) 10.49 (1H, 
s), 8.27 (1H, s), 7.88 (1H, s), 7.80 (1H, br d, J 4.5 Hz), 7.45 (1H, d, J 7.7 Hz), 7.22 (1H, d, J 8.1 Hz), 7.04 
(1H, apparent t), 6.98 (1H,apparent t), 5.59 (1H, d, J 5.2 Hz), 3.70 – 3.60 (1H, m), 3.08 – 3.01 (1H, m), 
2.97 (1H, s), 2.81 – 2.73 (1H, m), 2.65 (3H, d, J 4.7 Hz). δC (126 MHz, DMSO) 172.4, 151.7, 149.8, 145.6, 
136.3, 134.5, 133.2, 126.6, 124.4, 121.1, 118.6, 117.8, 111.2, 108.6, 57.5, 25.5, 25.3. ESI-HRMS: m/z 
calculated for C18H1635Cl2N4NaO [M+H]+ requires 397.0593. Found 397.0593.  
General Procedure 3: Esterification of amino acids  
6-fluoro-DL-tryptophan 42a (0.50 g, 2.28 mmol, 1 eq) was suspended in anhydrous MeOH (5 
cm3) under an N2 atmosphere in a flame dried round bottomed flask. The reaction flask was cooled to 
0 °C before dropwise addition of thionyl chloride (0.33 cm3, 4.56 mmol, 2 eq). The reaction vessel was 




allowed to slowly warm to room temperature and then stirred overnight. The resulting suspension 
was basified with the slow addition of saturated sodium bicarbonate solution (50 cm3) and the 
resulting solution gently stirred until CO2 production ceased. The aqueous phase was then extracted 
with EtOAc (3 x 50 cm3); combined organics were washed with water (50 cm3), brine (50 cm3) and then 
dried over MgSO4. After filtration the solvents were removed in vacuo to yield 43a as white flakes 
(0.54 g, 88 %). 
Generic structure of compounds 43a – f following general procedure 3 
 
Preparation of methyl 2-amino-3-(6-fluoro-1H-indol-3-yl)propanoate (43a) 
6-fluoro-DL-tryptophan 42a (0.50 g, 2.28 mmol, 1 eq) and thionyl chloride (0.33 cm3, 4.56 
mmol, 2 eq), were used in anhydrous MeOH (5 cm3) following general procedure 3. Gave 43a as white 
flakes (0.54 g, 88 %). δH (400 MHz, DMSO) 10.93 (1H, s), 7.46 (1H, dd, J 8.5, 5.7 Hz), 7.15 – 7.07 (2H, 
m), 6.88 – 6.79 (1H, m), 3.61 (1H, t, J 6.3 Hz), 3.54 (3H, s), 2.99 (1H, dd, J 14.2, 6.1 Hz), 2.92 (1H, dd, J 
14.2, 6.4 Hz), 1.77 (2H, br s). δC (101 MHz, DMSO) 175.6, 158.8 (d, J 233.6 Hz), 135.9 (d, J 12.7 Hz), 
124.3, 124.2 (d, J 3.5 Hz), 119.3 (d, J 10.3 Hz), 110.3, 106.7 (d, J 24.4 Hz), 97.3 (d, J 25.4 Hz), 55.1, 51.3, 
30.6. δF (376 MHz, DMSO) -122.6 (1F, s). CI-HRMS: m/z calculated for C12H14FN2O2 [M+H]+ requires 
237.1034. Found 237.1035. 
Preparation of methyl (S)-2-amino-3-(6-fluoro-1H-indol-3-yl)propanoate (43b) 
6-fluoro-L-tryptophan 42b (0.62 g, 2.84 mmol, 1eq) and thionyl chloride (0.41 cm3, 5.68 mmol, 
2 eq), were used in anhydrous MeOH (5 cm3) following general procedure 3. Gave 43b as white flakes 
(0.29 g, 44 %). δH (400 MHz, DMSO) 10.91 (1H, s), 7.46 (1H, dd, J 8.3, 5.8 Hz), 7.10 (2H, d, J 14.4 Hz), 
6.88 – 6.79 (1H, apparent t), 3.65 – 3.57 (1H, m), 3.54 (3H, s), 2.99 (1H, dd, J 14.2, 6.0 Hz), 2.91 (1H, 
dd, J 14.2, 6.4 Hz), 1.77 (2H, br s). CI-HRMS: m/z calculated for C12H14FN2O2 [M+H]+ requires 237.1034. 
Found 237.1043 




Preparation of methyl (S)-2-amino-3-(6-chloro-1H-indol-3-yl)propanoate (43c) 
6-chloro-L-tryptophan 42c (0.51 g, 2.11 mmol, 1 eq) and thionyl chloride (0.31 cm3, 4.23 mmol, 
2 eq), were used in anhydrous MeOH (5 cm3) following general procedure. Gave 43c as white to beige 
flakes (0.43 g, 85 %). δH (400 MHz, DMSO) 11.00 (1H, s), 7.48 (1H, d, J 8.4 Hz), 7.37 (1H, s), 7.17 (1H, 
s), 6.98 (1H, d, J 8.4 Hz), 3.61 (1H, t, J 6.3 Hz), 3.54 (3H, s), 2.99 (1H, dd, J 14.2, 6.1 Hz), 2.92 (1H, dd, J 
14.2, 6.4 Hz), 1.79 (2H, br s). δC (101 MHz, DMSO) 175.6, 136.4, 126.2, 125.6, 124.8, 119.7, 118.6, 
110.9, 110.4, 55.1, 51.3, 30.5. CI-HRMS: m/z calculated for C12H1435ClN2O2 [M+H]+ requires 253.0738. 
Found 253.0744 
Preparation of methyl (S)-2-amino-3-(5-fluoro-1H-indol-3-yl)propanoate (43d)  
5-fluoro-L-tryptophan monohydrate 42d (0.50 g, 2.08 mmol, 1eq) and thionyl chloride (0.60 
cm3, 8.32 mmol, 4 eq), were used in anhydrous MeOH (5 cm3) following general procedure 3. Gave 
43d as a white solid (0.47 g, 94 %). δH (500 MHz, MeOD) 7.29 (1H, dd, J 8.8, 4.4 Hz), 7.18 (1H, d, J 9.9 
Hz), 7.14 (1H, s), 6.89 – 6.83 (1H, apparent t), 3.75 (1H, t, J 6.1 Hz), 3.65 (3H, s), 3.14 (1H, dd, J 14.5, 
5.9 Hz), 3.08 (1 H, dd, J 14.5, 6.5 Hz). δC (126 MHz, MeOD) 176.6, 159.0 (d, J 232.3 Hz), 134.7, 129.1 (d, 
J 9.6 Hz), 126.7, 113.1 (d, J 9.7 Hz), 110.9 (d, J 4.8 Hz), 110.6 (d, J 26.5 Hz), 103.9 (d, J 23.7 Hz), 55.8, 
52.4, 31.3. δF (376 MHz, MeOD) -129.2 (1F, s). CI-HRMS: m/z calculated for C12H14FN2O2 [M+H]+ 
requires 237.1034. Found 237.1041. 
Preperation of methyl (S)-2-amino-3-(5-chloro-1H-indol-3-yl)propanoate (43e) 
5-chloro-L-tryptophan 42e (0.50 g, 2.10 mmol, 1 eq) and thionyl chloride (0.31 cm3, 4.19 mmol, 
2 eq), were used in anhydrous MeOH (5 cm3) following general procedure 3. Gave 43d as brown oil 
(0.46 g, 87 %). δH (500 MHz, CDCl3) 8.25 (1H, s), 7.56 (1H, d, J 2.0 Hz), 7.25 (1H, dd, J 8.6, 0.5 Hz), 7.13 
(1H, dd, J 8.6, 2.0 Hz), 7.08 (1H, d, J 2.0 Hz), 3.81 (1H, dd, J 7.4, 5.0 Hz), 3.72 (3H, s), 3.21 (1H, dd, J 
14.5, 5.0 Hz), 3.04 (1H, dd, J 14.5, 7.4 Hz). δC (126 MHz, CDCl3) 175.8, 134.7, 128.7, 125.5, 124.5, 122.6, 
118.5, 112.4, 111.1, 54.9, 52.2, 30.6. CI-HRMS: m/z calculated for C12H1435ClN2O2 [M+H]+ requires 
253.0738. Found 253.0739 
Preparation of methyl (S)-2-amino-3-(5-hydroxy-1H-indol-3-yl)propanoate (43f) 
5-hydroxy-L-tryptophan 42f (0.50 g, 2.28 mmol, 1eq) and thionyl chloride (0.33 cm3, 4.56 
mmol, 2 eq), were used in anhydrous MeOH (5 cm3) following general procedure 3. Gave 43f pale 
brown solid (0.37 g, 70 %). δH (500 MHz, DMSO) 10.52 (1H, s), 8.58 (1H, s), 7.11 (1H, d, J 8.6 Hz), 7.00 
(1H, d, J 2.3 Hz), 6.79 (1H, d, J 2.3 Hz), 6.58 (1H, dd, J 8.6, 2.3 Hz), 3.62 – 3.54 (4H, m), 2.93 (1H, dd, J 
14.2, 6.0 Hz), 2.82 (1H, dd, J 14.2, 6.5 Hz), 1.76 (2H, br s). δC (126 MHz, DMSO) 175.7, 150.3, 130.7, 




128.0, 124.1, 111.6, 111.2, 108.9, 102.2, 55.0, 51.3, 30.9. CI-HRMS: m/z calculated for C12H15N2O3 
[M+H]+ requires 235.1077. Found 235.1075. 
Generic structure of compounds 44a – f and 45a – f following general procedure 1 
 
Preparation of methyl (1R,3S / 1S,3R)-1-(2,4-dichlorophenyl)-7-fluoro-2,3,4,9-tetrahydro-1H-
pyrido[3,4-b]indole-3-carboxylate (44a) and methyl (1S,3S / 1R,3R)-1-(2,4-dichlorophenyl)-7-fluoro-
2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate (45a) 
Compound 43a (0.46 g, 1.93 mmol, 1 eq), 2,4-dichlorobenzaldehyde (0.37 g, 2.12 mmol, 1.1 
eq) and TFA (0.16 cm3, 2.12 mmol, 1.1 eq), were used in anhydrous DCM (10 cm3) following general 
procedure 1. Gave 44a as a white solid (0.17 g, 22 %). δH (400 MHz, CDCl3) 7.84 (1H, s), 7.49 – 7.41 
(2H, m), 7.12 (1H, d, J 8.3 Hz), 6.98 – 6.86 (3H, m), 5.80 (1H, s), 3.87 – 3.79 (1H, m), 3.73 (3H, s), 3.21 
(1H, dd, J 15.4, 4.9 Hz), 3.05 (1H, dd, J 15.4, 7.7 Hz), 2.77 (1H, s). δC (101 MHz, CDCl3) 173.7, 160.1 (d, 
J 237.9 Hz), 137.7, 136.4 (d, J 12.4 Hz), 134.5 (d, J 14.0 Hz), 131.9 (d, J 3.5 Hz), 130.9, 129.9, 127.3, 
123.5, 119.1 (d, J 10.2 Hz), 109.7, 108.4 (d, J 24.4 Hz), 97.7 (d, J 26.3 Hz), 52.4, 52.3, 51.2, 24.8. δF (376 
MHz, CDCl3) -120.5 (1F, s). ESI-HRMS: m/z calculated for C19H1635Cl2FN2O2 [M+H]+ requires 393.0567. 
Found 393.0566. 
The same procedure also gave 45a as a white solid (0.55 g, 72 %). δH (400 MHz, CDCl3) 7.63 
(1H, s), 7.47 (1H, s), 7.45 – 7.36 (2H, m), 7.21 (1H, d, J 8.3 Hz), 6.94 – 6.84 (2H, m), 5.79 (1H, s), 3.97 
(1H, dd, J 10.9, 3.9 Hz), 3.82 (3H, s), 3.19 (1H, dd, J 15.1, 2.4 Hz), 3.05 – 2.91 (1H, m), 2.62 (1H, s). δC 
(101 MHz, CDCl3) 173.0, 160.0 (d, J 237.8 Hz), 137.2, 136.2 (d, J 12.4 Hz), 134.8, 134.2, 133.6 (d, J 3.5 
Hz), 131.5, 129.5, 128.2, 123.6, 119.0 (d, J 10.2 Hz), 109.4, 108.5 (d, J 24.4 Hz), 97.7 (d, J 26.3 Hz), 56.6, 




52.5, 51.0, 25.4. δF (376 MHz, CDCl3) -120.6 (1F, s). ESI-HRMS: m/z calculated for C19H1635Cl2FN2O2 
[M+H]+ requires 393.0567. Found 393.0567. 
Preparation of methyl (1R,3S)-1-(2,4-dichlorophenyl)-7-fluoro-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole-3-carboxylate (44b) and methyl (1S,3S)-1-(2,4-dichlorophenyl)-7-fluoro-2,3,4,9-tetrahydro-
1H-pyrido[3,4-b]indole-3-carboxylate (45b) 
Compound 43b (0.21 g, 0.91 mmol, 1 eq), 2,4-dichlorobenzaldehyde (0.18 g, 1.00 mmol, 1.1 
eq) and TFA (0.08 cm3, 1.00 mmol, 1.1 eq), were used in anhydrous DCM (5 cm3) following general 
procedure 1. Gave 44b as a white solid (0.088 g, 25 %). δH (500 MHz, MeOD) 7.56 (1H, d, J 2.1 Hz), 
7.43 (1H, dd, J 8.7, 5.3 Hz), 7.21 (1H, dd, J 8.4, 2.2 Hz), 6.95 (1H, dd, J 10, 2.3 Hz), 6.84 – 6.79 (2H, m), 
5.81 (1H, s), 3.79 (1H, dd, J 8.6, 4.8 Hz), 3.72 (3H, s), 3.19 (1H, ddd, J 15.4, 4.8, 0.8 Hz), 2.98 (1 H, ddd, 
J 15.4, 8.6, 1.4 Hz). δC (126 MHz, MeOD) 174.8, 161.3 (d, J 235.5 Hz), 138.9, 138.3 (d, J 12.7 Hz), 135.9, 
135.5, 132.9 (d, J 3.6 Hz), 132.5, 130.6, 128.2, 124.6, 119.6 (d, J 10.0 Hz), 110.0, 108.3 (d, J 24.6 Hz), 
98.3 (d, J 26.2 Hz), 53.0, 52.7, 52.5, 25.6. δF (376 MHz, MeOD) -123.6 (1F, s). ESI-HRMS: m/z calculated 
for C19H1635Cl2FN2O2 [M+H]+ requires 393.0567. Found 393.0563. 
The same procedure also gave 45b as a white solid (0.20 g, 57 %). δH (500 MHz, MeOD) 7.56 
(1H, d, J 2.0 Hz), 7.40 (1H, dd, J 8.6, 5.3 Hz), 7.30 (1H, dd, J 8.4, 2.0 Hz), 7.22 (1H, d, J 8.4 Hz), 6.92 (1H, 
dd, J 10.0, 2.3 Hz), 6.82 – 6.76 (1H, m), 5.75 (1H, s), 3.96 (1H, dd, J 10.8, 4.3 Hz), 3.15 (1H, ddd, J 15.2, 
4.3, 1.7 Hz), 2.94 (1H, ddd, J 15.1, 10.9, 2.4 Hz). δC (126 MHz, MeOD) 174.4, 161.2 (d, J 235.2 Hz), 138.4 
(d, J 23.4 Hz), 138.2, 136.2, 135.7, 134.6 (d, J 2.8 Hz), 133.0 – 132.7 (m), 130.4, 128.9, 124.8, 119.5 (d, 
J 10.1 Hz), 109.7, 108.3 (d, J 24.8 Hz), 98.3 (d, J 26.2 Hz), 57.7, 52.7, 26.1. δF (376 MHz, DMSO) -121.9 
(1F, s). ESI-HRMS: m/z calculated for C19H1635Cl2FN2O2 [M+H]+ requires 393.0567. 
Preparation of methyl (1R,3S)-1-(2,4-dichlorophenyl)-7-chloro-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole-3-carboxylate (44c) and methyl (1S,3S)-1-(2,4-dichlorophenyl)-7-chloro-2,3,4,9-tetrahydro-
1H-pyrido[3,4-b]indole-3-carboxylate (45c) 
Compound 43c (0.43 g, 1.70 mmol, 1 eq), 2,4-dichlorobenzaldehyde (0.33 g, 1.87 mmol, 1.1 
eq) and TFA (0.14 cm3, 1.87 mmol, 1.1 eq), were used in anhydrous DCM (10 cm3)  following general 
procedure 1. Gave 44c as white crystals (0.14 g, 21 %). δH (500 MHz, CDCl3) 7.77 (1H, s), 7.47 (1H, d, J 
2.1 Hz), 7.44 (1H, d, J 8.4 Hz), 7.24 (1H, d, J 1.7 Hz), 7.14 – 7.09 (2H, m) 6.90 (1H, d, J 8.4 Hz), 5.81 (1H, 
s), 3.83 (1H, dd, J 7.5, 5.1 Hz), 3.73 (3H, s) 3.21 (1H, ddd, 15.4, 10.4, 0.7 Hz), 3.05 (1H, dd, J 15.4, 7.7 
Hz), 2.77 (1H, s). δC (126 MHz, CDCl3) 173.7, 137.6, 136.7, 134.7, 134.5, 132.4, 130.9, 130.0, 128.3, 
127.4, 125.5, 120.6, 119.3, 111.2, 109.8, 52.4, 52.3, 51.2, 24.8. ESI-HRMS: m/z calculated for 
C19H1635Cl3N2O2 [M+H]+ requires 409.0277. Found 409.0272. 




The same procedure also gave 45c as yellow needles (0.29 g, 42 %). δH (500 MHz, MeOD) 7.57 
(1H, d, J 1.7 Hz), 7.40 (1H, d, J 8.4), 7.30 (1H, dd, J 8.4, 1.8 Hz), 7.25 – 7.20 (2H, m), 6.98 (1H, dd, J 8.4, 
1.7 Hz), 5.75 (1H, s), 3.96 (1H, dd, J 10.9, 4.3 Hz), 3.78 (3H, s), 3.15 (1H, ddd, J 15.1, 4.0, 1.3 Hz), 2.93 
(1H, ddd, J 15.0, 10.9, 2.2 Hz). δC (126 MHz, MeOD) 174.3, 138.6, 138.3, 136.2, 135.7, 135.1, 132.9, 
130.4, 128.9, 128.4, 126.7, 120.5, 119.8, 112.0, 109.8, 57.7, 52.7, 26.1. 
Preparation of methyl (1R,3S)-1-(2,4-dichlorophenyl)-6-fluoro-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole-3-carboxylate (44d) and methyl (1S,3S)-1-(2,4-dichlorophenyl)-6-fluoro-2,3,4,9-tetrahydro-
1H-pyrido[3,4-b]indole-3-carboxylate (45d) 
Compound 43d (0.44 g, 1.84 mmol, 1 eq), 2,4-dichlorobenzaldehyde (0.36 g, 2.03 mmol, 1.1 
eq) and TFA (0.16 cm3, 2.03 mmol, 1.1 eq), were used in anhydrous DCM (10 cm3)  following general 
procedure 1. Gave 44d as a white flakes (0.073 g, 10 %). δH (500 MHz, MeOD) 7.58 (1H, d, J 2.1 Hz), 
7.24 – 7.18 (2H, m), 7.16 (1H, dd, J 9.6, 2.5 Hz), 6.85 (1H, apparent td), 6.80 (1H, d, J 8.4 Hz), 5.83 (1H, 
s), 3.80 (1H, dd, J 8.6, 4.9 Hz), 3.73 (3H, s), 3.18 (1H, dd, J 15.2, 4.9 Hz), 2.97 (1H, ddd, J 15.2, 8.6, 1.2 
Hz). δC (126 MHz, MeOD) 174.8, 159.1 (d, J 232.8 Hz), 139.0, 135.9, 135.5, 134.8, 134.6, 132.5, 130.6, 
128.24, 128.16, 112.8 (d, J 9.6 Hz), 110.7 (d, J 26.4 Hz), 110.1 (d, J 4.7 Hz), 103.7 (d, J 23.6 Hz), 53.0, 
52.7, 52.6, 25.6. δF (376 MHz, MeOD) -128.9 (1F, s). ESI-HRMS: m/z calculated for C19H1635Cl2FN2O2 
[M+H]+ requires 393.0567. Found 393.0569. 
The same procedure also gave 45d as a pale yellow solid (0.30 g, 42 %). δH (500 MHz, MeOD) 
7.56 (1H, d, J 2.1 Hz), 7.30 (1H, dd, J 8.4, 2.0 Hz), 7.23 (1H, d, J 8.4 Hz), 7.16 (1H, dd, J 8.8, 4.4 Hz), 7.12 
(1H, dd, J 9.6, 2.4 Hz), 6.81 (1H,apparent td), 5.76 (1H, s), 3.96 (1H, dd, J 10.9, 4.3 Hz), 3.78 (3H, s), 
3.13 (1H, ddd, J 15.0, 4.3, 1.6 Hz), 2.93 (1H, ddd, J 15.0, 10.9, 2.7 Hz). δC (126 MHz, MeOD) 174.4, 159.0 
(d, J 232.6 Hz), 138.5, 136.2, 136.2, 135.7, 134.8, 132.9 – 132.8 (m), 130.4, 128.8, 128.3 (d, J 9.9 Hz), 
112.9 (d, J 9.7 Hz), 110.4 (d, J 26.3 Hz), 109.8 (d, J 4.4 Hz), 103.5 (d, J 23.6 Hz), 57.7, 55.4, 52.7, 26.2. 
δF (376 MHz, MeOD) -128.9 (1F, s). ESI-HRMS: m/z calculated for C19H1635Cl2FN2O2 [M+H]+ requires 
393.0567. Found 393.0564. 
Preparation of methyl (1R,3S)-1-(2,4-dichlorophenyl)-6-chloro-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole-3-carboxylate (44e) and methyl (1S,3S)-1-(2,4-dichlorophenyl)-6-chloro-2,3,4,9-
tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate (45e) 
Compound 43e (0.45 g, 1.80 mmol, 1 eq), 2,4-dichlorobenzaldehyde (0.35 g, 1.98 mmol, 1.1 
eq) and TFA (0.15 cm3, 1.98 mmol, 1.1 eq), were used in anhydrous DCM (10 cm3)  following general 
procedure 1. Gave 44e as a pale to beige solid (0.19 g, 26 %). δH (500 MHz, CDCl3) 7.74 (1H, s), 7.51 
(1H, d, J 2.0 Hz), 7.47 (1H, d, J 2.1 Hz), 7.17 (1H, dd, J 8.6, 0.5 Hz), 7.15 – 7.10 (2H, m), 6.94 (1H, d, J 8.4 




Hz), 5.84 (1H, s), 3.86 (1H, dd, J 7.2, 5.1 Hz), 3.73 (3H, s), 3.20 (1H, ddd, J 15.3, 5.1, 1.1 Hz), 3.06 (1H, 
ddd, J 15.3, 7.3, 1.5 Hz). δC (126 MHz, CDCl3) 173.7, 137.7, 134.7, 134.4, 133.3, 130.9, 129.9, 128.0, 
127.5, 125.7, 122.7, 118.1, 112.1, 109.4, 52.4, 51.2, 24.7. ESI-HRMS: m/z calculated for C19H1635Cl3N2O2 
[M+H]+ requires 409.0272. Found 409.0287. 
The same procedure also gave 45e as a pale to beige solid (0.43 g, 59 %). δH (500 MHz, CDCl3) 
7.58 (1H, s), 7.49 (1H, d, J 2.0 Hz), 7.48 (1H, d, J 2.1 Hz), 7.40 (1H, d, J 8.4 Hz), 7.22 (1H, dd, J 8.4, 2.1 
Hz), 7.14 (1H, dd, J 8.6, 0.5 Hz), 7.10 (1H, dd, J 8.6, 2.0 Hz), 5.77 (1H, s), 3.97 (1H, dd, J 11.0, 4.1 Hz), 
3.82 (3H, s), 3.18 (1H, ddd, J 15.1, 4.1, 1.8 Hz), 2.97 (1H, ddd, J 15.1, 11.0, 2.5 Hz). δC (126 MHz, CDCl3) 
172.9, 134.94, 134.91, 134.6, 134.2, 131.51, 131.47, 129.6, 128.3, 128.2, 125.7, 122.5, 118.0, 112.1, 
109.2, 56.6, 52.5, 25.4. ESI-HRMS: m/z calculated for C19H1635Cl3N2O2 [M+H]+ requires 409.0272. Found 
409.0263. 
Preparation of methyl (1R,3S)-1-(2,4-dichlorophenyl)-6-hydroxy-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole-3-carboxylate (44f) and methyl (1S,3S)-1-(2,4-dichlorophenyl)-6-hydroxy-2,3,4,9-
tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate (45f) 
Compound 43f (0.37 g, 1.59 mmol, 1 eq), 2,4-dichlorobenzaldehyde (0.31 g, 1.75 mmol, 1.1 
eq) and TFA (0.13 cm3, 1.75 mmol, 1.1 eq), were used in anhydrous DCM (10 cm3)  following general 
procedure 1. Gave 44f as a brown solid (0.093 g, 15 %). δH (500 MHz, DMSO) 10.32 (1H, s), 8.62 (1H, 
s), 7.67 (1H, d, J 2.1 Hz), 7.31 (1H, dd, J 8.4, 2.0 Hz), 7.02 (1H, d, J 8.6 Hz), 6.82 (1H, d, J 8.4 Hz), 6.76 
(1H, d, J 2.0 Hz), 6.57 (1H, dd, J 8.6, 2.1 Hz), 5.65 (1H, d, J 3.3 Hz), 3.69 – 3.64 (1H, m), 3.63 (3H, s) 3.17 
(1H, d, J 5.2 Hz), 2.99 (1H, dd, J 15.0, 4.9 Hz), 2.78 (1H, dd, J 15.0, 8.5 Hz). δC (126 MHz, DMSO) 173.6, 
150.5, 139.0, 134.1, 133.0, 132.6, 131.5, 130.6, 128.9, 127.0, 111.5, 111.1, 107.0, 102.0, 51.7, 51.6, 
50.6, 24.8. ESI-HRMS: m/z calculated for C19H1735Cl2N2O3 [M+H]+ requires 391.0611. Found 391.0608. 
The same procedure also gave 45f as a brown solid (0.35 g, 56 %). δH (500 MHz, DMSO) 10.07 
(1H, s), 8.59 (1H, s), 7.67 (1H, d, J 2.1 Hz), 7.38 (1H, dd, J 8.4, 2.0 Hz), 7.26 (1H, d, J 8.4 Hz), 7.00 (1H, d, 
J 8.6 Hz), 6.73 (1H, d, J 2.1 Hz), 6.54 (1H, dd, J 8.6, 2.2 Hz), 5.60 (1H, d, J 5.6 Hz), 3.95 – 3.88 (1H, m), 
3.69 (3H, s), 2.93 (1H, dd, J 14.7, 3.5 Hz), 2.84 (1H, apparent t), 2.82 – 2.75 (1H, m). δC (126 MHz, 
DMSO) 172.8, 150.4, 138.4, 134.3, 134.2, 132.8, 130.8, 128.7, 127.5, 127.1, 111.5, 111.0, 106.7, 101.8, 








Generic structure of compounds 46 – 51 following general procedure 2 
 
Preparation of (1R,3S / 1S,3R)-1-(2,4-dichlorophenyl)-7-fluoro-N-methyl-2,3,4,9-tetrahydro-1H-
pyrido[3,4-b]indole-3-carboxamide (46) 
Compound 44a (0.17 g, 0.43 mmol, 1 eq) and methyl amine 33 % in EtOH (8.98 cm3, 71.81 
mmol, 167 eq), were used following general procedure 2. Gave 46 as white crystals (0.10 g, 61 %). δH 
(500 MHz, DMSO) 10.84 (1H, s), 7.71 (1H, q, J 4.7 Hz), 7.68 (1H, d, J 2.1 Hz), 7.46 (1H, dd, J 8.6, 5.6 Hz), 
7.31 (1H, dd, J 8.3, 2.1 Hz), 7.03 (1H, dd, J 10.1, 2.2 Hz), 6.89 – 6.82 (1H, m), 6.70 (1H, d, J 8.3 Hz), 5.54 
(1H, d, J 3.7 Hz), 3.37 – 3.33 (1H, m), 3.09 (1H, dd, J 9.3, 4.9 Hz), 2.98 (1H, dd, J 15.3, 4.5 Hz), 2.67 (1H, 
dd, J 15.3, 10.0 Hz), 2.59 (3H, d, J 4.7 Hz). δC (126 MHz, DMSO) 172.7, 158.9 (d, J 233.8 Hz), 138.7, 
136.0 (d, J 12.6 Hz), 134.5, 133.3 (d, J 3.4 Hz), 132.6, 131.2, 129.1, 126.8, 123.4, 118.6 (d, J 10.1 Hz), 
109.4, 106.7 (d, J 24.1 Hz), 97.3 (d, J 25.6 Hz). δF (376 MHz, DMSO) -121.8 (1F, s). ESI-HRMS: m/z 
calculated for C19H1735Cl2FN3O [M+H]+ requires 392.0727. Found 392.0727. Elemental Analysis 
Calculated for C19H1635Cl2FN3O requires C, 58.18 %, H, 4.11 %, N, 10.71 %. Found C, 58.54 %, H, 4.18 %, 
N, 10.39 %. IR (neat): νmax/cm-1: 3391 (w), 3378 (w), 3288 (m, br), 3241 (m, br), 2919 (w), 2846 (w), 
1658 (s), 1531 (m), 1466 (m), 1132 (s), 835 (s), 611(s). Melting Point oC: 236 – 238 (MeOH). HPLC 
(purity analysis %) found: Purity peak 1 53 %; Retention time: 8.90 min: Purity peak 2 47 %; Retention 
time: 17.29 min / 30 min (0.5 ml/min MeOH, Signal = 254 nm, CHIRACEL OJ column).  
Preparation of (1R,3S)-1-(2,4-dichlorophenyl)-7-fluoro-N-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole-3-carboxamide (47) 
Compound 44b (0.11 g, 0.29 mmol, 1 eq) and methyl amine 33 % in EtOH (6.03 cm3, 48.43 
mmol, 167 eq), were used following general procedure 2. Gave 47 as white crystals (0.11 g, 98 %). δH 
(500 MHz, DMSO) 10.84 (1H, s), 7.72 (1H, dd, J 9.2, 4.5 Hz), 7.68 (1H, d, J 2.2 Hz), 7.46 (1H, dd, J 8.6, 
5.5 Hz), 7.31 (1H, dd, J 8.3, 2.2 Hz), 7.03 (1H, dd, J 10.1, 2.3 Hz), 6.85 (1H, ddd, J 11.0, 8.7, 2.3 Hz), 6.70 
(1H, d, J 8.4 Hz), 5.54 (1H, d, J 4.8 Hz), 3.09 (1H, dd, J 9.7, 5.1 Hz), 2.98 (1H, dd, J 15.3, 4.5 Hz), 2.67 




(1H, ddd, J 15.3, 9.9, 1.2 Hz), 2.59 (3H, d, J 4.6 Hz). δC (126 MHz, DMSO) 172.7, 158.9 (d, J 233.6 Hz), 
138.7, 136.0 (d, J 12.5 Hz), 134.5, 133.3 (d, J 3.6 Hz), 132.6, 131.2, 129.1, 126.8, 123.4, 118.6 (d, J 10.5 
Hz), 109.4, 106.7 (d, J 24.2 Hz), 97.3 (d, J 25.5 Hz), 51.4, 50.7, 25.4, 25.1. δF (376 MHz, DMSO) -121.8 
(1F, s). ESI-HRMS: m/z calculated for C19H1735Cl2FN3O [M+H]+ requires 392.0727. Found 392.0723. 
Elemental Analysis Calculated for C19H1635Cl2FN3O requires C, 58.18 %, H, 4.11 %, N, 10.71 %. Found 
C, 58.03 %, H, 4.14 %, N, 10.77 %. IR (neat): νmax/cm-1: 3378 (w), 3355 (w), 3251 (m, br), 3240 (m, br), 
2932 (w), 2852 (w), 1668 (s), 1523 (m), 1486 (m), 1133 (s), 826 (s), 794 (s), 611(s). Melting Point oC: 
236 – 237 (MeOH). HPLC (purity analysis %) found: Purity 100 %; Retention time: 8.89 min / 30 min 
(0.5 ml/min MeOH, Signal = 254 nm, CHIRACEL OJ column).   
Crystal data and structure refinement for 47 
 
Identification code 47 
Empirical formula C19H16Cl2FN3O 
Formula weight 402.16 
Temperature/K 150.0 
Crystal system orthorhombic 












Radiation CuKα (λ = 1.54178) 
2Θ range for data collection/° 6.362 to 144.14 




Index ranges -5 ≤ h ≤ 9, -19 ≤ k ≤ 19, -29 ≤ l ≤ 34 
Reflections collected 22728 
Independent reflections 6865 [Rint = 0.0399, Rsigma = 0.0454] 
Data/restraints/parameters 6865/415/479 
Goodness-of-fit on F2 1.062 
Final R indexes [I>=2σ (I)] R1 = 0.0439, wR2 = 0.1106 
Final R indexes [all data] R1 = 0.0458, wR2 = 0.1121 
Largest diff. peak/hole / e Å-3 0.54/-0.52 




Compound 44c (0.13 g, 0.32 mmol, 1 eq) and methyl amine 33 % in EtOH (6.66 cm3, 53.44 
mmol, 167 eq), were used following general procedure 2. Gave 48 as white shards (0.042 g, 32 %). δH 
(500 MHz, DMSO) 10.91 (1H, s), 7.72 (1H, dd, J 9.2, 4.5 Hz), 7.69 (1H, d, J 2.2 Hz), 7.49 (1H, d, J 8.4 Hz), 
7.30 (2H, dd, J 8.3, 2.2 Hz), 7.01 (1H, dd, J 8.4, 1.9 Hz), 6.68 (1H, d, J 8.3 Hz), 5.56 (1H, d, J 4.9 Hz), 3.38 
– 3.33 (1H, m), 3.11 (1H, dd, J 9.8, 5.2 Hz), 2.99 (1H, dd, J 15.3, 4.5 Hz), 2.67 (1H, ddd, J 15.3, 9.9, 1.2 
Hz), 2.59 (3H, d, J 4.7 Hz). δC (101 MHz, DMSO) 172.7, 138.6, 136.5, 134.6, 133.9, 132.7, 131.2, 129.2, 
126.9, 125.8, 125.3, 119.1, 118.8, 110.8, 109.5, 51.4, 50.7, 25.5, 25.0. ESI-HRMS: m/z calculated for 
C19H1735Cl3N3O [M+H]+ requires 408.0432. Found 408.0440. Elemental Analysis Calculated for 
C19H16Cl3N3O requires C, 55.84 %, H, 3.95 %, N, 10.28 %. Found C, 55.97 %, H, 3.95 %, N, 10.33 %. IR 
(neat): νmax/cm-1: 3374 (w), 3281 (m), 3178 (m, br), 2933 (w, br), 1659 (s), 1525 (m), 1466 (s), 794 (s). 
Melting Point oC: 235 – 237 (MeOH) HPLC (purity analysis %) found: Purity 100 %; Retention time: 













Crystal data and structure refinement for 48 
 
 
Identification code 48 
Empirical formula C19H16Cl3N3O 
Formula weight 408.70 
Temperature/K 112.23 
Crystal system orthorhombic 












Radiation CuKα (λ = 1.54178) 
2Θ range for data collection/° 46.552 to 133.17 
Index ranges -6 ≤ h ≤ 10, -19 ≤ k ≤ 12, -30 ≤ l ≤ 31 
Reflections collected 6358 
Independent reflections 5191 [Rint = 0.0254, Rsigma = 0.0672] 
Data/restraints/parameters 5191/0/479 
Goodness-of-fit on F2 1.034 
Final R indexes [I>=2σ (I)] R1 = 0.0353, wR2 = 0.0901 
Final R indexes [all data] R1 = 0.0369, wR2 = 0.0912 
Largest diff. peak/hole / e Å-3 0.30/-0.36 
Flack parameter 0.034(7) 
 






Compound 44d (0.062 g, 0.16 mmol, 1 eq) and methyl amine 33 % in EtOH (3.32 cm3, 26.72 
mmol, 167 eq), were used following general procedure 2. Gave 49 as white crystals (0.050 g, 82 %). 
δH (500 MHz, MeOD) 7.56 (1H, d, J 2.1 Hz), 7.22 – 7.17 (2H, m), 7.16 (1H, dd, J 9.6, 2.5 Hz), 6.85 (1H, 
td, J 9.2, 2.5 Hz), 6.72 (1H, d, J 8.3 Hz), 5.72 (1H, s), 3.53 (1H, dd, J 10.2, 4.5 Hz), 3.13 (1H, dd, J 15.2, 
4.5 Hz), 2.82 (1H, ddd, J 15.2, 10.3, 1.0 Hz), 2.75 (3H, s). δC (126 MHz, MeOD) 175.8, 159.0 (d, J 232.6 
Hz), 139.1, 136.3, 135.3, 135.1, 134.7, 132.4, 130.7, 128.3 (d, J 9.8 Hz), 127.9, 112.8 (d, J 9.7 Hz), 110.9 
(d, J 4.6 Hz), 110.6 (d, J 26.3 Hz), 103.6 (d, J 23.6), 53.2, 52.8 (s), 26.3, 26.1. δF (376 MHz, MeOD) -127.5 
(1F, s). ESI-HRMS: m/z calculated for C19H1735Cl2FN3O [M+H]+ requires 392.0727. Found 392.0730. 
Elemental Analysis Calculated for C19H1635Cl2FN3O requires C, 58.18 %, H, 4.11 %, N, 10.71 %. Found 
C, 58.15 %, H, 4.13 %, N, 10.81 %. IR (neat): νmax/cm-1: 3382 (w), 3278 (m, br), 2943 (w), 2903 (w), 2853 
(w, br), 1660 (s), 1517 (m), 1489 (s), 1469 (s), 1133 (s), 823 (s), 794 (s). HPLC (purity analysis %) found: 
Purity 100 %; Retention time: 8.11 min / 30 min (0.5 ml/min MeOH, Signal = 254 nm, CHIRACEL OJ 
column).   
Preparation of (1R,3S)-1-(2,4-dichlorophenyl)-6-chloro-N-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole-3-carboxamide (50) 
Compound 44e (0.12 g, 0.29 mmol, 1eq) and methyl amine 33 % in EtOH (6.03 cm3, 48.43 
mmol, 167 eq), were used following general procedure 2. Gave 50 as a white solid (0.12 g, 99 %). δH 
(500 MHz, DMSO) 10.94 (1H, s), 7.72 (1H, q, J 4.6 Hz), 7.69 (1H, d, J 2.2 Hz), 7.51 (1H, d, J 2.0 Hz), 7.31 
(1H, dd, J 8.3, 2.2 Hz), 7.26 (1H, d, J 8.6 Hz), 7.05 (1H, dd, J 8.6, 2.1 Hz), 6.68 (1H, d, J 8.4 Hz), 5.57 (1H, 
d, J 4.9 Hz), 3.35 (1H, td, J, 9.8, 4.5 Hz), 3.12 (1H, dd, J 9.8, 5.2 Hz), 2.97 (1H, dd, J 15.3, 4.5 Hz), 2.67 
(1H, ddd, J 15.3, 9.9, 1.0 Hz), 2.59 (3H, d, J 4.6 Hz). δC (126 MHz, DMSO) 172.7, 138.6, 134.7, 134.6, 
134.5, 132.7, 131.2, 129.1, 127.7, 126.8, 123.2, 121.0, 117.1, 112.6, 109.2, 51.4, 50.7, 25.4, 24.9. ESI-
HRMS: m/z calculated for C19H1735Cl3N3O [M+H]+ requires 408.0432. Found 408.0434. Elemental 
Analysis Calculated for C19H16Cl3N3O requires C, 55.84 %, H, 3.95 %, N, 10.28 %. Found C, 55.81 %, H, 
3.94 %, N, 10.28 %. IR (neat): νmax/cm-1: 3377 (w), 3280 (s, br), 3178 (m, br), 2936 (w, br), 2903 (w, br), 
2870 (w, br), 2849 (w, br), 1656 (s), 1519 (m), 1449 (s), 827 (s), 801 (s). Melting Point oC: 243 – 246 
(MeOH). HPLC (purity analysis %) found: Purity 100 %; Retention time: 9.35 min / 30 min (0.5 ml/min 
MeOH, Signal = 254 nm, CHIRACEL OJ column).   
Preparation of (1R,3S)-1-(2,4-dichlorophenyl)-6-hydroxy-N-methyl-2,3,4,9-tetrahydro-1H-
pyrido[3,4-b]indole-3-carboxamide (51) Contaminated with 16 % cis product 




Compound 44f (0.078 g, 0.20 mmol, 1 eq) and methyl amine 33 % in EtOH (4.16 cm3, 33.4 
mmol, 167 eq), were used following general procedure 2. Gave 51 as a brown solid (0.069 g, 89 %). δH 
(500 MHz, MeOD) 7.54 (1H, d, J 2.1 Hz), 7.17 (1H, dd, J 8.3, 2.1 Hz), 7.07 (1H, d, J 8.6 Hz), 6.88 (1H, d, 
J 2.3 Hz), 6.72 (1H, d, J 8.4 Hz), 6.66 (1H, dd, J 8.6, 2.4 Hz), 5.66 (1H, s), 3.49 (1H, dd, J 10.4, 4.5 Hz), 
3.09 (1H, dd, J 15.2, 4.5 Hz), 2.80 – 2.76 (1H, m), 2.74 (3H, s). δC (126 MHz, MeOD) 175.9, 151.5, 151.4, 
139.2, 136.2, 135.2, 133.6, 133.1, 132.5, 130.6, 128.7, 127.8, 112.5, 110.0, 103.3, 53.2, 52.9, 26.3. ESI-
HRMS: m/z calculated for C19H1835Cl2N3O2 [M+H]+ requires 390.0771. Found 390.0771. Elemental 
Analysis Calculated for C19H17Cl2N3O2 requires C, 58.48 %, H, 4.39 %, N, 10.77 %. Found C, 56.42 %, H, 
4.36 %, N, 10.13 %.  
General Procedure 4: Formation of racemic N-Ac tryptophan derivatives following published 
procedure 
To 5, 6-difluoroindole 52a (3.03 g, 19.8 mmol, 1 eq) was added AcOH (50 cm3). The reaction 
flask was evacuated and backfilled with N2, Ac2O (16 cm3) followed by L-serine (4.16 g, 39.6 mmol, 2 
eq) were added sequentially to the flask. The flask was equipped with a reflux condenser and the 
system was evacuated again before backfilling with N2. The reaction mixture was heated to 80 °C for 
two hours. After the reaction was allowed to cool, the reaction mixture was diluted with Et2O (150 
cm3) and basified with 30 % NaOH slowly until pH 11 – 12. The aqueous layer was extracted with Et2O 
(3 x 150 cm3), combined organics were washed further with 2 M NaOH (3 x 50 cm3), the aqueous layers 
were combined. A few drops of 1 M sodium thiosulfate were added to the aqueous layers before the 
solution was acidified to pH 7 using 12 M HCl. The volume of the aqueous solution was reduced by 75 
%, if precipitates occurred these were collected by filtration and analysed by NMR, if they were 
deemed to be product they were combined to the total yield at the end of the procedure otherwise 
they were discarded. The remaining aqueous solution was acidified to approximately pH 3 with 12 M 
HCl and was extracted with EtOAc (3 x 100 cm3). Combined organics were washed with water (50 cm3) 
followed by brine (50 cm3). Organics were dried over MgSO4 and filtered; solvents were removed in 
vacuo to yield the product as a thick brown oil. To this oil was added MeOH (20 cm3) and solvent again 
removed in vavuo, this was repeated until the product 53a solidified as a dark brown powder (5.10 g, 









Generic structure of compounds 53a – c following general procedure 4 
 
Preparation of 2-acetamido-3-(5,6-difluoro-1H-indol-3-yl)propanoic acid (53a) 
5, 6-difluoroindole 52a (3.03 g, 19.8 mmol, 1 eq), AcOH (50 cm3), Ac2O (16 cm3) and L-serine 
(4.16 g, 39.6 mmol, 2 eq), were used following general procedure 4 gave 53a as a dark brown powder 
(5.10 g, 91 %). δH (500 MHz, MeOD) 10.49 (1H, s), 7.35 (1H, dd, J 11.3, 7.9 Hz), 7.16 (1H, dd, J 11.1, 6.8 
Hz), 7.13 (1H, d, J 2.0 Hz), 4.69 (1H, dd, J 7.9, 5.3 Hz), 3.27 (1H, ddd, J 14.8, 5.3, 0.5 Hz), 3.11 (1H, dd, J 
14.8, 7.9 Hz), 1.91 (3H, s). δC (126 MHz, MeOD) 175.0, 173.2, 149.0 (dd, J 206.1, 15.4 Hz), 147.2 (dd, J 
203.3, 15.5 Hz), 133.0 (dd, J 19.3, 10.5 Hz), 126.2 (dd, J 20.8, 3.5 Hz), 124.3 (dd, J 7.7, 4.4 Hz), 112.2 – 
111.1 (m), 105.7 (d, J 19.2 Hz), 99.9 (dd, J 21.5, 6.2 Hz), 54.6, 28.4, 22.4. δF (376 MHz, MeOD) -147.9 
(1F, d, J 20.2 Hz), -151.2 (1F, d, J 20.2 Hz). ESI-HRMS: m/z calculated for C13H13F2N2O3 [M+H]+ requires 
283.0889. Found 283.0893. 
Preparation of 2-acetamido-3-(4,6-difluoro-1H-indol-3-yl)propanoic acid (53b) 
4, 6-difluoroindole 52b (2.00 g, 13.1 mmol, 1 eq), AcOH (33 cm3), Ac2O (11 cm3) and L-serine 
(2.75 g, 26.1 mmol, 2 eq), were used following general procedure 4, reaction yielded multiple 
products, and the desired product was purified by column chromatography (100 % EtOAc) gave 53b 
as a pale brown powder (0.60 g, 19 %). δH (500 MHz, MeOD) 10.67 (1H, s), 7.04 (1 H, d, J 1.8 Hz), 6.87 
(1H, dd, J 9.4, 2.1 Hz), 6.55 (1H, ddd, J 11.4, 10.1, 2.0 Hz), 4.74 (1H, dd, J 8.9, 5.1 Hz), 3.44 – 3.39 (1H, 
m), 3.12 (1H, dd, J 14.8, 8.9 Hz), 1.90 (3H, s). δC (126 MHz, MeOD) 175.1, 173.2, 160.3 (dd, J 236.7, 
12.1 Hz), 157.7 (dd, J 246.4, 14.9 Hz), 140.1 – 139.7 (m), 125.4 – 125.1 (m), 114.1 – 113.8 (m), 110.1 – 
110.0 (m), 95.1 (dd, J 29.1, 24.4 Hz), 94.6 (dd, J 26.0, 4.4 Hz), 54.9 (s), 29.5 (s), 22.3 (s). δF (376 MHz, 
MeOD) -122.1 (1F, d, J 4.0 Hz), -123.0 (1F, d, J 4.0 Hz). ESI-HRMS: m/z calculated for C13H12F2N2NaO3 
[M+Na]+ requires 305.0708. Found 305.0711. 
Preparation of 2-acetamido-3-(6-chloro-5-fluoro-1H-indol-3-yl)propanoic acid (53c) 
6-chloro-5-fluoroindole 52c (1.61 g, 9.49 mmol, 1 eq), AcOH (24 cm3), Ac2O (8 cm3) and L-
serine (1.99 g, 18.92 mmol, 2 eq), were used following general procedure 4 gave 53c as a pale brown 
powder (2.61 g, 92 %). δH (400 MHz, MeOD) 10.56 (1H, s), 7.39 (1H, d, J 6.3 Hz), 7.36 (1H, d, J 10.2 Hz), 




7.18 (1H, s), 4.75 – 4.64 (1H, m), 3.30 – 3.24 (1H, m), 3.12 (1H, dd, J 14.7, 7.8 Hz), 1.92 (3H, s). δC (101 
MHz, MeOD) 175.0, 173.2, 153.8 (d, J 235.6 Hz), 134.3, 128.0 (d, J 8.4 Hz), 127.1, 115.7 (d, J 21.4 Hz), 
113.4, 111.8 (d, J 4.7 Hz), 105.3 (d, J 23.4 Hz), 54.6, 28.4, 22.4. δF (376 MHz, MeOD) -130.2 (1F, s). ESI-
HRMS: m/z calculated for C13H935ClFN2O3 [M-H]- requires 297.0448. Found 297.0438. 
General Procedure 5: Kinetic enzymatic resolution of acetylated unnatural amino acids following 
literature procedure 
To Compound 53a (2.50 g, 8.86 mmol, 1 eq) was added KH2PO4 buffer (525 cm3, pH 7.4). The 
reaction flask was left open to air and stirred vigorously at 38 °C until the starting material dissolved. 
To the reaction mixture was added 1 : 1 w / w of L-amano acylase (2.50 g) (≥30,000 U / g), and a trace 
amount of CoCl2 . 6 H2O. The mixture stirred gently for 48 hours. The mixture was allowed to cool to 
room temperature and the enzyme was denatured via addition of 12 M HCl to pH 1; the resulting 
precipitate was filtered through celite and washed with water (20 cm3). Solvents were removed in 
vacuo until approximately 100 cm3 remained. The water layer was extracted with EtOAc (3 x 100 cm3) 
to ensure removal of unwanted D-N-Ac amino acids. After neutralisation L-amino acids could not be 
extracted into an organic phase and the aqueous phase was evaporated to dryness. To the resulting 
inorganic salts was added MeOH 75 cm3 at a time and swirled vigorously ensuring the solid was 
present as a fine powder. The MeOH was triturated off and the above step repeated until TLC of salt 
washings showed no UV activity. The MeOH washings were combined, evaporated to dryness and 
analysed by NMR to indicate if the product was present, mass spectrums were not ran due to high salt 
contamination. Gave crude 54a as a pale brown solid, used crude in the next step without purification 
(see general procedure 3). D-N-Ac amino derivative D-53a was isolated as a brown solid (1.25 g, 50 % 
of starting racemic N-Ac mixture).  
Generic structure of compounds 54a – d  
 
Preparation of (S)-2-amino-3-(5,6-difluoro-1H-indol-3-yl)propanoic acid (54a) 
Compound 53a (2.50 g, 8.86 mmol, 1 eq), L-amano acylase (2.50 g) (≥30,000 U / g), a trace 
amount of CoCl2 . 6 H2O and KH2PO4 buffer (525 cm3, pH 7.4), were used following general procedure 




5. Gave crude 54a as a pale brown solid, used crude in the next step without purification. D-N-Ac amino 
derivative D-53a was isolated as a brown solid (1.25 g, 50 % of starting racemic N-Ac mixture). δH (500 
MHz, MeOD) 7.56 (1H, dd, J 11.3, 7.9 Hz), 7.26 (1H, s), 7.21 (1H, dd, J 11.0, 6.8 Hz), 3.83 (1H, dd, J 8.6, 
4.2 Hz), 3.41 (1H, ddd, J 15.3, 4.2, 0.6 Hz), 3.17 (1H, dd, J 15.3, 8.8 Hz). δC (126 MHz, MeOD) 174.3, 
149.2 (dd, J 217.3, 15.4 Hz), 147.3 (dd, J 214.0, 15.5 Hz), 133.3 (d, J 10.5 Hz), 127.1 (d, J 3.4 Hz), 123.9 
(d, J 8.5 Hz), 110.0 (d, J 3.5 Hz), 106.1 (d, J 19.6 Hz), 100.1 (d, J 21.7 Hz), 56.4, 28.2. δF (376 MHz, MeOD) 
-147.4 (1F, d, J 20.3 Hz), -150.7 (1F, d, J 20.2 Hz). 
Preparation of (S)-2-amino-3-(4,6-difluoro-1H-indol-3-yl)propanoic acid (54b) 
Compound 53b (0.55 g, 1.96 mmol, 1 eq), L-amano acylase (0.55 g) (≥30,000 U / g), a trace 
amount of CoCl2 . 6 H2O and KH2PO4 buffer (105 cm3, pH 7.4), were used following general procedure 
5. Gave crude 54b as a pale brown solid, used crude in the next step without purification. D-N-Ac 
amino derivative D-53b was isolated as a brown solid (0.275 g, 50 % of starting racemic N-Ac mixture). 
Compound too insoluble obtain 13C NMR. δH (500 MHz, DMSO) 11.25 (1H, s), 7.40 (2H, s), 7.17 (1H, d, 
J 1.8 Hz), 7.01 (1H, dd, J 9.6, 2.1 Hz), 6.81 – 6.72 (1H, m), 3.43 – 3.37 (2H, m), 2.88 (1H, dd, J 16.0, 10.9 
Hz). δF (376 MHz, DMSO) -120.1 (1F, d, J 3.7 Hz), -120.9 (1F, d, J 3.7 Hz). 
Preparation of (S)-2-amino-3-(6-chloro-5-fluoro-1H-indol-3-yl)propanoic acid (54c) (Only proton ran, 
data consistent with racemic 54d) 
Compound 53c (0.38 g, 1.26 mmol, 1 eq), L-amano acylase (0.38 g) (≥30,000 U / g), a trace 
amount of CoCl2 . 6 H2O and KH2PO4 buffer (105 cm3, pH 7.4), were used following general procedure 
5. Gave crude 54c as a pale brown solid, used crude in the next step without purification. D-N-Ac amino 
derivative D-53c was isolated as a pale brown solid (0.19 g, 50 % of starting racemic N-Ac mixture). δH 
(500 MHz, MeOD) 7.56 (1H, d, J 10.2 Hz), 7.43 (1H, d, J 6.2 Hz), 7.27 (1H, s), 3.81 (1H, dd, J 8.6, 4.3 Hz), 
3.40 (1H, dd, J 15.3, 4.3 0.7 Hz), 3.16 (1H, dd, J 15.3, 8.6 Hz). 
Preparation of 2-amino-3-(6-chloro-5-fluoro-1H-indol-3-yl)propanoic acid (54d) 
Compound 53c (0.50 g, 1.69 mmol, 1 eq) was placed in a sealed tube, to the flask was added 
6 M HCl (7 cm3) and the tube purged with N2. The flask was sealed and heated to 120 °C for three days. 
After cooling the reaction mixture was basified with 30 % NaOH to pH 7. Attempts to extract the 
product from the aqueous layer were unsuccessful. The organic and aqueous phases were combined 
and solvents removed in vacuo. To the resulting inorganic salts was added MeOH 15 cm3 at a time and 
swirled vigorously ensuring the solid was present as a fine powder. The MeOH was triturated off and 
the above step repeated until TLC of salt washings showed no UV activity. The MeOH washings were 
combined, evaporated to dryness and analysed by NMR and LRMS to indicate if the product was 




present. The crude product 54d was then used in the next step without further purification. δH (500 
MHz, MeOD) 7.56 (1H, d, J 10.1 Hz), 7.43 (1H, d, J 6.3 Hz), 7.27 (1H, s), 3.81 (1H, dd, J 8.6, 4.3 Hz), 3.40 
(1H, dd, J 15.3, 11.10 Hz), 3.17 (1H, dd, J 15.3, 8.6 Hz). δC (126 MHz, MeOD) 174.4, 153.9 (d, J 235.9 
Hz), 134.6, 127.9, 127.6 (d, J 8.8 Hz), 116.1 (d, J 21.3 Hz), 113.5, 110.2 (d, J 4.9 Hz), 105.7 (d, J 23.7 Hz), 
56.4, 28.3. ESI-LRMS: m/z calculated for C11H1035ClFN2NaO2 [M+Na]+ requires 279.0. Found 279.0.  
Generic structure of compounds 55a – d following general procedure 3 
 
Preparation of methyl (S)-2-amino-3-(5,6-difluoro-1H-indol-3-yl)propanoate (55a) 
Compound 54a (2.22 mmol, 1 eq) was used crude and thionyl chloride (0.32 cm3, 4.44 mmol, 
2 eq), was added to anhydrous MeOH (5 cm3) following general procedure 3. Gave 55a as a pale brown 
solid (0.19 g, 33 % over two steps). δH (500 MHz, CDCl3) 8.34 (1H, s), 7.31 (1H, dd, J 10.8, 7.8 Hz), 7.10 
(1H, dd, J 10.5, 6.6 Hz), 7.06 (1H, d, J 2.2 Hz), 3.79 (1H, dd, J 7.3, 5.0 Hz), 3.71 (3H, s), 3.18 (1H, ddd, J 
14.5, 5.0, 0.6 Hz), 3.02 (1H, dd, J 14.5, 7.3 Hz), 1.65 (3H, s). δC (126 MHz, CDCl3) 175.8, 148.4 (dd, J 
203.8, 15.4 Hz), 146.5 (dd, J 200.9, 15.3 Hz), 131.3 (d, J 10.3 Hz), 124.4 (d, J 3.7 Hz), 122.9 (d, J 8.7 Hz), 
111.5 (d, J 4.4 Hz), 105.5 (d, J 19.3 Hz), 99.3 (d, J 21.7 Hz), 54.9, 52.2, 30.6. δF (376 MHz, CDCl3) -143.7 
(d, J 20.9 Hz), -147.4 (d, J 20.9 Hz). CI-HRMS: m/z calculated for C12H13F2N2O2 [M+H]+ requires 255.0940 
Found 255.0933. 
Preparation of methyl (S)-2-amino-3-(4,6-difluoro-1H-indol-3-yl)propanoate (55b) 
Compound 54b (0.98 mmol, 1 eq) was used crude and thionyl chloride (0.21 cm3, 2.94 mmol, 
3 eq), was added to anhydrous MeOH (5 cm3) following general procedure 3. Gave 55b as a pale brown 
solid (0.08 g, 32 % over two steps). δH (500 MHz, MeOD) 7.04 (1H, s), 6.89 (1H, dd, J 9.4, 2.1 Hz), 6.55 
(1H, ddd, J 12.0, 10.1, 2.1 Hz), 3.78 (1H, apparent t), 3.65 (3H, s), 3.23 (1H, dd, J 14.3, 6.2 Hz), 3.04 (1H, 
dd, J 14.3, 7.4 Hz). δC (126 MHz, MeOD) 172.4, 160.4 (dd, J 236.8, 12.2 Hz), 157.6 (dd, J 246.0, 15.1 
Hz), 140.0 (t, J 14.5 Hz), 125.6, 113.8 (d, J 19.5 Hz), 109.7 (d, J 2.6 Hz), 95.4 – 94.6 (2C, m), 56.1 (d, J 
1.6 Hz), 52.3, 32.6. δF (376 MHz, MeOD) -121.9 (1F, d, J 3.9 Hz), -123.2 (1F, d, J 3.9 Hz). CI-HRMS: m/z 
calculated for C12H13F2N2O2 [M+H]+ requires 255.0940. Found 255.0947 




Preparation of methyl (S)-2-amino-3-(6-chloro-5-fluoro-1H-indol-3-yl)propanoate (55c) (No Mass 
spec, data consistent with racemic form 55d) 
Compound 54c (0.63 mmol, 1 eq) was used crude and thionyl chloride (0.14 cm3, 1.90 mmol, 
3 eq), was added to anhydrous MeOH (5 cm3) following general procedure 3. Gave 55c as a brown oil 
(0.075 g, 44 % over two steps). δH (500 MHz, MeOD) 7.40 (1H, d, J 6.3 Hz), 7.32 (1H, d, J 10.1 Hz), 7.17 
(1H, s), 3.74 (1H, t, J 6.2 Hz), 3.64 (3H, s), 3.11 (1H, dd, J 14.5, 5.9 Hz), 3.06 (1H, dd, J 14.5, 6.5 Hz). δC 
(126 MHz, MeOD) 176.5, 153.8 (d, J 235.7 Hz), 134.3, 127.8 (d, J 8.5 Hz), 127.3, 115.9 (d, J 21.4 Hz), 
113.5, 111.3 (d, J 4.7 Hz), 105.3 (d, J 23.5 Hz), 55.8, 52.5, 31.1. δF (376 MHz, MeOD) -130.1 (s). 
Preparation of methyl 2-amino-3-(6-chloro-5-fluoro-1H-indol-3-yl)propanoate (55d) 
Compound 54d (1.69 mmol, 1 eq) was used crude and thionyl chloride (0.23 cm3, 3.16 mmol, 
2 eq), was added to anhydrous MeOH (5 cm3) following general procedure 3. Gave 55d as a brown oil 
(0.17 g, 39 % over two steps). δH (500 MHz, MeOD) 7.40 (1H, d, J 6.2 Hz), 7.32 (1H, d, J 10.1 Hz), 7.17 
(1H, s), 3.79 – 3.72 (1H, m), 3.65 (3H, s), 3.17 – 3.02 (2H, m). δC (101 MHz, MeOD) 176.6, 153.8 (d, J 
235.8 Hz), 134.3, 127.8 (d, J 8.4 Hz), 127.3, 115.8 (d, J 21.4 Hz), 113.46 (s), 111.3 (d, J 4.6 Hz), 105.3 (d, 
J 23.5 Hz), 55.8, 52.4, 31.1. CI-HRMS: m/z calculated for C12H1335ClFN2O2 [M+H]+ requires 271.0644. 
Found 271.0647. 
Generic structure of compounds 56a – d and 57a – d following general procedure 1 
 
 




Preparation of methyl (1R,3S)-1-(2,4-dichlorophenyl)-6,7-difluoro-2,3,4,9-tetrahydro-1H-
pyrido[3,4-b]indole-3-carboxylate (56a) and methyl (1S,3S)-1-(2,4-dichlorophenyl)-6,7-difluoro-
2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate (57a) 
Compound 55a (0.18 g, 0.69 mmol, 1 eq), 2,4-dichlorobenzaldehyde (0.13 g, 0.76 mmol, 1.1 
eq) and TFA (0.06 cm3, 0.76 mmol, 1.1 eq), were used in anhydrous DCM (5 cm3) following general 
procedure 1. Gave 56a as a white solid (0.057 g, 20 %). δH (500 MHz, MeOD) 7.58 (1H, d, J 2.1 Hz), 7.31 
(1H, dd, J 11.0, 7.9 Hz), 7.23 (1H, dd, J 8.4, 2.1 Hz), 7.10 (1H, dd, J 11.0, 6.8 Hz), 6.81 (1H, d, J 8.4 Hz), 
5.82 (1H, s), 3.80 (1H, dd, J 8.3, 4.9 Hz), 3.73 (3H, s), 3.17 (1H, dd, J 15.3, 4.9 Hz), 2.96 (1H, ddd, J 15.3, 
8.4, 1.1 Hz). δC (126 MHz, MeOD) 174.7, 149.1 (dd, J 206.2, 15.4 Hz), 147.3 (dd, J 203.6, 15.3 Hz), 138.9, 
135.9, 135.6, 134.5 (d, J 3.6 Hz), 133.2 (d, J 10.4 Hz), 132.5, 130.6, 128.3, 123.3 (d, J 7.8 Hz), 110.2 (d, 
J 3.2 Hz), 105.5 (d, J 19.3 Hz), 100.0 (d, J 21.8 Hz), 53.0, 52.7, 52.5, 25.5. δF (376 MHz, MeOD) -147.2 
(1F, d, J 20.2 Hz), -151.0 (1F, d, J 20.2 Hz). ESI-HRMS: m/z calculated for C19H1535Cl2F2N2O2 [M+H]+ 
requires 411.0473. Found 411.0467. 
The same procedure also gave 57a as a white solid (0.15 g, 54 %). δH (500 MHz, DMSO) 10.62 
(1H, s), 7.69 (1H, d, J 2.1 Hz), 7.47 (1H, dd, J 11.2, 8.0 Hz), 7.39 (1H, dd, J 8.4, 2.1), 7.27 (1H, d, J 8.4 Hz), 
7.16 (1H, dd, J 11.2, 7.0 Hz), 5.61 (1H, s), 3.92 (1H, dd, J 10.9, 4.1 Hz), 3.69 (3H, s), 3.02 (1H, ddd, J 14.8, 
4.1, 1.6 Hz), 2.81 (1H, ddd, J 14.8, 10.9, 2.3 Hz). δC (126 MHz, DMSO) 172.6, 146.6 (dd, J 163.6, 15.3 
Hz), 144.7 (dd, J 161.3, 15.3 Hz), 138.0, 135.8 (dd, J 19.6, 3.5 Hz), 134.2, 133.0, 132.1, 131.2 (dd, J 19.4, 
10.6 Hz), 128.8, 127.6, 121.8 (d, J 8.0 Hz), 108.1, 104.6 (d, J 18.7 Hz), 99.1 (d, J 21.4 Hz), 55.9, 55.8, 
51.8, 24.9. δF (376 MHz, DMSO) -145.8 (1F, d, J 22.4 Hz), -149.1 (1F, d, J 22.4 Hz). ESI-HRMS: m/z 
calculated for C19H1535Cl2F2N2O2 [M+H]+ requires 411.0473. Found 411.0466. 
Preparation of methyl (1R,3S)-1-(2,4-dichlorophenyl)-5,7-difluoro-2,3,4,9-tetrahydro-1H-
pyrido[3,4-b]indole-3-carboxylate (56b) and methyl (1S,3S)-1-(2,4-dichlorophenyl)-5,7-difluoro-
2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate (57b) 
Compound 55b (0.081 g, 0.32 mmol, 1 eq), 2,4-dichlorobenzaldehyde (0.061 g, 0.35 mmol, 1.1 
eq) and TFA (0.027 cm3, 0.35 mmol, 1.1 eq), were used in anhydrous DCM (5 cm3) following general 
procedure 1. Gave 56b as a yellow solid (0.020 g, 15 %). δH (500 MHz, MeOD) 7.57 (1H, d, J 1.8 Hz), 
7.24 (1H, dd, J 8.4, 1.8 Hz), 6.85 (1H, d, J 8.4 Hz), 6.80 (1H, dd, J 9.4, 1.5 Hz), 6.57 (1H, dd, J 10.6, 1.5 
Hz), 5.80 (1H, s), 3.80 (1H, dd, J 8.3, 4.9 Hz), 3.73 (3H, s), 3.36 – 3.30 (1H, m, signal obscured by NMR 
solvent), 3.11 (1H, dd, J 15.6, 8.3 Hz). δC (126 MHz, MeOD) 174.7, 160.5 (dd, J 237.1, 12.1 Hz), 157.4 
(dd, J 246.3, 15.2 Hz), 139.8 (apparent t, J 14.4 Hz), 138.7, 136.0, 135.6, 133.1 (d, J 3.0 Hz), 132.5, 
130.7, 128.3, 113.3 (d, J 20.5 Hz), 108.1, 95.2 (dd, J 29.1, 23.6 Hz), 94.7 (dd, J 26.2, 4.3 Hz), 52.9, 52.7, 




52.3, 26.8. δF (376 MHz, MeOD) -121.3 (1F, d, J 3.6 Hz), -124.5 (1F, d, J 3.6 Hz). ESI-HRMS: m/z 
calculated for C19H1535Cl2F2N2O2 [M+H]+ requires 411.0473. Found 411.0468. 
The same procedure also gave 57b as a pale yellow solid (0.083 g, 64 %). δH (500 MHz, MeOD) 
7.57 (1H, d, J 1.4 Hz), 7.31 (1H, dd, J 8.4, 1.4 Hz), 7.24 (1H, d, J 8.4 Hz), 6.76 (1H, dd, J 9.4, 1.3 Hz), 6.53 
(1H, apparent t), 5.73 (1H, s), 3.96 (1H, dd, J 10.9, 4.2 Hz), 3.78 (3H, s), 3.31 – 3.26 (1H, m, signal 
obscured by NMR solvent) 3.11 – 3.00 (1H, m). δC (126 MHz, MeOD) 174.2, 160.3 (dd, J 236.7, 11.9 
Hz), 157.3 (dd, J 246.1, 15.2 Hz), 139.8 (apparent t, J 14.6 Hz), 138.2 (s), 136.2, 135.7, 134.8 (d, J 2.7), 
133.0 – 132.6 (m), 130.5, 128.9, 113.4 (d, J 19.2 Hz), 107.8, 95.1 (dd, J 29.1, 23.6 Hz), 94.7 (dd, J 26.3, 
4.3 Hz), 57.6, 55.4 – 55.0 (m), 52.7, 27.4. δF (376 MHz, MeOD) -121.6 (1F, br d, J 1.6 Hz), -124.7 (1F, br 
d, J 3.3 Hz). ESI-HRMS: m/z calculated for C19H1535Cl2F2N2O2 [M+H]+ requires 411.0473. Found 411.0471 
Preparation of methyl (1R,3S)-7-chloro-1-(2,4-dichlorophenyl)-6-fluoro-2,3,4,9-tetrahydro-1H-
pyrido[3,4-b]indole-3-carboxylate (56c) and methyl (1S,3S)-7-chloro-1-(2,4-dichlorophenyl)-6-
fluoro-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate (57c) No mass spec ran, NMR data 
consistent with racemic version 56d and 57d 
Compound 55c (0.075 g, 0.28 mmol, 1 eq), 2,4-dichlorobenzaldehyde (0.054 g, 0.31 mmol, 1.1 
eq) and TFA (0.024 cm3, 0.31 mmol, 1.1 eq), were used in anhydrous DCM (5 cm3) following general 
procedure 1.  Gave 56c as a yellow solid (0.022 g, 19 %). δH (500 MHz, MeOD) 7.57 (1H, d, J 2.1 Hz), 
7.31 (1H, d, J 1.6 Hz), 7.29 (1H, d, J 5.3 Hz), 7.22 (1H, dd, J 8.4, 2.1 Hz), 6.81 (1H, d, J 8.4 Hz), 5.82 (1H, 
s), 3.81 (1H, dd, J 8.3, 4.9 Hz), 3.72 (3H, s), 3.17 (1H, dd, J 15.3, 4.9 Hz), 2.96 (1H, ddd, J 15.3, 8.3, 1.2 
Hz). δC (126 MHz, MeOD) 174.7, 154.0 (d, J 236.2 Hz), 138.7, 135.9, 135.6, 135.5, 134.5, 132.4, 130.6, 
128.3, 126.9 (d, J 8.6 Hz), 115.9 (d, J 21.3 Hz), 113.2, 110.3 (d, J 4.5 Hz), 105.0 (d, J 23.4 Hz), 53.0, 52.7, 
52.4, 25.5. δF (376 MHz, MeOD) -129.8 (1F, s). 
The same procedure also gave 57c as a pale yellow needles (0.073 g, 61 %). δH (500 MHz, 
DMSO) 10.67 (1H, s), 7.70 (1H, d, J 2.1 Hz), 7.48 (1H, d, J 10.1), 7.39 (1H, dd, J 8.4, 2.1 Hz), 7.32 (1H, d, 
J 6.4 Hz), 7.27 (1H, d, J 8.4 Hz), 5.62 (1H, apparent d, J 6.8 Hz), 3.97 – 3.91 (1H, m), 3.69 (3H, s), 3.19 – 
3.15 (1H, m), 3.03 (1H, apparent dd, J 14.8, 3.9 Hz), 2.82 (1H, ddd, J 14.8, 11.0, 2.1 Hz). δC (126 MHz, 
DMSO) 172.6 (s), 151.6 (d, J 234.5 Hz), 137.8, 136.9, 134.2, 133.1, 132.7, 132.5, 132.1 (d, J 1.7 Hz), 
127.7, 125.4 (d, J 8.7 Hz), 112.7 (d, J 21.2 Hz), 112.0 (d, J 5.6 Hz), 108.4 (d, J 3.8 Hz), 104.3 (d, J 22.9 
Hz), 55.84, 55.76, 51.8, 25.0 (s). δF (376 MHz, DMSO) -128.3 (1F s). 
 




Preparation of methyl (1R,3S / 1S,3R)-7-chloro-1-(2,4-dichlorophenyl)-6-fluoro-2,3,4,9-tetrahydro-
1H-pyrido[3,4-b]indole-3-carboxylate (56d) and methyl (1S,3S /1R,3R)-7-chloro-1-(2,4-
dichlorophenyl)-6-fluoro-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate (57d) 
Compound 55d (0.17 g, 0.61 mmol, 1 eq), 2,4-dichlorobenzaldehyde (0.12 g, 0.67 mmol, 1.1 
eq) and TFA (0.051 cm3, 0.67 mmol, 1.1 eq), were used in anhydrous DCM (5 cm3) following general 
procedure 1. Gave 56d as a yellow crystals (0.041 g, 16 %). δH (500 MHz, CDCl3) 7.89 (1H, s), 7.45 (1H, 
d, J 2.1 Hz), 7.26 – 7.23 (2H, m), 7.12 (1 H, dd, J 8.3, 2.1 Hz), 6.89 (1H, d, J 8.3 Hz), 5.80 (1H, s), 3.83 
(1H, dd, J 7.5, 5.1 Hz), 3.73 (3H, s), 3.17 (1H, ddd, J 15.4, 5.1, 0.8 Hz), 3.01 (1 H, ddd, J 15.4, 7.6, 1.1 
Hz). δC (126 MHz, CDCl3) 173.6, 153.3 (d, J 238.4 Hz), 137.5, 134.8, 134.4, 134.1, 132.5, 130.9, 130.0, 
127.5, 125.9 (d, J 8.6 Hz), 115.9 (d, J 21.3 Hz), 112.3, 109.9 (d, J 4.4 Hz), 104.7 (d, J 23.5 Hz), 52.5, 52.4, 
51.2, 24.6). ESI-HRMS: m/z calculated for C19H1535Cl3FN2O2 [M+H]+ requires 427.0178. Found 427.0179. 
The same procedure also gave 57d as pale yellow needles (0.12 g, 47 %). δH (500 MHz, CDCl3) 
7.60 (1H, s), 7.47 (1H, d, J 2.1 Hz), 7.39 (1H, d, J 8.4 Hz), 7.25 – 7.19 (3H, m), 5.75 (1H, s), 3.96 (1H, dd, 
J 11.0, 4.1 Hz), 3.82 (3H, s), 3.14 (1H, ddd, J 15.0, 4.1, 1.7 Hz), 2.94 (1H, ddd, J 15.0, 11.0, 2.4 Hz), 2.64 
(1H, s). δC (126 MHz, CDCl3) 172.8, 153.3 (d, J 238.5 Hz), 136.9, 135.7, 135.0, 134.2, 132.5, 131.4, 129.6, 
128.3, 126.0 (d, J 8.6 Hz), 115.7 (d, J 21.2 Hz), 112.3, 109.7 (d, J 4.4 Hz), 104.6 (d, J 23.4 Hz), 56.5, 52.6, 
51.0, 25.3. ESI-HRMS: m/z calculated for C19H1535Cl3FN2O2 [M+H]+ requires 427.0178. Found 427.0175. 




Compound 56a (0.057 g, 0.14 mmol, 1 eq) and methyl amine 33 % in EtOH (2.91 cm3, 23.38 
mmol, 167 eq), were used following general procedure 2. Gave 58 as a white solid (0.034 g, 60 %). δH 
(500 MHz, MeOD) 7.56 (1H, d, J 2.1 Hz), 7.31 (1H, dd, J 11.0, 7.9 Hz), 7.20 (1H, dd, J 8.3, 2.1 Hz), 7.10 
(1H, dd, J 11.0, 6.8 Hz), 6.73 (1H, d, J 8.3 Hz), 5.70 (1H, s), 3.53 (1H, dd, J 10.1, 4.6 Hz), 3.11 (1H, dd, J 
15.3, 4.6 Hz), 2.81 (1H, ddd, J 15.3, 10.1, 1.4 Hz), 2.75 (3H, s). δC (126 MHz, MeOD) 175.7, 149.1 (dd, J 
204.9, 15.3 Hz), 147.2 (dd, J 202.4, 15.3 Hz), 139.0, 136.3, 135.4, 135.0 (d, J 3.6 Hz), 133.2 (d, J 10.4 




Hz), 132.4, 130.7, 128.0, 123.4 (dd, J 7.8, 1.1 Hz), 111.1 (dd, J 4.2, 1.3 Hz), 105.4 (dd, J 19.1, 0.7 Hz), 
99.9 (d, J 21.8 Hz), 53.2, 52.7, 26.3, 26.0. δF (376 MHz, MeOD) -147.2 (1F, d, J 20.2 Hz), -151.1 (1F, d, J 
20.2 Hz). ESI-HRMS: m/z calculated for C19H1635Cl2F2N3O [M+H]+ requires 410.0633. Found 410.0629. 
Elemental Analysis Calculated for C19H1535Cl2F2N3O requires C, 55.63 %, H, 3.69 %, N, 10.24 %. Found 
C, 54.67 %, H, 3.64 %, N, 9.89 %. IR (neat): νmax/cm-1: 3456 (w), 3368 (w), 3206 (m, br), 2907 (w), 2846 
(w), 1667 (s), 1526 (m), 1470 (s), 1308 (s), 1038 (m), 820 (s, br), 618 (s). HPLC (purity analysis %) found: 




Compound 56b (0.019 g, 0.046 mmol, 1 eq) and methyl amine 33 % in EtOH (4.16 cm3, 33.4 
mmol, 167 eq), were used following general procedure 2. Gave 59 as a white solid (0.016 g, 87 %). δH 
(500 MHz, MeOD) 7.57 (1H, s), 7.23 (1H, d, J 8.4 Hz), 6.79 (2H, apparent t), 6.56 (1H, apparent t, J 10.3 
Hz), 5.70 (1H, s), 3.53 (1H, dd, J 9.9, 4.2 Hz), 2.96 (1H, dd, J 15.3, 10.3 Hz), 2.75 (3H, s). (One aliphatic 
signal is lost under the NMR solvent peak.) δC (126 MHz, MeOD) 175.7, 160.5 (dd, J 237.2, 12.0 Hz), 
157.5 (dd, J 246.4, 14.9 Hz), 139.7, 138.8, 136.3, 135.4, 133.6 (d, J 3.0 Hz), 132.4, 130.8, 128.0, 113.4 
(d, J 21.3 Hz), 109.0, 95.1 (dd, J 29.1, 23.7 Hz), 94.7 (dd, J 25.9, 4.2 Hz), 53.1, 52.5, 27.4, 26.3. δF (376 
MHz, MeOD) -121.5 (d, J 3.5 Hz), -124.2 (d, J 3.5 Hz). ESI-HRMS: m/z calculated for C19H1635Cl2F2N3O 
[M+H]+ requires 410.0633. Found 410.0635. Elemental Analysis Calculated for C19H1535Cl2F2N3O 
requires C, 55.63 %, H, 3.69 %, N, 10.24 %. Found C, 55.43 %, H, 3.69 %, N, 10.11 %. IR (neat): νmax/cm-
1: 3366 (w), 3303 (w), 3368 (w), 3206 (m, br), 2907 (w), 2846 (w), 1667 (s), 1526 (m), 1470 (s), 1308 
(s), 1038 (m), 820 (s, br), 618 (s). HPLC (purity analysis %) found: Purity 100 %; Retention time: 7.23 
min / 30 min (0.5 ml/min MeOH, Signal = 254 nm, CHIRACEL OJ column). 
Preparation of (1R,3S)-7-chloro-1-(2,4-dichlorophenyl)-6-fluoro-N-methyl-2,3,4,9-tetrahydro-1H-
pyrido[3,4-b]indole-3-carboxamide (60) 
Compound 46c (0.022 g, 0.051 mmol, 1 eq) and methyl amine 33 % in EtOH (1.07 cm3, 8.59 
mmol, 167 eq), were used following general procedure 2. Gave 60 as a white solid (0.015 g, 68 %).  δH 
(500 MHz, MeOD) 7.57 (1H, d, J 2.1 Hz), 7.32 (1H, d, J 4.8 Hz), 7.31 (1H, d, J 0.9 Hz), 7.22 (1H, dd, J 8.3, 
2.2 Hz), 6.74 (1H, d, J 8.3 Hz), 5.72 (1H, s), 3.54 (1H, dd, J 10.0, 4.6 Hz), 3.12 (1H, dd, J 15.4, 4.6 Hz), 
2.82 (1H, ddd, J 15.4, 10.0, 1.4 Hz), 2.75 (3H, s). δC (126 MHz, MeOD) 175.7, 155.6 (d, J 171.4 Hz), 138.9, 
136.3, 136.0, 135.4, 134.5, 132.4, 130.8, 128.0, 127.1 (d, J 7.8 Hz), 115.8 (d, J 21.2 Hz), 113.2, 111.2, 
105.0 (d, J 23.3 Hz), 53.2, 52.7, 26.3, 25.9. δF (376 MHz, MeOD) -131.4. ESI-HRMS: m/z calculated for 




C19H1535Cl3FN3NaO [M+Na]+ requires 448.0162. Found 448.0155. Elemental Analysis Calculated for 
C19H1535Cl3FN3O requires C, 53.48 %, H, 3.54 %, N, 9.85 %. Found C, 53.54 %, H, 3.63 %, N, 9.70 %. IR 
(neat): νmax/cm-1: 3438 (w), 3309 (w), 3234 (m, br), 2906 (w), 2843 (w), 1667 (s), 1643 (m), 1562 (m), 
1511 (m), 1347 (s), 1151 (s), 820 (s), 606 (s). HPLC (purity analysis %) found: Purity 100 %; Retention 
time: 9.07 min / 30 min (0.5 ml/min MeOH, Signal = 254 nm, CHIRACEL OJ column). 
Preparation of (1R,3S / 1S,3S)-7-chloro-1-(2,4-dichlorophenyl)-6-fluoro-N-methyl-2,3,4,9-
tetrahydro-1H-pyrido[3,4-b]indole-3-carboxamide (61) 
Compound 56d (0.041 g, 0.096 mmol, 1eq) and methyl amine 33 % in EtOH (2.00 cm3, 16.03 
mmol, 167 eq), were used following general procedure 2.  Gave 61 as a white solid (0.028 g, 69 %). δH 
(500 MHz, DMSO) 10.99 (1H, s), 7.72 (1H, d, J 4.7 Hz), 7.69 (1H, d, J 2.2 Hz), 7.49 (1H, d, J 10.1 Hz), 7.41 
(1H, d, J 6.3 Hz), 7.31 (1H, dd, J 8.3, 2.2 Hz), 6.67 (1H, d, J 8.4 Hz), 5.56 (1 H, d, J 5.5 Hz), 3.38 – 3.28 
(1H, m (under solvent peak)), 3.13 (1H, dd, J 10.0, 5.3 Hz), 2.96 (1H, dd, J 15.3, 4.5 Hz), 2.66 (1H, dd, J 
15.3, 10.0 Hz), 2.59 (3H, d, J 4.5 Hz). δC (126 MHz, DMSO) 172.6, 151.6 (d, J 234.4 Hz), 138.5, 135.8, 
134.5, 132.7, 132.5, 131.2, 129.1, 126.9, 125.5 (d, J 8.6 Hz), 112.8 (d, J 21.1 Hz), 112.0 (s), 109.9 (d, J 
4.5 Hz), 104.3 (d, J 23.0 Hz), 51.3, 50.7, 25.4, 25.0. δF (376 MHz, DMSO) -128.5 (1F, s). ESI-HRMS: m/z 
calculated for C19H1635Cl3FN3O [M+H]+ requires 426.0337. Found 426.0341. Elemental Analysis 
Calculated for C19H15Cl2FN3O requires C, 53.48 %, H, 3.54 %, N, 9.85 %. Found C, 53.46 %, H, 3.55 %, N, 
9.84 %. IR (neat): νmax/cm-1: 3340 (m, br), 3303 (w, br), 3240 (s, br), 3069 (w, br) 2844 (w), 1666 (s), 
1524 (s), 1455 (s), 1222 (s), 835 (s). HPLC (purity analysis %) found: Purity peak 1 43 %; Retention time: 
9.09 min: purity peak 2 53 %; Retention time: 10.15 / 30 min (0.5 ml/min MeOH, Signal = 254 nm, 
CHIRACEL OJ column). 
Preparation of 1-tosyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde (63) 
 
To a suspension of 7-azaindole-3-carboxaldehyde 62 (5.00 g, 34.2 mmol, 1 eq), DMAP (0.42 g, 
3.42 mmol, 0.1 eq) and TsCl (9.78 g, 51.3 mmol, 1.5 eq) in anhydrous DCM (250 cm3) contained within 
a flame dried round bottomed flask, was added NEt3 (9.53 cm3, 68.4 mmol, 2 eq) at 0 °C under an 
argon atmosphere. The reaction was allowed to slowly warm to room temperature and left overnight. 
To the reaction mixture was added saturated NaHCO3 solution (200 cm3) and the mixture stirred 
vigorously for 2 hours. The DCM layer was separated and the aqueous phase extracted with DCM (2 x 




100 cm3). Combined organics were washed with water (2 x 50 cm3), brine (50 cm3) and were dried 
over MgSO4. After filtration solvents were removed in vacuo and the product purified by column 
chromatography (50 % EtOAc in hexane), yielded the product 63 as an off white solid (10.26 g, 99 %). 
δH (500 MHz, CDCl3) 10.04 (1H, s), 8.54 – 8.48 (2H, m), 8.39 (1H, s), 8.18 – 8.13 (2H, m), 7.36 – 7.29 
(3H, m), 2.40 (3H, s). δC (126 MHz, CDCl3) 185.3, 147.5, 146.8, 146.5, 135.9, 134.4, 131.5, 130.1, 128.82, 
120.8, 119.5, 119.1, 21.9. ESI-HRMS: m/z calculated for C15H12N2NaO3S [M+Na]+ requires 323.0461. 
Found 323.0462. 
Preparation of (1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methanol (64) 
 
To a stirred suspension of compound 63 (10.23 g, 34.1 mmol, 1 eq) in anhydrous EtOH (200 
cm3) was added sodium borohydride (2.58 g, 68.2 mmol, 2 eq) portion wise over the course of 
approximately one hour. The reaction was stirred overnight monitored by TLC until completion after 
which was quenched by careful addition of water (100 cm3); the volume of the solvent was reduced 
by approximately half in vacuo. The product was extracted from the aqueous phase into EtOAc (3 x 
100 cm3). The combined organics were washed with water (100 cm3), brine (100 cm3) and were dried 
over MgSO4. After filtration solvents were removed in vacuo to yield the product 64 as a white solid 
(9.56 g, 94 %). δH (500 MHz, CDCl3) 8.44 (1H, dd, J 4.8, 1.6 Hz), 8.08 – 8.04 (2H, m), 7.95 (1H, dd, J 7.9, 
1.6 Hz), 7.69 (1H, s), 7.28 – 7.24 (2H, m), 7.18 (1H, dd, J 7.9, 4.8 Hz), 4.82 (2H, s), 2.36 (3H, s), 1.73 (1H, 
s). δC (126 MHz, CDCl3) 147.8, 145.4, 145.3, 135.6, 129.8, 128.7, 128.2, 123.9, 122.0, 119.0, 118.8, 57.4, 














To a flame dried round bottom flask, was added compound 64 (5.95 g, 19.7 mmol, 1 eq) along 
with anhydrous DCM (50 cm3) and was stirred under argon at 0 °C. To the reaction mixture was added 
PBr3 (2.03 cm3, 21.6 mmol, 1.1 eq) and the reaction left to stir for 30 minutes. Once TLC showed no 
presence of start material the reaction was stopped immediately and quenched carefully and slowly 
by addition of saturated NaHCO3 solution (100 cm3) at 0 °C. Once CO2 production ceased the product 
was extracted into EtOAc (3 x 100 cm3). Combined organics were washed with water (100 cm3), brine 
(100 cm3) and were dried over MgSO4. After filtration solvents were removed in vacuo, and the 
product dried thoroughly on high vacuum. Whist the brominated compound 65 was under vacuum, 
the deprotonation of the Schöllkopf chiral auxiliary (66) was carried out. In a separate flame dried 
round bottom flask was added anhydrous THF (50 cm3) and the Schöllkopf chiral auxiliary (66) (3.70 
cm3, 21.0 mmol, 1.05 eq) under argon. The reaction mixture was cooled to -78 °C before dropwise 
addition of nBuLi 2.5 M (9.4 cm3, 23.6 mmol, 1.2 eq), the deprotonation was allowed to occur over 
approximately 25 minutes. During this time the brominated compound 65 was taken off vacuum and 
dissolved in anhydrous THF (50 cm3). The flask was placed under argon and cooled to -78 °C. The 
brominated compound was then transferred by cannula into the vessel containing the deprotonated 
auxiliary 67 over the course of approximately 10 minutes and reaction was left overnight. The reaction 
was quenched the following day with saturated NH4Cl (50 cm3), most of the THF was removed under 
vacuum before extraction of the aqueous phase with EtOAc (3 x 50 cm3). Combined organics were 
washed with water (50 cm3), brine (50 cm3) and dried over MgSO4. The product was purified by column 
chromatography (50 % EtOAc in hexane) followed by recrystallisation in 15 % DCM in hexane to yield 
the product 68 as colourless crystals (4.76 g, 52 % isolated yield). δH (500 MHz, CDCl3) 8.37 (1H, dd, J 
4.8, 1.6 Hz), 7.98 – 7.94 (2H, m), 7.83 (1H, dd, J 7.9, 1.6 Hz), 7.43 (1H, s), 7.25 – 7.21 (2H, m), 7.12 (1H, 
dd, J 7.9, 4.8 Hz), 4.34 – 4.28 (1H, m), 3.68 (3H, s), 3.65 (3H, s), 3.24 – 3.18 (2H, m), 3.15 (1H, ddd, J 
14.2, 4.2, 0.7 Hz), 2.35 (3H, s), 2.09 (1H, septd, J 6.8, 3.3 Hz), 0.87 (3H, d, J 6.9 Hz), 0.60 (3H, d, J 6.8 
Hz). δC (126 MHz, CDCl3) 164.3, 162.1, 147.3, 145.0, 144.8, 135.7, 129.7, 128.4, 127.8, 124.8, 123.9, 




118.5, 115.1, 60.6, 55.7, 52.5, 52.4, 31.6, 29.3, 21.7, 19.0, 16.6. CI-HRMS: m/z calculated for 
C24H29N4O4S [M+H]+ requires 469.1904. Found 469.1908. 
Crystal data and structure refinement for 68 
 
Identification code 68 
Empirical formula C24H28N4O4S 
Formula weight 468.56 
Temperature/K 150.0 
Crystal system monoclinic 












Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.95 to 52.882 
Index ranges -17 ≤ h ≤ 17, -11 ≤ k ≤ 11, -22 ≤ l ≤ 22 
Reflections collected 27357 
Independent reflections 9622 [Rint = 0.0373, Rsigma = 0.0422] 
Data/restraints/parameters 9622/1/605 
Goodness-of-fit on F2 1.042 
Final R indexes [I>=2σ (I)] R1 = 0.0378, wR2 = 0.0868 
Final R indexes [all data] R1 = 0.0487, wR2 = 0.0926 
Largest diff. peak/hole / e Å-3 0.30/-0.35 
Flack parameter 0.01(2) 







To compound 68 (2.53 g, 5.40 mmol, 1 eq) was added THF / MeOH in a 2 : 1 ratio (30 cm3) and 
Cs2CO3 (3.08 g, 9.46 mmol, 3 eq). The reaction was left to stir overnight at room temperature. Solvents 
were removed in vacuo and the residue dissolved in EtOAc (50 cm3) and water (50 cm3). The EtOAc 
was separated off and the aqueous phase extracted with EtOAc (2 x 50 cm3) combined organics were 
washed with water (50 cm3), brine (50 cm3) and dried over MgSO4. After filtration solvents were 
removed in vacuo to yield the product 69 as a yellow foam (1.69 g, 99 %). δH (500 MHz, CDCl3) 9.54 
(1H, s), 8.25 (1H, dd, J 4.7, 1.4 Hz), 7.95 (1H, dd, J 7.9, 1.4 Hz), 7.07 – 7.00 (1H, m), 4.34 (1H, dd, J 8.7, 
4.1 Hz), 3.68 (1H, s), 3.65 (1H, s), 3.37 (1H, t, J 3.5 Hz), 3.29 (1H, dd, J 14.4, 5.0 Hz), 3.24 (1H, dd, J 14.3, 
4.1 Hz), 2.12 (1H, septd, J 6.8, 3.3 Hz), 0.91 (1H, d, J 6.8 Hz), 0.61 (1H, d, J 6.8 Hz). δC (126 MHz, CDCl3) 
164.1, 162.8, 148.5, 142.8, 127.9, 123.4, 121.1, 115.4, 110.4, 60.6, 56.7, 52.4, 52.3, 31.5, 29.7, 19.1, 
16.6. CI-HRMS: m/z calculated for C17H23N4O2 [M+H]+ requires 315.1816. Found 315.1817. 
Preparation of propyl 2-amino-3-(1H-pyrrolo[2,3-b]pyridin-3-yl)propanoate (70) 
 
To compound 69 (0.98 g, 3.12 mmol, 1 eq) was added THF (20 cm3) and the solution cooled to 
0 °C. To the solution was added 2 M HCl (20 cm3) and the reaction stirred at room temperature for 2 
hours. The reaction was basified to pH 7 using 2 M NaOH. Attempts to extract the product into an 
organic layer failed. The methyl ester was hydrolysed with 1 M NaOH (10 cm3) overnight. The solvents 
were removed in vacuo, and the crude amino acid product and salts were then suspended in nPrOH 
(10 cm3) and placed under an argon atmosphere. Thionyl chloride (2.26 cm3, 31.2 mmol, 10 eq) was 
added at 0 °C. After warming to room temperature the flask was equipped with a reflux condenser 
and the system placed under argon. The reaction was the heated to reflux for 12 hours. TLC indicated 




the presence of a new spot, the reaction mixture was cooled and quenched with a saturated solution 
of NaHCO3 (50 cm3) slowly. Once CO2 production ceased the product was extracted into EtOAc (3 x 50 
cm3), combined organics were washed with water (50 cm3), brine (50 cm3) and dried over MgSO4. After 
filtration solvents were removed in vacuo to yield the product as a white solid 70 (0.13 g, 17 % over 3 
steps). HPLC at this stage confirmed racemisation had occurred.  δH (500 MHz, CDCl3) 9.37 (1H, s), 8.26 
(1H, d, J 4.4 Hz), 7.95 (1H, d, J 8.0 Hz), 7.19 (1H, s), 7.07 (1H, dd, J 7.7, 4.8 Hz), 4.08 – 3.99 (2H, m), 3.82 
(1H, apparent t), 3.24 (1H, dd, J 14.5, 5.2 Hz), 3.09 (1H, dd, J 14.5, 7.1 Hz), 2.09 (2H, s), 1.65 – 1.56 (2H, 
m), 0.87 (3H, t, J 7.4 Hz). δC (126 MHz, CDCl3) 175.0, 148.7, 142.2, 127.6, 124.3, 120.5, 115.3, 109.1, 
66.8, 55.1, 30.5, 21.9, 10.3. CI-HRMS: m/z calculated for C13H18N3O2 [M+H]+ requires 248.1394. Found 
248.1398. HPLC (purity analysis %) found: Purity peak 1 51 %; Retention time: 8.52 min: purity peak 2 
49 %; Retention time: 19.00 / 30 min (0.5 ml/min MeOH, Signal = 254 nm, CHIRACEL OJ column). 
Preparation of propyl (6S,8R / 6R,8S)-8-(2,4-dichlorophenyl)-6,7,8,9-tetrahydro-5H-pyrrolo[2,3-
b:5,4-c']dipyridine-6-carboxylate (71) and propyl (6S,8S / 6R,8R)-8-(2,4-dichlorophenyl)-6,7,8,9-
tetrahydro-5H-pyrrolo[2,3-b:5,4-c']dipyridine-6-carboxylate (72) 
 
In a flame dried round bottomed flask was added compound 70 (0.13 g, 0.51 mmol, 1 eq) and 
2, 4 dichlorobenzaldehyde (0.097 g, 0.56 mmol, 1.1 eq) and anhydrous toluene (5 cm3) under an argon 
atmosphere. The reaction was heated to reflux for 24 hours, the dark brown solution was evaporated 
to dryness and the residue dissolved in EtOAc (50 cm3) and brine (50 cm3). The EtOAc was separated 
and the brine layer extracted with EtOAc (2 x 50 cm3), combined organics were dried over MgSO4. 
After filtration, solvents were removed in vacuo and the product purified by column chromatography 
(100 % DCM to 20 % EtOAc in DCM). Cis and trans isomers were further purified by recrystallisation in 
MeOH, to yield 71 as a white powder (0.035 g, 16 %). δH (500 MHz, CDCl3) 10.72 (1H, s), 7.84 (1H, d, J 
7.7 Hz), 7.77 (1H, d, J 4.8 Hz), 7.52 (1H, d, J 1.8 Hz), 7.07 (1H, dd, J 8.3, 1.7 Hz), 7.00 (1H, dd, J 7.8, 4.9 
Hz), 6.90 (1H, d, J 8.4 Hz), 5.94 (1H, s), 4.09 (2H, t, J 6.7 Hz), 3.85 (1H, dd, J 7.4, 5.0 Hz), 3.22 (1H, dd, J 
15.3, 4.9 Hz), 3.08 (1H, dd, J 15.3, 7.6 Hz), 2.85 (1H, s), 1.70 – 1.60 (2H, m), 0.92 (3H, t, J 7.4 Hz). δC 
(126 MHz, CDCl3) 173.2, 149.2, 142.1, 137.6, 134.7, 134.7, 132.7, 131.0, 129.9, 127.5, 126.7, 119.8, 
115.8, 108.1, 67.0, 52.4, 51.4, 24.7, 22.1, 10.5. CI-HRMS: m/z calculated for C20H2035Cl2N3O2 [M+H]+ 
requires 404.0927. Found 404.0934. 





The same procedure also gave 72 as a white powder (0.027 g, 12 %). δH (500 MHz, CDCl3) 10.61 
(1H, s), 7.82 (1H, d, J 7.8 Hz), 7.61 (1H, d, J 4.4 Hz), 7.49 (1H, s), 7.26 (1H, d, J 8.0 Hz), 7.11 (1H, d, J 8.1 
Hz), 6.97 (1H, dd, J 7.6, 4.9 Hz), 5.83 (1H, s), 4.23 – 4.17 (1H, m), 4.17 – 4.11 (1H, m), 3.97 (1H, dd, J 
10.9, 3.6 Hz), 3.19 (1H, dd, J 15.1, 2.9 Hz), 3.04 – 2.94 (1H, m), 2.66 (1H, s), 1.79 – 1.68 (2H, m), 0.99 
(3H, t, J 7.4 Hz). δC (126 MHz, CDCl3) 172.5, 149.2, 142.0, 137.0, 135.0, 134.7, 134.1, 131.6, 129.5, 
128.2, 126.6, 119.9, 115.7, 108.0, 67.1, 56.7, 25.3, 22.1, 10.5. CI-HRMS: m/z calculated for 
C20H2035Cl2N3O2 [M+H]+ requires 404.0927. Found 404.0920. 
Preparation of (6S,8R / 6R,8S)-8-(2,4-dichlorophenyl)-N-methyl-6,7,8,9-tetrahydro-5H-pyrrolo[2,3-
b:5,4-c']dipyridine-6-carboxamide (73) 
 
Compound 71 (0.035 g, 0.085 mmol, 1 eq) and methyl amine 33 % in EtOH (1.77 cm3, 14.25 
mmol, 167 eq) were used following general procedure 2. Gave the desired product 73 as white crystals 
(0.016 g, 49 %). δH (500 MHz, MeOD) 8.14 (1H, d, J 4.9 Hz), 7.97 (1H, d, J 7.9 Hz), 7.58 (1H, d, J 2.0 Hz), 
7.21 (1H, dd, J 8.3, 2.0 Hz), 7.11 (1H, dd, J 7.8, 4.9 Hz), 6.75 (1H, d, J 8.3 Hz), 5.77 (1H, s), 3.56 (1H, dd, 
J 10.3, 4.5 Hz), 3.18 (1H, dd, J 15.5, 4.5 Hz), 2.85 (1H, dd, J 15.5, 10.3 Hz), 2.75 (3H, s). δC (126 MHz, 
MeOD) 175.6, 149.8, 143.2, 138.8, 136.4, 135.4, 134.6, 132.3, 130.8, 128.0, 127.9, 121.4, 116.6, 110.0, 
53.0, 52.6, 26.3, 25.7. CI-HRMS: m/z calculated for C18H1735Cl2N4O [M+H]+ requires 375.0774. Found 
375.0781. Elemental Analysis Calculated for C18H16Cl2N4O requires C, 57.61 %, H, 4.30 %, N, 14.93 %. 
Found C, 57.33 %, H, 4.30 %, N, 14.80 %. IR (neat): νmax/cm-1: 3404 (m), 3381 (m), 3138 (m, br), 3049 
(m, br), 2937 (m, br), 2895 (m, br), 2840 (m, br), 1672 (s), 1519 (s), 1409 (s), 1035 (m), 766 (s). HPLC 
(purity analysis %) found: Purity peak 1 53 %; Retention time: 7.65 min: purity peak 2 47 %; Retention 
time: 21.45 / 30 min (0.5 ml/min MeOH, Signal = 254 nm, CHIRACEL OJ column). 




Crystal data and structure refinement for 73 
 
Identification code 73 
Empirical formula C18H16N4OCl2 
Formula weight 375.253 
Temperature/K 150.0 
Crystal system orthorhombic 












Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.682 to 52.798 
Index ranges -27 ≤ h ≤ 27, -17 ≤ k ≤ 15, -27 ≤ l ≤ 27 
Reflections collected 33085 
Independent reflections 7084 [Rint = 0.0683, Rsigma = 0.0477] 
Data/restraints/parameters 7084/0/461 
Goodness-of-fit on F2 1.035 
Final R indexes [I>=2σ (I)] R1 = 0.0440, wR2 = 0.0906 
Final R indexes [all data] R1 = 0.0717, wR2 = 0.1006 
Largest diff. peak/hole / e Å-3 0.33/-0.44 
 
 




Molecular Modelling Protocol 
Compounds were first built in chemdraw and transferred to Spartan, compounds were then 
energy minimised, Spartan was used to compute local energy minimum geometry using molecular 
mechanics with the MMFF94 force field. Compounds were then docked in GOLD using the homology 
model previously built by our group. The docking protocol is outline in the table below. Early 
termination was not allowed and lone pairs were not saved, all other parameters were left default.   
Mg2+ Mg2+ present, no coordination geometry specified 
Protonation Hydrogens added 
Waters Water molecule HOH1091 extracted, all other waters 
deleted, water was set as toggle, spin 
Ligands CDPME extracted 
Binding site Defined as 6 Å of the CDPME ligand 
Number of GA Runs 10, 50, 100, 500 
Scoring Function GOLDscore 
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3.1 Chemotype Identification 
 In the previous chapter, SAR around the MMV008138 chemical scaffold was presented. As 
part of a wider research programme, we wanted explore and develop alternative novel inhibitors of 
PfIspD, and undertake a medicinal chemistry programme to optimise whole cell potency.  
 In order to identify a template for optimisation and development of SAR, an enzymatic HTS 
screen was undertaken using a chemoinformatics approach. A series of in silico similarity searches 
were carried out in order to explore chemical space for potential hits around known PfIspD active 
compounds. In addition scaffold-hopping methods were employed which allowed for identification of 
novel chemotypes. A compound library held by Biofocus of approximately 500,000 compounds was 
queried for potential drug molecules that incorporate numerous criteria as displayed below.1,2  
 Compounds structurally similar to IspD natural substrates (MEP, CTP (see Chapter 2 
for structures)) 
 Compounds structurally similar to IspC natural substrates (DXP) 
 Compounds structurally similar to known IspD inhibitors ≤ 1 M (azolopyrimidines) 
 Compounds structurally similar to known IspC inhibitors ≤ 1 M (Fosmidomycin (FOS) 
and other FOS mimetics) 
 Compounds that possess metal chelating moieties (Hydroxamic acids) 
 Compounds possessing biphosphate isosteres  
Screening for compounds in this way holds numerous advantages; firstly, using the similarity 
principle, structurally similar compounds to IspD substrates are more likely to show biological 
activity,3,4 therefore mimetics of the natural substrates of IspD could be potent inhibitors, secondly 
compounds were also cross-examined with structural similarities to both the IspC substrate and 
inhibitors such as fosmidomycin (FOS) which also shows some activity against IspD (IC50 = 20.4 ± 3.3 
mM EcIspD).5 Furthermore FOS and its derived mimics are substrate-like to MEP and therefore 
structures baring similarity to FOS my also show inhibitory IspD activity. Thirdly, the examination of 
compounds baring similarity to already known IspD inhibitors also raised the potential of finding a hit 
molecule, as the chemical space occupied by these ligands is already at least partially suited to the 
enzyme. Fourthly, all enzymes within the MEP pathway require a divalent metal ion to stabilise and 
coordinate the substrates and products for catalysis; the IspD enzyme requires Mg2+ to function, 
therefore by employing a strategy that searches for metal chelating moieties, any potential hit could 
possess enhanced binding energy within the active site via coordination to the metal group, which 
would prevent substrate entry.6 Finally, the substrates and product of the IspD enzymatic 
Chapter 3: Development of Alternate Inhibitors of PfIspD 
 181 
transformation all have phosphate moieties that possess crucial binding interactions in the active 
site.7–10 Replacement of these moieties with potential bioisosteres could lead to reasonable starting 
points for optimisation. 
The compounds were ranked for similarity using the Tanimoto co-efficient; this co-efficient is 
a similarity metric which takes values between 0 and 1 where 1 classes a compound as identical.11 For 
the study undertaken by our group, compounds possessing values greater than 0.7 were selected for 
further investigation. To incorporate scaffold hopping, compounds also possessing Tanimoto co-
efficient values between 0.2 and 0.4 were also selected for further investigation to increase compound 
diversity.1  
The end result of this computational screening process was a reduction of 500,000 potential 
compounds down to 23,000. In order to filter this down further, these 23,000 compounds were 
docked into the known crystal structures of both IspC and IspD. As the IspD crystal structure is not 
available for P. falciparum, docking was carried out on the active site of E. coli IspD and the allosteric 
binding site of A. thaliana IspD. Compounds were assessed and ranked according to their GOLD scores, 
which is a prediction of the binding affinity within the selected pocket. Compounds with high docking 
scores were favourable, as these were predicated to be inhibitors. Finally, compounds were also 
filtered according to their solubility assessment. Solubility was calculated computationally in 
collaboration with AstraZeneca and compounds were selected with calculated LogS (moldm-3) of 
greater than -3.5.12,13 Ultimately after the combination of chemoinformatics, computational docking 
and solubility assessment was undertaken, the 23,000 compounds were filtered into a focused library 
of 5000 compounds that could be taken forward into a HTS screening programme.1,2  
The HTS was carried out following the protocol for the IspD pyrophosphate release assay 
developed by our collaborators at Washington University (Odom group) was transferred to Biofocus.14 
The compounds were tested directly against purified PfIspD in order to determine the enzymatic 
inhibitory activities. Compounds were classified as hits when IC50 values of ≤ 20 M were observed. 
The 5000 compounds were successfully evaluated by Biofocus from the 5-point dose response 
screening of 316 plates.  Originally 76 compounds were identified to possess IspD inhibition activity, 
however, this number was reduced after confirming purity of the compounds by LCMS. For a 
compound to be classified as active it was required to possess purity greater than 75 %. After purity 
analysis, the compound set was reduced to 54. Across these 54 compounds there were 10 potential 
chemotypes identified for additional analysis. Across all the compounds, motifs possessing a 
benzoisothiazolone (BITZ) chemotype frequently were observed to be active, amongst which 
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compound 1 was identified as one of the most potent compounds in the series, with an IC50 value of 
480 nM (Figure 3.1).1 
 
Figure 3.1. Hit from HTS screen. 
 It was observed that all compounds possessing a BITZ core demonstrated good PfIspD activity 
(<1 M). Further to this, the synthesis of the BITZ chemotype appeared to possess tractable SAR, and 
finally, examination of the literature indicated that this compound class has never been used as an 
inhibitor of PfIspD, as a result, this chemotype was selected for SAR optimisation. 
3.2 Known BITZ SAR Exploration and Synthesis 
 Extensive SAR has been carried out by members of our group and is described briefly in the 
following sections. Hit 1, was difficult to synthesise and was replaced with compound 8 with the ortho 
morpholine removed from the C-ring (Scheme 3.1). Further to this compound 9 (also referred to as 
ebsulfur) was synthesised bearing no C-ring functionality, this molecule was important as it provided 
a distinct branching point from which further SAR was undertaken. Both compounds were synthesised 
by former PhD student Dr Kathryn Price following Scheme 3.1. 
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Scheme 3.1. Synthesis of compounds 8 and 9. 
Compound 8 was prepared via a 5-step synthesis as depicted by Scheme 3.1; first, 3-
nitrobenzene sulfonyl chloride (2) was coupled with morpholine to form the sulfonamide (3). This was 
followed by nitro group reduction in the presence of H2 using Pd / C hydrogenation conditions forming 
4.15,16 4 was coupled with 2-methylthiobenzoic acid (5), via SOCl2 mediated peptide coupling 
procedures which yielded 6a before sodium periodiate oxidised the thiol group gave the sulfoxide 
(7a), finally reaction of 7a with SOCl2 promotes ring closure to the desired target 8.17–19 Compound 9 
was made analogously to 8, however, aniline could be purchased used directly. Aniline was coupled 
with 5 to form 6b, oxidation of 6b yielded 7b, which after SOCl2 mediated ring closure yielded 9. The 
final step does appear to possess an unusual mechanism and follows a similar reaction to a Pummerer 
rearrangement as shown below (Figure 3.2) but does not form the Pummerer product.18 
 
Figure 3.2. Mechanism of sulfoxide ring closure. 
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 In addition to Scheme 3.1, a shorter alternative scheme was also utilised for the synthesis of 
8 and 9 (by former PhD student Dr Kathryn Price) using a copper-catalysed heteroatom ring closing 
reaction for the generation of BITZ compounds (Scheme 3.2).20  
 
Scheme 3.2. Alternate ring closing route using Cu catalysis. 
The reaction utilises ortho-iodobenzamide intermediates 10 or 11 as a coordinating group for 
a Cu(I) species. The mechanism is likely to proceed as follows. First the Cu(I) ligand species (Cu(I)L) is 
coordinated by the amide nitrogen (A), before deprotonation by base (B). Elemental sulfur (S8) then 
inserts between the Cu-N bond (C), the Cu(I) species is then set up for oxidative addition into the C-I 
bond forming a 6-membered intermediate and a unstable Cu(III) species (D), this can then reductively 
eliminate reforming the catalytic Cu(I) species and releases the product (E) (Figure 3.3). 
 
Figure 3.3. Mechanism of Cu promoted ring closure.  
 The advantage of the approach depicted in Scheme 3.2 vs Scheme 3.1 is that it is a shorter 
synthesis with a better-cost effectiveness in terms of starting materials. Furthermore the authors state 
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that this method is a more environmentally friendly synthesis than other reported methods for BITZ 
compound generation.20 Therefore this makes this route more attractive from a drug-development 
point of view. 
An additional approach that has been studied in detail in the group is depicted in Scheme 3.3. 
This approach provides a very fast and efficient way to generate BITZ compounds cleanly without the 
need for metal catalysts. The reaction involves the generation of 2-(chlorocarbonyl)phenyl 
hypochlorothioite (14), which can be successfully synthesised via a two-step procedure. Starting from 
2,2′-dithiodibenzoic acid (12) and refluxing in dichloroethane (DCE) in the presence of SOCl2 forms the 
acyl chloride intermediate (13). The disulfide bridge within 13 can be cleaved in situ, the addition of a 
source of Cl2 such as SO2Cl2 followed by heating generates two equivalents of 14 in quantitative yield.21 
Compound 14 is stable and is a versatile intermediate that can be stored for many months. Reaction 
with an amine results in ring closure in a two-step process.22,23 Reactions often proceed cleanly and 
can occasionally be purified from just a simple work-up (Scheme 3.3). 
 
Scheme 3.3. S-Cl / COCl mediated ring closure. 
3.2.1 C-ring Modifications  
 Described below are the biological data that has been previously obtained within our group 
for the purpose of developing a novel hit that effectively targets both PfIspD and Pf3D7 cells.  
As previously described compounds 8 and 9 (Figure 3.4) were synthesised according to 
Schemes 3.1 and 3.2. In order to confirm activity of the series these two compounds were tested 
against both purified PfIspD and Pf3D7 whole cells. 8 expressed comparable activity to 1 with a PfIspD 
IC50 value of 656 nM, however, upon testing vs Pf3D7 whole cells, 8 displayed a disappointing EC50 
value of 8020 nM. 9 was more potent than 8 at 600 nM against enzyme and 5490 nM against Pf3D7 
malaria parasites.  
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Figure 3.4. Activity of compounds 8 and 9. 
 The first area of SAR that was explored was modifications to the C-ring. In order to quickly 
determine a path of SAR that could be developed compounds 15 – 17 were purchased and tested 
against both enzyme and Pf3D7 malaria parasites with activity values shown in Table 3.1 below. 
 
Table 3.1. Biological activities of purchased compounds 15, 16 and 17. 
Compound PfIspD IC
50
 (nM)  Pf3D7 EC
50
 (nM)  
15 9050 ± 2890 n = 4 17100 ± 9400 n = 3 
16 445 ± 79 n = 3 4320 ± 183 n = 3 
17 >50,000 n = 1 16000 n = 1 
 
It was clear from the data that there was a requirement for the C-ring to be substituted at the 
meta-position as compound 17 possessing para substitution displayed a loss of potency against the 
enzyme. What was also apparent from the limited SAR carried out was that there was a degree of 
steric manipulation that can also be carried out around the C-ring with potency against enzyme being 
maintained in compounds 1, 8, 9, and 16. Despite the loss of potency observed with a change of ortho-
substituent in 15 when compared to 1, ortho-substituted OH or OMe derivatives possessing various 
sulfonamides were synthesised in order to examine if potency could be recovered and be comparable 
to 1 (Synthesis carried out by former Erasmus student Maria Mondini). However, in most cases this 
led to a loss of IspD activity and thus the decision was taken that for all future SAR only meta-
substitution would be explored. Further to this, the group decided to move away from sulfonamides 
as they possessed no advantage in potency in comparison to either 1 or 9.  
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3.2.2 D-ring Modifications 
The results described above led the group to explore the effect of adding an extra phenyl ring 
at the meta-position of the C-ring; this new D-ring itself had substitution at its para-position. Table 3.2 
below shows the compounds developed by former PhD student Dr Kathryn Price, and the biological 
data obtained after testing.2  
 
Table 3.2. Biological data of biphenyl BITZ compounds developed by Dr K. Price. Compound properties are ranked using 
a traffic light system. Green = good, amber = acceptable, red = poor. 
Compound R PfIspD IC
50
 (nM)  Pf3D7 EC
50
 (nM)  CLogP 
18 OCH3 206 ± 89 n = 3 920 ± 66 n = 9 5.16 
19 Cl 73 ± 20 n = 3 1080 ± 164 n = 5 5.95 
20 CF3 273 ± 15 n = 3 646 ± 21 n = 6 6.12 
21 OCF3 290 ± 195 n = 3 411 n =1 6.27 
22 CO2CH3 393 ± 96 n = 3 1000 ± 237 n = 5 5.21 
23 OH 660 n = 1 2450 n = 1 4.57 
24 3-thiophene 265 ± 21 n = 2 2877 n = 1 6.78 
  
Notably all but compound 23 possessed increased potency vs PfIspD than compounds 1, 8 and 
9, in addition to this, compounds 18, 20 and 21, also displayed cell growth inhibition activities in the 
sub-micromolar range for the first time with this chemotype. Compound 19 was interesting as it was 
over 2-fold more potent than the next most active compound (18) against the enzyme, however, this 
promising enzyme activity was not transferred to the whole cell assay. It is evident from the CLogP 
values that these compounds are very lipophilic and thus would likely show a poor DMPK profile; this 
was a problem with this series that needed to be addressed. It was clear that there was a large degree 
of steric manipulation from meta-substitution of the C-ring that could be undertaken, it was therefore 
decided to incorporate solubilising groups at the end of the D-ring, from this compounds 25 – 29 were 
synthesised (By former PhD student Dr Kathryn Price) and biological activities are shown below (Table 
3.3).2 
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Table 3.3. Biological data of biphenyl BITZ compounds possessing solubilising groups developed by Dr K. Price. 
Compound properties are ranked using a traffic light system. Green = good, amber = acceptable, red = poor. 
Compound R PfIspD IC
50
 (nM)  Pf3D7 EC
50
 (nM)  CLogP 
25 O 400 ± 82 n = 3 413 ± 82 n = 4 4.99 
26 CHF 862 ± 107 n = 3 323 ± 92 n = 5 5.96 
27 NCH3 446 ± 75 n = 3 416 ± 6 n = 3 5.55 
28 NH 160 ± 7 n = 2 3250 n = 1 4.97 
29 NSO2CH3 523 ± 90 n = 3 1470 n = 1 4.99 
 
   Promisingly the incorporation of sterically demanding solubilising groups did not diminish 
potency in the cell assay for compounds 25 – 27, and enzymatic activity was also retained across all 
compounds. Despite this promising result, the lipophilicity of these compounds is still above an ideal 
threshold for a drug candidate. Focus was switched from this biphenyl series to a mono-phenyl series 
with the benzyl-linked solubilising groups attached to the meta-position of the C-ring the generic 
structure of these compounds is displayed below (30) (Figure 3.5).  
 
Figure 3.5. Generic structure of mono-phenyl series (30). 
The rationale behind these compounds was to further reduce CLogP while also incorporating 
the desired meta-substitution of the C-ring. Analogous mono-phenyl compounds from both Tables 3.2 
and 3.3 were synthesised (by former PhD students Dr Kathryn Price and Dr Natalie Roberts) and in 
general PfIspD activity was comparable to the biphenyl series. However, across the whole mono-
substituted series Pf3D7 potency was significantly reduced. It appeared as through there was indeed 
a requirement either for a high CLogP of the compounds, or there was a specific hydrophobic 
interaction that made this extra phenyl ring favourable for activity.  
Alternatively the reactivity of the N-S could be very crucial, and may require strict electronic 
properties in order to optimise cellular potency. As described in Section 3.3 below, the proposed 
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mechanism of action of these compounds involves covalent modification of the enzyme active site. 
This occurs is by ring opening of the BITZ core via nucleophilic attack of a crucial cysteine residue in 
the IspD active site with the sulfur atom of the BITZ compounds. If this reactivity is too high, the 
compound may ring open before it is able to reach the apicoplast; if this reactivity is too low it may 
not react with the cysteine residue once bound in the active site.  
3.2.3 Further SAR Investigations 
 
Figure 3.6. Generic structures of further SAR investigations on the BITZ chemotype (31) and (32). 
 As previously mentioned numerous group members have carried out extensive SAR on this 
chemotype. With the scope of this thesis it is not possible to disclose all data obtained. A series of A-
ring substituted compounds were developed by former PhD student Dr Natalie Roberts for the 
purpose of improving the DMPK profile of the series as a whole (Figure 3.6). Halogens, OMe, NO2 and 
N were incorporated into the A-ring, similar to the MMV008138 template, to block potential sites of 
metabolism, whilst also exploring the effects of changing the electronics and sterics of the BITZ core. 
Along with A-ring modifications alterations to the C-ring and its side chain were also synthesised in 
these series. Unfortunately a general trend across the series was compounds possessed only 
moderate activity in the PfIspD assay and poor potency in the Pf3D7 assay. 
 
Figure 3.7. Generic structure of CH2 linked aromatic BITZ compounds (33) and (34). 
Other work carried out by the group also involved the incorporation of a CH2 linker introduced 
between the B and C-rings (Figure 3.7). This was carried out for the purpose of adding flexibility to the 
molecule ‘side arm’ as a study to examine if any extra interactions could be captured within the active 
site. In a final study a nitrogen atom was also incorporated into both C and D-phenyl rings, this was 
carried out for the purpose of potentially picking up an extra hydrogen bond in the active site of the 
enzyme, and attempt to reduce the ClogP of the series as a whole. Again in general across all these 
series there was a mixture of success with inhibition of the enzyme, but the main drawbacks of all 
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series investigated was the lack of whole cell potency in comparison to the biphenyl series (EC50 = ~ 
>2000 – 100,000 nM Pf3D7). 
3.3 BITZ Chemotype Mechanism of Action 
 Before continuing, it is important to consider the mechanism of action of this series. The BITZ 
chemotype has an unusual structure, possessing an N-S single bond, which is susceptible to 
nucleophilic attack. Therefore the proposed mechanism of action for the inhibition of PfIspD via the 
BITZ series is believed to proceed through firstly a non-covalent recognition / docking event followed 
by a covalent binding mechanism via nucleophilic attack from a cysteine residue that is found within 
the PfIspD active site (A). This forms a disulfide bridge and pushes electron density onto the nitrogen 
atom. The now covalently bound drug is thought to block the binding of substrates in the active site 
due to the chemical modification of the cysteine residue preventing substrate entry (B) (Figure 3.8). 
 
Figure 3.8. Proposed mechanism of action of the BITZ chemotype. 
 The resulting negative charge on nitrogen can be stabilised before protonation via 
delocalisation into the adjacent aromatic ring system and amide moiety. The stabilisation of charge 
should favour ring opening and thus the more stable the charge the more active a compound was 
expected to be following this mechanism. Furthermore the addition of electron withdrawing groups 
on the aromatic C-ring was expected to also increase the likelihood of ring opening as the N-S bond is 
be expected to be further weakened as it becomes more polarised.  
To examine if the molecule was a covalent inhibitor, compound 20 was examined by our 
collaborators in Washington University St Louis (Odom group) in a mechanistic study. Wild type E. coli 
IspD (EcIspD) possesses no cysteine residue in the active site, it is instead replaced by an alanine 
residue denoted A14. Therefore testing 20 against EcIspD should lead too poor potency, which was 
observed as displayed in Figure 3.9 (IC50 > 100,000 nM). Mutating this wild type EcIspD replacing A14 
with cysteine (A14C mutation) and retesting 20 for inhibitory activity against mutated EcIspD brought 
back potency of the compound(IC50 ~500 nM), giving an indication that a cysteine residue is crucial for 
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activity (Figure 3.9 left graph).24 Note in an analogous study 18 was also examined and gave a 
concordant result.2  
 
Figure 3.9. Left graph (A), activity of 20 before and after A14C mutation of E. coli IspD. Right graph (B), activity of 20 
before and after DTT (35) is added to the assay.  
A second in vitro study to examine if the cysteine covalently binds compound 20 was also 
carried out by treating the assay with dithiothreitol (DTT) (35) a reducing agent (Figure 3.10)  When 
no DTT is added the activity is retained, when DDT is added at 7 minutes, inhibitory activity 
immediately decreases until 20 is inactive (Figure 3.9 right graph). This suggests that the postulated 
disulfide formed between 20 and the cysteine residue is being reduced to an inactive thiol derivative 
of the parent drug (36) (Figure 3.10), which could explain the loss of activity.24 
 
Figure 3.10. Structure of DTT (35) and inactive thiol derivative 36. 
 Before continuing it is important to point out that the development of drugs whose 
mechanism of action is via covalent modification can pose a risk to off target effects that can cause 
toxicity problems. During the exploration of the BITZ chemotype, we noticed that it was identified in 
a publication as a possible pan assay interference compound (PAIN). The paper suggested that 
medicinal chemistry programmes using this moiety should avoid wasting ‘time and research money’.25 
Originally, this chemotype was not defined as a PAIN by the authors of the same commentary in their 
initial publication.25–27 In fact they had attempted to use it to target Trypanosoma brucei farnesyl 
pyrophosphate synthase (FPPS). However, the project was unsuccessful, and because of 
uninterpretable SAR they have since categorised this chemotype as a PAIN.25,26  
A B 
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 Pan-assay interference compounds (PAINS) are synthetic chemical compounds or natural 
products that can cause false positive assay signals.25–33 These compounds can cause false positives 
due to intrinsic redox activity, chemical reactivity, instability, or they can form aggregates.25–33 Other 
false positives can occur due to autofluorescence, metal chelation, membrane disruption, 
decomposition in buffers, or covalent modification of proteins, which is the proposed mechanism of 
action of our BITZ chemotype.2,25–33 Currently, PAINS are identified via substructure matching with 
published moieties.30  
 The term, pan assay interference compounds (PAINS), was first coined by Baell et al. after he 
established a general purpose HTS library consisting of 100,000 compounds that appeared optimisable 
and lead-like in the year 2003.26,27,34 The Baell group ran their biochemical assays in the presence of 
detergent to avoid aggregate formation, and identified numerous potent and selective hits for their 
various targets.34 However, within the first few years, the group wasted time on hits that ended up 
being non-developable.34 In the simplest case, hits that were resynthesised or repurified did not 
reproduce biological activity.34 In more difficult cases the group found that some compounds 
possessed early SAR, but this eventually ended in flat or uninterpretable SAR.25–27,29,34 The group 
noticed that similar looking compounds consistently appeared in different screens, and developed the 
idea that classes of intrinsically promiscuous compounds share common substructural motifs.26,27,34 
They observed that these problematic compounds possessed different forms of chemical reactivity 
and could interfere with biochemical assays through the mechanisms mentioned above.34 Baell 
collated a list of substructural filters to identify PAINS compounds.26,27,34 As noted above, the BITZ 
chemotype was not added to the original published PAINS filters, it was instead branded a PAIN later 
by the Baell group.25–27,29,34   
 Crucially, it is important to realise that the PAIN nomenclature is class-based and that 
individual compounds recognised by a PAINS substructure do not necessarily exhibit broad spectrum 
interference.27,34 PAINS compounds are present in approximately 6 – 7 % (over 60) FDA approved 
drugs and so exclusion of these structural classes is not necessarily a good solution.27,28,31,33,35 
Therefore, it is reasonable to say that disregarding all potentially reactive or problematic compounds 
would be as detrimental to medicinal chemistry just as much as ignoring PAINS classified compounds 
would be.30 It is also important to note that no PAINS-containing drug has ever been developed 
starting from a protein-reactive PAINS target based screening hit.33,36  
Two subsequent large scale studies of PAINS suggest that the structural context in which 
PAINS occur play a role in the undesired effects and should be examined.30,35 It seems reasonable not 
to discard a template containing a PAINS substructure, but instead perform follow up experiments 
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and orthogonal assays to determine genuine biological activity.33,37 Such follow up assays include 
screening the molecule against unrelated enzyme targets as well as determining whether it competes 
with a ligand known to bind to the active site.33,37 Potentially the most important criterion to 
distinguish a PAIN from a non-PAIN is thorough logical SAR.33,37   
 We have previously stated that we know our BITZ chemotype acts through covalent 
modification, and that it reacts with a cysteine thiol in the PfIspD.2 While this may raise questions on 
whether this chemotype is selective or not, we are confident that it is selective and only reacts with 
one cysteine residue in the active site of PfIspD. We can justify this through the studies describing the 
proposed mechanism of action above.2 Firstly, the BITZ chemotype appears to only modify one 
cysteine residue in the PfIspD protein, this residue is denoted Cys-202.2 In E.coli IspD this residue is 
replaced with alanine (denoted A14) (Figure 3.11), and our compounds show no activity against 
EcIspD.2 If EcIspD has this A14 residue exchanged with a cysteine residue, and the assay repeated with 
mutated EcIspD we observe the BITZ chemotype is then active against mutated EcIspD.2 Secondly, if 
PfIspD has its Cys-202 exchanged to alanine, we observe loss of potency of the chemotype which again 
appears to back up our postulation that the BITZ chemotype is showing genuine activity against 
PfIspD.2 It is appropriate to note that there is more than one cysteine residue in both PfIspD and EcIspD 
homologues (Figure 3.11). Therefore, the change of inhibitory activity of the BITZ chemotype observed 
through subtraction or addition of a single cysteine residue in the active sites of these homologues 
appears to back up that our compounds are selectively only targeting one cysteine residue. Thirdly, 
the Plasmodium vivax homologue of IspD retains the proposed active cysteine residue (denoted Cys-
197) responsible for inhibitor activity in the PfIspD active site (Figure 3.11).2 In previous research, we 
have shown that PvIspD is also potently inhibited by our BITZ compounds.2 Fourthly, in previous 
research we have shown that the BITZ chemotype is competitive with cytidine triphosphate during 
short incubation periods, but enzymatic inhibition cannot be out-competed following prolonged 
incubation of PfIspD with the inhibitor which suggest that a covalent bond is likely formed.2 This 
observation meets one of the criteria to rule out potential interference.33,37 Fifthly, as a control, the 
original assay to determine PfIspD potency for our HTS was different to that described in Chapter 2. 
This alternative assay for phosphate release was the BIOMOL Green assay.38 The difference between 
the alternate assay and the MESG / PNPase assay described in Chapter 2 is; the MESG / PNPase assay 
is a continuous assay, while the BIOMOL Green assay is an end point assay only.2,14 Both assays use 
fluorescence to measure IC50 values, however, the measurement of absorbance of the active 
ingredient in the BIOMOL Green assay (malachite green) is measured at 620 nm instead of 360 nm for 
the MESG / PNPase assay.38,39 This assay has been repeated by our collaborators and has confirmed 
that the BITZ chemotype is active vs PfIspD.14 Therefore, we have conducted an orthogonal assay in 
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order to rule out potential interference from our compounds.33,37 We acknowledge that to confirm 
beyond any doubt that the molecules are not interfering in the assay, a counter screen of the 
compounds against unrelated targets will likely be required, this should be carried out as part of future 
work. In addition to this, all tested compounds should also be screened within the BIOMOL Green 
assay or another orthogonal assay. 
 
Figure 3.11. Alignment of IspD homologs: active site Cys residue is conserved in Plasmodium species, but is absent in 
bacterial orthologs that are insensitive to BITZ inhibitors. Figure reproduced from Price. K. E. et al.2 Permissions for use 
are granted under the Creative Commons Attribution 4.0 International License.   
There is some concern that the MESG / PNPase assay described in Chapter 2 (Figure 2.9) could 
cause false readouts when using the BITZ chemotype as the inhibitor, as MESG and its resultant 
product from the assay contains an aromatic thiol which may be nucleophilic enough to ring open our 
BITZ compounds before they have a chance to bind to the enzyme (Chapter 2 Figure 2.9). While we 
have not examined decomposition of our inhibitors by stirring MESG or its assay product in the 
presence of our BITZ compounds alone, we are confident that our activities are genuine, as the 
BIOMOL Green assay does not possess a moiety with a potentially reactive thiol, and when measured, 
BITZ compounds activities were replicated when measured with the BIOMOL Green assay.14 In 
addition, as we know E. coli IspD is insensitive to inhibition via BITZ compounds, our collaborators 
have compared the pyrophosphate released using E. coli IspD in the presence and absence of BITZ 
inhibitors and there is no difference in pyrophosphate release with or without inhibitor.14 Therefore, 
there is no evidence of altered activity and this suggests that there is no reaction of the BITZ 
compounds with MESG or its assay product.14 We acknowledge that the control of stirring an active 
BITZ compound in the presence of MESG and / or its resulting assay product alone will need to be 
carried out as part of future work.  
In summary, we acknowledge that the use of covalent modifiers can be risky and understand 
that identified PAINS substructures can be a problem and is an important area of research. Recent 
literature has shown that an identified PAIN substructure does not necessarily mean that any given 
compound (such as the BITZ chemotype) will result in presumed off target effects. We also note that 
there is significant evidence that covalent modifiers can be successful in medicinal chemistry 
programmes. Aspirin for example is one of the world’s most widely used drug compounds and its 
mechanism of action is through covalent modification.40  
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3.4 Results and Discussion 
 To begin the new SAR on the BITZ compounds we had two main aims. Firstly we wanted to 
explore new chemical space around the IspD active site, and secondly we wanted to attempt to 
correlate activity with N-S bond strength. A novel chemotype not yet explored in the group was the 
2,1-BITZ chemotype (Figure 3.12), an isomeric variant of the 1,2 BITZ compounds described above.  
 
Figure 3.12. 2,1-BITZ template. 
 The isomeric chemotype has the N-S bond in alternate positions and could lead to interesting 
SAR. By alternating the N-S, orientation we can probe both reactivity, and steric demands of the drug 
template within the active site. In addition, by having comparative 1,2 and 2,1 isomers of the same 
template there is the potential to gain insight of the available chemical space from which new SAR 
investigations could be developed. To explore the SAR of this template the functionality of the R group 
on the nitrogen atom was altered using both aliphatic and aromatic side-chains. 
3.4.1 Synthesis of 2,1 BITZ Compounds 
 The production of 2,1-BITZ compounds is not well documented and there are few reports of 
their generation available in the literature. Despite this there is a general route for their synthesis as 
depicted by Scheme 3.4. 41–43 
 
Scheme 3.4. General synthesis of 2,1-BITZ compounds.43 
The synthesis begins by saturating a solution of water or methanol basified by 1 equivalent of 
hydroxide with hydrogen sulfide gas.41–43 Isatoic anhydride (37) was then added and the reaction left 
for one hour allowing ring opening and loss of CO2 to yield thiolate 38. 38 is then oxidised in situ by 
hydrogen peroxide, followed by ring closure to the un-substituted 2,1 BITZ intermediate 39. 39 can 
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then be coupled with an appropriate halogenated electrophile following SN2 substitution to yield the 
desired targets.43  
 We were required to make a modification to step one of the published procedure to avoid the 
use of H2S. Examination of the literature elucidated that the reaction could be successfully achieved 
by dissolving excess Li2S in a protic solvent in order to generate LiOH and HLiS as the nucleophile. In 
the same step, a catalytic amount of hydrochloric acid was added before the addition of isatoic 
anhydride (37) (Scheme 3.5), unfortunately a yield is not specified for the reaction in the literature.44  
 
Scheme 3.5. Modified procedure en route to 2,1-BITZ compounds.44 
Following the reported procedure problems were immediately encountered, 1H NMR 
confirmed the correct number of protons for the isolated product but the mass spectrometry analysis 
yielded a molecular ion peak that did not correspond to the product. Disappointingly repetition of the 
reaction varying time and temperature gave the same result.  
To determine what the problem was the reaction was repeated using phenyl-isatoic anhydride 
(49), which should yield N-phenyl-2,1 benzoisothiazolone (50) (see scheme 3.8 below for synthesis), 
however, again the mass spectrometry analysis was incorrect. The product was further confirmed to 
be incorrect by IR analysis which indicated the presence of a broad peak across the N-H, O-H stretching 
frequency range, neither of which should be present in 50. We suspected that hydroxide generated in 
situ by the reaction of Li2S with H2O was acting as the nucleophile instead of the mono-lithium sulfide.  
To confirm our suspicions the unsubstituted isatoic anhydride reaction was attempted once 
more, but using methanol as solvent instead of water. After completion of the reaction, TLC analysis 
of the reaction mixture showed a non-polar product had developed. After isolation, we saw a new 
peak in the NMR corresponding to methoxy protons. This is consistent with mono-lithium sulfide not 
acting as a nucleophile, but rather methoxide exclusively reacting with 37, yielding methyl 2-
aminobenzoate (40) (Scheme 3.6). Carrying out the reaction analogously in water results in the 
production of anthranillic acid.  
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Scheme 3.6. Predominant reaction resulting in the failed synthesis of 2,1-BITZ compounds. 
After examination of the procedure we followed we could only conclude that the HCl added 
was not catalytic, and that the authors had stated 1000 fold fewer equivalents than actually used.44 
This conclusion was supported by the fact that the problem was overcome using ~1.5 eq of HCl with 
respect to Li2S. After altering the conditions, using 37 as the starting material, the synthesis of 39 was 
successful and has been repeated giving consistent yields of ~67 %. 
With appropriate amounts of this intermediate available we were able to undertake SAR on 
this template, synthesising targets that were analogous to those already developed by other group 
members for the isomeric 1,2-BITZ series. CH2 linked aromatic side chains (41 – 44) were first chosen 
for the synthesis due to their apparent ease of synthesis (Figure 3.13).43  
 
Figure 3.13. Generic structure of CH2 linked aromatic 2,1-BITZ compounds 41 - 44. 
We used molecular modelling studies to guide our SAR in the early stages of compound 
development; examination of the docking pose of 41 within the homology model of PfIspD developed 
by our group suggested that CH2 linked pyridyl substituents could coordinate to the crucial Mg2+ ion 
in the active site which may improve activity (Figure 3.14). From the modelling data it appeared that 
any of ortho (42), meta (43), or para (44) CH2 linked pyridyls had a chance of extra coordination and 
so were synthesised along with the benzyl substituent 41. Docking was carried out by Dr Alexandre 
Lawrenson.45   
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Figure 3.14. Docking pose of covalently bound 23 with cysteine residue in active site, of homology model of PfIspD. 
Image generated in PyMol46 by Dr Alexandre Lawrenson.45 Atoms are coloured by element, carbon in light blue, oxygen 
in red, nitrogen in blue, hydrogen in white, Mg2+ shown as green sphere. Protein backbone rendered as cartoon. 
The reaction generating 41 was not carried out under reflux as described by Scheme 3.4, 
instead 39 was allowed to react overnight at room temperature yielding 41 in near quantitative yields. 
Problems were encountered when synthesising CH2 linked pyridyl analogues; it was found that under 
reflux conditions decomposition was observed by TLC for all three isomers, though to a lesser extent 
for the meta isomer (43), which gave enough product for analysis and testing. These reactions were 
repeated at room temperature and were complete within one to two hours, giving excellent yields of 
83 % for ortho (42) and 87 % for para (44) substituents (Table 3.4). It is worth noting that TLC had to 
be used monitor the reaction frequently, as unknown reaction products began to form over time after 
the reaction was completed. 
 




The SAR was further explored utilising a benzoyl moiety to potentially pick up an extra 
hydrogen bond in the active site. Generation of compound 45 was accomplished by allowing the 
reaction of  39 with benzoyl chloride to yield 45 in 63 % yield (Scheme 3.7). Furthermore, an analogous 
1,2 BITZ compound 47 was also synthesised for a comparative study as it was not yet synthesised by 
the group. Following the same procedure as 45, 1,2-benzoisothiazolone (46) was reacted with benzoyl 
chloride to form 47 in low yield of 24 % due to suspected double addition of benzoyl chloride.  
Compound R Yield % 
41 Bn 94 
42 CH2-2-pyridyl 83 
43 CH2-3-pyridyl 29 
44 CH2-4-pyridyl 87 
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Scheme 3.7. Synthesis of 27 and 28. 
Interestingly there was an anomaly regarding 45 in its mass spectrum. An [M+H]+ peak for the 
product in either ES or CI conditions is not observed, however, 2 peaks are observed one 
corresponding to [M+Na]+, and the other with a 0.1 increase in mass that seems to correspond to [M-
S+(MeOH+Na+)]+. The reason for this unusual fragment pattern even under ES conditions could be an 
insight into the liability of the N-S bond in the 2,1 BITZ structure, furthermore, this same pattern is not 
seen in the 1,2 isomer. Therefore it could be reasonably predicted that 45 could potentially show 
activity higher than that of 47 if its N-S bond is weaker. It cannot be ruled out that 45 is unstable in 
aqueous buffer, as it contains a withdrawn thioester bond that may be susceptible to hydrolysis. 
Therefore, as part of future work, stirring the compound in buffer solution to assess its stability will 
need to carried out to determine if the activity is true or is the result of a possible decomposition 
product in the bioassay conditions. 
In addition to the benzyl linked 2,1-BITZ series, a phenyl linked series was also investigated. 
There is very little in the literature as to how to install on aromatic side chain on this template, 
however, one method is to start the reaction with N-functionalisation already attached to isatoic 
anhydride.42 N-phenyl-isatoic anhydride 49 was synthesised in 75 % yield from the reaction between 
N-phenylanthranilic acid (48) and diphosgene (Scheme 3.8). 49 was then reacted analogously to 
compound 37 to yield compound 50 in low isolated yield of 26 %. It should be noted that there was a 
side product very close to the product on TLC that was difficult to separate, which was a contributing 
factor to the low yield. This product was not able to be isolated but it is reasonable to assume this 
could be a disulfide, as a similar reaction using H2S gas and sodium hydroxide as the reagents has been 
attempted in the literature once, and the group yielded exclusive disulfide formation, something not 
observed using our modified procedure.42 In order to confirm whether the isolated product was 
correct and not a disulfide, we carried out IR analysis on the product. IR gives us a clear determination 
Chapter 3: Development of Alternate Inhibitors of PfIspD 
 200 
on whether cyclisation had occurred, as an N-H peak would be observed if it had not, crucially no N-H 
peak was observed for 50 confirming its structure to be correct.  
 
Scheme 3.8. Synthesis of 49 and 50. 
Because of the difficulties in the synthesis and purification of 2,1 BITZ compounds directly 
bound to aromatic rings this compound series was abandoned as it became apparent we could not 
easily generate an array of compounds mimicking compounds from the 1,2 series. 
3.4.2 Biological Activity of 2,1-BITZ Compounds 
All synthesised 2,1-BITZ compounds were tested in vitro for their inhibitory activity against 
PfIspD and were also tested against Pf3D7 cells as displayed in Table 3.5. As a direct comparison 
compounds from the 1,2-BITZ chemotype are also displayed in the table.  
 
Table 3.5. Biological data comparison of 2,1 and 1,2-BITZ compounds. Compound properties are ranked using a traffic 
light system. Green = good, amber = acceptable, red = poor. 
Compound Chemotype R PfIspD IC
50
 (nM)  Pf3D7 EC
50
 (nM)  CLogP 
39 2,1-BITZ H >100,000 n = 1 41,000 n = 1 1.69 
41 2,1-BITZ Bn >25,000 n = 2 28,000 n = 1 4.03 
42 2,1-BITZ CH2-2-pyridyl >50,000 n = 1 >50,000 n = 1 2.53 
43 2,1-BITZ CH2-3-pyridyl >100,000 n = 1 >50,000 n = 1 2.53 
44 2,1-BITZ CH2-4-pyridyl >100,000 n = 1 >50,000 n = 1 2.53 
45 2,1-BITZ Bz 303 n = 1 >50,000 n = 1 4.31 
50 2,1-BITZ ph 4140 ± 441 n = 2 23,600 n = 1 4.01 
9 1,2-BITZ Ph 600 n = 1 5490 n = 1 3.35 
47 1,2-BITZ Bz 4346 n = 1 >100,000 n = 1 3.39 
51* 1,2-BITZ Bn 2430 n = 1 46,450 n = 1 2.90 
52* 1,2-BITZ CH2-2-pyridyl 1900 n = 1 >25,000 n = 1 1.41 
* Compounds synthesised by Dr Natalie Roberts 
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 A clear trend across the series as a whole is that the 2,1-BITZ chemotype holds no advantages 
over its 1,2-BITZ counterpart. In 39 the compound holds no functionality on the nitrogen atom and 
thus, its inactivity can be attributed to a potential loss of crucial binding interactions in the IspD active 
site. Interestingly the compound is more active in the whole cell assay than against the enzyme, which 
suggests this compound may show off target effects. 41 is also inactive, this was disappointing 
considering that its 1,2-BITZ counterpart 51 through only weakly active, did show IspD activity. Much 
to our surprise all the pyridyl analogues 42 – 44 showed poor potency in both enzyme and cell assays, 
this was unexpected considering a close analogue from the 1,2-BITZ series 52 displayed moderate 
activity against PfIspD. Perhaps most disappointingly from the series was compound 50, which though 
weakly active against PfIspD was 7 fold less active than its regioisomer 9, and was over 4-fold less 
active against Pf3D7 whole cells. These results suggest that the 2,1 series is not optimal for further 
SAR development using the same strategies as employed for the 1,2 series.  
 Despite these negative results from the 2,1-BITZ series, there was one compound in the series 
45 of comparable potency to other 1,2-BITZ analogues. 45 displayed excellent potency giving an IC50 
value of 303 nM against PfIspD. 45 was also 2-fold more potent than 9. It appears that for the 2,1-BITZ 
series there is a specific requirement within the active site of the enzyme for an amide bond directly 
linked to the BITZ core for this series to show activity. It is reasonable to assume that this could be due 
to conformational locking and / or the potential for the carbonyl oxygen to pick up a hydrogen bond. 
Interestingly compound 47 the regioisomer of 45, displayed weak potency vs PfIspD. 
 As this result was curious, we were interested in docking compounds 45 and 47 into the 
homology model following the protocol outlined in Chapter 2 to examine if there is a major difference 
in their binding modes. Displayed below are the two poses for 45 and 47, for 45 there were numerous 
potential poses, with a standard deviation (SD) in docking scores of 2.1 and an average score of 43.1, 
thus we chose a pose close to this average with a score of 42.7  (Figure 3.15 and Table 3.6). For 47 
there was very little difference between the most of the poses observed, only two poses did not match 
the others and one of these possessed a significantly lower score that will have affected the SD and 
mean (2.24, 45.48, respectively). Therefore the pose selected was the one with the best docking score 
of 47.32 (Figure 3.16 and Table 3.7).  
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Figure 3.15. Binding pose of 45. Binding site is rendered as a white surface, 45 is rendered as sticks, carbon coloured 
yellow, nitrogen in blue, oxygen in red, sulfur in dark yellow. Crucial amino acids are rendered as sticks carbon coloured 
grey, nitrogen in blue, oxygen in red, sulfur in yellow. 
Table 3.6. Main ligand – protein interactions of 45. 
Residue(s) Moiety Interaction Distance Å 
Cys-202, Gly-204 B-ring-S Electrostatic 1,7 
Gln-216 B-ring-C=O H-bond 3.4 
Gly-204 B-ring-N Electrostatic 2.6 
 
 
Figure 3.16. Binding pose of 47. Binding site is rendered as a white surface, Mg2+ is depicted as a green cross, 47 is 
rendered as sticks, carbon coloured yellow, nitrogen in blue, oxygen in red, sulfur in dark yellow. Crucial amino acids are 
rendered as sticks carbon coloured grey, nitrogen in blue, oxygen in red, sulfur in yellow. 
Table 3.7. Main ligand – protein interactions of 47. 
Residue(s) Moiety Interaction Distance Å 
Gly-204 B-ring-S Electrostatic 2.4 
Gly-204 B-ring-N Weak electrostatic 3.5 
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In terms of the available interactions of the two molecules, it appears as though compound 
45 has more potential interactions that it can make with the enzyme active site compared with 47, 
forming a potential hydrogen bond with Gln-296 and two close electrostatic interactions with Gly-204. 
In addition it is in close proximity to the crucial cysteine thiol at 5.9 Å which as described in Section 
3.3 is thought to form a covalent adduct with the BITZ inhibitors. The sulfur atom is very close to the 
nitrogen atom of Gly-204 potentially favourable interaction. 47, on the other hand does not form 
similar hydrogen bonds and therefore may potentially lose some potency because of this, however, it 
is also further away from the cysteine thiol at 5.9 Å. Therefore it could be rationalised that this 
molecule shows weaker activity than 45 as it is less likely to interact with the cysteine residue. The 
binding poses of the two molecules are similar where both the A and B-rings are bound within a small 
cavity close to the cysteine residue whilst the benzoyl portion points out into solvent exposed space. 
Based on the weak activity seen for the series, the overall comparative high lipophilicity and 
challenging restrictive chemistry, we made the decision to terminate studies on the 2,1-BITZ 
chemotype. 
3.4.3 Conclusion of 2,1-BITZ Compounds 
 
Figure 3.17. Conclusion of 2,1 BITZ SAR. 
 Of all tested compounds from the 2,1-BITZ series only 45 showed very good activity against 
PfIspD. There seems to be a strict spatial and / or electronical requirement in the active site for the 
series, as CH2 linked compounds are not tolerated and show little to no activity against the enzyme 
and cell. Compound 50 possessed weak activity vs the enzyme but was much less potent than its 
regioisomer 9 suggesting there is an unfavourable interaction with the phenyl ring. The observation 
that 45 is active suggests that the IspD binding pocket is very tight, as there is an unexpectedly large 
gain of potency on alternating from benzyl derivatives to benzoyl. The conformational locking 
properties that an amide bond gives could give rise to a favourable binding pose; in addition the 
potential gain of a hydrogen bonding interaction could contribute to this large gain in potency of this 
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compound. All compounds, however, are poorly active against cell and are at a disadvantage vs the 
1,2 BITZ chemotype as their CLogP is higher than the analogous regioisomers (Figure 3.17). As 45 is 
more potent than its regioisomer 47, this series of compounds could be worth revisiting in the future 
adding solubilising groups to the phenyl ring in an attempt to reduce CLogP. Prior to examining further 
benzoyl derivatives, stability assessment in aqueous buffer must first be carried out in order to 
determine if activity is genuine or is the result of a decomposition product resulting from potential 
hydrolysis of the thioester bond.  
3.4.4 Returning to SAR on 1,2-BITZ Compounds 
 We decided to return to further explore the 1,2-BITZ chemotype; most of the compounds 
generated within the group had focused on installing aromatic or CH2-linked aromatic side arms (C-
ring onwards) to the BITZ core. With the exception of the biphenyl series of compounds previously 
mentioned, all compounds failed to show desirable Pf3D7 activity even if they showed excellent PfIspD 
activity. We postulated that there was a requirement of specific reactivity of the N-S bond that needed 
to be met in order to for a compound to show cell activity. In addition to the biphenyl series, we also 
needed to reduce the CLogP of the active compounds as a whole. As a result the aim for the new 1,2-
BITZ SAR is described in Figure 3.18.   
 
Figure 3.18. Aim for new 1,2 BITZ SAR. 
3.4.5 Synthesis of 1,2-BITZ Compounds 
 In order to address these two problems we decided to move away from planar aromatic 
compounds with either a direct link or one carbon link to the nitrogen atom of the BITZ core. We 
began our SAR studies by installing a urea like moiety to the molecule in order to modulate the 
characteristics of the N-S bond, and to add a hydrogen bond donor accepter pair to molecule to 
potentially increase binding energy within the IspD active site. This moiety was introduced into the 
molecule following the reported procedure by Liu et al.47 (Scheme 3.9). 
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Scheme 3.9. Installation of urea moiety into the 1,2-BITZ chemotype. 
The synthetic route was a one step process taking commercially available 1,2 
benzoisothiazolone (46) and reacting with the relevant isocyanate to yield the target compounds in 
one-step in excellent yields. In order to create a comparative study from similar molecules other group 
members previously had synthesised in the mono-phenyl series, our R groups were chosen to be 
phenyl (53), 4-chloro-phenyl (54), and benzyl (55). The synthesis was carried out according to Scheme 
3.9 and the reaction yields are summarised in Table 3.8 below. 
 
Table 3.8 Yields of urea linked 1,2 BITZ compounds 

















The targets were successfully obtained with full data and good purity by elemental analysis, 
but suffered a drawback of poor solubility in all common solvents. 1H NMR could be successfully 
achieved in CDCl3 as the solvent, however, in order to get a 13C NMR we required the use d6 DMSO. 
Upon re-examining the 1H NMR spectra in DMSO new peaks emerged in the spectra and the relative 
proportions of these peaks changed over time (within one hour). The identity of the structure 
corresponding to these peaks was unknown. It may be possible that the molecules are reactive and 
decompose readily in solvents with any possible nucleophilic centre, as the same effect was observed 
when the solvent was altered to methanol. This was only observed for 53 and 54 but not 55. 
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 The issues in solubility and apparent instability in DMSO, led us to pursue other final targets. 
In sticking with a non-aromatic linked compounds; compounds 61 – 66, were synthesised again to 
modulate the N-S bond strength and to interrogate the available sterics in the active site of the 
enzyme. 
 Compounds 61 and 63 (Scheme 3.10 and 3.11), were already discovered from the HTS carried 
out by Biofocus described in Section 3.1.48 Both compounds were shown to be active possessing 
PfIspD activities of 165 nM and 356 nM, respectively. In addition, in collaboration with Astra-Zeneca 
(AZ) LogD values of 61 and 63 were calculated based on prediction software provided by AZ.12,13 Both 
compounds displayed ClogD7.4 values of 3.55 and 2.99, respectively. These values are in an acceptable 
to desirable range. This ideally means that for these compounds aqueous solubility and metabolic 
stability data are more likely to also be in a desirable range. As previously mentioned in Chapter 2 a 
compound possessing an optimal DMPK profile is less likely to fail in the clinic, therefore these two 
molecules provided a good starting point for further SAR. 
 In order to reconfirm activity compounds 61 and 63 were synthesised via two differing routes 
as described below in Scheme 3.10 and Scheme 3.11. The synthesis of 61 began through coupling N-
Boc-Glycine (56) via standard peptide coupling procedures with 2-adamantylamine to give 57a in 62 
% yield. The Boc group was then deprotected in the presence of TFA in DCM giving 58a in 79 % yield, 
58a can then be coupled into intermediate 14, resulting in the formation of 61 in 84 % yield. We were 
interested in investigating the effect of changing the substituent position of the adamantyl ring on 
biological activity, thus compound 62 was synthesised analogously to 61. N-Boc-Glycine (56) was 
coupled with 1-adamantylamine to yield 57b in 76 % yield. 57b was then deprotected in the presence 
of TFA in DCM to form 58b in 74 % yield before final coupling into intermediate 14 to form 62 in 80 % 
yield.  To examine an alternate synthesis, the route towards 63 began through coupling 2,4-dimethyl 
aniline with bromoacetyl bromide (59) giving 60 in 70 % yield. 1,2-benzoisothiazolinone (46) was then 
deprotonated in the presence of NaH and then coupled to 60 to yield 63 in a low yield of 15 %.49  
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Scheme 3.10 Synthesis of 61 and 62 
 
Scheme 3.11. Synthesis of 63.  
In an analogous study we also examined if both 2-adamantyl and 1-adamantyl rings could be 
tolerated directly bound to the BITZ core, in addition to this we also wanted to examine what effect 
using a smaller ring system such as cyclohexyl has on activity. In the group no SAR had been 
undertaken on aliphatic C-rings attached directly to the BITZ core and so if this compound showed 
good activity, it could allow another avenue of SAR to begin. Compounds 64 – 66 were synthesised 
from direct coupling of 2-adamantylamine, 1-adamantylamine, and cyclohexylamine into 
intermediate 14 (Scheme 3.12) in 41 %, 80 % and 74 % yield, respectively. 
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Scheme 3.12. Synthesis of 64 - 66. 
 
3.4.6 Biological Activity of 1,2-BITZ Compounds 
 
Table 3.9. Biological data of 55 and 61 – 66. Compound properties are ranked using a traffic light system. Green = good, 
amber = acceptable, red = poor. 
Compound PfIspD IC
50
 (nM)  Pf3D7 EC
50
 (nM)  CLogP 
55 6170 ± 32 n = 2 26,400 n = 1 3.54 
61 ~20,000 n = 1 Not tested 4.92 
62 >10,000 n = 1 Not tested 3.52 
63 No inhibition n = 1 Not tested 2.80 
64 No inhibition n = 1 Not tested 5.18 
65 >10,000 n = 1 Not tested 4.14 
66 No inhibition n = 1 Not tested 3.52 
 
All compounds were screened for at least PfIspD activity (Table 3.9).  A trend across all 
compounds is that they are poorly potent or show no inhibitory activity against the enzyme. 55 
displayed the highest potency of all the compounds but was only weakly potent against both enzyme 
and cell. Disappointingly the activity of 61 and 63 was not reconfirmed from the HTS carried out by 
Biofocus indicating that these two compounds from the screen were unfortunately false positives. 62 
also showed poor activity against the enzyme. 
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 From the analogous study, compounds 64 – 66 also displayed poor to no activity against the 
enzyme. In the case of 64 and 65, the inactivity could be attributed to sterics, as the adamantyl group 
is very large and may not fit into the active site. Alternatively the adamantyl group may be acting as a 
protecting group for the N-S bond. Due to the size of the adamantyl moiety, the crucial cysteine 
residue responsible for activity may not be able bypass this bulky group to attack the sulfur atom of 
the BITZ core. This would therefore, prevent disulfide formation. 
 Most surprisingly from the study was the result obtained from 66. Comparing the cyclohexane 
ring to the phenyl ring in 9, the steric effects are not significantly different between the two molecules. 
This suggests three possibilities; firstly a tight bonding pocket were the phenyl ring of 9 resides; 
secondly a specific requirement for a planar aromatic ring at this position; or thirdly a specific 
electronical requirement for a phenyl ring, or an electron withdrawing moiety to be present either 
directly linked, or close to the nitrogen atom harbouring the N-S bond. This would likely be required 
in order to sufficiently weaken this bond so that it may be cleaved via nucleophilic attack of the 
cysteine thiol. As a final remark, due to the disappointing activities of all compounds against PfIspD, 
compounds 61 – 66, were not tested against Pf3D7 whole cells. 
 To try to rationalise these results we examined the binding poses of three of the molecules 
61, 65, and 66 again following the protocol described in Chapter 2, in each case the pose with best 
fitness score was chosen for display. Poses and interactions are shown in Figures 3.19 – 3.21 and 
Tables 3.10 – 3.12.  
61 Docking score = 54.2, mean = 52.0, SD = 2.1 
 
Figure 3.19. Binding pose of 61. Binding site is rendered as a white surface, Mg2+ is depicted as a green cross, 61 is 
rendered as sticks, carbon coloured yellow, nitrogen in blue, oxygen in red, sulfur in dark yellow. Crucial amino acids are 
rendered as sticks carbon coloured grey, nitrogen in blue, oxygen in red, sulfur in yellow. 
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Table 3.10. Main ligand – protein interactions of 61. 
Residue(s) Moiety Interaction Distance Å 
Cys-202, Gly-204 CH2C=O Weak electrostatic, H-bond 3.5, 2.8 
Gly-204 B-ring-C=O H-bond 3.5 
 
65 Docking score = 47.2, mean = 46.3, SD = 0.8 
 
Figure 3.20. Binding pose of 65. Binding site is rendered as a white surface, Mg2+ is depicted as a green cross, 65 is 
rendered as sticks, , carbon coloured yellow, nitrogen in blue, oxygen in red, sulfur in dark yellow. Crucial amino acids 
are rendered as sticks carbon coloured grey, nitrogen in blue, oxygen in red, sulfur in yellow. 
Table 3.11. Main ligand – protein interactions of 65. 
Residue(s) Moiety Interaction Distance Å 
Cys-202 B-ring-C=O Electrostatic  3.2 
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66 Docking score = 44.3, mean = 44.1, SD = 0.1 
 
Figure 3.21. Binding pose of 66. Binding site is rendered as a white surface, Mg2+ is depicted as a green cross, 66 is 
rendered as sticks, , carbon coloured yellow, nitrogen in blue, oxygen in red, sulfur in dark yellow. Crucial amino acids 
are rendered as sticks carbon coloured grey, nitrogen in blue, oxygen in red, sulfur in yellow. 
Table 3.12. Main ligand – protein interactions of 66. 
Residue(s) Moiety Interaction Distance Å 
Cys-202 B-ring-C=O H-Bond 3.0 
Mg2+ B-ring-S Very weak electrostatic 3.8 
  
The docking runs of compounds 61, 65, and 66 show that the A and B-rings of these structures 
do not reside in the same pocket as the previously docked compounds 45 and 47. Instead the bulky 
adamantyl rings in both 61 and 65 and the cyclohexyl ring in 66 are predicted to bind in the pocket 
where the A and B-rings of 45 and 47 lie, most likely forming Van der Waals interactions with the 
nearby Leu-201 residue. In this pose the carbonyl groups form hydrogen bonds with nearby Cys-202 
and Gly-204 residues. In 61 and 65 the B-ring nitrogen atom can also weakly interact with with Gly-
204 at 3.7 Å. Finally in 65 and 66 the sulfur atom can potentially electrostatically coordinate weakly to 
the Mg2+ ion at 3.8 to 3.9 Å.  In all cases from the modelling studies, there is a clear trend that the 
sulfur atom is now bound between 8.8 and 9.9 Å. This is out of proximity of the cysteine residue 
responsible for the ring opening of the BITZ compounds. Therefore, it can be rationalised that the lack 
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3.4.7 Conclusion of 1,2-BITZ Compounds 
 
Figure 3.22. Conclusion of D-ring SAR. 
 Re-examination of the 1,2-BITZ chemotype was largely disappointing (Figure 3.22). 
Unfortunately no compound showed significant inhibition of the PfIspD enzyme, and because of this 
lack of potency, most compounds were not tested for the whole cell growth inhibitory activity. 
 From the HTS screen carried out by Biofocus two compounds came out as active against the 
IspD enzyme compounds 61 and 63. To reconfirm activity both compounds were resynthesised, re-
examination of their activity showed them to be inactive, suggesting that these two hits from the 
screen were unfortunately false positives. As could be expected, structurally related 62 was also 
inactive. We also carried out an analogous study, synthesising compounds 64 – 66 that possessed 2-
adamantyl, 1-adamantyl, and cyclohexyl groups bound to the nitrogen atom of the BITZ core, 
respectively. Unfortunately all of these compounds were also inactive, which was surprising 
particularly in the case of 66. It apears that there is a specific requirement for either sterics and / or 
electronics of this chemotype, as comparing 66 to 9 it is unexpected to see such a loss of potency 
based on sterics alone from alternating from a phenyl ring to a cyclohexyl ring.   
3.5 B-ring Modification, Compounds Representing Organoselenium Drug Ebselen 
 It is clear from examination of the literature that the use of organoselenium compounds for 
use in the pharmaceutical industry has in the past been severely disfavoured by the apparent lack of 
available drugs containing a selenium moiety there are in the literature. This is understandable, as 
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selenium has long been considered toxic, even if it is an essential element for the body.50 
Unfortunately the required therapeutic doses of most drugs would far exceed the expected safe level 
of selenium intake, therefore, are postulated to be toxic, preventing their development.50 However, 
as is now known, the key for a successful non-toxic organoselenium compound is to stop the selenium 
atom becoming bioavailable, a good way to do this is to lock the element within a heterocycle.50–55 
 More recently there is evidence in the literature where selenium has replaced its counterpart 
sulfur to yield improved biological activity and in some cases a better toxicity profile. Wiles et al. were 
successful in the development of a piperidinyl quinolone with fused selenophene moiety which 
displayed improved activity against its target DNA gyrase, improved activity against a panel of clinical 
MRSA isolates, and importantly a reduced hERG channel inhibition than its thiophene counterpart.51  
 Since the reactivity of Ebselen (67) with cysteine thiols has been widely documented, we 
reasoned that a seleno series of analogues might express activity vs PfIspD.52,55,56 The organoselenium 
drug ebselen (67) (rat oral LD50 ≥ 6810 mgkg-1), is the seleno-version of our BITZ compound 9 (Ebsulfur) 
(Figure 3.23).51,57 
 
Figure 3.23. Structure of Ebselen (67) vs 9. 
 Ebselen (67) was designed for the treatment of ischaemic stroke via the inhibition of lipid 
peroxidation, however, it was halted in the final stage of clinic trials due to poor efficacy.58 Since its 
abandonment the drug was rescued after it was discovered that the trial data showed it was clinically 
safe. It is now being tested for a new treatment of bipolar disorder, hearing loss, as an anticancer 
drug, as an antiviral, and as an antibiotic.56,59–64 With this in mind we decided to examine modification 
of the B-ring of the biaryl BITZ series of compounds, via replacement of sulfur with selenium.  
3.5.1 Synthesis of Ebselen Derived Compounds 
5 compounds were successfully synthesised, namely 77 – 81, and these were compared with 
their sulfur analogues compounds 20, 21, 25 – 27. In addition one compound, 82 from the mono-
phenyl series was also synthesised and compared with its sulfur analogue 83 (compound synthesised 
by Dr Kathryn Price). 
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All the requisite side chains required syntheses, and this was successfully carried out according 
to Scheme 3.13 below. First, the desired amines were coupled into (4-(bromomethyl) phenyl) boronic 
acid (68) to produce 69a – 69c in varying yields (see Table 3.13).65 These boronic acids were then 
coupled with 3-bromoanline (70) using Suzuki chemistry to form 71a – e .2,66  
 
Scheme 3.13 Synthesis of 71a – e.   
 In order to synthesise the side chain of the mono-phenyl compound, first morpholine was 
coupled into 1-(bromomethyl)-3-nitrobenzene forming 73 in 99 % yield.65 We attempted a Pd / C 
hydrogenation reaction to reduce the nitro group to the amine 74, however, when we did this, what 
we isolated was morpholine and m-toluidine by C-N bond cleavage.67 To circumvent this problem, we 
instead synthesised 74 through a Fe / AcOH single electron transfer reduction in 96 % yield (Scheme 
3.14).68  
 
Scheme 3.14. Synthesis of 74. 
We then investigated how best to carry out the ring closing reactions. We first examined the 
possibility of preparing 77 – 82 through analogous procedures to Scheme 3.3, through a Se-Cl / acid 
chloride mediated ring closure. However, the desired starting material 2,2'-diselanediyldibenzoic acid, 
was not commercially available. We investigated methods to synthesise this starting material, 
however, it required the use of Na2Se2, which also was not commercially available. There are 
procedures reported for the synthesis of Na2Se2, however, some of them reported H2Se gas release as 
a side product. H2Se gas is highly poisonous and we deemed it too dangerous to attempt the synthesis 
of Na2Se2 even via the procedures not reporting H2Se in the absence of a glovebox.69–72 Therefore, all 
compounds were synthesised according to the ring closure analogous to Scheme 3.2. Intermediates 
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76a – f were first synthesised using peptide coupling procedures, reacting 2-iodobenzoic acid (75) in 
the presence of oxalyl chloride followed by amines 71a – e and 74. Ring closure to compounds 77 – 
82 was then accomplished via the replacement of elemental sulfur for elemental selenium as depicted 
below (Scheme 3.15).56,73,74 
 
Scheme 3.15. Synthesis of 77 – 82. 
 
Table 3.13. Summary of yields obtained synthesising mono-phenyl and biphenyl targets. 
Final 
Compound 
R (In final compound) % yield 
69a – c 
% yield  
71a – e 
% yield  
76a – f 
% yield 77 
– 82 
77 CF3 - 75 25 7 
78 OCF3 - 82 35 20 
79 CH2-morpholine 87 90 58 18 
80 CH2-(4F)-piperidine 95 50 53 11 
81 CH2-(NMe)piperazine 46 94 74 7 
82 - - - 78 15 
 
The yields of steps en route to final compounds are reported in Table 3.13. As can be seen the 
amine couplings gave good yields with the exception of 69c which was difficult to isolate and extract 
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due to the high polarity of the compound, and its tendency to stay in an aqueous phase. Nevertheless, 
the low yield of 46 % was acceptable to carry on the synthesis. In general, the synthesis of 
intermediates 71a – e proceeded very well following Suzuki coupling procedures, generally giving high 
yields. The synthesis of 76a – f via amide coupling procedures gave a high degree of variation with 
yields. Interestingly the final ring closing step to compounds 77 – 82 consistently produced low yields; 
this is in contradiction to the literature method which is reported to give high yields.73 It should be 
noted, however, that the substrates used here are larger and more complex than those reported in 
the literature, and perhaps this could justify these results. In some cases we varied the loading of CuI, 
however, this had little impact on yields obtained.       
3.5.2 Biological Data of Ebselen Derived Compounds 
 All compounds were screened for PfIspD and Pf3D7 activity and are summarised in Table 3.14 
below. For direct comparison, data for the sulfur analogues are also displayed.   
 
Table 3.14. Biological data comparison of Ebselen mimetics and 1,2-BITZ compounds. Compound properties are ranked 
using a traffic light system. Green = good, amber = acceptable, red = poor. 1,2 BITZ compounds were synthesised by 
former PhD student Dr Kathryn Price. 
Compound R X PfIspD IC
50
 (nM)  Pf3D7 EC
50
 (nM)  CLogP 
20 CF3 S 273 ± 15 n = 3 646 ± 21 n = 6 6.12 
21 OCF3 S 290 ± 195 n = 3 411 n = 1 6.27 
25 CH2-morpholine S 400 ± 82 n = 3 413 ± 82 n = 4 4.99 
26 CH2-(4F)-piperidine S 862 ± 107 n = 3 323 ± 92 n = 5 5.96 
27 CH2-(NMe)piperazine S 446 ± 75 n = 3 416 ± 6 n = 3 5.55 
77 CF3 Se 11900 3010 6.48 
78 OCF3 Se >50000 3250 ± 1340 6.62 
79 CH2-morpholine Se 132 3040 5.34 
80 CH2-(4F)-piperidine Se 160 2834 ± 373 6.31 
81 CH2-(NMe)piperazine Se 133 5250 5.9 
82 - Se 281 ± 4  14900 3.45 
83* - S 540 n = 1 5710 n = 1 3.10 
* Compound synthesised by Dr Kathryn Price 
    The results from the testing data are very interesting, replacing the sulfur atom to selenium 
in 20 and 21, forming 77 and 78, led to a large loss of potency against the enzyme and a loss of potency 
against 3D7 whole cells. It is interesting to note that the potency in the cellular assay is greater than 
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that for the IspD assay; this suggests that these two compounds demonstrate off target effects, and 
this can be confirmed in the future through an IPP rescue screen. Comparing 20 and 21 to 77 and 78, 
it is unexpected to see such a drop in potency, we postulate this could be due to the increased 
lipophilicity, poorer aqueous solubility and greater reactivity for these matched pairs.  
 When solubilising groups were incorporated into the structure, as can be seen in compounds 
79 – 81, PfIspD activity was regained and demonstrated excellent activity. Comparing these 
compounds to the sulfur analogues 25 – 27, all variants displayed improved potency. However, the 
drawback of the series again was the loss of potency observed in the cellular assay; unfortunately 
these compounds are either too reactive and ring open before reaching the apicoplast, or 
alternatively, are not able to penetrate the apicoplast. One thing to note is that if transportation into 
the apicoplast is the issue, it is not related to CLogP entirely. When comparing the CLogP of 79 to 26, 
79 possesses a lower CLogP than 26, however, 26 is still potent in the whole cell assay. Therefore, this 
could be an indication that electronics and reactivity play a crucial role in determining whole cell 
activity. 
 We also investigated one compound possessing a mono-phenyl ring with a morpholine group 
amended meta to the ring by a methyl linker 82. Similar to above, 82 displayed improved potency 
against the enzyme, however, the compound again lost activity in the cellular assay in comparison to 
sulfur analogue 83. Furthermore, 82 was the least potent compound against Pf3D7 cells in the 
selenium analogue series. It should be noted that this loss of potency here was in part expected, as 83 
was also weakly potent in the cell assay. This compound backed up our hypothesis that compounds 
possessing a biphenyl moiety are required for cell activity.  
 As part of other work within the group, former PhD student Dr Natalie Roberts also 
synthesised ebselen related compounds based on other areas of SAR around the BITZ chemotype. As 
part of this study ebselen (67) itself was also synthesised and displayed poorer enzyme and whole cell 
activity than 9. Other than 67, in general, the findings from this analogous study elucidated that 
selenium analogues display improved enzyme activity when comparing to the analogous BITZ 
compounds with variable effects on whole cell activity. 
 We investigated the docking poses of compounds 77 and 79, respectively into the active site 
of our IspD homology model to shed some light on why 77 demonstrated poor activity whilst 79 
demonstrated good enzymatic potency. Again the protocol in Chapter 2 was followed once more. For 
compound 77, most poses were in similar orientation and the SD of the data was low, giving mean 
and SD values of 53.4 and 0.8, respectively, thus we selected the best binding score (53.9) for the pose 
of this compound (Figure 3.24, Table 3.15). 79, however, had many varying poses giving mean and SD 
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values of 52.6 and 2.7, respectively. One pose, though being the second lowest fitness score (51.4), 
was in close proximity to the crucial Cys-202 residue, and this was selected for display (Figure 3.25, 
Table 3.16). Finally for completeness a covalently bound docking pose was generated for 79 showing 
how the pose may look once the Cys-202 residue has been chemically modified. The covalent docking 
was carried out in GOLD though linking the C-α carbon of Cys-202 to 79 (Figure 3.26, Table 3.17). 
 
Figure 3.24. Binding pose of 77. Binding site is rendered as a white surface, Mg2+ is depicted as a green cross, 77 is 
rendered as sticks, carbon coloured yellow, fluorine in sky blue, nitrogen in blue, oxygen in red, selenium in orange. 
Crucial amino acids are rendered as sticks carbon coloured grey, nitrogen in blue, oxygen in red, sulfur in yellow. 
Table 3.15. Main ligand – protein interactions of 77. 
Residue(s) Moiety Interaction Distance Å 
Asp 294 B-ring-Se Electrostatic 3.2 
Mg2+ B-ring-C=O Weak electrostatic 3.5 
 
 
Figure 3.25. Binding pose of 79. Binding site is rendered as a white surface, Mg2+ is depicted as a green cross, 79 is 
rendered as sticks, carbon coloured yellow, fluorine in sky blue, nitrogen in blue, oxygen in red, selenium in orange. 
Crucial amino acids are rendered as sticks carbon coloured grey, nitrogen in blue, oxygen in red, sulfur in yellow. 
Table 3.16. Main ligand – protein interactions of 79. 
Residue(s) Moiety Interaction Distance Å 
Cys-202, Gly-204   B-ring-Se Weak electrostatic 3.6, 3.6 
Mg2+ B-ring-C=O Electrostatic 3.2 
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Examination of the pose of 77 reveals that the A and B-rings are buried within the same 
binding pocket that the same ring system of MMV008138 is bound within. This allows for one strong 
and two weak potential electrostatic interactions of the selenium atom with neighboring Leu-201 and 
Gly-204 residues whilst the carbonyl of the B-ring is able to coordinate the Mg2+ ion, the remaining 
biphenyl moiety is pointing into solvent exposed space picking up no notable further interactions. The 
Se atom is located quite far away from the cysteine thiol in this pose at 7.5 Å, which may account for 
the lack of activity observed with 77 as it is not in suitable proximity for covalent modification to occur.  
In contrast, 79 shows a pose closer the cysteine thiol at 6.2 Å. In this pose the Se atom can 
form weak electrostatic interactions with the Cys-202 and Gly-204 nitrogen atoms, which may bring 
the molecule within close proximity to the thiol of Cys-202 to allow for covalent modification. In 
addition the B-ring carbonyl can coordinate with the Mg2+ ion and Gly-204 suitably anchoring the 
molecule for covalent modification. Finally the morpholine ring may also pick up a weak electrostatic 
interaction with Lys-412 at 4.1 Å; such an interaction is not present in 77. Taken all together this pose 
could explain why the analogues possessing solubilising groups are able to demonstrate PfIspD 
potency. After covalent modification of Cys-202 occurs we were interested to examine what other 
interactions may be gained from the now bound inhibitor, displayed below is the docking pose of 79 
after covalent modification (Figure 3.26 and Table 3.17).         
 
Figure 3.26. Covalent binding pose of 79. Binding site is rendered as a white surface, Mg2+ is depicted as a green cross, 79 
is rendered as sticks, , carbon coloured yellow, fluorine in sky blue, nitrogen in blue, oxygen in red, selenium in orange. 
Crucial amino acids are rendered as sticks carbon coloured grey, nitrogen in blue, oxygen in red, sulfur in yellow. 
Table 3.17. Main ligand – protein interactions of ring opened 79. 
Residue(s) Moiety Interaction Distance Å 
Mg2+ Ex-B-ring N Electrostatic 3.5 
Mg2+ C-ring π-cation ~3.5 
 
 Interestingly after covalent docking 79 in PfIspD active site and choosing a suitable docking 
pose, the molecule picks up different interactions to that prior to covalent binding. The molecule has 
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altered orientation which allows for the Cys-202 and Gly-204 to weakly interact with the ring opened 
B-ring carbonyl, the Se is flanked by two Glycine residues which may also pick up weak electrostatic 
interactions. The ring opened nitrogen atom can coordinate the Mg2+ ion and may pick up a weak 
interaction with the neighboring Gly-204 residue. In addition the C-ring can also form a π-cation 
interaction with the Mg2+, however, the angle of the ring is skewed from the Mg2+ slightly. Finally, the 
morpholine ring can be anchored with Lys-207, now forming two weak interactions vs the one from 
Lys-412 in the previous pose. These poses potentially indicate that the mechanism of these 
compounds is first through non-covalent recognition, which then drives the covalent bond formation 
between protein and ligand.   
3.5.3 Conclusion of Ebselen Derived Compounds 
Altering the B-ring of the BITZ core via the substitution of the sulfur atom to selenium yielded 
interesting results. Of the biphenyl series, compounds 79 – 81 demonstrated potent activity against 
PfIspD giving IC50 values <200 nM. In these cases enzymatic potency was improved over the 
corresponding BITZ compounds. Interestingly all of these compounds harboured a solubilising 6-
membered amine ring liking to the aromatic D-ring through a methyl linker. If this ring was removed 
as in the case of compounds 77 and 78 activity against the enzyme is lost, this was surprising 
considering in this case the equivalent BITZ compounds retain activity. At this time the reason for loss 
of activity is unknown, we postulate that the lipophilicity of the compounds are too high and thus 
cannot pass inside the polar enzyme active site.  
 One mono-phenyl compound 82 was also made with the C-ring substituted at the meta-
position by a methyl linked morpholine ring. Similar to the biphenyl series this compound also showed 
improved PfIspD activity over the analogous BITZ compound 83. However, both chemotypes were 
poorly potent against Pf3D7 whole cells. 
 Similar to the mono-phenyl series the biphenyl series also demonstrated a loss of potency in 
the whole cell assay. The reasons for this unexpected loss of cellular potency are not clear, however, 
we can postulate two reasons for their inactivity; i) the ebselen series is too reactive, and thus ring 
open before entering the apicolplast resulting in an inactive compound; ii) the compounds are not 
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3.6 Future Work of all Investigated Series 
 2.1-BITZ Series 
For future work, as compound 45 was the only compound possessing enzymatic potency in 
the series, it could be worth examining other benzoyl derivatives in order to further explore chemical 
space, or to incorporate solubilising groups. However, it cannot be ruled out that 45 is unstable in 
aqueous buffer. Therefore assessment of the stability of 45 aqueous buffer will need to carried out to 
determine if the activity is true, or is the result of a possible decomposition product resulting from 
bioassay conditions. This will need to be undertaken before examining further benzoyl derivatives. 
Examples of future compounds are displayed below (84 – 88) (Figure 3.27). In addition to benzoyl 
compounds one compound possessing an N-linked thiophene moiety (88) demonstrated good Pf3D7 
potency and was identified in the Tres-Cantos antimalarial set (TCAMS).32 Unfortunately it is not 
known if this compound targets IspD to date and a method for its synthesis has not yet been identified 
by us or released into the literature.  
 
Figure 3.27. Potential future targets from the 2,1-BITZ series. 
1,2-BITZ Series and Ebselen Series 
With regards to future work of both series it is not clear what else could be synthesised to 
regain cellular potency. The ebselen biphenyl series does not mirror the Pf3D7 whole cell potency of 
the analogous BITZ chemotype. However, it could be worth examining further substitution of the D-
ring as to date, substitution has focused mainly on methyl linked 6-membered tertiary amine rings. 
Rings of differing sizes (compounds 89, 90) and altered to secondary amines such as compound 91 
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could provide us with the cell activity that we are aiming to achieve (Figure 3.28). With regards to the 
future work of the 1,2-BITZ series, the analogous compounds can also be tested for potency.  
 
Figure 3.28. Potential future targets for the ebselen series. 
Towards the end of the project on the BITZ compounds we noticed that the class had been 
identified as a PAIN. While we are confident our molecules are not interfering in the assay, we 
acknowledge that to confirm beyond any doubt that this is the case, a counter screen of the 
compounds against unrelated targets will be required to be carried out as part of future work along 
with any added orthogonal assay. In addition to this, all tested compounds should also be screened 
within the alternate BIOMOL Green assay (see Section 3.3). The control experiment of stirring an 
active BITZ compound in the presence of MESG and / or its resultant product will also be carried out 
as part of future work.  
3.7 Benzothiazines as Potential Inhibitors of PfIspD 
 Following on from the HTS carried out by Biofocus a second HTS (HTS2) was undertaken 
following similar methods to those described in Section 3.1. In HTS2, 5000 compounds were selected 
via computational testing and were interrogated for potency against PfIspD by Biofocus. From all 5000 
compounds screened 17 of them were identified to possess reproducible IspD potency of < 1 M along 
with good purity. Of greatest interest from the screen was a related series of 3 compounds, two of 
which demonstrated potency of <1 M.75 
 These three identified compounds were of great interest as they already showed early 
indications of SAR, furthermore the chemistry en route to the compounds seemed straightforward, 
cheap, and scalable, potentially allowing for rapid compound generation. The compounds belong to a 
benzothiazinone (BTZ) chemotype, and are displayed below (Figure 3.29). 
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Figure 3.29. Compounds of interest from HTS2. 
 The early SAR looked very interesting; with regards to the left hand side of the molecule there 
seems to be a specific requirement for the incorporation of the methyl adjacent to the sulfur atom 
when the right hand side of the molecule harbours a secondary amide. Removal of this methyl results 
in an 18 fold drop of activity, however, if this secondary amide is replaced with a tertiary amide, 
activity returns in the absence of the methyl on the BTZ core. It may be the case that reincorporation 
of the methyl could boost activity even further. As a starting point we focused on the development 
101 was it showed the most potent inhibitory activity.  
 There are many possible sites within the template which can be manipulated which made it 
an exciting template to work on. The main goal of the SAR was to focus on the right hand side of the 
molecule by examining the effect of substituting the terminal amide ring system with rings of altering 
sizes in order to probe sterics. In addition to this promising line of SAR, the molecules look favourable 
in terms of their drug like properties, with 101 possessing a promising ClogP value of 1.28.  
3.7.1 Synthesis of BTZ Compounds  
The route to the targets is shown below (Scheme 3.16); the chemistry towards the BTZ core 
was adapted from work published by Yamamoto et al. followed by standard peptide coupling and de-
protection strategies to yield the final compounds.76 Note the starting thiol is racemic as the chirality 
of the methyl group was not deemed important at this stage.  
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Scheme 3.16. Synthesis of 101 – 107. 
 The synthesis begins with the nucleophilic aromatic substitution reaction of 4-chloro-3-
nitrobenzoic acid (92) with ethyl 2-mercaptopropanoate (93) forming 94. The acid moiety of 94 is then 
esterified via the formation of an acyl chloride, which can then be quenched with excess EtOH forming 
the desired ethyl ester 95. The next step involved reduction of the nitro group followed by in situ ring 
closure to the BTZ ethyl ester core 96. The initial reduction route planned was through Pd / C 
conditions under a H2 atmosphere as reported by the literature.76 However, upon repetition of this, 
the reaction constantly failed yielding only starting materials, this is likely due to catalyst poisoning by 
the sulfur atom. Therefore we decided to utilise the SET reduction method using Fe and AcOH as 
previously used for ebselen series of compounds, this reaction successfully formed the BTZ ethyl ester 
core 96.68  
We next installed the amide functionality of the molecule, in order to do this, however, 96 
was hydrolysed to its acid form 97 via basic hydrolysis in the presence of 1 M NaOH. As 97 was an 
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important intermediate it was subsequently stockpiled. To install amide functionality we decided to 
utilise peptide coupling reagents that would generate an activated ester in situ which can be 
sequentially attacked by the amine nucleophile forming the amide bond. This reaction was carried out 
using EDC.HCl and HOBT as reagents to form the activated ester before addition of the desired amine, 
ethyl 2-(piperazin-1-yl)-acetate (98), which successfully yielded intermediate 99. It should be noted 
that this compound can synthesised via the generation of an acyl chloride as the electrophile for the 
amine, however, when we used this method we found that reaction yields were low and purification 
was more difficult therefore we preferred to use peptide coupling reagents. 
Again we wanted to install amide functionality for the right hand side of the molecule; 
therefore the ethyl ester of 99 was hydrolysed to its acid 100 in the presence of 1 M LiOH which was 
found to proceed faster than using 1 M NaOH for the same reaction. Unfortunately 100 could not be 
isolated successfully, during work up it was found that it remained in the water layer at various pH 
values, this is likely due to the presence of amphoteric sites. After formation of 100 was confirmed by 
TLC, the aqueous phase was neutralised to approximately pH 7 and solvents were removed under 
vacuum. After mass spectrometry and 1H NMR confirmed the correct product, 100 was used crude 
directly in the next step. 
The final step of the reaction was again an amide coupling reaction, however, this was our 
branching point for SAR. From intermediate 100 we generated final compounds 101 – 107, using a 
slightly different peptide coupling procedure were HATU was used as the peptide coupling reagent to 
generate the activated ester. We chose this method as it was believed that reactions occur faster and 
any side products would be easier to remove.77 The yields for the final peptide coupling steps are 
summarised in Table 3.18. Note that yields are reported over two steps as 100 could not be isolated.  
 
Table 3.18. Yields of final coupling steps. 
Final Compound R (In final 
compound) 
% Yield over 2-steps 
101 NH-cyclopropyl 36 % 
102 NH-cyclobutyl 27 % 
103 NH-cyclopentyl 29 % 
104 NH-cyclohexyl 81 % 
105 NH-iPr 63 % 
106 NMe-cyclopentyl 66 % 
107 NH-(4F)-Ph 52 % 
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In general all yields for all steps up to the final coupling proceed very well giving yields 
between 70 and 99 %. However, the final couplings gave a large degree of variation to the yields, we 
propose that this is related to how efficiently the previous step is neutralised, as any residual lithium 
carboxylate salts are less likely to react with the peptide coupling reagents, resulting in the failure to 
generate the activated ester required for peptide coupling. 
3.7.2 Biological Data of BTZ Compounds 
 
Table 3.19. Biological data of BTZ compounds. Compound properties are ranked using a traffic light system. Green = 
good, amber = acceptable, red = poor. 
Compound R IC50 PfIspD (nM) EC50 Pf3D7 
(nM) 
ClogP 
99* OEt >100,000 n = 1 >100,000 n = 1 2.14 
101 NH-cyclopropyl >100,000 n = 1 >50,000 n = 1 1.28 
102 NH-cyclobutyl >100,000 n = 1 >50,000 n = 1 1.61 
103 NH-cyclopentyl >100,000 n = 1 >50,000 n = 1 2.16 
104 NH-cyclohexyl >100,000 n = 1 48,000 n = 1 2.72 
105 NH-iPr >100,000 n = 1 >100,000 n = 1 1.60 
106 NMe-cyclopentyl >100,000 n = 1 >100,000 n = 1 2.59 
107 NH-(4F)-Ph >100,000 n = 1 >100,000 n = 1 2.95 
   * Compound sent for testing was synthesised by former masters student Charles Evans 
The results from the biological data set were disappointing (Table 3.19). It is clear that none 
of the compounds possess potency against enzyme or Pf3D7 cells and unfortunately no compound is 
of comparable activity to the assay conducted by BioFocus. Therefore, this suggests that there were 
at least 2 false positives from the HTS. Interestingly compounds 101 – 104 did show some minor 
activity against Pf3D7 cells but again the activity is poor and is suggestive that the compounds 
demonstrate off target effects as the inhibition of IspD is lower than that of the cellular assay. A small 
trend that can be observed from compounds 101 – 104 is that as lipophilicity increases Pf3D7 potency 
slightly increases. However, this trend fails when taking 106 and 107 into account. For 106 the 
methylated tertiary amide may be too hindered to allow any possible binding which could explain the 
loss of activity. For 107 this loss could be due to the electron withdrawing nature of the aromatic ring 
causing delocalisation of nitrogen lone pairs which may be crucial to any minor activity.  
We do not yet understand exactly why there are differences between the BioFocus and 
Washington University assay results; LCMS data for the molecule looked correct and had good purity 
so this issue requires investigation. To confirm the correct structure of 101, we successfully crystallised 
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compound 101 and determined its relative structure by X-ray crystallography. The crystal structure of 
101 was resolved by Dr Craig Robertson and imaged in OLEX2 (Figure 3.30).78 
 
Figure 3.30. X-ray structure of 101. Image is rendered as ball and stick, carbon, coloured in grey, hydrogen in white, 
nitrogen in blue, oxygen in red, sulfur in yellow. Compound was visualised using OLEX2.78 
The crystal structure confirmed the correct structure for 101. Depicted below is the X-ray 
image of both enantiomers together forming a hydrogen bond donor / accepter pair between the BTZ 
ring nitrogen atom and the carbonyl oxygen linking the piperazine ring. The confirmation of the correct 
structure gave us confidence that the discrepancies observed between the two assays carried out by 
BioFocus and the Odom group was not due to any mistake on our part.        
3.7.3 Conclusion of BTZ Compounds 
 Unfortunately all compounds from the BTZ series of compounds demonstrated poor potency 
against both PfIspD and Pf3D7 cells. This was disappointing; especially considering all compounds 
possessed attractive CLogP values. Due to the results from the Biofocus assay, we decided to focus on 
substituting the amide moiety at the right hand side of the hit molecule 101, and as protocol, we 
resynthesised 101 and sent it for biological evaluation. All compounds from this series were inactive 
in both enzyme and cellular assays and unfortunately, did not mirror the results from the Biofocus 
assay, suggesting that 101 was a false positive. Ester 99 was also sent for evaluation and was also 
inactive. 
 Within the group an analogous study was also undertaken (by former Masters student Charles 
Evans). Compound 110 was successfully synthesised to mirror the second BTZ hit 108 from the 
Biofocus screen, but included the methyl group within the BTZ core (Figure 3.31). This compound did 
demonstrate improved potency against IspD than the analogous study, however, potency is still poor, 
and Pf3D7 activity is comparable to that described above. With regards to any future work it is 
important to understand if 101 was a PfIspD false positive before synthesising anymore derivatives, 
however, as cell potency is poor anyway this series is not likely worth expanding upon.  
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Figure 3.31. Biological data of 108 compared with 110. 
3.8 Experimental Procedures 
General Procedure 1: 2,1 benzoisothiazolinone synthesis. 
Lithium sulfide (1.06 g, 23.00 mmol, 2.5 eq) was added to water (100 cm3) at 0 °C, to the stirred 
solution was added 1 M HCl (34.2 cm3, 34.20 mmol, 3.7 eq) dropwise over 15 minutes. Isatoic 
anhydride (37) (1.50 g, 9.2 mmol, 1 eq) was added portion wise over 15 minutes and the solution 
allowed to stir for a further 45 minutes at room temperature. The reaction mixture was filtered and 
purged with N2 for one hour before cooling to 0 °C. To the solution was added hydrogen peroxide 
(1.13 cm3, 11.04 mmol, 30 % w / w 1.2 eq) dropwise, the solution was allowed to warm to room 
temperature followed by stirring for 45 minutes. The mixture was filtered and to the filtrate was 
adjusted to pH 6. The desired product precipitated out and was filtered under vacuum to give the 
product 39 as a light brown solid (0.93 g, 67 %).  
Preparation of benzo[c]isothiazol-3(1H)-one (39) 
 
Isatoic anhydride (37) (1.50 g, 9.2 mmol, 1 eq), lithium sulfide (1.06 g, 23.00 mmol, 2.5 eq), 1 
M HCl (34.2 cm3, 34.20 mmol, 3.7 eq), and hydrogen peroxide (1.13 cm3, 11.04 mmol, 1.2 eq) were 
used in water (100 cm3) following general procedure 1 to give the product 39 as a light brown solid 
(0.93 g, 67 %). δH (400 MHz, CDCl3) 7.84 (1H, d, J 8.0 Hz), 7.58 – 7.53 (1H, m), 7.26 (1H, d, J 8.4 Hz), 
7.14 (1H, t, J 7.5 Hz), 5.87 (1H, br s). δC (101 MHz, CDCl3) 192.9, 154.4, 133.5, 123.2, 121.1, 120.5, 
115.4. CI-HRMS: m/z calculated for C7H6NOS [M+H]+ requires 152.0165. Found 152.0166. Elemental 
Analysis Calculated for C7H5NOS requires, C, 55.61; H, 3.33; N, 9.26; S, 21.21, found, C, 55.58; H, 3.32; 
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N, 9.19; S, 21.26. IR (neat): νmax/cm-1: 3069 (br), 2843 (br), 1615 (s), 1593 (s), 1474 (m), 1341 (w). 
Melting Point oC: 134 – 136 (H2O). 
General Procedure 2: 2, 1 benzoisothiazolone SN2 reactions 
To benzo[c]isothiazol-3(1H)-one (39) (0.10 g, 0.65 mmol, 1 eq) was added acetone (10 cm3), 
benzyl bromide (0.10 cm3, 0.85 mmol, 1.3 eq) and potassium carbonate (0.18 g, 1.30 mmol, 2 eq) 
sequentially, and the reaction left to stir at room temperature under a N2 atmosphere overnight. 
Solvents were removed in vacuo and to the residue was added water (50 cm3). The product was 
extracted into ethyl acetate (3 x 50 cm3), the organics were washed with water (50 cm3), brine (50 
cm3) and dried over MgSO4. The product was purified by flash column chromatography (10 % EtOAC / 
Hex – 100% EtOAc) to yield the product 41 as a yellow oil (0.16 g, 94 %).   
Generic structure of compounds 41 – 45 
 
Preparation of 1-benzylbenzo[c]isothiazol-3(1H)-one (41) 
Compound 39 (0.10 g, 0.65 mmol, 1 eq), benzyl bromide (0.10 cm3, 0.85 mmol, 1.3 eq) and 
potassium carbonate (0.18 g, 1.30 mmol, 2 eq), were used in acetone (10 cm3) following general 
procedure 2 to give 41 as a yellow oil (0.16 g, 94 %). δH (400 MHz, CDCl3) 7.83 (1H, dd, J 8.0, 0.4 Hz), 
7.56 – 7.50 (1H, m), 7.39 – 7.32 (3H, m), 7.30 – 7.26 (2H, m), 7.24 (1H, d, J 8.6 Hz), 7.04 (1H, t, J 7.4 
Hz), 4.99 (2H, s). δC (101 MHz, CDCl3) 189.6, 153.8, 135.7, 134.1, 129.1, 128.6, 127.6, 124.4, 122.5, 
120.0, 112.6, 52.7. ESI-HRMS: m/z calculated for C14H12NOS [M+H]+ requires 242.0634. Found 
242.0641 Elemental Analysis Calculated for C14H11NOS requires, C, 69.68; H, 4.59; N, 5.80; S, 13.29, 
found, C, 70.03; H, 4.66; N, 5.78; S, 13.24. IR (neat): νmax/cm-1: 3062 (br), 2916 (br), 1647 (s), 1597 (s), 
1471 (s), 1332 (m), 1158 (m). 
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Preparation of 1-(pyridin-2-ylmethyl)benzo[c]isothiazol-3(1H)-one (42) 
Compound 39 (0.061 g, 0.41 mmol, 1 eq), 2-(bromomethyl)pyridine hydrobromide (0.10 g, 
0.41 mmol, 1.0 eq) and potassium carbonate (0.18 g, 1.22 mmol, 3 eq), were used in acetone (10 cm3) 
following a modified general procedure 2. Reaction was complete within 2 hours at room temperature 
rather than left overnight. This gave 42 as a yellow oil (0.082 g, 83 %). δH (400 MHz, CDCl3) 8.62 (1H, 
s), 7.86 (1H, d, J 7.9 Hz), 7.68 (1H, apparent t), 7.54 (1H, apparent t), 7.30 – 7.22 (2H, m), 7.16 (1H, d, 
J 7.7 Hz), 7.07 (1H, apparent t), 5.15 (2H, s). δC (101 MHz, CDCl3) 189.5, 155.7, 153.6, 149.9, 137.3, 
134.3, 124.4, 123.3, 122.1, 121.5, 120.0, 112.6, 54.0. ESI-HRMS: m/z calculated for C13H10N2NaOS 
[M+Na]+ requires 265.0406. Found 265.0408. Elemental Analysis Calculated for C13H10N2OS requires 
C, 64.44, H, 4.16, N, 11.56, S, 13.23, found C, 64.17, H, 4.28, N, 11.45, S, 13.10. IR (neat): νmax/cm-1: 
3064 (br), 2923 (br), 1631 (s), 1597 (s), 1472 (s), 1332 (m), 1159 (m). 
Preparation of 1-(pyridin-3-ylmethyl)benzo[c]isothiazol-3(1H)-one (43) 
Compound 39 (0.081 g, 0.54 mmol, 1 eq), 3-(bromomethyl)pyridine hydrobromide (0.18 g, 
0.70 mmol, 1.3 eq) and potassium carbonate (0.22 g, 1.61 mmol, 3 eq), were used following a modified 
general procedure 2. Reaction was refluxed in acetone (10 cm3) and was complete within 2 hours 
rather than left overnight. This gave 43 as a yellow semi solid / paste (0.037 g, 29 %). δH (400 MHz, 
CDCl3) 8.61 – 8.57 (2H, m), 7.83 (1H, d, J 8.0 Hz), 7.60 (1H, apparent dt), 7.58 – 7.54 (1H, m), 7.29 (1H, 
dd, J 7.9, 4.9 Hz), 7.25 (1H, d, J 7.7 Hz), 7.07 (1H, t, J 7.5 Hz), 5.01 (2H, s). δC (101 MHz, CDCl3) 189.3, 
153.7, 150.1, 149.1, 135.4, 134.4, 131.3, 124.6, 124.0, 122.7, 120.5, 112.6, 50.4. CI-HRMS: m/z 
calculated for C13H11N2OS [M+H]+ requires 243.0587. Found 243.0592. Elemental Analysis Calculated 
for C13H10N2OS requires C, 64.44, H, 4.16, N, 11.56, S, 13.23, found, C, 63.27, H, 4.34, N, 10.87, S, 12.45. 
IR (neat): νmax/cm-1: 3040 (br), 2923 (br), 1642 (s), 1598 (s), 1469 (s), 1325 (m). 
Preparation of 1-(pyridin-4-ylmethyl)benzo[c]isothiazol-3(1H)-one (44) 
Compound 39 (0.083 g, 0.55 mmol, 1 eq), 4-(bromomethyl)pyridine hydrobromide (0.14 g, 
0.55 mmol, 1.0 eq) and potassium carbonate (0.23 g, 1.64 mmol, 3 eq), were used in acetone (10 cm3) 
following a modified general procedure 2. Reaction was complete within 2 hours at room temperature 
rather than left overnight. This gave 44 as a yellow solid (0.12 g, 87 %). δH (400 MHz, CDCl3) 8.59 (2H, 
s), 7.85 (1H, d, J 7.8 Hz), 7.59 – 7.48 (1H, m), 7.17 (2H, s), 7.15 – 7.04 (2H, m), 5.00 (2H, s). δC (101 MHz, 
CDCl3) 189.1, 153.6, 150.8, 150.4, 145.0, 134.5, 124.6, 122.3, 121.9, 120.5, 112.3, 51.5. ESI-HRMS: m/z 
calculated for C13H11N2OS [M+H]+ requires 243.0587. Found 243.0596. Elemental Analysis Calculated 
for C13H10N2OS requires C, 64.44, H, 4.16, N, 11.56, S, 13.23, found C, 64.38, H, 4.12, N, 11.56, S, 13.30. 
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IR (neat): νmax/cm-1: 3150 (br), 3084 (br), 2981 (br), 2923 (br), 1624 (s), 1599 (s), 1480 (m), 1277 (m). 
Melting Point oC: 157 – 158 (melted and decomposed) (EtOAC / Hex). 
General Procedure 3: Peptide coupling via acyl halide 
 To benzo[c]isothiazol-3(1H)-one (39) (0.082 g, 0.54 mmol, 1 eq) was added anhydrous DCM 
(10 cm3), triethylamine (0.083 cm3, 0.60 mmol, 1.1 eq), and benzoyl chloride (0.07 cm3, 0.60 mmol, 
1.1 eq). The reaction was stirred for two hours to overnight under a N2 atmosphere. The organic layer 
was washed with 2 M HCl (50 cm3), saturated sodium bicarbonate solution (3 x 50 cm3), water (50 
cm3) and brine (50 cm3), then dried over MgSO4. Solvents were removed in vacuo and product purified 
by column chromatography using 50 % DCM in hexane, followed by recrystallisation in the same 
system, to yield 45 as white needles (0.14 g, 63 %). 
Preparation of 1-benzoylbenzo[c]isothiazol-3(1H)-one (45) 
Compound 39 (0.082 g, 0.54 mmol, 1 eq), triethylamine (0.083 cm3, 0.60 mmol, 1.1 eq), and 
benzoyl chloride (0.07 cm3, 0.60 mmol, 1.1 eq), were used in anhydrous DCM (10 cm3) following 
general procedure 3. Column purification using 50 % DCM in hexane, followed by recrystallisation in 
the same system yielded 45 as white needles (0.14 g, 63 %). δH (400 MHz, CDCl3) 8.47 (1H, d, J 8.6 Hz), 
7.95 – 7.90 (1H, m), 7.76 – 7.68 (3H, m), 7.66 – 7.59 (1H, m), 7.57 – 7.48 (2H, m), 7.41 – 7.33 (1H, m). 
δC (101 MHz, CDCl3) 187.7, 168.2, 148.4, 135.1, 134.7, 132.7, 128.9, 128.3, 125.5, 125.2, 123.9, 120.2. 
ESI-HRMS: m/z calculated for C14H9NNaO2S [M+Na]+ requires 278.0246. Found 278.0256, and 
278.0724 [(M-S)+MeOH+Na]+. Elemental Analysis Calculated for C14H9NO2S requires: C, 65.87, H, 3.55, 
N, 5.49, S, 12.56, found, C, 65.85, H, 3.54, N, 5.50, S, 12.68. IR (neat): νmax/cm-1: 3104 – 2922 (br), 1760 
(s), 1609 (m), 1597 (m), 1461 (m), 1308 (m). Melting Point oC:  91 – 92 (DCM / Hex). 
Preparation of 2-benzoylbenzo[d]isothiazol-3(2H)-one (47) 
 
Benzo[d]isothiazol-3(2H)-one (46), triethylamine (0.083 cm3, 0.60 mmol, 1.1 eq), and benzoyl 
chloride (0.07 cm3, 0.60 mmol, 1.1 eq), were used in anhydrous DCM (10 cm3) following general 
procedure 3. Column purification using 50 % DCM in hexane, following recrystallisation in the same 
system yielded 47 as white needles (0.044 g, 24 %).  δH (400 MHz, CDCl3) 7.96 (1H, d, J 7.9 Hz), 7.77 – 
7.69 (3H, m), 7.62 – 7.54 (2H, m), 7.48 (2H, apparent t), 7.40 (1H, t, J 7.6 Hz). δC (101 MHz, CDCl3) 
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169.1, 163.3, 141.6, 134.7, 133.1, 132.7, 129.2, 128.2, 128.1, 126.2, 125.3, 120.8. CI-HRMS: m/z 
calculated for C14H10NO2S [M+H]+ requires 256.0427. Found 256.0423. Elemental Analysis Calculated 
for C14H9NO2S requires: C, 65.87, H, 3.55, N, 5.49, S, 12.56, found, C, 65.64, H, 3.56, N, 5.57, S, 12.83. 
IR (neat): νmax/cm-1: 3091 – 3026 (br), 1708 (s), 1664 (s), 1579 (m), 1447 (m), 1273 (s). Melting Point 
oC:  163 – 164 (DCM / Hex). 
Preparation of 1-phenyl-2H-benzo[d][1,3]oxazine-2,4(1H)-dione (49) 
 
To N-phenylanthranilic acid (48) (2.01 g, 9.41 mmol 1 eq) was added anhydrous dioxane (25 
cm3). The solution was put under an N2 atmosphere and cooled to 0 °C. Diphosgene (1.7 cm3, 14.1 
mmol, 1.5 eq) was added dropwise over five minutes and the solution stirred for one hour before 
warming to room temperature and stirring for a further 23 hours. Solvents were removed in vacuo, 
the solid washed with diethyl ether and dried by filtration, yielding the product as a brown solid (2.25 
g, 75 %). δH (400 MHz, DMSO) 8.07 (1H, dd, J 7.8, 1.1 Hz), 7.69 – 7.55 (4H, m), 7.53 – 7.46 (2H, m), 7.32 
(1H, t, J 7.6 Hz), 6.41 (1H, d, J 8.4 Hz). δC (101 MHz, DMSO) 159.2, 147.0, 143.4, 136.8, 136.0, 130.3, 
129.5, 129.2, 128.8, 123.7, 115.3, 111.3. CI-HRMS: m/z calculated for C14H10NO3 [M+H]+requires 
240.0655. Found 240.0659.  
Preparation of 1-phenylbenzo[c]isothiazol-3(1H)-one (50) 
 
Compound 49 (1.00 g, 4.19 mmol, 1 eq) lithium sulfide (0.48 g, 10.48 mmol, 2.5 eq), 1 M HCl 
(15.5 cm3, 15.5 mmol, 3.7 eq), and hydrogen peroxide (0.51 cm3, 5.03 mmol, 1.2 eq) were used in 
water (50 cm3) following a modified general procedure 1. No precipitation occurred after adjusting 
the pH to 6. The product was extracted into ethyl acetate (3 x 100 cm3) washed with water (3 x 50 
cm3) basified by DIPEA (1 %). Organics were washed with brine (50 cm3) , dried over MgSO4, solvents 
removed in vacuo and product purified via purified by column chromatography (0.1 % DIPEA / 4.9 % 
EtOAc / 95 % hex) to give the product 50 as a dark yellow oil (0.25 g, 26 %). δH (400 MHz, CDCl3) 7.89 
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(1H, d, J 8.0 Hz), 7.52 – 7.42 (5H, m), 7.41 – 7.35 (1H, m), 7.24 (1H, d, J 8.6 Hz), 7.08 (1H, t, J 7.5 Hz). δC 
(101 MHz, CDCl3) 190.1, 152.7, 139.5, 134.1, 130.1, 128.1, 126.6, 124.2, 122.6, 120.5, 113.5. CI-HRMS: 
m/z calculated for C13H10NOS [M+H]+ requires 228.0478. Found 228.0483. Elemental Analysis 
Calculated for C13H9NO2S requires, C, 68.70; H, 3.99; N, 6.16; S, 14.11, found, C, 68.81; H, 4.05; N, 6.11; 
S, 14.08. IR (neat): νmax/cm-1: 3062 (br), 1651 (s), 1588 (s), 1460 (s), 1325 (s). 
General Procedure 4: Installation of urea moiety into 1,2 benzoisothiazolinone  
 To benzo[d]isothiazol-3(2H)-one (46) (0.30 g, 1.98 mmol, 1 eq) was added anhydrous THF (5 
cm3) and phenylisocyanate (0.22 cm3, 1.98 mmol, 1 eq). The reaction was refluxed for one hour, 
solvents were removed in vacuo and the residue suspended in acetone (7 cm3) and water (7 cm3), 
precipitates were filtered by vacuum and washed with 1 : 1 water / acetone (3 x 5 cm3) to give 53 as 
white crystals (0.53 g, 74 %). 
Generic structure of 33 – 35 following general procedure 4 
 
Preparation of 3-oxo-N-phenylbenzo[d]isothiazole-2(3H)-carboxamide (53) 
Benzo[d]isothiazol-3(2H)-one (46) (0.30 g, 1.98 mmol, 1 eq) and phenylisocyanate (0.22 cm3, 
1.98 mmol, 1 eq) were used in anhydrous THF (5 cm3) following general procedure 4 to give 53 as 
white crystals (0.53 g, 74 %). δH (400 MHz, CDCl3) 10.99 (1H, s), 8.08 (1H, d, J 7.9 Hz), 7.79 – 7.71 (1H, 
m), 7.67 – 7.55 (3H, m), 7.51 – 7.42 (1H, m), 7.42 – 7.36 (2H, m), 7.17 (1H, t, J 7.4 Hz). δC (100 MHz, 
CDCl3) 165.3, 148.4, 140.8, 136.8, 134.1, 129.2, 127.4, 126.0, 124.9, 124.8, 120.6, 120.2. ESI-HRMS: 
m/z calculated for C14H10N2NaO2S requires 293.0355. Found 293.0370. Elemental Analysis Calculated 
for C14H10N2O2S requires, C, 62.21; H, 3.73; N, 10.36; S, 11.86, found, C, 61.95; H, 3.83; N, 10.32; S, 
11.95. IR (neat): νmax/cm-1: 3133 (br, N-H amide), 3076 (br, C-H aromatic), 1709, (s, C=O amide), 1592 
(s, C=O amide), 1592 (s, C-C aromatic). Melting Point oC: 199 – 201 (Acetone / H2O). 
Preparation of N-(4-chlorophenyl)-3-oxobenzo[d]isothiazole-2(3H)-carboxamide (54) 
Benzo[d]isothiazol-3(2H)-one (46) (0.15 g, 0.99 mmol, 1 eq) and 4-chlorophenylisocyanate 
(0.13 cm3, 0.99 mmol, 1 eq) were used in anhydrous THF (5 cm3) following general procedure 4 to give 
54 as white crystals (0.28 g, 93 %). δH (400 MHz, CDCl3) 11.09 (1H, s), 8.07 (1H, d, J 8.0 Hz), 7.81 – 7.70 
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(1H, m), 7.62 (1H, d, J 8.1 Hz), 7.61 – 7.53 (2H, m), 7.51 – 7.43 (1H, m), 7.38 – 7.30 (2H, m). ESI-HRMS: 
m/z calculated for C14H10ClN2NaO2S requires 326.9965, found 326.9959. Elemental Analysis 
Calculated for C14H9ClN2O2S requires, C, 55.18; H, 2.98; N, 9.19; S, 10.52, found, C, 55.21; H, 3.13; N, 
9.28; S, 10.03. IR (neat): νmax/cm-1: 3225 (br), 3116 (br), 1708 (s), 1650 (s), 1595 (s). Melting Point oC: 
204 – 205 (Acetone / H2O). 
Preparation of N-benzyl-3-oxobenzo[d]isothiazole-2(3H)-carboxamide (55) 
Benzo[d]isothiazol-3(2H)-one (46) (0.15 g, 0.99 mmol, 1 eq) and benzylisocyanate (0.12 cm3, 
0.99 mmol, 1 eq) were used in anhydrous THF (5 cm3) following general procedure 4 to give 55 as 
white crystals (0.25 g, 92 %).  δH (400 MHz, DMSO) 9.29 (1H, t, J 5.9 Hz), 8.02 (1H, d, J 8.2 Hz), 7.95 
(1H, d, J 7.9 Hz), 7.82 – 7.76 (1H, m), 7.52 – 7.46 (1H, m), 7.39 – 7.33 (4H, m), 7.30 – 7.25 (1H, m), 4.55 
(2H, d, J 6.0 Hz). δC (101 MHz, DMSO) 164.4, 150.9, 140.8, 138.5, 134.0, 128.5, 127.4, 127.2, 126.5, 
126.0, 124.7, 122.1, 43.5. ESI-HRMS: m/z calculated for C15H12N2NaO2S [M+Na]+ requires 307.0512. 
Found 307.0516. Elemental Analysis Calculated for C15H12N2O2S requires, C, 63.36; H, 4.25; N, 9.85; S, 
11.28, found, C, 63.44; H, 4.31; N, 9.92; S, 11.59. IR (neat): νmax/cm-1: 3252 (br), 3090 (w), 3063 (w), 
1704 (s), 1650 (s), 1530 (s), 1445 (s), 1300 (s), 1178 (br, s). Melting Point oC: 170 – 171 (Acetone / 
H2O). 
General Procedure 5: Amide coupling via HATU 
 To desired N-Boc-glycine (56) (0.50 g, 2.85 mmol, 1 eq) was added HATU (1.63 g, 4.28 mmol, 
1.5 eq) DIPEA (1.99 cm3 11.42 mmol, 4 eq) and DMF (10 cm3). The resulting solution was stirred for 5 
minutes before addition of the 2-adamantylamine hydrochloride (0.64 g, 3.43 mmol, 1.2 eq). The 
solution was placed under an N2 atmosphere and stirred overnight. Solvents were removed in vacuo 
and organics taken back into EtOAc (50 cm3). Organics were washed with 2 M HCl (50 cm 3), saturated 
sodium bicarbonate solution (50 cm3), water (50 cm3), brine (50 cm3) and dried over MgSO4. Solvents 
were removed in vacuo and purified via column chromatography 25 % EtOAc in hexane yields 57a as 
a white solid (0.55 g, 62 %). 
 Generic structure of compounds 57a and 57b 
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Preparation of tert-butyl (2-(adamantan-2-yl)amino)-2-oxoethyl)carbamate (57a)  
N-Boc-glycine (56) (0.50 g, 2.85 mmol, 1 eq), HATU (1.63 g, 4.28 mmol, 1.5 eq) DIPEA (1.99 
cm3 11.42 mmol, 4 eq), and 2-adamantylamine hydrochloride (0.64 g, 3.43 mmol, 1.2 eq), were used 
in DMF (10 cm3) following general procedure 5 column chromatography in 25 % EtOAc in hexane 
yields 57a as a white solid (0.55 g, 62 %). δH (400 MHz, CDCl3) 6.71 (1H, br s), 5.31 (1H,  br s), 4.03 (1H, 
br d, J 7.7 Hz), 3.77 (2H, d, J 5.9 Hz), 1.91 (2H, s), 1.88 – 1.79 (7H, m), 1.75 (3H, d, J 12.8 Hz), 1.63 (2H, 
d, J 13.1 Hz), 1.46 (9H, s). δC (101 MHz, CDCl3) 168.8, 156.5, 80.4, 53.4, 45.2, 37.6, 37.2, 32.0, 31.9, 
28.4, 27.3, 27.2. ESI-HRMS: m/z calculated for C17H28N2NaO3 [M+Na]+ requires 331.1992. Found 
331.1990. 
Preparation of tert-butyl (2-adamantan-1-yl)amino)-2-oxoethyl)carbamate (57b) 
N-Boc-glycine (56) (0.50 g, 2.85 mmol, 1 eq), HATU (1.63 g, 4.28 mmol, 1.5 eq) DIPEA (1.99 
cm3 11.42 mmol, 4 eq), and 1-adamantylamine (0.52 g, 3.43 mmol, 1.2 eq), were used in DMF (10 cm3) 
following general procedure 5 column chromatography in 25 % EtOAc in hex yields 57b as a white 
solid (0.67 g, 76 %). δH (400 MHz, CDCl3) 5.69 (1H, s), 5.18 (1H, s), 3.66 (2H, d, J 5.3 Hz), 2.07 (3H, s), 
1.98 (6H, d, J 2.5 Hz), 1.67 (6H, s), 1.45 (9H, s). δC (101 MHz, CDCl3) 168.3, 156.2, 80.2, 52.1, 45.2, 41.7, 
36.4, 29.5, 28.4. ESI-HRMS: m/z calculated for C17H28N2NaO3 [M+Na]+ requires 331.1992. Found 
331.1988. 
General Procedure 6: Boc deprotection in TFA 
 To compound 57a (0.55 g, 1.77 mmol, 1 eq) was added DCM (5 cm3) the solution was placed 
under an N2 atmosphere and cooled to 0 °C before addition of TFA (1.36 cm3, 17.71 mmol, 10 eq). The 
solution was allowed to warm to room temperature and left to stir overnight. The reaction was 
quenched by slow addition of saturated sodium bicarbonate solution (50 cm3) and the organics 
extracted into DCM (3 x 50 cm3). Combined organics were washed with water (50 cm3), brine (50 cm3) 
and dried over MgSO4. Solvents removed in vacuo to yield and product purified by trituration with 
Et2O, to yield 58a as a white solid (0.37 g, 79 %).    
Generic structure of compounds 58a and 58b 
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Preparation of N-(adamantan-2-yl)-2-aminoacetamide (58a)  
 Compound 57a (0.55 g, 1.77 mmol, 1 eq) and TFA (1.36 cm3, 17.71 mmol, 10 eq), were used 
in DCM (5 cm3) following general procedure 6. Purified by trituration with Et2O, to yield 58a as a white 
solid (0.37 g, 79 %). δH (400 MHz, CDCl3) 7.79 (1H, s), 4.08 (1H, d, J 8.6 Hz), 3.36 (2H, s), 1.94 – 1.79 
(10H, m), 1.75 (2H, s), 1.65 (2H, d, J 12.4), 1.50 (2H, s). δC (101 MHz, CDCl3) 171.7, 52.6, 45.1, 37.7, 
37.3, 32.3, 32.1, 27.4, 27.3. CI-HRMS: m/z calculated for C12H21N2O [M+H]+ requires 209.1654. Found 
209.1658. 
Preparation of N-(adamantan-1-yl)-2-aminoacetamide (58b) 
Compound 57b (0.67 g, 2.17 mmol, 1 eq) and TFA (1.66 cm3, 21.72 mmol, 10 eq), were used 
following general procedure 6. Purified by trituration with Et2O, to yield 58b as a white solid (0.45 g, 
74 %). δH (400 MHz, CDCl3) 6.89 (1H, s), 3.22 (2H, s), 2.08 (3H, s), 2.02 (6H, d, J 2.6 Hz), 1.74 – 1.65 (6H, 
m), 1.44 (2H, s). δC (101 MHz, CDCl3) 171.7, 51.3, 45.6, 41.8, 36.5, 29.6. CI-HRMS: m/z calculated for 
C12H21N2O [M+H]+ requires 209.1654. Found 209.1652 
Preparation of 2-bromo-N-(2,4-dimethylphenyl) acetamide (60) 
 
 2,4 Dimethylaniline (0.10 cm3, 0.84 mmol, 1 eq), bromoacetyl bromide (59) (0.074 cm3, 0.84 
mmol, 1 eq) and triethylamine (0.13 cm3, 0.93 mmol, 1.1 eq), were used in anhydrous DCM (15 cm3)  
following general procedure 3 to give the product 60 as a white solid (0.14 g, 70 %). This was used in 
the next step without purification. δH (400 MHz, CDCl3) 8.06 (1H, s), 7.65 (1H, d, J 8.2 Hz), 7.06 – 7.01 
(2H, m), 4.07 (2H, s), 2.30 (3H, s), 2.26 (3H, s). δC (101 MHz, CDCl3) 163.4, 135.8, 132.4, 131.4, 129.6, 
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Preparation of 2-(chlorocarbonyl)phenyl hypochlorothioite (14) 
 
 To 2,2'-dithiodibenzoic acid (12) (3.00 g, 9.80 mmol, 1 eq) was added DCE (20 cm3) and placed 
under a N2 atmosphere. To the reaction mixture was added thionyl chloride (5.00 cm3, 7 eq) dropwise 
followed by the addition of DMF (0.20 cm3). The resulting solution was refluxed at 80 °C for two hours 
after which the reaction suspension turned into a brown solution. The solution was cooled to 50 °C 
before addition of sulfuryl chloride (1.00 cm3, 1.3 eq), the reaction was left to stir at this temperature 
for one hour, the reaction mixture was cooled and solvents removed in vacuo to yield 14 as a bright 
yellow solid (4.1 g, >99 %). δH (400 MHz, CDCl3) 8.33 (1H, s), 7.92 (1H, s), 7.76 (1H, d, J 4.5 Hz), 7.42 
(1H, d, J 4.9 Hz). δC (101 MHz, CDCl3) 169.6, 146.1, 135.9, 134.8, 127.5, 125.9, 124.5. CI-LRMS: m/z 
calculated for C7H3ClOS [M-HCl]+ requires 170.0. Found 170.0. 
Generic structure of compounds 61 – 66 
 
Preparation of N-(adamantan-2-yl)-2-(3-oxobenzo[d]isothiazol-2(3H)-yl)acetamide (61) 
Compound 14 (0.14 g, 0.66 mmol, 1 eq), compound 58a (0.15 g, 0.72 mmol, 1.1 eq) and 
triethylamine (0.20 cm3, 1.44 mmol, 2.2 eq), were used in anhydrous DCM (10 cm3) following general 
procedure 3, the compound was purified by recrystallisation in DCM to yield 61 as a pale yellow solid 
(0.19 g, 84 %). δH (400 MHz, CDCl3) 8.07 (1H, d, J 7.9 Hz), 7.69 – 7.62 (1H, m), 7.59 (1H, d, J 8.1 Hz), 
7.43 (1H, dd, J 16.1, 8.5 Hz), 6.86 (1H, d, J 6.9 Hz), 4.50 (1H, s), 4.03 (1H, br d, J 8.0 Hz), 1.89 (1H, s), 
1.83 – 1.75 (3H, m), 1.71 – 1.65 (2H, m), 1.56 (1H, br d, J 13.0 Hz). δC (101 MHz, CDCl3) 166.3, 166.2, 
141.1, 132.6, 127.0, 126.0, 123.5, 120.6, 53.8, 48.5, 37.6, 37.1, 31.9, 31.9, 27.21, 27.15. ESI-HRMS: 
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m/z calculated for C19H22N2NaO2S [M+H]+ requires 365.1294. Found 365.1288. Elemental Analysis 
Calculated for C19H12N2O2S requires C, 66.64; H, 6.48; N, 8.18; S, 9.36 found C, 66.83; H, 6.57; N, 8.29; 
S, 9.08. IR (neat): νmax/cm-1: 3335 (m), 3223 (w), 3062 (w), 2907 (m), 2851 (m), 1647 (s), 1609 (s), 1547 
(s), 1445 (m), 1343 (m). Melting Point oC: 202 – 204 (DCM). 
Preparation of N-(adamantan-1-yl)-2-(3-oxobenzo[d]isothiazol-2(3H)-yl)acetamide (62) 
Compound 14 (0.14 g, 0.66 mmol, 1 eq), compound 58b (0.15 g, 0.72 mmol, 1.1 eq) and 
triethylamine (0.20 cm3, 1.44 mmol, 2.2 eq), were used in anhydrous DCM (10 cm3) following general 
procedure 3, the compound was purified by recrystallisation in DCM to yield 62 as a yellow solid (0.18 
g, 80 %). δH (400 MHz, CDCl3) 8.05 (1H, d, J 7.9 Hz), 7.64 (1H, apparent t), 7.57 (1H, d, J 8.1), 7.42 (1H, 
t, J 7.5 Hz), 5.96 (1H, s), 4.40 (2H, s), 2.07 – 2.02 (3H, m), 1.97 (6H, d, J 2.3 Hz), 1.64 (6H, br s). δC (101 
MHz, CDCl3) 166.0, 165.9, 141.3, 132.5, 127.0, 125.8, 123.6, 120.6, 52.6, 48.6, 41.5, 36.4, 29.5. ESI-
HRMS: m/z calculated for C19H22N2NaO2S [M+H]+ requires 365.1294. Found 365.1292. Elemental 
Analysis Calculated for C19H12N2O2S requires C, 66.64; H, 6.48; N, 8.18; S, 9.36 found C, 66.54; H, 6.45; 
N, 8.24; S, 9.47. IR (neat): νmax/cm-1: 3290 (m), 3067 (w), 2916 (m), 2882 (s), 2851 (m), 1643 (s), 1593 
(m), 1448 (s), 1417 (s), 1342 (m), 1234 (m). Melting Point oC:  222 – 213 (DCM). 
Preparation of N-(2,4-dimethylphenyl)-2-(3-oxobenzo[d]isothiazol-2(3H)-yl)acetamide (63) 
Benzo[d]isothiazol-3(2H)-one (46) (0.07 g, 0.46 mmol, 1 eq) was dissolved in anhydrous DMF 
(5 cm3) and the solution cooled to 0 °C. To the solution was added sodium hydride 60 % in mineral oil 
(0.018 g, 0.46mmol, 1 eq) and the solution was stirred for 30 mins under a N2 atmosphere. To the 
reaction mixture was added compound 60 (0.11 g, 0.46 mmol, 1 eq) pre-dissolved in DMF (1 cm3) and 
the reaction mixture heated to 80 °C overnight. Solvents were removed in vacuo and the residue taken 
into EtOAc (50 cm3), organics were washed with 2 M HCl (50 cm3), saturated HNaCO3 solution (50 cm3), 
water (50 cm3) and brine (50 cm3). The organics were dried over MgSO4, solvents removed in vacuo 
and the compound was purified by column chromatography (20 % EtOAc in Hexane) followed by 
recrystallisation in DCM to yield 63 as a white solid (0.021 g, 15 %). δH (400 MHz, CDCl3) 8.06 (1H, s), 
7.96 (1H, d, J 8.0 Hz), 7.84 (1H, d, J 8.2 Hz), 7.79 (1H, d, J 8.1 Hz), 7.59 (1H,apparent t), 7.46 (1H, 
apparent t), 7.04 (1H, d, J 8.3 Hz), 7.01 (1H, s), 5.22 (2H, s), 2.30 (3H, s), 2.20 (3H, s). δC (101 MHz, 
CDCl3) 165.8, 160.9, 152.6, 135.4, 132.3, 131.3, 129.2, 129.0, 127.6, 125.1, 124.5, 122.9, 122.5, 120.7, 
67.9, 21.0, 17.6. ESI-HRMS: m/z calculated for C17H16N2NaO2S [M+Na]+ requires 335.0825. Found 
335.0827. Elemental Analysis Calculated for C17H16N2O2S requires C, 65.36; H, 5.16; N, 8.97; S, 10.26 
found C, 65.31; H, 5.26; N, 8.69; S, 10.17. IR (neat): νmax/cm-1: 3241 (m), 3020 (w), 2920 (w), 1669 (s), 
1534 (m), 1511 (m), 1360 (s). Melting Point oC:  177 – 178 (DCM). 
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Preparation of 2-(adamantan-2-yl)benzo[d]isothiazol-3(2H)-one (64) 
Compound 14 (0.13 g, 0.60 mmol, 1 eq), 2-adamantylamine hydrochloride (0.12 g, 0.66 mmol, 
1.1 eq) and triethylamine (0.25 cm3, 1.80 mmol, 3 eq), were used in anhydrous DCM (10 cm3) following 
general procedure 3, the compound was purified by recrystallisation in DCM to yield 64 as a pale 
yellow solid (0.071 g, 41 %). δH (400 MHz, CDCl3) 8.02 (1H, d, J 7.9 Hz), 7.60 – 7.50 (2H, m), 7.36 (1H, 
apparent t), 4.73 (1H, s), 2.39 (2H, s), 2.27 (2H, d, J 13.2 Hz), 2.04 – 1.88 (6H, m), 1.82 – 1.69 (4H, m). 
δC (101 MHz, CDCl3) 166.1, 140.4, 131.5, 126.4, 125.3, 124.8, 119.9, 61.0, 38.3, 37.7, 32.5, 32.2, 27.5, 
27.1. CI-HRMS: m/z calculated for C17H20NOS [M+H]+ requires 286.1260. Found 286.1264. Elemental 
Analysis Calculated for C17H19NOS requires C, 71.54; H, 6.70; N, 4.95; S, 10.71 found C, 71.54; H, 6.71; 
N, 4.95; S, 10.90. IR (neat): νmax/cm-1: 2905 (m), 2848 (m), 1630 (s), 1592 (m), 1446 (s), 1296 (m). 
Melting Point oC:  148 – 150 (DCM). 
Preparation of 2-(adamantan-2-yl)benzo[d]isothiazol-3(2H)-one (65) 
Compound 14 (0.13 g, 0.60 mmol, 1 eq), 1-adamantylamine (0.10 g, 0.66 mmol, 1.1 eq) and 
triethylamine (0.17 cm3, 1.20 mmol, 2 eq), were used in anhydrous DCM (10 cm3) following general 
procedure 3, the compound was purified by recrystallisation in DCM to yield 65 as a white solid (0.14 
g, 80 %). δH (400 MHz, CDCl3) 7.95 (1H, d, J 7.9 Hz), 7.58 – 7.53 (1H, m), 7.50 (1H, d, J 8.0 Hz), 7.38 – 
7.33 (1H, m), 2.45 (6H, d, J 2.6 Hz), 2.20 (3H, s), 1.84 – 1.70 (6H, m). δC (101 MHz, CDCl3) 165.5, 140.0, 
131.3, 127.3, 126.2, 125.2, 119.9, 59.9, 40.7, 36.3, 30.1. CI-HRMS: m/z calculated for C17H20NOS 
[M+H]+ requires 286.1260. Found 286.1264. Elemental Analysis Calculated for C17H19NOS requires C, 
71.54; H, 6.70; N, 4.95; S, 10.71 found C, 71.36; H, 6.80; N, 4.90; S, 11.18. IR (neat): νmax/cm-1: 2898 
(m), 2849 (m), 1630 (s), 1446 (m), 1300 (m). Melting Point oC: 178 – 180 (DCM). 
Preparation of 2-cyclohexylbenzo[d]isothiazol-3(2H)-one (66) 
Compound 14 (0.13 g, 0.60 mmol, 1 eq), cyclohexylamine (0.07 cm3, 0.66 mmol, 1.1 eq) and 
triethylamine (0.17 cm3, 1.20 mmol, 2 eq) was used following general procedure 3, the compound 
was purified by recrystallisation in DCM to yield 66 as a yellow solid (0.10 g, 74 %). δH (400 MHz, CDCl3) 
8.03 (1H, d, J 7.9 Hz), 7.61 – 7.53 (2H, m), 7.41 – 7.35 (1H, m), 4.60 (1H, tt, J 11.5, 3.9 Hz), 2.04 (2H, 
apparent d, J 11.7 Hz), 1.87 (2H, apparent d, J 13.0 Hz), 1.78 – 1.68 (1H, m), 1.62 – 1.40 (4H, m), 1.26 
– 1.14 (1H, m). δC (101 MHz, CDCl3) 164.9, 140.4, 131.5, 126.6, 125.6, 125.4, 120.5, 53.3, 33.0, 25.7, 
25.4. CI-HRMS: m/z calculated for C13H16NOS [M+H]+ requires 234.0947. Found 234.0952. Elemental 
Analysis Calculated for C13H16NOS requires C, 69.92; H, 6.48; N, 6.00; S, 13.74 found C, 66.56; H, 6.45; 
N, 6.03; S, 13.30. IR (neat): νmax/cm-1: 2927 (m), 2854 (m), 1639 (s), 1446 (m), 1332 (m). Melting Point 
oC: 78 – 81 °C (DCM). 
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General Procedure 7: Preparation of amine coupled aryl side chains 
To (4-(bromomethyl)phenyl)boronic acid (68) (1.01 g, 4.71 mmol, 1 eq) was added THF (10 
cm3), DIPEA (0.98 cm3, 5.65 mmol, 1.2 eq) and morpholine (0.62 cm3, 7.06 mmol, 1.5 eq). The reaction 
was stirred at room temperature under a N2 atmosphere overnight. The reaction was diluted with 
brine (50 cm3) and extracted into ethyl acetate (3 x 50 cm3), dried with MgSO4 and solvents removed 
in vacuo to yield the product 69a as an off white solid (0.91 g, 87 %).  Which was used without further 
purification. 
Generic structure of compounds 69a –c following general procedure 7 
 
Preparation of (4-(morpholinomethyl)phenyl)boronic acid (69a) 
(4-(bromomethyl)phenyl)boronic acid (68) (1.01 g, 4.71 mmol, 1 eq), morpholine (0.62 cm3, 
7.06 mmol, 1.5 eq), and DIPEA (0.98 cm3, 5.65 mmol, 1.2 eq), were used in THF (10 cm3) following 
general procedure 7 to give 69a as an off white solid (0.91 g, 87 %). δH (400 MHz, CDCl3) 8.07 – 7.68 
(2H, m), 7.29 (2H, d, J 6.9 Hz), 3.77 – 3.65 (4H, m), 3.53 (2H, s), 2.46 (4H, s). δC (101 MHz, CDCl3) 134.1, 
128.6, 67.0, 63.7, 53.7. CI-HRMS: m/z calculated for C11H15NO [M-(BO2H)+H]+ requires 178.1226. 
Found 178.1232. 
Preparation of (4-((4-fluoropiperidin-1-yl)methyl)phenyl)boronic acid (69b) 
(4-(bromomethyl)phenyl)boronic acid (68) (0.52 g, 2.41 mmol, 1 eq) 4-fluoropiperidine 
hydrochloride (0.36 g, 2.53 mmol, 1.05 eq), and DIPEA (0.92 cm3, 5.30 mmol, 2.2 eq), were used in 
THF (5 cm3) following general procedure 7 to give 69b as a white foam (0.54 g, 95 %). δH (400 MHz, 
DMSO) 8.05 (2H, s), 7.71 (2H, d, J 7.8 Hz), 7.24 (2H, d, J 7.8 Hz), 3.44 (2H, s), 3.38 – 3.12 (2H, m), 2.45 
(1H, s), 2.25 (1H, br s), 1.90 – 1.60 (2H, m). δC (101 MHz, DMSO) 140.4, 134.3, 128.3, 88.8 (d, J 168.6 
Hz), 62.2, 49.3, 31.3 (d, J 19.0 Hz). CI-HRMS: m/z calculated for C12H16FN [M-(BO2H)+H]+ requires 
194.1340. Found 194.1334, and 176.1436 [(M-BO2H-F)+H]+.   
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Preparation of (4-((4-methylpiperazin-1-yl)methyl)phenyl)boronic acid (69c) 
(4-(bromomethyl)phenyl)boronic acid (68) (1.01 g, 4.71 mmol, 1 eq), N-methylpiperazine 
(0.63 cm3, 5.65 mmol, 1.2 eq), and DIPEA (0.98 cm3, 5.65 mmol, 1.2 eq), were used in THF (10 cm3)  
following general procedure 7 to give 69c as a white solid (0.51 g, 46 %). δH (400 MHz, MeOD) 7.60 
(2H, d, J 6.9 Hz), 7.30 (2H, d, J 7.8 Hz), 3.57 (1H, s), 2.57 (8H, s), 2.34 (3H, s). δC (101 MHz, DMSO) 140.5, 
140.2, 134.1, 133.9, 128.0, 127.9, 62.2, 54.7, 52.6, 45.7. CI-HRMS: m/z calculated for C12H19N2 [M-
(BO2H)+H]+ requires 191.1543. Found 191.1547.  
General Procedure 8: Suzuki couplings 
To a mixture of THF (5 cm3) and water (5 cm3) was added 3-bromoaniline (2.18 cm3, 20.01 
mmol, 3 eq) and potassium carbonate (2.78 g, 20.01 mmol, 3 eq) the flask was evacuated and 
backfilled with N2. (4-(Trifluoromethyl)phenyl)boronic acid (1.27 g, 6.67 mmol, 1 eq) was added, the 
flask evacuated and backfilled with N2. Finally palladium tetrakis (0.19 g, 0.17 mmol, 0.025 eq) was 
added and the reaction vessel was evacuated and backfilled with N2 before refluxing at 80 °C 
overnight. The reaction mixture was diluted with brine (50 cm3) and product extracted into ethyl 
acetate (3 x 50 cm3). Organics were dried with MgSO4 and product purified by column chromatography 
(20 % EtOAc in Hex) to give 71a as a white solid (1.58 g, 75 %). 
Generic structure of compounds 71a – e following general procedure 8 
 
Preparation of 4'-(trifluoromethyl)-[1,1'-biphenyl]-3-amine (71a) 
(4-(Trifluoromethyl)phenyl)boronic acid (1.27 g, 6.67 mmol, 1 eq), 3-bromoaniline (70) (2.18 
cm3, 20.01 mmol, 3 eq), potassium carbonate (2.78 g, 20.01 mmol, 3 eq), and palladium tetrakis (0.19 
g, 0.17 mmol, 0.025 eq), were used in THF (5 cm3) and water (5 cm3) following general procedure 8, 
purified by column chromatography (20 % EtOAc in Hexane) to give 71a as a white solid (1.58 g, 75 
%). δH (400 MHz, CDCl3) 7.69 – 7.62 (4H, m), 7.25 (1H, apparent t), 6.98 (1H, d, J 7.6 Hz), 6.89 (1H, s), 
6.72 (1H, dd, J 7.9, 1.8 Hz), 3.76 (2H, br s). δC (101 MHz, CDCl3) 146.9, 144.9, 141.0, 129.9, 129.3 (q, J 
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32.4 Hz), 127.4, 125.6 (q, J 3.8 Hz), 124.4 (q, J 271.8 Hz), 117.7, 114.9, 113.9. CI-HRMS: m/z calculated 
for C13H11F3N [M+H]+ requires 238.0838. Found 238.0845. 
Preparation of 4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-amine (71b) 
(4-(Trifluoromethoxy)phenyl)boronic acid (0.36 g, 1.74 mmol, 1.2 eq), 3-bromoaniline (70) 
(0.16 cm3, 1.45 mmol, 1 eq), potassium carbonate (0.60 g, 4.35 mmol, 3 eq), and palladium tetrakis 
(0.043 g, 0.036 mmol, 0.025 eq) were used in THF (5 cm3) and water (5 cm3) following general 
procedure 8, purified by column chromatography (20 % EtOAc in Hex) to give 71b as a brown oil (0.30 
g, 82 %). δH (400 MHz, CDCl3) 7.58 – 7.54 (2H, m), 7.28 – 7.19 (3H, m), 6.94 (1H, ddd, J 7.6, 1.5, 0.9 Hz), 
6.86 (1H, apparent t), 6.69 (1H, ddd, J 7.9, 2.3, 0.8 Hz), 3.75 (2H, br s). δC (101 MHz, CDCl3) 148.7 (q, J 
1.6 Hz), 147.0, 141.2, 140.3, 130.0, 128.5, 121.2, 120.7 (q, J 257.1 Hz), 117.7, 114.6, 113.9. δF (375 
MHz, CDCl3) -57.8 (3F, s). CI-HRMS: m/z calculated for C13H11F3NO [M+H]+ requires 254.0787. Found 
254.0789. 
Preparation of 4'-(morpholinomethyl)-[1,1'-biphenyl]-3-amine (71c) 
Compound 69a (0.91 g, 4.09 mmol, 1 eq), 3-bromoaniline (70) (1.32 cm3, 12.27 mmol, 3 eq), 
potassium carbonate (0.57 g, 12.27 mmol, 3 eq), and palladium tetrakis (0.12 g, 0.10 mmol, 0.025 eq), 
were used following general procedure 8 purified by column chromatography (40 % EtOAc in Hex) to 
give 71c as a yellow to orange oil (0.98 g, 90 %). δH (400 MHz, CDCl3) 7.52 (2H, d, J 8.1 Hz), 7.37 (2H, d, 
J 8.1 Hz), 7.22 (1H, apparent t, J 7.8 HZ), 6.99 (1H, d, J 7.7 Hz), 6.90 (1H, apparent t), 6.67 (1H, dd, J 
7.9, 1.6 Hz), 3.76 – 3.70 (4H, apparent t), 3.53 (2H, s), 2.48 (4H, br s). δC (101 MHz, CDCl3) 146.8, 142.2, 
140.4, 136.8, 129.8, 129.7, 127.1, 117.7, 114.2, 113.9, 67.1, 63.3, 53.8. ESI-HRMS: m/z calculated for 
C17H21N2O [M+H]+ requires 269.1648. Found 269.1647. 
Preparation of 4'-((4-fluoropiperidin-1-yl)methyl)-[1,1'-biphenyl]-3-amine (71d) 
Compound 69b (0.54 g, 2.29 mmol, 1 eq), 3-bromoaniline (70) (0.75 cm3, 6.87 mmol, 3 eq), 
potassium carbonate (0.95 g, 6.87 mmol, 3 eq), and palladium tetrakis (0.066 g, 0.057 mmol, 0.025 
eq) were used in THF (5 cm3) and water (5 cm3)  following general procedure 8 purified by column 
chromatography (40 % EtOAc in Hex) to give 71d as a clear yellow oil (0.32 g, 50 %). δH (400 MHz, 
CDCl3) 7.52 (2H, d, J 8.1 Hz), 7.36 (2H, d, J 8.1 Hz), 7.22 (1H, t, J 7.8 Hz), 6.99 (1H, d, J 7.7 Hz), 6.91 (1H, 
apparent t), 6.67 (1H, dd, J 7.9, 2.2 Hz), 4.79 – 4.59 (1H, m), 3.54 (2H, s), 2.68 – 2.55 (2H, m), 2.46 – 
2.36 (2H, m), 2.00 – 1.81 (4H, m). δC (101 MHz, CDCl3) 146.9, 142.3, 140.3, 137.5, 129.8, 129.5, 127.1, 
117.7, 114.2, 113.9, 88.9 (d, J 171.6 Hz), 62.8, 49.7 (d, J 5.8 Hz), 31.7 (d, J 19.4 Hz). ESI-HRMS: m/z 
calculated for C18H22FN2 [M+H]+ requires 285.1762. Found 285.1772. 
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Preparation of 4'-((4-methylpiperazin-1-yl)methyl)-[1,1'-biphenyl]-3-amine (71e) 
Compound 69c (0.89 g, 3.80 mmol, 1 eq) 3-bromoaniline (70) (1.24 cm3, 11.41 mmol, 3 eq), 
potassium carbonate (1.58 g, 11.41 mmol, 3 eq), and palladium tetrakis (0.11 g, 0.095 mmol, 0.025 
eq) were used in THF (5 cm3) and water (5 cm3) following general procedure 8 purified by column 
chromatography (5 % MeOH in EtOAc) to give 71e as a clear orange oil (1.01 g, 94 %). δH (400 MHz, 
CDCl3) 7.50 (2H, d, J 8.1 Hz), 7.36 (2H, d, J 8.1 Hz), 7.21 (1H, apparent t, J 7.8 Hz), 6.98 (1H, d, J 7.7 Hz), 
6.90 (1H, apparent t), 6.67 (1H, dd, J 7.8, 1.8 Hz), 3.73 (2H, br s), 3.54 (2H, s), 2.48 (8H, s, J 11.3 Hz), 
2.29 (3H, s). δC (101 MHz, CDCl3) 146.8, 142.3, 140.3, 137.3, 129.8, 129.6, 127.0, 117.7, 114.1, 113.9, 
62.9, 55.3, 53.2, 46.2. ESI-HRMS: m/z calculated for C18H24N3 [M+H]+ requires 282.1965. Found 
282.1969. 
Preparation of 4-(3-nitrobenzyl)morpholine (73) 
 
1-(bromomethyl)-3-nitrobenzene (72) (2.00 g, 9.27 mmol, 1 eq),  morpholine (0.81 cm3, 9.27 
mmol, 1 eq), and DIPEA (1.94 cm3, 11.12 mmol, 1.2 eq) were used in THF (20 cm3) following general 
procedure 7 to give 73 as a white solid (2.04 g, 99 %). δH (400 MHz, CDCl3) 8.22 (1H, s), 8.12 (1H, d, J 
8.2 Hz), 7.68 (1H, d, J 7.6 Hz), 7.49 (1H, apparent t, J 7.9 Hz), 3.76 – 3.69 (4H, m apparent t), 2.50 – 
2.42 (4H, apparent t). δC (101 MHz, CDCl3) 148.5, 140.4, 135.2, 129.4, 123.9, 122.5, 67.0, 62.5, 53.7. 
CI-HRMS: m/z calculated for C11H15N2O3 [M+H]+ requires 223.1077. Found 223.1086. 
General procedure 9: Reduction of nitro group via Fe AcOH 
To compound 73 (2.04 g, 9.16 mmol, 1 eq) was added ethanol (20 cm3), acetic acid (20 cm3) 
and iron powder (2.56 g, 45.79 mmol, 5 eq). The reaction was refluxed overnight under an N2 
atmosphere. Reaction mixture was filtered through celite, and washed with EtOAc (50 cm3), solvents 
were removed in vacuo. Water (100 cm3) was added and the product extracted into EtOAc (3 x 100 
cm3), organics washed with saturated HNaCO3 (100 cm3), water (100 cm3), brine (100 cm3) and dried 
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Preparation of 3-(morpholinomethyl)aniline (74) 
 
Compound 73 (2.04 g, 9.16 mmol, 1 eq) and iron powder (2.56 g, 45.79 mmol, 5 eq) were used 
in ethanol (20 cm3) and acetic acid (20 cm3) following general procedure 9 to give 74 as a brown oil 
(1.68 g, 96 %). δH (400 MHz, CDCl3) 7.09 (1H, apparent t), 6.72 – 6.68 (2H, m), 6.60 – 6.56 (1H, m), 3.77 
– 3.59 (6H, m), 3.40 (2H, s), 2.48 – 2.38 (4H, m). δC (101 MHz, CDCl3) 146.5, 139.1, 129.2, 119.7, 115.9, 
114.1, 67.1, 63.6, 53.8. CI-HRMS: m/z calculated for C11H17N2O [M+H]+ requires 193.1335. Found 
193.1340.  
General Procedure 10: Amide couplings via oxalyl chloride 
 To desired 2-iodobenzoic acid (75) (1.50 g, 6.04 mmol, 1.2 eq) was added anhydrous DCM (10 
cm3) under a N2 atmosphere. The resulting solution was then cooled to 0 °C before the addition of 
oxalyl chloride (1.06 cm3, 12.58 mmol, 2.5 eq) and a catalytic amount of DMF (1 drop). The resulting 
solution was stirred for 3 hours, after this time solvents were removed in vacuo to yield the acyl 
chloride, this is then used immediately via re-dissolving in anhydrous DCM (10 cm3) under a N2 
atmosphere before addition of compound 71a (1.19 g, 5.03 mmol, 1 eq), and triethylamine (0.84 cm3, 
6.04 mmol, 1.2 eq). The solution is then left to stir overnight. The organics were washed with 2 M HCl 
(50 cm3), a saturated solution of HNaCO3 (50 cm3), water (50 cm3) and brine (50 cm3) and dried over 
MgSO4. Solvents were removed in vacuo to yield 76a as a white solid (1.38 g, 49 %). Compound used 
in the next step without further purification. 
Generic structure of compounds 76a – f following general procedure 10 
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Preparation of 2-iodo-N-(4'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)benzamide (76a) 
Compound 71a (1.19 g, 5.03 mmol, 1 eq), 2-iodobenzoic acid (75) (1.50 g, 6.04 mmol, 1.2 eq), 
oxalyl chloride (1.06 cm3, 12.58 mmol, 2.5 eq), triethylamine (0.84 cm3, 6.04 mmol, 1.2 eq), and 
catalytic DMF (1 drop) were used in anhydrous DCM (10 cm3) following general procedure 10 to give 
76a as a white solid (1.38 g, 49 %). Compound used in the next step without further purification. δH 
(400 MHz, CDCl3) 7.97 (1H, s), 7.92 (1H, d, J 7.9 Hz), 7.75 – 7.67 (4H, m), 7.65 – 7.57 (2H, m), 7.56 – 
7.52 (1H, m), 7.50 – 7.38 (3H, m), 7.16 (1H, apparent td). δC (101 MHz, CDCl3) 167.5, 144.2, 142.1, 
141.0, 140.3, 138.3, 132.3 – 131.9 (m), 129.9, 129.8 (q, J 33.0 Hz), 128.7, 128.6, 127.7, 125.9 (q, J 3.8 
Hz), 124.4 (q, J 272.1 Hz), 123.9, 119.8, 119.1, 92.5. δF (375 MHz, CDCl3) -62.4 (3F, s). ESI-HRMS: m/z 
calculated for C20H13F3INNaO [M+Na]+ requires 489.9886. Found 489.9890. 
Preparation of 2-iodo-N-(4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-yl)benzamide (76b) 
Compound 71b (0.27 g, 1.07 mmol, 1.2 eq), 2-iodobenzoic acid (75) (0.22 g, 0.89 mmol, 1 eq), 
oxalyl chloride 2 M solution in DCM (0.89 cm3, 1.78 mmol, 2 eq), triethylamine (0.15 cm3, 1.07 mmol, 
1.2 eq), and catalytic DMF (1 drop) were used in anhydrous DCM (5 cm3) following general procedure 
10 to give 76b as an off white to yellow powder (0.15 g, 35 %). Used in the next step without further 
purification. δH (400 MHz, CDCl3) 7.95 – 7.88 (2H, m), 7.66 – 7.57 (4H, m), 7.54 (1H, dd, J 7.6, 1.3 Hz), 
7.48 – 7.41 (2H, m), 7.37 (1H, d, J 7.7 Hz), 7.28 (2H, d, J 8.2 Hz), 7.16 (1H, apparent td). δC (101 MHz, 
CDCl3) 167.4, 149.0, 142.1, 141.1, 140.3, 139.5, 138.2, 131.8, 129.8, 128.8, 128.6, 123.8, 121.4, 119.4, 
119.0, 92.5. ESI-HRMS: m/z calculated for C20H13F3INNaO2 [M+Na]+ requires 505.9835. Found 
505.9847. 
Preparation of 2-iodo-N-(4'-(morpholinomethyl)-[1,1'-biphenyl]-3-yl)benzamide (76c) 
Compound 71c (1.07 g, 3.98 mmol, 1 eq), 2-iodobenzoic acid (1.19 g, 4.78 mmol, 1.2 eq), oxalyl 
chloride (0.67 cm3, 7.96 mmol, 2 eq), triethylamine (0.67 cm3, 4.48 mmol, 1.2 eq), and catalytic DMF 
(1 drop) were used in anhydrous DCM (10 cm3) following general procedure 10, note HCl not used in 
workup. Purified by column chromatography (50 % EtOAc in Hex) to give 76c as a white solid (1.15 g, 
58 %). δH (400 MHz, CDCl3) 7.94 – 7.88 (2H, m), 7.66 – 7.59 (2H, m), 7.59 – 7.52 (3H, m), 7.47 – 7.38 
(5H, m), 7.15 (1H, apparent td), 3.75 – 3.69 (4H, apparent t), 3.54 (2H, s), 2.51 – 2.44 (4H, apparent t). 
δC (101 MHz, CDCl3) 167.4, 142.3, 142.2, 140.2, 139.6, 138.1, 137.4, 131.7, 129.8, 129.7, 128.7, 128.5, 
127.3, 123.7, 119.0, 118.9, 92.5, 67.2, 63.2, 53.8. ESI-HRMS: m/z calculated for C24H27IN2O2 [M+H]+ 
requires 499.0877. Found 499.0877. 
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Preparation of N-(4'-((4-fluoropiperidin-1-yl)methyl)-[1,1'-biphenyl]-3-yl)-2-iodobenzamide (76d) 
Compound 71d (0.32 g, 1.12 mmol, 1 eq), 2-iodobenzoic acid (0.29 g, 1.18 mmol, 1.05 eq), 
oxalyl chloride (0.19 cm3, 2.24 mmol, 2 eq), triethylamine (0.16 cm3, 1.18 mmol, 1.05 eq), and catalytic 
DMF (1 drop) were used in anhydrous DCM (5 cm3) following general procedure 10, note HCl not used 
in workup. Purified by column chromatography (100 % EtOAc) to give 76d as a white solid (0.31 g, 53 
%). δH (400 MHz, CDCl3) 7.95 – 7.86 (2H, m), 7.69 – 7.59 (2H, m), 7.59 – 7.49 (3H, m), 7.47 – 7.33 (5H, 
m), 7.14 (1H, t, J 7.4 Hz), 4.79 – 4.55 (1H, m), 3.55 (2H, s), 2.69 – 2.54 (2H, m), 2.50 – 2.32 (2H, m), 2.01 
– 1.74 (4H, m). δC (101 MHz, CDCl3) 167.4, 142.2, 142.2, 140.2, 139.5, 138.1, 137.9, 131.7, 129.7, 128.7, 
128.5, 127.2, 123.7, 119.0, 118.9, 92.5, 88.8 (d, J 170.1 Hz), 62.7, 49.6 (d, J 6.0 Hz), 31.6 (d, J 19.4 Hz). 
ESI-HRMS: m/z calculated for C25H25FIN2O [M+H]+ requires 515.0990. Found 515.0978. 
Preparation of 2-iodo-N-(4'-((4-methylpiperazin-1-yl)methyl)-[1,1'-biphenyl]-3-yl)benzamide (76e) 
Compound 71e (0.74 g, 2.64 mmol, 1 eq), 2-iodobenzoic acid (0.72 g, 2.90 mmol, 1.1 eq), 
oxalyl chloride (0.45 cm3, 5.27 mmol, 2 eq), triethylamine (0.40 cm3, 2.90 mmol, 1.2 eq), and catalytic 
DMF (1 drop) were used in anhydrous DCM (5 cm3) following general procedure 10, note HCl not used 
in workup. Purified by column chromatography (10 % MeOH in EtOAc and a few drops of NEt3) to give 
76e as a sticky off white to light yellow foam (1.00 g, 74 %). δH (400 MHz, CDCl3) 7.92 (1H, d, J 7.9 Hz), 
7.87 (1H, s), 7.66 – 7.60 (2H, m), 7.58 – 7.53 (3H, m), 7.48 – 7.42 (2H, m), 7.42 – 7.37 (3H, m), 7.16 
(1H,apparent td), 3.55 (2H, s), 2.51 (8H, s), 2.31 (3H, s). δC (101 MHz, CDCl3) 167.4, 142.2, 142.2, 140.2, 
139.5, 138.1, 137.7, 131.7, 129.8, 129.7, 128.7, 128.5, 127.2, 123.8, 119.0, 118.9, 92.5, 62.8, 55.2, 
53.1, 46.1. ESI-HRMS: m/z calculated for C25H26IN3O [M+H]+ requires 512.1193. Found 512.1197. 
Preparation of 2-iodo-N-(3-(morpholinomethyl)phenyl)benzamide (76f)  
Compound 74 (1.01 g, 5.23 mmol, 1 eq), 2-iodobenzoic acid (1.56 g, 6.27 mmol, 1.2 eq), oxalyl 
chloride (0.88 cm3, 10.45 mmol, 2 eq), triethylamine (0.88 cm3, 5.23 mmol, 1.2 eq), and catalytic DMF 
(1 drop) were used in anhydrous DCM (10 cm3) following general procedure 10, note HCl not used in 
workup. To give 76f as a white to yellow semi solid (1.71 g, 78 %). Compound used without further 
purification. δH (400 MHz, CDCl3) 7.90 (1H, d, J 7.8 Hz), 7.65 (1 H, s), 7.59 – 7.55 (2H, m), 7.50 (1H, dd, 
J 7.6, 1.5 Hz), 7.44 – 7.39 (1H, m), 7.32 (1H, apparent t), 7.17 – 7.11 (2H, m), 3.72 – 3.66 (4H, m), 3.50 
(2H, s), 2.50 – 2.40 (4H, m). δC (101 MHz, CDCl3) 167.4, 142.2, 140.2, 139.2, 137.7, 131.6, 129.1, 128.6, 
128.5, 125.7, 120.7, 119.1, 92.5, 67.1, 63.3, 53.7. ESI-HRMS: m/z calculated for C18H20IN2O2 [M+H]+ 
requires 423.0564. Found 423.0568. 
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General Procedure 11: Cyclisation to 1,2 benzoisoselenazoles 
To a stirred solution of DMF (5 cm3) was added copper(I) iodide (0.28 g, 1.46 mmol, 1 eq) and 
1, 10-phenanthroline (0.26 g, 1.46 mmol, 1 eq) and was stirred for five minutes. Selenium powder 
(0.14 g, 1.76 mmol, 1.2 eq), potassium carbonate (0.32 g, 2.34 mmol, 1.6 eq) and compound 76a (0.68 
g, 1.46 mmol, 1 eq), were added sequentially. The reaction mixture was heated under reflux at 120 °C 
for 20 hours under a N2 atmosphere. The mixture was poured into brine (50 cm3) and stirred for three 
hours. The product was filtered under vacuum and extracted into ethyl acetate (3 x 50 cm3) washed 
with brine (50 cm3) and dried with MgSO4. Solvents removed in vacuo and the product purified by 
column chromatography (20 % EtOAc in Hex). Solvents were removed in vacuo and the residue was 
recrystallised from ethyl acetate to give 77 as white crystals (0.042 g, 7 %).  
Generic structure of compounds 77 – 82  
 
Preparation of 2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)benzo[d][1,2]selenazol-3(2H)-one (77) 
Compound 76a (0.68 g, 1.46 mmol, 1 eq), CuI (0.28 g, 1.46 mmol, 1 eq), 1,10-phenanthroline 
(0.26 g, 1.46 mmol, 1 eq), potassium carbonate (0.32 g, 2.34 mmol, 1.6 eq) and selenium powder (0.14 
g, 1.76 mmol, 1.2 eq), were used in DMF (5 cm3) following general procedure 11, product purified by 
column chromatography (20 % EtOAc in hexane). Solvents were removed in vacuo and the residue 
was recrystallised from ethyl acetate to give 77 as white crystals (0.042 g, 7 %). δH (400 MHz, CDCl3) 
8.14 (1H, d, J 7.8 Hz), 7.94 (1H, s), 7.76 – 7.65 (6H, m), 7.62 (1H, br d, J 7.3 Hz), 7.58 – 7.45 (3H, m). δC 
(101 MHz, CDCl3) 166.0, 143.9, 141.2, 140.0, 137.7, 132.9, 130.1, 129.8, 129.6, 127.8, 127.6, 126.9, 
126.0 (q, J 3.7 Hz), 125.7, 125.1, 124.5, 123.9. δF (375 MHz, CDCl3) -62.5 (3F, s). ESI-HRMS: m/z 
calculated for C20H12F3NNaOSe [M+Na]+ requires 441.9928. Found 441.9929. Elemental Analysis 
Calculated for C20H12F3NOSe requires C, 57.43; H, 2.89; N, 3.35, found C, 57.46; H, 2.83; N, 3.28. IR 
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(neat): νmax/cm-1: 3088 (w), 3052 (w), 1599 (s), 1563 (s), 1485 (m), 1326 (s), 1305 (s), 1125 (s), 1108 
(s). Melting Point oC: 223 – 224 °C (EtOAc). 
Preparation of 2-(4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-yl)benzo[d][1,2]selenazol-3(2H)-one (78) 
Compound 76b (0.14 g, 0.28 mmol, 1 eq), CuI (0.026 g, 0.14 mmol, 0.5 eq), 1,10-
phenanthroline (0.025 g, 0.14 mmol, 0.5 eq), potassium carbonate (0.077 g, 0.56 mmol, 2 eq) and 
selenium powder (0.027 g, 0.34 mmol, 1.2 eq) were used in DMF (3 cm3) following general procedure 
11, product purified by column chromatography (25 % EtOAc in hexane). Solvents were removed in 
vacuo and the residue was recrystallised from ethyl acetate to give 78 as a static white solid (0.024 g, 
20 %). δH (400 MHz, CDCl3) 8.14 (1H, d, J 7.8 Hz), 7.89 (1H, apparent t, J 1.8), 7.69 – 7.66 (2H, m), 7.66 
– 7.62 (2H, m), 7.62 – 7.58 (1H, m), 7.54 – 7.45 (3H, m), 7.30 (2H, d, J 8.1 Hz). δC (101 MHz, CDCl3) 
166.0, 149.1, 141.3, 139.8, 139.1, 137.7, 132.9, 130.0, 129.6, 128.8, 127.6, 126.8, 125.6, 124.6, 124.3, 
123.9, 121.5. ESI-HRMS: m/z calculated for C20H12F3NNaO2Se [M+Na]+ requires 457.9878. Found 
457.9881. Elemental Analysis Calculated for C20H12F3NO2Se requires, C, 55.31; H, 2.79; N, 3.23, found, 
C, 54.79; H, 2.71; N, 3.09. IR (neat): νmax/cm-1: 3088 (w), 3053 (w), 1597 (s), 1563 (s), 1483 (m), 1443 
(m), 1269 (s, br), 1204 (s, br), 1154 (s, br). Melting Point oC: 204 – 205 (EtOAc). 
Preparation of 2-(4'-(morpholinomethyl)-[1,1'-biphenyl]-3-yl)benzo[d][1,2]selenazol-3(2H)-one (79) 
Compound 76c (0.58 g, 1.16 mmol, 1 eq), CuI (0.22 g, 1.16 mmol, 1 eq), 1,10-phenanthroline 
(0.21 g, 1.16 mmol, 1 eq), potassium carbonate (0.26 g, 1.86 mmol, 1.6 eq) and selenium powder (0.11 
g, 1.39 mmol, 1.2 eq), were used in DMF (5 cm3)  following general procedure 11, product purified by 
column chromatography (50 % EtOAc in hexane). Solvents were removed in vacuo and the residue 
was recrystallised from ethyl acetate to give 79 as a white solid (0.094 g, 18 %). δH (400 MHz, CDCl3) 
8.14 (1H, d, J 7.8 Hz), 7.87 (1H, s), 7.71 – 7.63 (2H, m), 7.61 – 7.54 (3H, d + another m underneath, J 
8.0 Hz), 7.53 – 7.46 (3H, m), 7.41 (2H, d, J 8.0 Hz), 3.78 – 3.69 (4H, apparent t), 3.54 (2H, s), 2.48 (4H, 
br s). δC (101 MHz, CDCl3) 165.9, 142.5, 139.7, 139.3, 137.8, 137.6, 132.8, 129.83, 129.81, 129.6, 127.7, 
127.3, 126.8, 125.6, 124.3, 124.2, 123.9, 67.2, 63.2, 53.8. ESI-HRMS: m/z calculated for C24H23N2O2Se 
[M+H]+ requires 451.0919. Found 451.0906. Elemental Analysis Calculated for C24H22N2O2Se requires, 
C, 64.14; H, 4.93; N, 6.23, found C, 63.73; H, 4.82; N, 6.09. IR (neat): νmax/cm-1: 3088 (w), 3053 (w), 
2856 (w), 2800 (w), 1587 (s), 1561 (s), 1441 (m), 1307 (s), 1108 (s). Melting Point oC: 179 – 180 (EtOAc). 
Preparation of 2-(4'-((4-fluoropiperidin-1-yl)methyl)-[1,1'-biphenyl]-3-yl)benzo[d][1,2]selenazol-
3(2H)-one (80) 
Compound 76d (0.31 g, 0.60 mmol, 1 eq), CuI (0.11 g, 0.60 mmol, 1 eq), 1,10-phenanthroline 
(0.11 g, 0.60 mmol, 1 eq), potassium carbonate (0.13 g, 0.95 mmol, 1.6 eq) and selenium powder 
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(0.056 g, 0.71 mmol, 1.2 eq), were used in DMF (5 cm3) following general procedure 11, product 
purified by column chromatography (100 % EtOAc). Solvents were removed in vacuo and the residue 
was recrystallised from ethyl acetate to give 80 as a white solid (0.030 g, 11 %). δH (400 MHz, CDCl3) 
8.14 (1H, d, J 7.8 Hz), 7.87 (1H, s), 7.70 – 7.63 (2H, m), 7.62 – 7.54 (3H, m), 7.53 – 7.45 (3H, m), 7.40 
(2H, d, J 8.0 Hz), 4.81 – 4.57 (1H, m), 3.55 (2H, s), 2.69 – 2.56 (2H, m), 2.45 – 2.32 (2H, m), 2.00 – 1.83 
(4H, m). δC (101 MHz, CDCl3) 165.9, 142.5, 139.7, 139.1, 138.3, 137.8, 132.8, 129.8, 129.7, 129.6, 127.7, 
127.3, 126.8, 125.6, 124.3, 124.2, 123.9, 88.9 (d, J 169.9 Hz), 62.8, 49.7 (d, J 6.0 Hz), 31.7 (d, J 19.4 Hz). 
ESI-HRMS: m/z calculated for C25H23FN2OSe [M+H]+ requires 467.1032. Found 467.1028. Elemental 
Analysis Calculated for C25H23FN2OSe requires C, 64.52; H, 4.98; F, 4.08; N, 6.02, found C, 64.70; H, 
4.90; N, 5.97. Melting Point oC: 181 – 182 °C (EtOAc). 
Preparation of 2-(4'-((4-methylpiperazin-1-yl)methyl)-[1,1'-biphenyl]-3-yl)benzo[d][1,2]selenazol-
3(2H)-one (81) 
 Compound 76e (0.19 g, 0.38 mmol, 1 eq), CuI (0.036 g, 0.19 mmol, 0.5 eq), 1,10-
phenanthroline (0.034 g, 0.19 mmol, 0.5 eq), potassium carbonate (0.11 g, 0.73 mmol, 2 eq) and 
selenium powder (0.036 g, 0.45 mmol, 1.2 eq), were used in DMF (3 cm3) following general procedure 
11, product purified by column chromatography (20 % MeOH in EtOAc with a few drops of NEt3) to 
give 81 as a yellow to off white foam (0.012 g, 7 %). δH (400 MHz, CDCl3) 8.13 (1H, d, J 7.8), 7.86 (1H, 
s), 7.72 – 7.64 (2H, m), 7.61 – 7.54 (3H, m), 7.52 – 7.46 (3H, m), 7.39 (2H, d, J 8.0), 3.57 (2H, s), 2.60 
(8H, br s), 2.38 (3H, s). δC (101 MHz, CDCl3) 165.9, 142.4, 139.7, 139.2, 137.83, 137.81, 132.7, 129.8, 
129.5, 127.7, 127.2, 126.7, 125.5, 124.3, 124.2, 124.0, 62.7, 55.1, 52.9, 46.0. ESI-HRMS: m/z calculated 
for C25H26N3OSe [M+H]+ requires 464.1236. Found 464.1243. Elemental Analysis Calculated for 
C25H25N3OSe requires, C, 64.93; H, 5.45; N, 9.09, found, C, 61.78; H, 5.25; N, 8.60. 
Preparation of 2-(3-(morpholinomethyl)phenyl)benzo[d][1,2]selenazol-3(2H)-one (82)  
Compound 76f (0.65 g, 1.53 mmol, 1 eq), CuI (0.15 g, 0.77 mmol, 0.5 eq), 1,10-phenanthroline 
(0.14 g, 0.77 mmol, 0.5 eq), potassium carbonate (0.34 g, 2.45 mmol, 1.6 eq) and selenium powder 
(0.12 g, 1.84 mmol, 1.2 eq), were used in DMF (5 cm3) following general procedure 11, product 
purified by column chromatography (100 % EtOAc). Solvents were removed in vacuo and the residue 
was recrystallised from ethyl acetate to give 82 as a white Solid (0.088 g, 15 %). δH (400 MHz, CDCl3) 
8.11 (1H, d, J 7.9 Hz), 7.69 – 7.62 (3H, m), 7.53 – 7.45 (2H, m), 7.38 (1H, t, J 7.8 Hz), 7.27 – 7.23 (1H, 
m), 3.76 – 3.68 (4H, apparent t), 3.53 (2H, s), 2.47 (4H, br s). δC (101 MHz, CDCl3) 165.8, 139.6, 139.2, 
137.7, 132.7, 129.5, 129.3, 127.7, 127.6, 126.7, 126.1, 124.2, 123.9, 67.2, 63.1, 53.7. ESI-HRMS: m/z 
calculated for C18H19N2O2Se [M+H]+ requires 375.0606. Found 375.0615. Elemental Analysis 
Calculated for C18H18N2O2Se requires, C, 57.91; H, 4.86; N, 7.50, found, C, 57.77; H, 4.79; N, 7.42. IR 
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(neat): νmax/cm-1: 3087 (w), 3054 (w), 2972 (w), 2858 (w), 2801 (w), 1590 (s), 1561 (s), 1442 (s), 1330 
(s), 1087 (s). Melting Point oC: 179 – 180 (EtOAc). 
Preparation of 4-((1-ethoxy-1-oxopropan-2-yl)thio)-3-nitrobenzoic acid (94) 
 
To 4-chloro-3-nitrobenzoic acid (92) (2.01 g, 9.97 mmol, 1 eq), pyridine (15 cm3) was added 
under an N2 atmosphere. To the resultant viscous fluid ethyl-2-mercaptopropionate (93) (1.61 cm3, 
12.4 mmol, 1.2 eq) was added and stirred under reflux overnight. The resultant solution was acidified 
with 2 M hydrochloric acid, extracted with ethyl acetate (3 x 50 cm3) the organic layers were collected, 
dried with magnesium sulfate and the solvent removed in vacuo. The resultant brown oil was left 
overnight and solidified. The brown solid was washed with hexane and diethyl ether, the mixture of 
solvents was pipetted out of the flask and excess solvents removed in vacuo to give 94 as a yellow 
brown solid (2.46 g, 82 %). δH (400 MHz, CDCl3) 8.91 (1H, d, J 1.8 Hz), 8.22 (1H, dd, J 8.5, 1.8 Hz), 7.73 
(1H, d, J 8.6 Hz), 4.26 – 4.16 (2H, m), 4.12 (1H, q, J 7.3 Hz), 1.68 (3H, d, J 7.2 Hz), 1.25 (3H, t, J 7.1 Hz). 
δC (101 MHz, CDCl3) 171.9, 169.7, 145.6, 143.3, 134.1, 128.0, 127.7, 126.5, 62.3, 43.4, 17.2, 14.2. ESI-
HRMS: m/z calculated for C12H13NNaO6S [M+Na]+ requires 322.0256. Found 322.0359. 
Preparation of ethyl 4-((1-ethoxy-1-oxopropan-2-yl)thio)-3-nitrobenzoate (95) 
 
To 94 (6.75 g, 23 mmol, 1 eq) was added 2 M oxalyl chloride (22.5 cm3, 45 mmol, 2 eq) in a N2 
atmosphere. Four drops of DMF was added and the reaction left to stir for two hours. Solvents were 
removed in vacuo, product re-dissolved ethanol was added and stirred under an N2 atmosphere for 
30 minutes. Solvents were concentrated in vacuo and ethyl acetate (25 cm3) was added to the residue. 
This was washed with saturated HNaCO3 solution (3 x 50 cm3) and brine (50 cm3). Organic layer was 
collected and solvents removed in vacuo to yield 95 as a brown oil (7.53 g, 96 %). δH (400 MHz, CDCl3) 
8.81 (1H, d, J 1.9), 8.17 (1H, dd, J 8.5, 1.9), 7.67 (1H, d, J 8.6), 4.41 (2H, q, J 7.1), 4.24 – 4.14 (2H, m), 
4.09 (1H, q, J 7.2), 1.65 (3H, d, J 7.2), 1.41 (3H, t, J 7.1), 1.23 (3H, t, J 7.1). δC (101 MHz, CDCl3) 171.8, 
164.4, 145.7, 141.7, 133.7, 127.9, 127.6, 127.2, 62.1, 61.9, 43.4, 17.1, 14.4, 14.2. CI-HRMS: m/z 
calculated for C14H18NO6S [M+H]+ requires 328.0849. Found 328.0858. 
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Preparation of ethyl 2-methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxylate (96) 
 
Compound 95 (1.30 g, 3.98 mmol, 1 eq) and iron powder (1.33 g, 23.88 mmol, 6 eq), were 
used in acetic acid (10 cm3) and water (10 cm3) following general procedure 9. Reduction and 
cyclisation occurs in situ to give 96 as pale yellow crystals (0.99 g, 99 %). δH (400 MHz, CDCl3) 8.57 (1H, 
s), 7.68 (1H, dd, J 8.1, 1.6 Hz), 7.58 (1H, d, J 1.5 Hz), 7.37 (1H, d, J 8.1 Hz), 4.39 (2H, q, J 7.1 Hz), 3.60 
(1H, q, J 7.1 Hz), 1.51 (3H, d, J 7.1 Hz), 1.39 (3H, t, J 7.1 Hz). δC (101 MHz, CDCl3) 168.2, 165.9, 136.1, 
129.5, 128.0, 125.6, 124.7, 117.9, 61.5, 37.0, 15.7, 14.4. CI-HRMS: m/z calculated for C12H14NO3S 
[M+H]+ requires 252.0689. Found 252.0693. 
Preparation of 2-methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxylic acid (97) 
 
To compound 96 (0.93 g, 3.71 mmol, 1 eq) sodium hydroxide (1 M, 10 cm3) and ethanol (10 
cm3) was added and stirred overnight under a N2 atmosphere. Solvents where removed in vacuo, 
residue acidified with HCl (2 M), washed with ethyl acetate (3 x 50 cm3) and dried with MgSO4. Solvents 
removed in vacuo to give 97 as pale yellow crystals (0.83 g, 99 %). δH (400 MHz, DMSO) 13.01 (1H, s), 
10.75 (1H, s), 7.57 (1H, d, J 1.5), 7.52 (1H, dd, J 8.1, 1.6), 7.43 (1H, d, J 8.1), 3.73 (1H, q, J 7.0), 1.32 (3H, 
d, J 7.0). δC (101 MHz, DMSO) 167.2, 166.7, 137.0, 129.4, 127.7, 124.3, 123.6, 117.4, 35.5, 15.3. CI-
HRMS: m/z calculated C10H10NO3S [M+H]+ requires 224.0376. Found 224.0384. 
Preparation of ethyl 2-(4-(2-methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-
carbonyl)piperazin-1-yl)acetate (99) 
 
Compound 97 (3.01 g, 13.47 mol, 1 eq), was suspended in DCM (50 cm3), this was cooled to 0 
°C and placed under an N2 atmosphere. EDC . HCl (3.10 g, 16.16 mmol, 1.2 eq), HOBT (2.46 g, 16.16 
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mmol, 1.2 eq) and DIPEA (7.04 cm3, 40.40 mmol, 3 eq) were added. The reaction was allowed to stir 
until the suspension dissolved, after which ethyl 2-(piperazin-1-yl)acetate (98) (2.51 cm3, 14.81 mmol, 
1.1 eq) was added and the reaction allowed to warm to room temperature and was left to stir 
overnight. The reaction mixture was washed with saturated HNaCO3 solution (50 cm3), followed by 2 
M HCl (50 cm3) the organic phase was disposed of and the acidified product neutralised with 1 M 
NaOH and extracted back into DCM (3 x 50 cm3). Organics were washed with brine (50 cm3), and dried 
over MgSO4. Solvents were removed in vacuo and the product purified by trituration with Et2O to give 
99 as faded white crystals (3.56 g, 70 %). δH (400 MHz, CDCl3) 8.64 (1H, s), 7.32 (1H, d, J 8.3 Hz), 7.04 
– 6.97 (2H, m), 4.19 (2H, q, J 7.1 Hz), 3.84 (2H, br s), 3.63 – 3.46 (3H, m), 3.27 (2H, s), 2.64 (4H, br s), 
1.50 (3H, d, J 7.1 Hz), 1.28 (3H, t, J 7.1 Hz). δC (101 MHz, CDCl3) 170.1, 169.3, 168.4, 136.7, 134.3, 127.8, 
122.1, 121.7, 116.4, 60.9, 59.2, 53.1 (br), 52.6 (br), 47.8 (br), 42.3 (br), 36.9, 15.7, 14.3. ESI-HRMS: m/z 
calculated for C18H23N3NaO4S [M+Na]+ requires 400.1301. Found 400.1300. Elemental Analysis 
Calculated for C18H23N3O4S requires, C, 57.28; H, 6.14; N, 11.13; S, 8.49, found, C, 57.11; H, 6.12; N, 
10.97; S, 7.86. IR (neat): νmax/cm-1: 3217 (br), 3147 (br), 2931 (s), 1739 (s), 1682 (s), 1597 (s), 1562 (s), 
1184 (s), 1022 (s). Melting Point oC 182 – 184 °C (Et2O). 
Preparation of 2-(4-(2-methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carbonyl)piperazin-1-
yl)acetic acid (100) 
 
To compound 99 (0.20 g, 0.54 mmol, 1 eq) in dioxane (6 cm3) was added and LiOH 1 M (2 cm3). 
The solution was stirred at room temperature for 2 hours. After completion of the reaction extraction 
into organic phase using ethyl acetate (50 cm3) failed, aqueous phase was removed in vacuo to give 
100 as a hydroscopic orange solid used crude in the next step. δH (400 MHz, MeOD) 7.42 (1H, d, J 8.0 
Hz), 7.12 (1H, dd, J 8.0, 1.7 Hz), 7.06 (1H, d, J 1.6 Hz), 3.83 (4H, br s), 3.65 – 3.58 (3H, m), 3.20 (4H, br 
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Compound 100 (0.54 mmol, 1 eq), HATU (0.25 g, 0.65 mmol, 1.2 eq), DIPEA (0.37 cm3, 2.16 
mmol, 4 eq) and cyclopropylamine (0.05 cm3, 0.64 mmol, 1.2 eq), were used in DMF (5 cm3) following 
general procedure 5, purified by column chromatography (100 % EtOAc to 5 % MeOH in EtOAc) 
followed by trituration with Et2O to give 101 as a white solid (0.075 g, 36 % over two steps). X-ray 
crystal was generated through slow recrystallisation from EtOAc. δH (400 MHz, CDCl3) 9.49 (1H, s), 7.30 
(1H, d, J 7.9 Hz), 7.10 (1H, s), 7.04 (1H, s), 6.98 (1H, d, J 7.9 Hz), 3.78 (2H, s), 3.61 – 3.40 (3H, m), 3.02 
(2H, s), 2.77 – 2.66 (1H, m), 2.51 (4H, s), 1.48 (3H, d, J 7.0 Hz), 0.83 – 0.77 (2H, m), 0.55 – 0.44 (2H, m). 
δC (101 MHz, CDCl3) 171.1, 169.5, 168.4, 136.8, 134.0, 127.9, 122.0, 121.9, 116.4, 61.6, 53.4 (br), 47.9 
(br), 42.6 (br), 36.9, 22.2, 15.7, 6.7. CI-HRMS: m/z calculated for C19H25N4O3S [M+H]+ requires 
389.1642. Found 389.1656. Elemental Analysis Calculated for C19H24N4O3S requires, C, 58.74; H, 6.23; 
N, 14.42; S, 8.25, found, C, 57.85; H, 6.31; N, 14.02; S, 7.97. IR (neat): νmax/cm-1:  3289 (br), 3146 (br), 
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Crystal data and structure refinement for 101. 
 
 
Identification code 101 
Empirical formula C19H25N4O3S 
Formula weight 388.48 
Temperature/K 100.02 
Crystal system monoclinic 












Radiation CuKα (λ = 1.54178) 
2Θ range for data collection/° 5.912 to 83.972 
Index ranges -5 ≤ h ≤ 5, -24 ≤ k ≤ 25, -8 ≤ l ≤ 4 
Reflections collected 2684 
Independent reflections 1214 [Rint = 0.0184, Rsigma = 0.0265] 
Data/restraints/parameters 1214/0/245 
Goodness-of-fit on F2 1.097 
Final R indexes [I>=2σ (I)] R1 = 0.0537, wR2 = 0.1143 
Final R indexes [all data] R1 = 0.0615, wR2 = 0.1184 








Compound 100 (0.50 mmol, 1 eq), HATU (0.23 g, 0.60 mmol, 1.2 eq), DIPEA (0.33 cm3, 1.89 
mmol, 4 eq) and cyclobutylamine (0.06 cm3, 0.75 mmol, 1.5 eq), were used in DMF (5 cm3) following 
general procedure 5, purified by column chromatography (2 % MeOH in EtOAc) followed by trituration 
with Et2O to give 102 as a white solid (0.054 g, 27 % over two steps). δH (400 MHz, CDCl3) 7.31 (1H, d, 
J 7.9 Hz), 7.13 (1H, d, J 8.0 Hz), 6.97 (1H, d, J 7.9 Hz), 6.93 (1H, s), 4.44 – 4.30 (1H, m), 3.76 (2H, s), 3.64 
– 3.43 (3H, m), 2.99 (2H, s), 2.53 (4H, br, s), 2.38 – 2.27 (2H, m), 1.91 – 1.79 (2H, m), 1.76 – 1.65 (2H, 
m), 1.46 (3H, d, J 7.1 Hz). δC (101 MHz, MeOD, 2 drops of CDCl3) 170.9, 170.6, 169.6, 137.6, 134.7, 
128.8, 122.8, 122.7, 116.4, 61.6, 54.1, 53.6, 45.2, 43.0, 37.4, 31.2, 15.9, 15.7. CI-HRMS: m/z calculated 
for C20H27N4O3S [M+H]+ requires 403.1798. Found 403.1782. Elemental Analysis Calculated for 
C20H26N4O3S requires, C, 59.68; H, 6.51; N, 13.92; S, 7.97, found, C, 58.37; H, 6.46; N, 13.51; S, 7.90. IR 
(neat): νmax/cm-1:  3218 (br), 2969 (br), 2943 (s), 1685 (s), 1653 (s), 1612 (s), 1568 (s). Melting Point oC:  
208 – 210 °C (diethyl ether). 
Preparation of N-cyclopentyl-2-(4-(2-methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-
carbonyl)piperazin-1-yl)acetamide (103) 
Compound 100 (0.49 mmol, 1 eq), HATU (0.28 g, 0.74 mmol, 1.5 eq), DIPEA (0.34 cm3, 1.96 
mmol, 4 eq) and cyclopentylamine (0.07 cm3, 0.74 mmol, 1.5 eq), were used in DMF (5 cm3) following 
general procedure 5, purified by column chromatography (100 % EtOAc) followed by trituration with 
Et2O to give 103 as a white solid (0.059 g, 29 % over two steps).  δH (400 MHz, CDCl3) 9.29 (1H, s), 7.31 
(1H, d, J 7.9), 7.07 (1H, s), 6.99 (1H, d, J 7.9), 6.93 (1H, d, J 7.6), 4.28 – 4.17 (1H, m), 3.92 – 3.57 (3H, 
m), 3.51 – 3.40 (2H, m), 3.03 (2H, s), 2.55 (4H, s), 2.03 – 1.93 (2H, m), 1.72 – 1.55 (4H, m), 1.48 (3H, d, 
J 7.1), 1.43 – 1.31 (2H, m). δC (101 MHz, CDCl3) 169.5, 168.9, 168.4, 136.8, 134.1, 128.0, 122.1, 122.0, 
116.3, 61.6, 53.7 – 53.3 (m), 50.7, 36.9, 33.3, 23.8, 15.7. CI-HRMS: m/z calculated for C21H29N4O3S 
[M+H]+ requires 417.1955. Found 417.1960. Elemental Analysis Calculated for C21H28N4O3S requires, 
C, 60.55; H, 6.78; N, 13.45; S, 7.70, found, C, 59.80; H, 6.75; N, 13.24; S, 7.50. IR (neat): νmax/cm-1:   




Compound 100 (0.40 mmol, 1 eq), HATU (0.23 g, 0.59 mmol, 1.5 eq), DIPEA (0.21 cm3, 1.19 
mmol, 3 eq) and cyclohexylamine (0.05 cm3, 0.44 mmol, 1.1 eq), were used in DMF (5 cm3) following 
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general procedure 5, purified by column chromatography (100 % EtOAc) to give 104 as a white solid 
(0.14 g, 81 % over two steps). δH (400 MHz, CDCl3) 8.19 (1H, s), 7.34 (1H, d, J 7.9 Hz), 7.02 (1H, dd, J 
7.9, 1.2 Hz), 6.97 (1H, s), 6.88 (1H, s), 3.88 – 3.68 (3H, m), 3.65 – 3.46 (3H, m), 3.04 (2H, s), 2.56 (4H, 
s), 1.94 – 1.85 (2H, m), 1.75 – 1.66 (2H, m), 1.66 – 1.53 (2H, m + H2O), 1.50 (3H, d, J 7.1 Hz), 1.45 – 1.33 
(2H, m), 1.23 – 1.15 (2H, m). δC (101 MHz, CDCl3) 169.5, 168.5, 136.7, 134.1, 127.9, 122.0, 121.9, 116.3, 
61.6, 53.9 – 53.1 (br, m), 47.6, 42.9 – 42.0 (br, m), 36.9, 33.2, 25.6, 24.8, 15.7. ESI-HRMS: m/z 
calculated for C22H30N4NaO3S [M+Na]+ requires 453.1931. Found 453.1925. Elemental Analysis 
Calculated for C22H30N4O3S requires, C, 61.37; H, 7.02; N, 13.01; S, 7.45, found, C, 60.82; H, 6.86; N, 
12.61; S, 6.80. IR (neat): νmax/cm-1:  3216 (br), 3144 (br), 2931 (s), 1686 (s), 1660 (s), 1611 (s), 1567 (s). 
Melting Point oC:  196 – 198 (EtOAc). 
Preparation of N-isopropyl-2-(4-(2-methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-
carbonyl)piperazin-1-yl)acetamide (105) 
Compound 100 (0.40 mmol, 1 eq), HATU (0.23 g, 0.60 mmol, 1.5 eq), DIPEA (0.21 cm3, 1.20 
mmol, 3 eq) and isopropylamine (0.11 cm3, 1.24 mmol, 3.1 eq), were used in DMF (5 cm3) following 
general procedure 5, purified by column chromatography (100 % EtOAc) to give 105 as a white solid 
(0.098 g, 63 % over two steps). δH (400 MHz, CDCl3) 9.28 (1H, s), 7.31 (1H, d, J 7.9 Hz), 7.07 (1H, d, J 
1.2 Hz), 7.00 (1H, dd, J 7.9, 1.3 Hz), 6.80 (1H, d, J 8.2 Hz), 4.15 – 4.04 (1H, m), 3.80 (2H, br s), 3.65 – 
3.43 (3H, m), 3.02 (2H, s), 2.55 (4H, br s), 1.49 (3H, d, J 7.1 Hz), 1.16 (6H, d, J 6.6 Hz). δC (101 MHz, 
CDCl3) 169.5, 168.6, 168.4, 136.7, 134.1, 128.0, 122.1, 122.0, 116.3, 61.6, 54.8 – 51.9 (m), 41.0, 36.9, 
23.0, 15.7. ESI-HRMS: m/z calculated for C19H26N4NaO3S [M+Na]+ requires 413.1618. Found 413.1627. 
Elemental Analysis Calculated for C19H26N4O3S requires, C, 58.44; H, 6.71; N, 14.35; S, 8.21, found, C, 
57.83; H, 6.85; N, 13.62; S, 7.80. IR (neat): νmax/cm-1:  3217 (br), 2969 (br), 2932 (s), 1677 (s), 1624 (s), 
1566 (s). Melting Point oC: 110 – 112 (Et2O) 
Preparation of N-cyclopentyl-N-methyl-2-(4-(2-methyl-3-oxo-3,4-dihydro-2H-
benzo[b][1,4]thiazine-6-carbonyl)piperazin-1-yl)acetamide (106) 
Compound 100 (0.54 mmol, 1 eq), HATU (0.31 g, 0.81 mmol, 1.5 eq), DIPEA (0.28 cm3, 1.62 
mmol, 3 eq) and N-methylcyclopentylamine (0.07 cm3, 0.59 mmol, 1.1 eq), were used in DMF (5 cm3) 
following general procedure 5, purified by column chromatography (100 % EtOAc) to give 106 as a 
white solid (0.15 g, 66 % over two steps). Note: Peaks around the terminal amide bond appear to be 
rotameric. The major rotamer contributes approximately 55 %, whilst the minor contributes 45 % in 
the 1H NMR. The chemical shifts of the molecule on the left hand side are unaffected by the rotamer. 
Reported below is the proton spectrum where major and minor rotamers will be noted as appropriate. 
All observable 13C peaks are reported, it was not possible to identify clearly which peaks belonged to 
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rotamers or other 13C chemical shifts nor was it clear in all cases which peak was major or minor. δH 
(400 MHz, CDCl3) 9.19 (1H, d, J 11.7 Hz), 7.30 (1H, d, J 7.9 Hz), 7.08 (1H, s), 7.00 (1H, d, J 7.9 Hz), 4.92 
(1H, apparent p (Minor), 4.39 – 4.27 (1H, m (Major)), 3.81 (2H, s), 3.60 – 3.41 (3H, m), 3.30 (2H, s 
(Major)), 3.22 (2H, s (Minor)), 2.87 (3H, s (Minor)), 2.79 (3H, s (Major)), 2.57 (4H, br, s), 1.89 – 1.53 
(8H, m), 1.48 (3H, d, J 7.1 Hz). δC (101 MHz, CDCl3) 169.34, 169.31, 168.9, 168.8, 168.3, 136.7, 134.5, 
134.4, 127.9, 122.1, 121.71, 121.69, 116.3, 60.9, 60.7, 58.1, 54.5, 53.6 – 52.3 (m), 37.0, 29.4, 29.3, 
28.3, 27.6, 24.6, 24.4, 15.7. ESI-HRMS: m/z calculated for C22H31N4O3S [M+H]+ requires 431.2111. 
Found 431.2112. Elemental Analysis Calculated for C22H30N4O3S requires, C, 61.37; H, 7.02; N, 13.01; 
S, 7.45, found, C, 60.86; H, 6.90; N, 12.69; S, 7.31. IR (neat): νmax/cm-1:  3222 (br), 3183 (br), 2953 (s), 
1688 (s), 1634 (s), 1600 (s), 1567 (s). Melting Point oC: 174 – 175 (EtOAc). 
Preparation of N-(4-fluorophenyl)-2-(4-(2-methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-
carbonyl)piperazin-1-yl)acetamide (107) 
Compound 100 (0.54 mmol, 1 eq), HATU (0.31 g, 0.81 mmol, 1.5 eq), DIPEA (0.28 cm3, 1.62 
mmol, 3 eq) and 4-fluoroaniline (0.06 cm3, 0.59 mmol, 1.1 eq), was used in DMF (5 cm3) following 
general procedure 5, purified by column chromatography (100 % EtOAc) to give 107 as a white solid 
(0.12 g, 52 % over two steps). δH (400 MHz, CDCl3) 9.09 (1H, s), 8.92 (1H, s), 7.52 (2H, dd, J 8.8, 4.7 Hz), 
7.33 (1H, d, J 7.9 Hz), 7.08 (1H, s), 7.07 – 6.97 (3H, m), 3.99 – 3.61 (4H, m), 3.56 (2H, q, J 7.1 Hz), 3.21 
(2H, s), 2.67 (4H, s), 1.50 (3H, d, J 7.1 Hz). δC (101 MHz, CDCl3) 169.5, 168.3, 159.6 (d, J 244.0 Hz), 136.8, 
134.0, 133.5 (d, J 2.8 Hz), 128.0, 122.2, 122.1, 121.5 (d, J 7.9 Hz), 116.3, 115.9 (d, J 22.5 Hz), 62.0, 53.9 
– 53.3 (m), 37.0, 15.7. δF (376 MHz, CDCl3) -117.60 (1F, s). ESI-HRMS: m/z calculated for C22H23FN4O3S 
[M+Na]+ requires 465.1367. Found 465.1371. Elemental Analysis Calculated for C22H23FN4O3S 
requires, C, 59.71; H, 5.24; N, 12.66; found, C, 58.67; H, 5.15; N, 12.32. IR (neat): νmax/cm-1: 3219 (br), 
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Molecular Modelling Protocol 
Compounds were first built in chemdraw and transferred to Spartan, compounds were then 
energy minimised, Spartan was used to compute local energy minimum geometry using molecular 
mechanics with the MMFF94 forcefield. Compounds were then docked in GOLD using the homology 
model previously built by our group. The docking protocol is outlined in the below. Early termination 
was not allowed and lone pairs were not saved, all other parameters were left default. Covalent 
docking was carried by linking the Cα of the Cys-202 with the ring opened form of 79.  
Mg2+ Mg2+ present, no coordination geometry specified 
Protonation Hydrogens added 
Waters Water molecule HOH1091 extracted, all other waters 
deleted, water was set as toggle, spin 
Ligands CDPME extracted 
Binding site Defined as 6 Å of the CDPME ligand 
Number of GA Runs 10, 50, 100, 500 
Scoring Function GOLDscore 
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HPLC traces of ethyl ester 
derivative of compound 70 as 
chirally pure starting material 
(top), followed by ethyl ester 
derivative of 71 showing 
racemisation from Pictet-Spengler 
reaction.  
